Selective Antisense Compounds and Uses Thereof

ABSTRACT

The present invention provides oligomeric compounds. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

FIELD OF THE INVENTION

The present invention pertains generally to chemically-modifiedoligonucleotides for use in research, diagnostics, and/or therapeutics.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing inelectronic format. The Sequence Listing is provided as a file entitledCORE0099USA2C1SEQ_ST25.txt, created Dec. 17, 2018 which is 300 Kb insize. The information in the electronic format of the sequence listingis incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Antisense compounds have been used to modulate target nucleic acids.Antisense compounds comprising a variety of chemical modifications andmotifs have been reported. In certain instances, such compounds areuseful as research tools, diagnostic reagents, and as therapeuticagents. In certain instances antisense compounds have been shown tomodulate protein expression by binding to a target messenger RNA (mRNA)encoding the protein. In certain instances, such binding of an antisensecompound to its target mRNA results in cleavage of the mRNA. Antisensecompounds that modulate processing of a pre-mRNA have also beenreported. Such antisense compounds alter splicing, interfere withpolyadenlyation or prevent formation of the 5′-cap of a pre-mRNA.

SUMMARY OF THE INVENTION

In certain embodiments, the present invention provides oligomericcompounds comprising oligonucleotides. In certain embodiments, sucholigonucleotides comprise a region having a gapmer motif. In certainembodiments, such oligonucleotides consist of a region having a gapmermotif.

The present disclosure provides the following non-limiting numberedembodiments:

-   -   Embodiment 1: A oligomeric compound comprising a modified        oligonucleotide consisting of 10 to 30 linked nucleosides,        wherein the modified oligonucleotide has a modification motif        comprising: a 5′-region consisting of 2-8 linked 5′-region        nucleosides, each independently selected from among a modified        nucleoside and an unmodified deoxynucleoside, provided that at        least one 5′-region nucleoside is a modified nucleoside and        wherein the 3′-most 5′-region nucleoside is a modified        nucleoside;        -   a 3′-region consisting of 2-8 linked 3′-region nucleosides,            each independently selected from among a modified nucleoside            and an unmodified deoxynucleoside, provided that at least            one 3′-region nucleoside is a modified nucleoside and            wherein the 5′-most 3′-region nucleoside is a modified            nucleoside; and        -   a central region between the 5′-region and the 3′-region            consisting of 6-12 linked central region nucleosides, each            independently selected from among: a modified nucleoside and            an unmodified deoxynucleoside, wherein the 5′-most central            region nucleoside is an unmodified deoxynucleoside        -   and the 3′-most central region nucleoside is an unmodified            deoxynucleoside;        -   wherein the modified oligonucleotide has a nucleobase            sequence complementary to the nucleobase sequence of a            target region of a target nucleic acid.    -   Embodiment 2: The oligomeric compound of embodiment 1, wherein        the nucleobase sequence of the target region of the target        nucleic acid differs from the nucleobase sequence of at least        one non-target nucleic acid by 1-3 differentiating nucleobases.    -   Embodiment 3: The oligomeric compound of embodiment 1, the        nucleobase sequence of the target region of the target nucleic        acid differs from the nucleobase sequence of at least one        non-target nucleic acid by a single differentiating nucleobase.    -   Embodiment 4: The oligomeric compound of embodiment 2 or 3,        wherein the target nucleic acid and the non-target nucleic acid        are alleles of the same gene.    -   Embodiment 5: The oligomeric compound of embodiment 4, wherein        the single differentiating nucleobase is a single-nucleotide        polymorphism.    -   Embodiment 6: The oligomeric compound of embodiment 5, wherein        the single-nucleotide polymorphism is associated with a disease.    -   Embodiment 7: The oligomeric compound of embodiment 6, wherein        the disease is Huntington's disease.    -   Embodiment 8: The oligomeric compound of embodiment 6, wherein        the single-nucleotide polymorphism is selected from among:        rs6446723, rs3856973, rs2285086, rs363092, rs916171, rs6844859,        rs7691627, rs4690073, rs2024115, rs11731237, rs362296,        rs10015979, rs7659144, rs363096, rs362273, rs16843804, rs362271,        rs362275, rs3121419, rs362272, rs3775061, rs34315806, rs363099,        rs2298967, rs363088, rs363064, rs363102, rs2798235, rs363080,        rs363072, rs363125, rs362303, rs362310, rs10488840, rs362325,        rs35892913, rs363102, rs363096, rs11731237, rs10015979,        rs363080, rs2798235, rs1936032, rs2276881, rs363070, rs35892913,        rs12502045, rs6446723, rs7685686, rs3733217, rs6844859, and        rs362331.    -   Embodiment 9: The oligomeric compound of embodiment 8, wherein        the single-nucleotide polymorphism is selected from among:        rs7685686, rs362303 rs4690072 and rs363088    -   Embodiment 10: The oligomeric compound of embodiment 2 or 3,        wherein the target nucleic acid and the non-target nucleic acid        are transcripts from different genes.    -   Embodiment 11: The oligomeric compound of any of embodiments        1-10, wherein the 3′-most 5′-region nucleoside comprises a        bicyclic sugar moiety.    -   Embodiment 12: The oligomeric compound of embodiment 11, wherein        the 3′-most 5′-region nucleoside comprises a cEt sugar moiety.    -   Embodiment 13: The oligomeric compound of embodiment 11, wherein        the 3′-most 5′-region nucleoside comprises an LNA sugar moiety.    -   Embodiment 14: The oligomeric compound of any of embodiments        1-13, wherein the central region consists of 6-10 linked        nucleosides.    -   Embodiment 15: The oligomeric compound of any of embodiments        1-14, wherein the central region consists of 6-9 linked        nucleosides.    -   Embodiment 16: The oligomeric compound of embodiment 15, wherein        the central region consists of 6 linked nucleosides.    -   Embodiment 17: The oligomeric compound of embodiment 15, wherein        the central region consists of 7 linked nucleosides.    -   Embodiment 18: The oligomeric compound of embodiment 15, wherein        the central region consists of 8 linked nucleosides.    -   Embodiment 19: The oligomeric compound of embodiment 15, wherein        the central region consists of 9 linked nucleosides.    -   Embodiment 20: The oligomeric compound of any of embodiments        1-19, wherein each central region nucleoside is an unmodified        deoxynucleoside.    -   Embodiment 21: The oligomeric compound of any of embodiments        1-19, wherein at least one central region nucleoside is a        modified nucleoside.    -   Embodiment 22: The oligomeric compound of embodiment 21, wherein        one central region nucleoside is a modified nucleoside and each        of the other central region nucleosides is an unmodified        deoxynucleoside.    -   Embodiment 23: The oligomeric compound of embodiment 21, wherein        two central region nucleosides are modified nucleosides and each        of the other central region nucleosides is an unmodified        deoxynucleoside.    -   Embodiment 24: The oligomeric compound of any of embodiments        21-23 wherein at least one modified central region nucleoside is        an RNA-like nucleoside.    -   Embodiment 25: The oligomeric compound of any of embodiments        21-23 comprising at least one modified central region nucleoside        comprising a modified sugar moiety.    -   Embodiment 26: The oligomeric compound of any of embodiments        21-25 comprising at least one modified central region nucleoside        comprising a 5′-methyl-2′-deoxy sugar moiety.    -   Embodiment 27: The oligomeric compound of any of embodiments        21-26 comprising at least one modified central region nucleoside        comprising a bicyclic sugar moiety.    -   Embodiment 28: The oligomeric compound of any of embodiments        21-27 comprising at least one modified central region nucleoside        comprising a cEt sugar moiety.    -   Embodiment 29: The oligomeric compound of any of embodiments        21-28 comprising at least one modified central region nucleoside        comprising an LNA sugar moiety.    -   Embodiment 30: The oligomeric compound of any of embodiments        21-29 comprising at least one modified central region nucleoside        comprising an α-LNA sugar moiety.    -   Embodiment 31: The oligomeric compound of any of embodiments        21-29 comprising at least one modified central region nucleoside        comprising a 2′-substituted sugar moiety.    -   Embodiment 32: The oligomeric compound of embodiment 31 wherein        at least one modified central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: halogen, optionally substituted allyl, optionally        substituted amino, azido, optionally substituted SH, CN, OCN,        CF3, OCF3, O, S, or N(Rm)-alkyl; O, S, or N(Rm)-alkenyl; O, S or        N(Rm)-alkynyl; optionally substituted O-alkylenyl-O-alkyl,        optionally substituted alkynyl, optionally substituted alkaryl,        optionally substituted aralkyl, optionally substituted        O-alkaryl, optionally substituted O-aralkyl, O(CH2)2SCH3,        O—(CH2)2-O—N(Rm)(Rn) or O—CH2-C(═O)—N(Rm)(Rn), where each Rm and        Rn is, independently, H, an amino protecting group or        substituted or unsubstituted C₁-C₁₀ alkyl;        -   wherein each optionally substituted group is optionally            substituted with a substituent group independently selected            from among: hydroxyl, amino, alkoxy, carboxy, benzyl,            phenyl, nitro (NO₂), thiol, thioalkoxy (S-alkyl), halogen,            alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 33: The oligomeric compound of embodiment 32 wherein        at least one modified central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: a halogen, OCH₃, OCH₂F, OCHF₂, OCF₃, OCH₂CH₃,        O(CH₂)₂F, OCH₂CHF₂, OCH₂CF₃, OCH₂—CH═CH₂, O(CH₂)₂—OCH₃,        O(CH₂)₂—SCH₃, O(CH₂)₂—OCF₃, O(CH₂)₃—N(R₁)(R₂),        O(CH₂)₂—ON(R₁)(R₂), O(CH₂)₂—O(CH₂)₂—N(R₁)(R₂),        OCH₂C(═O)—N(R₁)(R₂), OCH₂C(═O)—N(R₃)—(CH₂)₂—N(R₁)(R₂), and        O(CH₂)₂—N(R₃)—C(═NR₄)[N(R₁)(R₂)]; wherein R₁, R₂, R₃ and R₄ are        each, independently, H or C₁-C₆ alkyl.    -   Embodiment 34: The oligomeric compound of embodiment 33 wherein        the 2′ substituent is selected from among: a halogen, OCH₃,        OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂, O(CH₂)₂—OCH₃ (MOE),        O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 35: The oligomeric compound of any of embodiments        21-34 comprising at least one modified central region nucleoside        comprising a 2′-MOE sugar moiety.    -   Embodiment 36: The oligomeric compound of any of embodiments        21-35 comprising at least one modified central region nucleoside        comprising a 2′-OMe sugar moiety.    -   Embodiment 37: The oligomeric compound of any of embodiments        21-36 comprising at least one modified central region nucleoside        comprising a 2′-F sugar moiety.    -   Embodiment 38: The oligomeric compound of any of embodiments        21-37 comprising at least one modified central region nucleoside        comprising a 2′-(ara)-F sugar moiety.    -   Embodiment 39: The oligomeric compound of any of embodiments        21-38 comprising at least one modified central region nucleoside        comprising a sugar surrogate.    -   Embodiment 40: The oligomeric compound of embodiment 39        comprising at least one modified central region nucleoside        comprising an F-HNA sugar moiety.    -   Embodiment 41: The oligomeric compound of embodiment 39 or 40        comprising at least one modified central region nucleoside        comprising an HNA sugar moiety.    -   Embodiment 42: The oligomeric compound of any of embodiments        21-41 comprising at least one modified central region nucleoside        comprising a modified nucleobase.    -   Embodiment 43: The oligomeric compound of embodiment 42        comprising at least one modified central region nucleoside        comprising a modified nucleobase selected from a 2-thio        pyrimidine and a 5-propyne pyrimidine.    -   Embodiment 44: The oligomeric compound of any of embodiments        21-43, wherein the 2^(nd) nucleoside from the 5′-end of the        central region is a modified nucleoside.    -   Embodiment 45: The oligomeric compound of any of embodiments        21-44, wherein the 3^(rd) nucleoside from the 5′-end of the        central region is a modified nucleoside.    -   Embodiment 46: The oligomeric compound of any of embodiments        21-45, wherein the 4^(th) nucleoside from the 5′-end of the        central region is a modified nucleoside.    -   Embodiment 47: The oligomeric compound of any of embodiments        21-46, wherein the 5^(th) nucleoside from the 5′-end of the        central region is a modified nucleoside.    -   Embodiment 48: The oligomeric compound of any of embodiments        21-47, wherein the 6^(th) nucleoside from the 5′-end of the        central region is a modified nucleoside.    -   Embodiment 49: The oligomeric compound of any of embodiments        21-48, wherein the 8^(th) nucleoside from the 3′-end of the        central region is a modified nucleoside.    -   Embodiment 50: The oligomeric compound of any of embodiments        21-49, wherein the 7^(th) nucleoside from the 3′-end of the        central region is a modified nucleoside.    -   Embodiment 51: The oligomeric compound of any of embodiments        21-50, wherein the 6^(th) nucleoside from the 3′-end of the        central region is a modified nucleoside.    -   Embodiment 52: The oligomeric compound of any of embodiments        21-51, wherein the 5^(th) nucleoside from the 3′-end of the        central region is a modified nucleoside.    -   Embodiment 53: The oligomeric compound of any of embodiments        21-52, wherein the 4^(th) nucleoside from the 3′-end of the        central region is a modified nucleoside.    -   Embodiment 54: The oligomeric compound of any of embodiments        21-53, wherein the 3^(rd) nucleoside from the 3′-end of the        central region is a modified nucleoside.    -   Embodiment 55: The oligomeric compound of any of embodiments        21-54, wherein the 2^(nd) nucleoside from the 3′-end of the        central region is a modified nucleoside.    -   Embodiment 56: The oligomeric compound of any of embodiments        21-55, wherein the modified nucleoside is a 5′-methyl-2′-deoxy        sugar moiety.    -   Embodiment 57: The oligomeric compound of any of embodiments        21-55, wherein the modified nucleoside is a 2-thio pyrimidine.    -   Embodiment 58: The oligomeric compound of any of embodiments        21-55, wherein the central region comprises no region having        more than 4 contiguous unmodified deoxynucleosides.    -   Embodiment 59: The oligomeric compound of any of embodiments        21-55, wherein the central region comprises no region having        more than 5 contiguous unmodified deoxynucleosides.    -   Embodiment 60: The oligomeric compound of any of embodiments        21-55, wherein the central region comprises no region having        more than 6 contiguous unmodified deoxynucleosides.    -   Embodiment 61: The oligomeric compound of any of embodiments        21-55, wherein the central region comprises no region having        more than 7 contiguous unmodified deoxynucleosides.    -   Embodiment 62: The oligomeric compound of any of embodiments        1-14 or 21-59, wherein the central region has a nucleoside motif        selected from among: DDDDDDDDDD, DDDDXDDDDD; DDDDDXDDDDD;        DDDXDDDDD; DDDDXDDDDDD; DDDDXDDDD; DDXDDDDDD; DDDXDDDDDD;        DXDDDDDD; DDXDDDDDDD; DDXDDDDD; DDXDDDXDDD; DDDXDDDXDDD;        DXDDDXDDD; DDXDDDXDD; DDXDDDDXDDD; DDXDDDDXDD; DXDDDDXDDD;        DDDDXDDD; DDDXDDD; DXDDDDDDD; DDDDXXDDD; and DXXDXXDXX; wherein        -   each D is an unmodified deoxynucleoside; and each X is a            modified nucleoside.    -   Embodiment 63: The oligomeric compound of any of embodiments        1-14 or 21-59, wherein the central region has a nucleoside motif        selected from among: DDDDDDDDD; DXDDDDDDD; DDXDDDDDD; DDDXDDDDD;        DDDDXDDDD; DDDDDXDDD; DDDDDDXDD; DDDDDDDXD; DXXDDDDDD;        DDDDDDXXD; DDXXDDDDD; DDDXXDDDD; DDDDXXDDD; DDDDDXXDD;        DXDDDDDXD; DXDDDDXDD; DXDDDXDDD; DXDDXDDDD; DXDXDDDDD;        DDXDDDDXD; DDXDDDXDD; DDXDDXDDD; DDXDXDDDD; DDDXDDDXD;        DDDXDDXDD; DDDXDXDDD; DDDDXDDXD; DDDDXDXDD; and DDDDDXDXD        wherein each D is an unmodified deoxynucleoside; and each X is a        modified nucleoside.    -   Embodiment 64: The oligomeric compound of any of embodiments        1-14 or 21-59, wherein the central region has a nucleoside motif        selected from among: DDDDDDDD, DDDDXDDDD, DXDDDDDDD, DXXDDDDDD,        DDXDDDDDD, DDDXDDDDD, DDDDXDDDD, DDDDDXDDD, DDDDDDXDD, and        DDDDDDDXD.    -   Embodiment 65: The oligomeric compound of any of embodiments        1-14 or 21-59, wherein the central region has a nucleoside motif        selected from among: DDDDDDDD, DXDDDDDD, DDXDDDDD, DDDXDDDD,        DDDDXDDD, DDDDDXDD, DDDDDDXD, DXDDDDXD, DXDDDXDD, DXDDXDDD,        DXDXDDDD, DXXDDDDD, DDXXDDDD, DDXDXDDD, DDXDDXDD, DXDDDDXD,        DDDXXDDD, DDDXDXDD, DDDXDDXD, DDDDXXDD, DDDDXDXD, and DDDDDXXD.    -   Embodiment 66: The oligomeric compound of any of embodiments        1-14 or 21-59, wherein the central region has a nucleoside motif        selected from among: DDDDDDD, DXDDDDD, DDXDDDD, DDDXDDD,        DDDDXDD, DDDDDXD, DXDDDXD, DXDDXDD, DXDXDDD, DXXDDDD, DDXXDDD,        DDXDXDD, DDXDDXD, DDDXXDD, DDDXDXD, and DDDDXXD.    -   Embodiment 67: The oligomeric compound of any of embodiments        1-14 or 21-59, wherein the central region has a nucleoside motif        selected from among: DDDDDD, DXDDDD, DDXDDD, DDDXDD, DDDDXD,        DXXDDD, DXDXDD, DXDDXD, DDXXDD, DDXDXD, and DDDXXD.    -   Embodiment 68: The oligomeric compound of any of embodiments        1-14 or 21-59, wherein the central region has a nucleoside motif        selected from among: DDDDDD, DDDDDDD, DDDDDDDD, DDDDDDDDD,        DDDDDDDDDD, DXDDDD, DDXDDD, DDDXDD, DDDDXD, DXDDDDD, DDXDDDD,        DDDXDDD, DDDDXDD, DDDDDXD, DXDDDDDD, DDXDDDDD, DDDXDDDD,        DDDDXDDD, DDDDDXDD, DDDDDDXD, DXDDDDDDD; DDXDDDDDD, DDDXDDDDD,        DDDDXDDDD, DDDDDXDDD, DDDDDDXDD, DDDDDDDXD, DXDDDDDDDD,        DDXDDDDDDD, DDDXDDDDDD, DDDDXDDDDD, DDDDDXDDDD, DDDDDDXDDD,        DDDDDDDXDD, and DDDDDDDDXD.    -   Embodiment 69: The oligomeric compound of embodiments 62-68,        wherein each X comprises a modified nucleobase.    -   Embodiment 70: The oligomeric compound of embodiments 62-68,        wherein each X comprises a modified sugar moiety.    -   Embodiment 71: The oligomeric compound of embodiments 62-68,        wherein each X comprises 2-thio-thymidine.    -   Embodiment 72: The oligomeric compound of embodiments 62-68,        wherein each X nucleoside comprises an F-HNA sugar moiety.    -   Embodiment 73: The oligomeric compound of embodiments 62-68,        wherein the nucleobase sequence of the target region of the        target nucleic acid differs from the nucleobase sequence of at        least one non-target nucleic acid by a single differentiating        nucleobase, and wherein the location of the single        differentiating nucleobase is represented by X.    -   Embodiment 74: The oligomeric compound of embodiment 73, wherein        the target nucleic acid and the non-target nucleic acid are        alleles of the same gene.    -   Embodiment 75: The oligomeric compound of embodiment 73, wherein        the single differentiating nucleobase is a single-nucleotide        polymorphism.    -   Embodiment 76: The oligomeric compound of any of embodiments        1-75, wherein the 5′ region consists of 2 linked 5′-region        nucleosides.    -   Embodiment 77: The oligomeric compound of any of embodiments        1-75, wherein the 5′ region consists of 3 linked 5′-region        nucleosides.    -   Embodiment 78: The oligomeric compound of any of embodiments        1-75, wherein the 5′ region consists of 4 linked 5′-region        nucleosides.    -   Embodiment 79: The oligomeric compound of any of embodiments        1-75, wherein the 5′ region consists of 5 linked 5′-region        nucleosides.    -   Embodiment 80: The oligomeric compound of any of embodiments        1-75, wherein the 5′ region consists of 6 linked 5′-region        nucleosides.    -   Embodiment 81: The oligomeric compound of any of embodiments        1-80, wherein at least one 5′-region nucleoside is an unmodified        deoxynucleoside.    -   Embodiment 82: The oligomeric compound of any of embodiments        1-80, wherein each 5′-region nucleoside is a modified        nucleoside.    -   Embodiment 83: The oligomeric compound of any of embodiments        1-80 wherein at least one 5′-region nucleoside is an RNA-like        nucleoside.    -   Embodiment 84: The oligomeric compound of any of embodiments        1-80 wherein each 5′-region nucleoside is an RNA-like        nucleoside.    -   Embodiment 85: The oligomeric compound of any of embodiments        1-80 comprising at least one modified 5′-region nucleoside        comprising a modified sugar.    -   Embodiment 86: The oligomeric compound of embodiment 80        comprising at least one modified 5′-region nucleoside comprising        a bicyclic sugar moiety.    -   Embodiment 87: The oligomeric compound of embodiment 86        comprising at least one modified 5′-region nucleoside comprising        a cEt sugar moiety.    -   Embodiment 88: The oligomeric compound of embodiment 85 or 86        comprising at least one modified 5′-region nucleoside comprising        an LNA sugar moiety.    -   Embodiment 89: The oligomeric compound of any of embodiments        76-80 comprising of at least one modified 5′-region nucleoside        comprising a 2′-substituted sugar moiety.    -   Embodiment 90: The oligomeric compound of embodiment 89 wherein        at least one modified central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: halogen, optionally substituted allyl, optionally        substituted amino, azido, optionally substituted SH, CN, OCN,        CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, or N(R_(m))-alkenyl;        O, S or N(R_(m))-alkynyl; optionally substituted        O-alkylenyl-O-alkyl, optionally substituted alkynyl, optionally        substituted alkaryl, optionally substituted aralkyl, optionally        substituted O-alkaryl, optionally substituted O-aralkyl,        O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or        O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,        independently, H, an amino protecting group or substituted or        unsubstituted C₁-C₁₀ alkyl;        -   wherein each optionally substituted group is optionally            substituted with a substituent group independently selected            from among: hydroxyl, amino, alkoxy, carboxy, benzyl,            phenyl, nitro (NO₂), thiol, thioalkoxy (S-alkyl), halogen,            alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 91: The oligomeric compound of embodiment 90 wherein        at least one modified 5′-region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′-substituent selected        from among: a halogen, OCH₃, OCH₂F, OCHF₂, OCF₃, OCH₂CH₃,        O(CH₂)₂F, OCH₂CHF₂, OCH₂CF₃, OCH₂—CH═CH₂, O(CH₂)₂—OCH₃ (MOE),        O(CH₂)₂—SCH₃, O(CH₂)₂—OCF₃, O(CH₂)₃—N(R₁)(R₂),        O(CH₂)₂—ON(R₁)(R₂), O(CH₂)₂—O(CH₂)₂—N(R₁)(R₂),        OCH₂C(═O)—N(R₁)(R₂), OCH₂C(═O)—N(R₃)—(CH₂)₂—N(R₁)(R₂), and        O(CH₂)₂—N(R₃)—C(═NR₄)[N(R₁)(R₂)]; wherein R₁, R₂, R₃ and R₄ are        each, independently, H or C₁-C₆ alkyl.    -   Embodiment 92: The oligomeric compound of embodiment 91, wherein        the 2′-substituent is selected from among: a halogen, OCH₃,        OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂, O(CH₂)₂—OCH₃,        O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 93: The oligomeric compound of any of embodiments        89-92 comprising at least one modified 5′-region nucleoside        comprising a 2′-MOE sugar moiety.    -   Embodiment 94: The oligomeric compound of any of embodiments        89-92 comprising at least one modified 5′-region nucleoside        comprising a 2′-OMe sugar moiety.    -   Embodiment 95: The oligomeric compound of any of embodiments        89-92 comprising at least one modified 5′-region nucleoside        comprising a 2′-F sugar moiety.    -   Embodiment 96: The oligomeric compound of any of embodiments        89-92 comprising at least one modified 5′-region nucleoside        comprising a 2′-(ara)-F sugar moiety.    -   Embodiment 97: The oligomeric compound of any of embodiments        82-96 comprising of at least one modified 5′-region nucleoside        comprising a sugar surrogate.    -   Embodiment 98: The oligomeric compound of embodiment 97        comprising at least one modified 5′-region nucleoside comprising        an F-HNA sugar moiety.    -   Embodiment 99: The oligomeric compound of embodiment 97 or 98        comprising at least one modified 5′-region nucleoside comprising        an HNA sugar moiety.    -   Embodiment 100: The oligomeric compound of any of embodiments        1-99 comprising at least one modified 5′-region nucleoside        comprising a modified nucleobase.    -   Embodiment 101: The oligomeric compound of embodiment 100,        wherein the modified nucleoside comprises 2-thio-thymidine.    -   Embodiment 102: The oligomeric compound of any of embodiments        1-101, wherein the 5′-region has a motif selected from among:        -   ADDA; ABDAA; ABBA; ABB; ABAA; AABAA; AAABAA; AAAABAA;            AAAAABAA; AAABAA; AABAA; ABAB; ABADB; ABADDB; AAABB; AAAAA;            ABBDC; ABDDC; ABBDCC; ABBDDC; ABBDCC; ABBC; AA; AAA; AAAA;            AAAAB; AAAAAAA; AAAAAAAA; ABBB; AB; ABAB; AAAAB; AABBB;            AAAAB; and AABBB,        -   wherein each A is a modified nucleoside of a first type,            each B is a modified nucleoside of a second type, each C is            a modified nucleoside of a third type, and each D is an            unmodified deoxynucleoside.    -   Embodiment 103: The oligomeric compound of any of embodiments        1-101, wherein the 5′-region has a motif selected from among:        -   AB, ABB, AAA, BBB, BBBAA, AAB, BAA, BBAA, AABB, AAAB, ABBW,            ABBWW, ABBB, ABBBB, ABAB, ABABAB, ABABBB, ABABAA, AAABB,            AAAABB, AABB, AAAAB, AABBB, ABBBB, BBBBB, AAABW, AAAAA,            BBBBAA, and AAABW wherein each A is a modified nucleoside of            a first type, each B is a modified nucleoside of a second            type, and each W is a modified nucleoside of a third type.    -   Embodiment 104: The oligomeric compound of any of embodiments        1-101, wherein the 5′-region has a motif selected from among:        ABB; ABAA; AABAA; AAABAA; ABAB; ABADB; AAABB; AAAAA; AA; AAA;        AAAA; AAAAB; ABBB; AB; and ABAB, wherein each A is a modified        nucleoside of a first type, each B is a modified nucleoside of a        second type, and each W is a modified nucleoside of a third        type.    -   Embodiment 105: The oligomeric compound of embodiments 102-104,        wherein each A nucleoside comprises a 2′-substituted sugar        moiety.    -   Embodiment 106: The oligomeric compound of embodiment 105        wherein at least one central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: halogen, optionally substituted allyl, optionally        substituted amino, azido, optionally substituted SH, CN, OCN,        CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, or N(R_(m))-alkenyl;        O, S or N(R_(m))-alkynyl; optionally substituted        O-alkylenyl-O-alkyl, optionally substituted alkynyl, optionally        substituted alkaryl, optionally substituted aralkyl, optionally        substituted O-alkaryl, optionally substituted O-aralkyl,        O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or        O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,        independently, H, an amino protecting group or substituted or        unsubstituted C₁-C₁₀ alkyl;        -   wherein each optionally substituted group is optionally            substituted with a substituent group independently selected            from among: hydroxyl, amino, alkoxy, carboxy, benzyl,            phenyl, nitro (NO₂), thiol, thioalkoxy (S-alkyl), halogen,            alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 107: The oligomeric compound of embodiment 102-106,        wherein each A nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: a        halogen, OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂,        O(CH₂)₂—OCH₃, O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 108: The oligomeric compound of embodiment 107,        wherein each A nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: F, OCH₃,        O(CH₂)₂—OCH₃.    -   Embodiment 109: The oligomeric compound of embodiments 102-106,        wherein each A nucleoside comprises a bicyclic sugar moiety.    -   Embodiment 110: The oligomeric compound of embodiment 109,        wherein each A nucleoside comprises a bicyclic sugar moiety        selected from among: cEt, cMOE, LNA, α-LNA, ENA and 2′-thio LNA.    -   Embodiment 111: The oligomeric compound of any of embodiments        102-110, wherein each A comprises a modified nucleobase.    -   Embodiment 112: The oligomeric compound of embodiment 111,        wherein each A comprises a modified nucleobase selected from        among a 2-thio pyrimidine and a 5-propyne pyrimidine.    -   Embodiment 113: The oligomeric compound of embodiment 112,        wherein each A comprises 2-thio-thymidine.    -   Embodiment 114: The oligomeric compound of embodiment 102-106,        wherein each A nucleoside comprises an unmodified        2′-deoxyfuranose sugar moiety.    -   Embodiment 115: The oligomeric compound of embodiment 102-106,        wherein each A nucleoside comprises an F-HNA sugar moiety.    -   Embodiment 116: The oligomeric compound of any of embodiments        102-115, wherein each B nucleoside comprises a 2′-substituted        sugar moiety.    -   Embodiment 117: The oligomeric compound of embodiment 116,        wherein at least one central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: halogen, optionally substituted allyl, optionally        substituted amino, azido, optionally substituted SH, CN, OCN,        CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, or N(R_(m))-alkenyl;        O, S or N(R_(m))-alkynyl; optionally substituted        O-alkylenyl-O-alkyl, optionally substituted alkynyl, optionally        substituted alkaryl, optionally substituted aralkyl, optionally        substituted O-alkaryl, optionally substituted O-aralkyl,        O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or        O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,        independently, H, an amino protecting group or substituted or        unsubstituted C₁-C₁₀ alkyl; wherein each optionally substituted        group is optionally substituted with a substituent group        independently selected from among: hydroxyl, amino, alkoxy,        carboxy, benzyl, phenyl, nitro (NO₂), thiol, thioalkoxy        (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 118: The oligomeric compound of embodiment 117,        wherein each B nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: a        halogen, OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂,        O(CH₂)₂—OCH₃, O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 119: The oligomeric compound of embodiment 118,        wherein each B nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: F, OCH₃,        O(CH₂)₂—OCH₃.    -   Embodiment 120: The oligomeric compound of any of embodiments        102-115, wherein each B nucleoside comprises a bicyclic sugar        moiety.    -   Embodiment 121: The oligomeric compound of embodiment 120,        wherein each B nucleoside comprises a bicyclic sugar moiety        selected from among: cEt, cMOE, LNA, α-LNA, ENA and 2′-thio LNA.    -   Embodiment 122: The oligomeric compound of any of embodiments        102-115, wherein each B comprises a modified nucleobase.    -   Embodiment 123: The oligomeric compound of embodiment 122,        wherein each B comprises a modified nucleobase selected from        among a 2-thio pyrimidine and a 5-propyne pyrimidine.    -   Embodiment 124: The oligomeric compound of embodiment 123,        wherein each B comprises 2-thio-thymidine.    -   Embodiment 125: The oligomeric compound of embodiment 102-106,        wherein each B nucleoside comprises an unmodified        2′-deoxyfuranose sugar moiety.    -   Embodiment 126: The oligomeric compound of embodiment 102-115,        wherein each B nucleoside comprises an F-HNA sugar moiety.    -   Embodiment 127: The oligomeric compound of any of embodiments        102-126, wherein each C nucleoside comprises a 2′-substituted        sugar moiety.    -   Embodiment 128: The oligomeric compound of embodiment 127,        wherein at least one central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: halogen, optionally substituted allyl, optionally        substituted amino, azido, optionally substituted SH, CN, OCN,        CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, or N(R_(m))-alkenyl;        O, S or N(R_(m))-alkynyl; optionally substituted        O-alkylenyl-O-alkyl, optionally substituted alkynyl, optionally        substituted alkaryl, optionally substituted aralkyl, optionally        substituted O-alkaryl, optionally substituted O-aralkyl,        O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or        O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,        independently, H, an amino protecting group or substituted or        unsubstituted C₁-C₁₀ alkyl;        -   wherein each optionally substituted group is optionally            substituted with a substituent group independently selected            from among: hydroxyl, amino, alkoxy, carboxy, benzyl,            phenyl, nitro (NO₂), thiol, thioalkoxy (S-alkyl), halogen,            alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 129: The oligomeric compound of embodiment 128,        wherein each C nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: a        halogen, OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂,        O(CH₂)₂—OCH₃, O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 130: The oligomeric compound of embodiment 129,        wherein each C nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: F, OCH₃,        O(CH₂)₂—OCH₃.    -   Embodiment 131: The oligomeric compound of any of embodiments        102-126, wherein each C nucleoside comprises a bicyclic sugar        moiety.    -   Embodiment 132: The oligomeric compound of embodiment 131,        wherein each C nucleoside comprises a bicyclic sugar moiety        selected from among: cEt, cMOE, LNA, α-LNA, ENA and 2′-thio LNA.    -   Embodiment 133: The oligomeric compound of any of embodiments        102-126, wherein each C comprises a modified nucleobase.    -   Embodiment 134: The oligomeric compound of embodiment 133,        wherein each C comprises a modified nucleobase selected from        among a 2-thio pyrimidine and a 5-propyne pyrimidine.    -   Embodiment 135: The oligomeric compound of embodiment 134,        wherein each C comprises 2-thio-thymidine.    -   Embodiment 136: The oligomeric compound of embodiment 102-126,        wherein each C comprises an F-HNA sugar moiety.    -   Embodiment 137: The oligomeric compound of embodiment 102-126,        wherein each C nucleoside comprises an unmodified        2′-deoxyfuranose sugar moiety.    -   Embodiment 138: The oligomeric compound of any of embodiments        102-138, wherein each W nucleoside comprises a 2′-substituted        sugar moiety.    -   Embodiment 139: The oligomeric compound of embodiment 138,        wherein at least one central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: halogen, optionally substituted allyl, optionally        substituted amino, azido, optionally substituted SH, CN, OCN,        CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, or N(R_(m))-alkenyl;        O, S or N(R_(m))-alkynyl; optionally substituted        O-alkylenyl-O-alkyl, optionally substituted alkynyl, optionally        substituted alkaryl, optionally substituted aralkyl, optionally        substituted O-alkaryl, optionally substituted O-aralkyl,        O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or        O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,        independently, H, an amino protecting group or substituted or        unsubstituted C₁-C₁₀ alkyl; wherein each optionally substituted        group is optionally substituted with a substituent group        independently selected from among: hydroxyl, amino, alkoxy,        carboxy, benzyl, phenyl, nitro (NO₂), thiol, thioalkoxy        (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 140: The oligomeric compound of embodiment 139,        wherein each W nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: a        halogen, OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂,        O(CH₂)₂—OCH₃, O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 141: The oligomeric compound of embodiment 139,        wherein each W nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: F, OCH₃,        O(CH₂)₂—OCH₃.    -   Embodiment 142: The oligomeric compound of any of embodiments        102-137, wherein each W nucleoside comprises a bicyclic sugar        moiety.    -   Embodiment 143: The oligomeric compound of embodiment 142,        wherein each W nucleoside comprises a bicyclic sugar moiety        selected from among: cEt, cMOE, LNA, α-LNA, ENA and 2′-thio LNA.    -   Embodiment 144: The oligomeric compound of any of embodiments        102-137, wherein each W comprises a modified nucleobase.    -   Embodiment 145: The oligomeric compound of embodiment 144,        wherein each W comprises a modified nucleobase selected from        among a 2-thio pyrimidine and a 5-propyne pyrimidine.    -   Embodiment 146: The oligomeric compound of embodiment 145,        wherein each W comprises 2-thio-thymidine.    -   Embodiment 147: The oligomeric compound of embodiment 102-137,        wherein each W comprises an F-HNA sugar moiety.    -   Embodiment 148: The oligomeric compound of embodiment 102-137,        wherein each W nucleoside comprises an unmodified        2′-deoxyfuranose sugar moiety.    -   Embodiment 149: The oligomeric compound of any of embodiments        1-148, wherein the 3′ region consists of 2 linked 3′-region        nucleosides.    -   Embodiment 150: The oligomeric compound of any of embodiments        1-148, wherein the 3′ region consists of 3 linked 3′-region        nucleosides.    -   Embodiment 151: The oligomeric compound of any of embodiments        1-148, wherein the 3′ region consists of 4 linked 3′-region        nucleosides.    -   Embodiment 152: The oligomeric compound of any of embodiments        1-148, wherein the 3′ region consists of 5 linked 3′-region        nucleosides.    -   Embodiment 153: The oligomeric compound of any of embodiments        1-148, wherein the 3′ region consists of 6 linked 3′-region        nucleosides.    -   Embodiment 154: The oligomeric compound of any of embodiments        1-153, wherein at least one 3′-region nucleoside is an        unmodified deoxynucleoside.    -   Embodiment 155: The oligomeric compound of any of embodiments        1-154, wherein each 3′-region nucleoside is a modified        nucleoside.    -   Embodiment 156: The oligomeric compound of any of embodiments        1-153, wherein at least one 3′-region nucleoside is an RNA-like        nucleoside.    -   Embodiment 157: The oligomeric compound of any of embodiments        1-154, wherein each 3′-region nucleoside is an RNA-like        nucleoside.    -   Embodiment 158: The oligomeric compound of any of embodiments        1-153, comprising at least one modified 3′-region nucleoside        comprising a modified sugar.    -   Embodiment 159: The oligomeric compound of embodiment 158,        comprising at least one modified 3′-region nucleoside comprising        a bicyclic sugar moiety.    -   Embodiment 160: The oligomeric compound of embodiment 159,        comprising at least one modified 3′-region nucleoside comprising        a cEt sugar moiety.    -   Embodiment 161: The oligomeric compound of embodiment 159,        comprising at least one modified 3′-region nucleoside comprising        an LNA sugar moiety.    -   Embodiment 162: The oligomeric compound of any of embodiments        1-162 comprising of at least one modified 3′-region nucleoside        comprising a 2′-substituted sugar moiety.    -   Embodiment 163: The oligomeric compound of embodiment 162,        wherein at least one central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: halogen, optionally substituted allyl, optionally        substituted amino, azido, optionally substituted SH, CN, OCN,        CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, or N(R_(m))-alkenyl;        O, S or N(R_(m))-alkynyl; optionally substituted        O-alkylenyl-O-alkyl, optionally substituted alkynyl, optionally        substituted alkaryl, optionally substituted aralkyl, optionally        substituted O-alkaryl, optionally substituted O-aralkyl,        O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or        O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,        independently, H, an amino protecting group or substituted or        unsubstituted C₁-C₁₀ alkyl; wherein each optionally substituted        group is optionally substituted with a substituent group        independently selected from among: hydroxyl, amino, alkoxy,        carboxy, benzyl, phenyl, nitro (NO₂), thiol, thioalkoxy        (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 164: The oligomeric compound of embodiment 163        wherein at least one modified 3′-region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′-substituent selected        from among: a halogen, OCH₃, OCH₂F, OCHF₂, OCF₃, OCH₂CH₃,        O(CH₂)₂F, OCH₂CHF₂, OCH₂CF₃, OCH₂—CH═CH₂, O(CH₂)₂—OCH₃ (MOE),        O(CH₂)₂—SCH₃, O(CH₂)₂—OCF₃, O(CH₂)₃—N(R₁)(R₂),        O(CH₂)₂—ON(R₁)(R₂), O(CH₂)₂—O(CH₂)₂—N(R₁)(R₂),        OCH₂C(═O)—N(R₁)(R₂), OCH₂C(═O)—N(R₃)—(CH₂)₂—N(R₁)(R₂), and        O(CH₂)₂—N(R₃)—C(═NR₄)[N(R₁)(R₂)]; wherein R₁, R₂, R₃ and R₄ are        each, independently, H or C₁-C₆ alkyl.    -   Embodiment 165: The oligomeric compound of embodiment 164,        wherein the 2′-substituent is selected from among: a halogen,        OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂, O(CH₂)₂—OCH₃,        O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 166: The oligomeric compound of any of embodiments        162-165 comprising at least one modified 3′-region nucleoside        comprising a 2′-MOE sugar moiety.    -   Embodiment 167: The oligomeric compound of any of embodiments        162-166 comprising at least one modified 3′-region nucleoside        comprising a 2′-OMe sugar moiety.    -   Embodiment 168: The oligomeric compound of any of embodiments        162-167 comprising at least one modified 3′-region nucleoside        comprising a 2′-F sugar moiety.    -   Embodiment 169: The oligomeric compound of any of embodiments        162-168 comprising at least one modified 3′-region nucleoside        comprising a 2′-(ara)-F sugar moiety.    -   Embodiment 170: The oligomeric compound of any of embodiments        162-169 comprising of at least one modified 3′-region nucleoside        comprising a sugar surrogate.    -   Embodiment 171: The oligomeric compound of embodiment 170        comprising at least one modified 3′-region nucleoside comprising        an F-HNA sugar moiety.    -   Embodiment 172: The oligomeric compound of embodiment 170        comprising at least one modified 3′-region nucleoside comprising        an HNA sugar moiety.    -   Embodiment 173: The oligomeric compound of any of embodiments        1-172 comprising at least one modified 3′-region nucleoside        comprising a modified nucleobase.    -   Embodiment 174: The oligomeric compound of any of embodiments        1-173, wherein each A comprises a 2′-substituted sugar moiety        comprising a 2′-substituent selected from among: F, OCH₃,        O(CH₂)₂—OCH₃, and each B comprises a bicylic sugar moiety        selected from among: LNA and cEt.    -   Embodiment 175: The oligomeric compound of embodiment 174,        wherein each A comprises O(CH₂)₂—OCH₃ and each B comprises cEt.    -   Embodiment 176: The oligomeric compound of any of embodiments        1-175, wherein the 3′-region has a motif selected from among:        ABB, ABAA, AAABAA, AAAAABAA, AABAA, AAAABAA, AAABAA, ABAB,        AAAAA, AAABB, AAAAAAAA, AAAAAAA, AAAAAA, AAAAB, AAAA, AAA, AA,        AB, ABBB, ABAB, AABBB, wherein each A is a modified nucleoside        of a first type, each B is a modified nucleoside of a second        type.    -   Embodiment 177: The oligomeric compound of embodiments 1-175,        wherein the 3′-region has a motif selected from among: ABB;        AAABAA; AABAA; AAAABAA; AAAAA; AAABB; AAAAAAAA; AAAAAAA; AAAAAA;        AAAAB; AB; ABBB; and ABAB, wherein each A is a modified        nucleoside of a first type, each B is a modified nucleoside of a        second type.    -   Embodiment 178: The oligomeric compound of embodiments 1-175,        wherein the 3′-region has a motif selected from among: BBA, AAB,        AAA, BBB, BBAA, AABB, WBBA, WAAB, BBBA, BBBBA, BBBB, BBBBBA,        ABBBBB, BBAAA, AABBB, BBBAA, BBBBA, BBBBB, BABA, AAAAA, BBAAAA,        AABBBB, BAAAA, and ABBBB, wherein each A is a modified        nucleoside of a first type, each B is a modified nucleoside of a        second type, and each W is a modified nucleoside of a first        type, a second type, or a third type.    -   Embodiment 179: The oligomeric compound of embodiments 176-178,        wherein each A nucleoside comprises a 2′-substituted sugar        moiety.    -   Embodiment 180: The oligomeric compound of embodiments 176-178,        wherein at least one central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: halogen, optionally substituted allyl, optionally        substituted amino, azido, optionally substituted SH, CN, OCN,        CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, or N(R_(m))-alkenyl;        O, S or N(R_(m))-alkynyl; optionally substituted        O-alkylenyl-O-alkyl, optionally substituted alkynyl, optionally        substituted alkaryl, optionally substituted aralkyl, optionally        substituted O-alkaryl, optionally substituted O-aralkyl,        O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or        O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,        independently, H, an amino protecting group or substituted or        unsubstituted C₁-C₁₀ alkyl;        -   wherein each optionally substituted group is optionally            substituted with a substituent group independently selected            from among: hydroxyl, amino, alkoxy, carboxy, benzyl,            phenyl, nitro (NO₂), thiol, thioalkoxy (S-alkyl), halogen,            alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 181: The oligomeric compound of embodiment 180,        wherein each A nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: a        halogen, OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂,        O(CH₂)₂—OCH₃, O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 182: The oligomeric compound of embodiment 181,        wherein each A nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: F, OCH₃,        O(CH₂)₂—OCH₃.    -   Embodiment 183: The oligomeric compound of embodiments 176-178,        wherein each A nucleoside comprises a bicyclic sugar moiety.    -   Embodiment 184: The oligomeric compound of embodiment 183,        wherein each A nucleoside comprises a bicyclic sugar moiety        selected from among: cEt, cMOE, LNA, α-LNA, ENA and 2′-thio LNA.    -   Embodiment 185: The oligomeric compound of any of embodiments        176-178, wherein each B nucleoside comprises a 2′-substituted        sugar moiety.    -   Embodiment 186: The oligomeric compound of embodiment 185,        wherein at least one modified central region nucleoside        comprises a 2′-substituted sugar moiety comprising a 2′        substituent selected from among: halogen, optionally substituted        allyl, optionally substituted amino, azido, optionally        substituted SH, CN, OCN, CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O,        S, or N(R_(m))-alkenyl; O, S or N(R_(m))-alkynyl; optionally        substituted O-alkylenyl-O-alkyl, optionally substituted alkynyl,        optionally substituted alkaryl, optionally substituted aralkyl,        optionally substituted O-alkaryl, optionally substituted        O-aralkyl, O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or        O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,        independently, H, an amino protecting group or substituted or        unsubstituted C₁-C₁₀ alkyl;        -   wherein each optionally substituted group is optionally            substituted with a substituent group independently selected            from among: hydroxyl, amino, alkoxy, carboxy, benzyl,            phenyl, nitro (NO₂), thiol, thioalkoxy (S-alkyl), halogen,            alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 187: The oligomeric compound of embodiment 185,        wherein each B nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: a        halogen, OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂,        O(CH₂)₂—OCH₃, O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 188: The oligomeric compound of embodiment 187,        wherein each B nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: F, OCH₃,        O(CH₂)₂—OCH₃.    -   Embodiment 189: The oligomeric compound of any of embodiments        176-178, wherein each B nucleoside comprises a bicyclic sugar        moiety.    -   Embodiment 190: The oligomeric compound of embodiment 189,        wherein each B nucleoside comprises a bicyclic sugar moiety        selected from among: cEt, cMOE, LNA, α-LNA, ENA and 2′-thio LNA.    -   Embodiment 191: The oligomeric compound of any of embodiments        176-190, wherein each A comprises a 2′-substituted sugar moiety        comprising a 2′-substituent selected from among: F, OCH₃,        O(CH₂)₂—OCH₃, and each B comprises a bicylic sugar moiety        selected from among: LNA and cEt.    -   Embodiment 192: The oligomeric compound of embodiment 191,        wherein each A comprises O(CH₂)₂—OCH₃ and each B comprises cEt.    -   Embodiment 193: The oligomeric compound of any of embodiments        176-192, wherein each W nucleoside comprises a 2′-substituted        sugar moiety.    -   Embodiment 194: The oligomeric compound of embodiment 193,        wherein at least one central region nucleoside comprises a        2′-substituted sugar moiety comprising a 2′ substituent selected        from among: halogen, optionally substituted allyl, optionally        substituted amino, azido, optionally substituted SH, CN, OCN,        CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, or N(R_(m))-alkenyl;        O, S or N(R_(m))-alkynyl; optionally substituted        O-alkylenyl-O-alkyl, optionally substituted alkynyl, optionally        substituted alkaryl, optionally substituted aralkyl, optionally        substituted O-alkaryl, optionally substituted O-aralkyl,        O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_(m))(R_(n)) or        O—CH₂—C(═O)—N(R_(m))(R_(n)), where each R_(m) and R_(n) is,        independently, H, an amino protecting group or substituted or        unsubstituted C₁-C₁₀ alkyl; wherein each optionally substituted        group is optionally substituted with a substituent group        independently selected from among: hydroxyl, amino, alkoxy,        carboxy, benzyl, phenyl, nitro (NO₂), thiol, thioalkoxy        (S-alkyl), halogen, alkyl, aryl, alkenyl and alkynyl.    -   Embodiment 195: The oligomeric compound of embodiment 193,        wherein each W nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: a        halogen, OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH═CH₂,        O(CH₂)₂—OCH₃, O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(═O)—N(H)CH₃,        OCH₂C(═O)—N(H)—(CH₂)₂—N(CH₃)₂, and OCH₂—N(H)—C(═NH)NH₂.    -   Embodiment 196: The oligomeric compound of embodiment 195,        wherein each W nucleoside comprises a 2′-substituted sugar        moiety comprising a 2′-substituent selected from among: F, OCH₃,        O(CH₂)₂—OCH₃.    -   Embodiment 197: The oligomeric compound of any of embodiments        176-192, wherein each W nucleoside comprises a bicyclic sugar        moiety.    -   Embodiment 198: The oligomeric compound of embodiment 197,        wherein each W nucleoside comprises a bicyclic sugar moiety        selected from among: cEt, cMOE, LNA, α-LNA, ENA and 2′-thio LNA.    -   Embodiment 199: The oligomeric compound of any of embodiments        176-192, wherein each W comprises a modified nucleobase.    -   Embodiment 200: The oligomeric compound of embodiment 199,        wherein each W comprises a modified nucleobase selected from        among a 2-thio pyrimidine and a 5-propyne pyrimidine.    -   Embodiment 201: The oligomeric compound of embodiment 200,        wherein each W comprises 2-thio-thymidine.    -   Embodiment 202: The oligomeric compound of embodiment 176-192,        wherein each W comprises an F-HNA sugar moiety.    -   Embodiment 203: The oligomeric compound of embodiment 202,        wherein each W nucleoside comprises an unmodified        2′-deoxyfuranose sugar moiety.    -   Embodiment 204: The oligomeric compound of embodiments 1-203,        wherein the 5′-region has a motif selected from among: AB, ABB,        AAA, BBB, BBBAA, AAB, BAA, BBAA, AABB, AAAB, ABBW, ABBWW, ABBB,        ABBBB, ABAB, ABABAB, ABABBB, ABABAA, AAABB, AAAABB, AABB, AAAAB,        AABBB, ABBBB, BBBBB, AAABW, AAAAA, and BBBBAA;        -   wherein the 3′-region has a motif selected from among: BBA,            AAB, AAA, BBB, BBAA, AABB, WBBA, WAAB, BBBA, BBBBA, BBBB,            BBBBBA, ABBBBB, BBAAA, AABBB, BBBAA, BBBBA, BBBBB, BABA,            AAAAA, BBAAAA, AABBBB, BAAAA, and ABBBB;        -   wherein the central region has a nucleoside motif selected            from among: DDDDDD, DDDDDDD, DDDDDDDD, DDDDDDDDD,            DDDDDDDDDD, DXDDDDDDD, DDXDDDDDD, DDDXDDDDD, DDDDXDDDD,            DDDDDXDDD, DDDDDDXDD, DDDDDDDXD, DXXDDDDDD, DDDDDDXXD,            DDXXDDDDD, DDDXXDDDD, DDDDXXDDD, DDDDDXXDD, DXDDDDDXD,            DXDDDDXDD, DXDDDXDDD, DXDDXDDDD, DXDXDDDDD, DDXDDDDXD,            DDXDDDXDD, DDXDDXDDD, DDXDXDDDD, DDDXDDDXD, DDDXDDXDD,            DDDXDXDDD, DDDDXDDXD, DDDDXDXDD, and DDDDDXDXD, DDDDDDDD,            DXDDDDDD, DDXDDDDD, DDDXDDDD, DDDDXDDD, DDDDDXDD, DDDDDDXD,            DXDDDDXD, DXDDDXDD, DXDDXDDD, DXDXDDDD, DXXDDDDD, DDXXDDDD,            DDXDXDDD, DDXDDXDD, DXDDDDXD, DDDXXDDD, DDDXDXDD, DDDXDDXD,            DDDDXXDD, DDDDXDXD, and DDDDDXXD, DXDDDDD, DDXDDDD, DDDXDDD,            DDDDXDD, DDDDDXD, DXDDDXD, DXDDXDD, DXDXDDD, DXXDDDD,            DDXXDDD, DDXDXDD, DDXDDXD, DDDXXDD, DDDXDXD, and DDDDXXD,            DXDDDD, DDXDDD, DDDXDD, DDDDXD, DXXDDD, DXDXDD, DXDDXD,            DDXXDD, DDXDXD, and DDDXXD; and        -   wherein each A is a modified nucleoside of a first type,            each B is a modified nucleoside of a second type, each W is            a modified nucleoside of a first type, a second type, or a            third type, each D is an unmodified deoxynucleoside, and            each X is a modified nucleoside or a modified nucleobase.    -   Embodiment 205: The oligomeric compound of embodiment 204,        wherein the 5′-region has a motif selected from among:        -   AB, ABB, AAA, BBB, BBBAA, AAB, BAA, BBAA, AABB, ABBW, ABBWW,            ABBB, ABBBB, ABAB, ABABAB, ABABBB, ABABAA, AAABB, AAAABB,            AABB, AAAAB, AABBB, ABBBB, BBBBB, AAABW, and BBBBAA; and            wherein the 3′-region has a BBA motif    -   Embodiment 206: The oligomeric compound of embodiment 204 or        205, wherein one of A or B comprises a bicyclic sugar moiety,        another of A or B comprises a 2′-MOE sugar moiety, and W        comprises a 2-thio-thymidine nucleobase.    -   Embodiment 207: The oligomeric compound of embodiment 204 or        205, wherein one of A or B comprises a bicyclic sugar moiety,        another of A or B comprises a 2′-MOE sugar moiety, and W        comprises FHNA.    -   Embodiment 208: The oligomeric compound of embodiment 204 or        205, wherein one of A or B comprises cEt, another of A or B        comprises a 2′-modified sugar moiety, and W comprises a        2-thio-thymidine nucleobase.    -   Embodiment 209: The oligomeric compound of embodiment 204 or        205, wherein one of A or B comprises cEt, another of A or B        comprises a 2′-modified sugar moiety, and W comprises FHNA.    -   Embodiment 210: The oligomeric compound of embodiment 204 or        205, wherein each A comprises MOE, each B comprises cEt, and        each W is selected from among cEt or FHNA.    -   Embodiment 211: The oligomeric compound of embodiment 204 or        205, wherein each W comprises cEt.    -   Embodiment 212: The oligomeric compound of embodiment 204 or        205, wherein each W comprises 2-thio-thymidine.    -   Embodiment 213: The oligomeric compound of embodiment 204 or        205, wherein each W comprises FHNA.    -   Embodiment 214: The oligomeric compound of any of embodiments        1-213 comprising at least one modified internucleoside linkage.    -   Embodiment 215: The oligomeric compound of embodiment 214,        wherein each internucleoside linkage is a modified        internucleoside linkage.    -   Embodiment 216: The oligomeric compound of embodiment 214 or 215        comprising at least one phosphorothioate internucleoside        linkage.    -   Embodiment 217: The oligomeric compound of any of embodiments        214 or 215 comprising at least one methylphosphonate        internucleoside linkage.    -   Embodiment 218: The oligomeric compound of any of embodiments        214 or 215 comprising one methylphosphonate internucleoside        linkage.    -   Embodiment 219: The oligomeric compound of any of embodiments        214 or 215 comprising two methylphosphonate internucleoside        linkages.    -   Embodiment 220: The oligomeric compound of embodiment 217,        wherein at least one of the 3^(rd), 4^(th), 5^(th), 6^(th)        and/or 7^(th) internucleoside from the 5′-end is a        methylphosphonate internucleoside linkage.    -   Embodiment 221: The oligomeric compound of embodiment 217,        wherein at least one of the 3^(rd) 4^(th), 5^(th), 6^(th) and/or        7^(th) internucleoside from the 3′-end is a methylphosphonate        internucleoside linkage.    -   Embodiment 222: The oligomeric compound of embodiment 217,        wherein at least one of the 3^(rd) 4^(th), 5^(th), 6^(th),        7^(th), 8^(th), 9^(th), 10^(th), 11^(th), and/or 12^(th)        internucleoside from the 5′-end is a methylphosphonate        internucleoside linkage, and wherein at least one of the 3^(rd),        4^(th), 5^(th), 6^(th), 7^(th), 8^(th), 9^(th), 10^(th),        11^(th), and/or 12^(th) internucleoside from the 5′-end is a        modified nucleoside.    -   Embodiment 223: The oligomeric compound of embodiment 217,        wherein at least one of the 3^(rd) 4^(th), 5^(th), 6^(th),        7^(th), 8^(th), 9^(th), 10^(th), 11 ^(th), and/or 12^(th)        internucleoside from the 3′-end is a methylphosphonate        internucleoside linkage, and wherein at least one of the 3^(rd),        4^(th), 5^(th), 6^(th), 7^(th), 8^(th), 9^(th), 10^(th),        11^(th), and/or 12^(th) internucleoside from the 3′-end is a        modified nucleoside.    -   Embodiment 224: The oligomeric compound of any of embodiments        1-223 comprising at least one conjugate group.    -   Embodiment 225: The oligomeric compound of embodiment 1-223,        wherein the conjugate group consists of a conjugate.    -   Embodiment 226: The oligomeric compound of embodiment 225,        wherein the conjugate group consists of a conjugate and a        conjugate linker.    -   Embodiment 227: The oligomeric compound of any of embodiments        1-226, wherein the nucleobase sequence of the modified        oligonucleotide is 100% complementary to the nucleobase sequence        of the target region of the target nucleic acid.    -   Embodiment 228: The oligomeric compound of any of embodiments        1-226, wherein the nucleobase sequence of the modified        oligonucleotide contains one mismatch relative to the nucleobase        sequence of the target region of the target nucleic acid.    -   Embodiment 229: The oligomeric compound of any of embodiments        1-226, wherein the nucleobase sequence of the modified        oligonucleotide contains two mismatches relative to the        nucleobase sequence of the target region of the target nucleic        acid.    -   Embodiment 230: The oligomeric compound of any of embodiments        1-226, wherein the nucleobase sequence of the modified        oligonucleotide comprises a hybridizing region and at least one        non-targeting region, wherein the nucleobase sequence of the        hybridizing region is complementary to the nucleobase sequence        of the target region of the target nucleic acid.    -   Embodiment 231: The oligomeric compound of embodiment 230,        wherein the nucleobase sequence of the hybridizing region is        100% complementary to the nucleobase sequence of the target        region of the target nucleic acid.    -   Embodiment 232: The oligomeric compound of embodiment 230,        wherein the nucleobase sequence of the hybridizing region        contains one mismatche relative to the nucleobase sequence of        the target region of the target nucleic acid.    -   Embodiment 233: The oligomeric compound of any of embodiments        230-232, wherein the nucleobase sequence of at least one        non-targeting region is complementary to a portion of the        hybridizing region of the modified oligonucleotide.    -   Embodiment 234: The oligomeric compound of embodiment 233,        wherein the nucleobase sequence of at least one non-targeting        region is 100% complementary to a portion of the hybridizing        region of the modified oligonucleotide.    -   Embodiment 235: The oligomeric compound of embodiment 1-234        wherein the nucleobase sequence of the modified oligonucleotide        comprises two non-targeting regions flanking a central        hybridizing region.    -   Embodiment 236: The oligomeric compound of embodiment 235,        wherein the two non-targeting regions are complementary to one        another.    -   Embodiment 237: The oligomeric compound of embodiment 236,        wherein the two non-targeting regions are 100% complementary to        one another.    -   Embodiment 238: The oligomeric compound of any of embodiments        2-237, wherein the nucleobase sequence of the modified        oligonucleotide aligns with the nucleobase of the target region        of the target nucleic acid such that a distinguishing nucleobase        of the target region of the target nucleic acid aligns with a        target-selective nucleoside within the central region of the        modified oligonucleotide.    -   Embodiment 239: The oligomeric compound of any of embodiments        3-237, wherein the nucleobase sequence of the modified        oligonucleotide aligns with the nucleobase of the target region        of the target nucleic acid such that the single distinguishing        nucleobase of the target region of the target nucleic acid        aligns with a target-selective nucleoside within the central        region of the modified oligonucleotide.    -   Embodiment 240: The oligomeric compound of embodiment 238 or        239, wherein the target-selective nucleoside is the 5′-most        nucleoside of the central region.    -   Embodiment 241: The oligomeric compound of embodiment 238 or        239, wherein the target-selective nucleoside is the 2^(nd)        nucleoside from the 5′-end of the central region.    -   Embodiment 242: The oligomeric compound of embodiment 238 or        239, wherein the target-selective nucleoside is at the 3^(th)        nucleoside from the 5′-end of the central region.    -   Embodiment 243: The oligomeric compound of embodiment 238 or        239, wherein the target-selective nucleoside is at the 5^(th)        nucleoside from the 5′-end of the central region.    -   Embodiment 244: The oligomeric compound of embodiment 238 or        239, wherein the target-selective nucleoside is at the 7^(th)        nucleoside from the 5′-end of the central region.    -   Embodiment 245: The oligomeric compound of embodiment 238 or        239, wherein the target-selective nucleoside is at the 9^(th)        nucleoside from the 5′-end of the central region.    -   Embodiment 246: The oligomeric compound of any of embodiments        238 or 239, or 241-245, wherein the target-selective nucleoside        is at the 2^(nd) nucleoside from the 3′-end of the central        region.    -   Embodiment 247: The oligomeric compound of any of embodiments        238 or 239, or 241-245, wherein the target-selective nucleoside        is at the 5^(th) nucleoside from the 3′-end of the central        region.    -   Embodiment 248: The oligomeric compound of any of embodiments        1-247, wherein target-selective nucleoside is an unmodified        deoxynucleoside.    -   Embodiment 249: The oligomeric compound of any of embodiments        1-247, wherein target-selective nucleoside is a modified        nucleoside.    -   Embodiment 250: The oligomeric compound of embodiment 249,        wherein the target-selective nucleoside is a sugar modified        nucleoside.    -   Embodiment 251: The oligomeric compound of embodiment 250,        wherein the target-selective nucleoside comprises a sugar        modification selected from among: 2′-MOE, 2′-F, 2′-(ara)-F, HNA,        FHNA, cEt, and α-L-LNA.    -   Embodiment 252: The oligomeric compound of any of embodiments        1-251, wherein the target-selective nucleoside comprises a        nucleobase modification.    -   Embodiment 253: The oligomeric compound of embodiment 252,        wherein the modified nucleobase is selected from among: a 2-thio        pyrimidine and a 5-propyne pyrimidine.    -   Embodiment 254: The oligomeric compound of any of embodiments        1-253, wherein the oligomeric compound is an antisense compound.    -   Embodiment 255: The oligomeric compound of embodiment 254,        wherein the oligomeric compound selectively reduces expression        of the target relative to the non-target.    -   Embodiment 256: The oligomeric compound of embodiment 255,        wherein the oligomeric compound reduces expression of target at        least two-fold more than it reduces expression of the        non-target.    -   Embodiment 257: The oligomeric compound of embodiment 256,        having an EC₅₀ for reduction of expression of target that is at        least least two-fold lower than its EC₅₀ for reduction of        expression of the non-target, when measured in cells.    -   Embodiment 258: The oligomeric compound of embodiment 256,        having an ED₅₀ for reduction of expression of target that is at        least least two-fold lower than its ED₅₀ for reduction of        expression of the non-target, when measured in an animal.    -   Embodiment 259: The oligomeric compound of embodiments 1-10,        having an E-E-E-K-K-(D)₇-E-E-K motif, wherein each E is a 2′-MOE        nucleoside and each K is a cEt nucleoside.    -   Embodiment 260: A method comprising contacting a cell with an        oligomeric compound of any of embodiments 1-259.    -   Embodiment 261: The method of embodiment 260, wherein the cell        is in vitro.    -   Embodiment 262: The method of embodiment 260, wherein the cell        is in an animal.    -   Embodiment 263: The method of embodiment 262, wherein the animal        is a human.    -   Embodiment 264: The method of embodiment 263, wherein the animal        is a mouse.    -   Embodiment 265: A pharmaceutical composition comprising an        oligomeric compound of any of embodiments 1-259 and a        pharmaceutically acceptable carrier or diluent.    -   Embodiment 266: A method of administering a pharmaceutical        composition of embodiment 265 to an animal.    -   Embodiment 267: The method of embodiment 266, wherein the animal        is a human.    -   Embodiment 268: The method of embodiment 266, wherein the animal        is a mouse.    -   Embodiment 269: Use of an oligomeric compound of any of        embodiments 1-259 for the preparation of a medicament for the        treatment or amelioration of Huntington's disease.    -   Embodiment 270: A method of ameliorating a symptom of        Huntington's disease, comprising administering an oligomeric        compound of any of embodiments 1-259 to an animal in need        thereof.    -   Embodiment 271: The method of embodiment 270, wherein the animal        is a human.    -   Embodiment 272: The method of embodiment 270, wherein the animal        is a mouse.

In certain embodiments, including but not limited to any of the abovenumbered embodiments, oligomeric compounds including oligonucleotidesdescribed herein are capable of modulating expression of a target RNA.In certain embodiments, the target RNA is associated with a disease ordisorder, or encodes a protein that is associated with a disease ordisorder. In certain embodiments, the oligomeric compounds oroligonucleotides provided herein modulate the expression of function ofsuch RNA to alleviate one or more symptom of the disease or disorder.

In certain embodiments, oligomeric compounds including oligonucleotidesdescribe herein are useful in vitro. In certain embodiments sucholigomeric compounds are used in diagnostics and/or for targetvalidation experiments.

DETAILED DESCRIPTION OF THE INVENTION

It is to be understood that both the foregoing general description andthe following detailed description are exemplary and explanatory onlyand are not restrictive of the invention, as claimed. Herein, the use ofthe singular includes the plural unless specifically stated otherwise.As used herein, the use of “or” means “and/or” unless stated otherwise.Furthermore, the use of the term “including” as well as other forms,such as “includes” and “included”, is not limiting. Also, terms such as“element” or “component” encompass both elements and componentscomprising one unit and elements and components that comprise more thanone subunit, unless specifically stated otherwise.

The section headings used herein are for organizational purposes onlyand are not to be construed as limiting the subject matter described.All documents, or portions of documents, cited in this application,including, but not limited to, patents, patent applications, articles,books, and treatises, are hereby expressly incorporated by reference intheir entirety for any purpose.

A. Definitions

Unless specific definitions are provided, the nomenclature used inconnection with, and the procedures and techniques of, analyticalchemistry, synthetic organic chemistry, and medicinal and pharmaceuticalchemistry described herein are those well known and commonly used in theart. Standard techniques may be used for chemical synthesis, andchemical analysis. Certain such techniques and procedures may be foundfor example in “Carbohydrate Modifications in Antisense Research” Editedby Sangvi and Cook, American Chemical Society, Washington D.C., 1994;“Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa.,21^(st) edition, 2005; and “Antisense Drug Technology, Principles,Strategies, and Applications” Edited by Stanley T. Crooke, CRC Press,Boca Raton, Fla.; and Sambrook et al., “Molecular Cloning, A laboratoryManual,” 2′ Edition, Cold Spring Harbor Laboratory Press, 1989, whichare hereby incorporated by reference for any purpose. Where permitted,all patents, applications, published applications and other publicationsand other data referred to throughout in the disclosure are incorporatedby reference herein in their entirety.

Unless otherwise indicated, the following terms have the followingmeanings:

As used herein, “nucleoside” means a compound comprising a nucleobasemoiety and a sugar moiety. Nucleosides include, but are not limited to,naturally occurring nucleosides (as found in DNA and RNA) and modifiednucleosides. Nucleosides may be linked to a phosphate moiety.

As used herein, “chemical modification” means a chemical difference in acompound when compared to a naturally occurring counterpart. Chemicalmodifications of oligonucleotides include nucleoside modifications(including sugar moiety modifications and nucleobase modifications) andinternucleoside linkage modifications. In reference to anoligonucleotide, chemical modification does not include differences onlyin nucleobase sequence.

As used herein, “furanosyl” means a structure comprising a 5-memberedring comprising four carbon atoms and one oxygen atom.

As used herein, “naturally occurring sugar moiety” means a ribofuranosylas found in naturally occurring RNA or a deoxyribofuranosyl as found innaturally occurring DNA.

As used herein, “sugar moiety” means a naturally occurring sugar moietyor a modified sugar moiety of a nucleoside.

As used herein, “modified sugar moiety” means a substituted sugar moietyor a sugar surrogate.

As used herein, “substituted sugar moiety” means a furanosyl that is nota naturally occurring sugar moiety. Substituted sugar moieties include,but are not limited to furanosyls comprising substituents at the2′-position, the 3′-position, the 5′-position and/or the 4′-position.Certain substituted sugar moieties are bicyclic sugar moieties.

As used herein, “2′-substituted sugar moiety” means a furanosylcomprising a substituent at the 2′-position other than H or OH. Unlessotherwise indicated, a 2′-substituted sugar moiety is not a bicyclicsugar moiety (i.e., the 2′-substituent of a 2′-substituted sugar moietydoes not form a bridge to another atom of the furanosyl ring.

As used herein, “MOE” means —OCH₂CH₂OCH₃.

As used herein, “2′-F nucleoside” refers to a nucleoside comprising asugar comprising fluoroine at the 2′ position. Unless otherwiseindicated, the fluorine in a 2′-F nucleoside is in the ribo position(replacing the OH of a natural ribose).

As used herein, “2′-(ara)-F” refers to a 2′-F substituted nucleoside,wherein the fluoro group is in the arabino position.

As used herein the term “sugar surrogate” means a structure that doesnot comprise a furanosyl and that is capable of replacing the naturallyoccurring sugar moiety of a nucleoside, such that the resultingnucleoside sub-units are capable of linking together and/or linking toother nucleosides to form an oligomeric compound which is capable ofhybridizing to a complementary oligomeric compound. Such structuresinclude rings comprising a different number of atoms than furanosyl(e.g., 4, 6, or 7-membered rings); replacement of the oxygen of afuranosyl with a non-oxygen atom (e.g., carbon, sulfur, or nitrogen); orboth a change in the number of atoms and a replacement of the oxygen.Such structures may also comprise substitutions corresponding to thosedescribed for substituted sugar moieties (e.g., 6-membered carbocyclicbicyclic sugar surrogates optionally comprising additionalsubstituents). Sugar surrogates also include more complex sugarreplacements (e.g., the non-ring systems of peptide nucleic acid). Sugarsurrogates include without limitation morpholinos, cyclohexenyls andcyclohexitols.

As used herein, “bicyclic sugar moiety” means a modified sugar moietycomprising a 4 to 7 membered ring (including but not limited to afuranosyl) comprising a bridge connecting two atoms of the 4 to 7membered ring to form a second ring, resulting in a bicyclic structure.In certain embodiments, the 4 to 7 membered ring is a sugar ring. Incertain embodiments the 4 to 7 membered ring is a furanosyl. In certainsuch embodiments, the bridge connects the 2′-carbon and the 4′-carbon ofthe furanosyl.

As used herein, “nucleotide” means a nucleoside further comprising aphosphate linking group. As used herein, “linked nucleosides” may or maynot be linked by phosphate linkages and thus includes, but is notlimited to “linked nucleotides.” As used herein, “linked nucleosides”are nucleosides that are connected in a continuous sequence (i.e. noadditional nucleosides are present between those that are linked).

As used herein, “nucleobase” means a group of atoms that can be linkedto a sugar moiety to create a nucleoside that is capable ofincorporation into an oligonucleotide, and wherein the group of atoms iscapable of bonding with a complementary naturally occurring nucleobaseof another oligonucleotide or nucleic acid. Nucleobases may be naturallyoccurring or may be modified.

As used herein the terms, “unmodified nucleobase” or “naturallyoccurring nucleobase” means the naturally occurring heterocyclicnucleobases of RNA or DNA: the purine bases adenine (A) and guanine (G),and the pyrimidine bases thymine (T), cytosine (C) (including 5-methylC), and uracil (U).

As used herein, “modified nucleobase” means any nucleobase that is not anaturally occurring nucleobase.

As used herein, “modified nucleoside” means a nucleoside comprising atleast one chemical modification compared to naturally occurring RNA orDNA nucleosides. Modified nucleosides comprise a modified sugar moietyand/or a modified nucleobase.

As used herein, “bicyclic nucleoside” or “BNA” means a nucleosidecomprising a bicyclic sugar moiety.

As used herein, “constrained ethyl nucleoside” or “cEt” means anucleoside comprising a bicyclic sugar moiety comprising a4′-CH(CH₃)—O-2′bridge.

As used herein, “locked nucleic acid nucleoside” or “LNA” means anucleoside comprising a bicyclic sugar moiety comprising a4′-CH₂—O-2′bridge.

As used herein, “2′-substituted nucleoside” means a nucleosidecomprising a substituent at the 2′-position other than H or OH. Unlessotherwise indicated, a 2′-substituted nucleoside is not a bicyclicnucleoside.

As used herein, “2′-deoxynucleoside” means a nucleoside comprising 2′-Hfuranosyl sugar moiety, as found in naturally occurringdeoxyribonucleosides (DNA). In certain embodiments, a 2′-deoxynucleosidemay comprise a modified nucleobase or may comprise an RNA nucleobase(e.g., uracil).

As used herein, “RNA-like nucleoside” means a modified nucleoside thatadopts a northern configuration and functions like RNA when incorporatedinto an oligonucleotide. RNA-like nucleosides include, but are notlimited to 3′-endo furanosyl nucleosides and RNA surrogates.

As used herein, “3′-endo-furanosyl nucleoside” means an RNA-likenucleoside that comprises a substituted sugar moiety that has a 3′-endoconformation. 3′-endo-furanosyl nucleosides include, but are not limitedto: 2′-MOE, 2′-F, 2′-OMe, LNA, ENA, and cEt nucleosides.

As used herein, “RNA-surrogate nucleoside” means an RNA-like nucleosidethat does not comprise a furanosyl. RNA-surrogate nucleosides include,but are not limited to hexitols and cyclopentanes.

As used herein, “oligonucleotide” means a compound comprising aplurality of linked nucleosides. In certain embodiments, anoligonucleotide comprises one or more unmodified ribonucleosides (RNA)and/or unmodified deoxyribonucleosides (DNA) and/or one or more modifiednucleosides.

As used herein “oligonucleoside” means an oligonucleotide in which noneof the internucleoside linkages contains a phosphorus atom. As usedherein, oligonucleotides include oligonucleosides.

As used herein, “modified oligonucleotide” means an oligonucleotidecomprising at least one modified nucleoside and/or at least one modifiedinternucleoside linkage.

As used herein “internucleoside linkage” means a covalent linkagebetween adjacent nucleosides in an oligonucleotide.

As used herein “naturally occurring internucleoside linkage” means a 3′to 5′ phosphodiester linkage.

As used herein, “modified internucleoside linkage” means anyinternucleoside linkage other than a naturally occurring internucleosidelinkage.

As used herein, “oligomeric compound” means a polymeric structurecomprising two or more sub-structures. In certain embodiments, anoligomeric compound comprises an oligonucleotide. In certainembodiments, an oligomeric compound comprises one or more conjugategroups and/or terminal groups. In certain embodiments, an oligomericcompound consists of an oligonucleotide.

As used herein, “terminal group” means one or more atom attached toeither, or both, the 3′ end or the 5′ end of an oligonucleotide. Incertain embodiments a terminal group is a conjugate group. In certainembodiments, a terminal group comprises one or more terminal groupnucleosides.

As used herein, “conjugate” means an atom or group of atoms bound to anoligonucleotide or oligomeric compound. In general, conjugate groupsmodify one or more properties of the compound to which they areattached, including, but not limited to pharmacodynamic,pharmacokinetic, binding, absorption, cellular distribution, cellularuptake, charge and/or clearance properties.

As used herein, “conjugate linking group” means any atom or group ofatoms used to attach a conjugate to an oligonucleotide or oligomericcompound.

As used herein, “antisense compound” means a compound comprising orconsisting of an oligonucleotide at least a portion of which iscomplementary to a target nucleic acid to which it is capable ofhybridizing, resulting in at least one antisense activity.

As used herein, “antisense activity” means any detectable and/ormeasurable change attributable to the hybridization of an antisensecompound to its target nucleic acid.

As used herein, “detecting” or “measuring” means that a test or assayfor detecting or measuring is performed. Such detection and/or measuringmay result in a value of zero. Thus, if a test for detection ormeasuring results in a finding of no activity (activity of zero), thestep of detecting or measuring the activity has nevertheless beenperformed.

As used herein, “detectable and/or measureable activity” means ameasurable activity that is not zero.

As used herein, “essentially unchanged” means little or no change in aparticular parameter, particularly relative to another parameter whichchanges much more. In certain embodiments, a parameter is essentiallyunchanged when it changes less than 5%. In certain embodiments, aparameter is essentially unchanged if it changes less than two-foldwhile another parameter changes at least ten-fold. For example, incertain embodiments, an antisense activity is a change in the amount ofa target nucleic acid. In certain such embodiments, the amount of anon-target nucleic acid is essentially unchanged if it changes much lessthan the target nucleic acid does, but the change need not be zero.

As used herein, “expression” means the process by which a geneultimately results in a protein. Expression includes, but is not limitedto, transcription, post-transcriptional modification (e.g., splicing,polyadenlyation, addition of 5′-cap), and translation.

As used herein, “target nucleic acid” means a nucleic acid molecule towhich an antisense compound is intended to hybridize.

As used herein, “non-target nucleic acid” means a nucleic acid moleculeto which hybridization of an antisense compound is not intended ordesired. In certain embodiments, antisense compounds do hybridize to anon-target, due to homology between the target (intended) and non-target(un-intended).

As used herein, “mRNA” means an RNA molecule that encodes a protein.

As used herein, “pre-mRNA” means an RNA transcript that has not beenfully processed into mRNA. Pre-RNA includes one or more intron.

As used herein, “object RNA” means an RNA molecule other than a targetRNA, the amount, activity, splicing, and/or function of which ismodulated, either directly or indirectly, by a target nucleic acid. Incertain embodiments, a target nucleic acid modulates splicing of anobject RNA. In certain such embodiments, an antisense compound modulatesthe amount or activity of the target nucleic acid, resulting in a changein the splicing of an object RNA and ultimately resulting in a change inthe activity or function of the object RNA.

As used herein, “microRNA” means a naturally occurring, small,non-coding RNA that represses gene expression of at least one mRNA. Incertain embodiments, a microRNA represses gene expression by binding toa target site within a 3′ untranslated region of an mRNA. In certainembodiments, a microRNA has a nucleobase sequence as set forth inmiRBase, a database of published microRNA sequences found athttp://microrna.sanger.ac.uk/sequences/. In certain embodiments, amicroRNA has a nucleobase sequence as set forth in miRBase version 12.0released September 2008, which is herein incorporated by reference inits entirety.

As used herein, “microRNA mimic” means an oligomeric compound having asequence that is at least partially identical to that of a microRNA. Incertain embodiments, a microRNA mimic comprises the microRNA seed regionof a microRNA. In certain embodiments, a microRNA mimic modulatestranslation of more than one target nucleic acids. In certainembodiments, a microRNA mimic is double-stranded.

As used herein, “differentiating nucleobase” means a nucleobase thatdiffers between two nucleic acids. In certain instances, a target regionof a target nucleic acid differs by 1-4 nucleobases from a non-targetnucleic acid. Each of those differences is referred to as adifferentiating nucleobase. In certain instances, a differentiatingnucleobase is a single-nucleotide polymorphism.

As used herein, “target-selective nucleoside” means a nucleoside of anantisense compound that corresponds to a differentiating nucleobase of atarget nucleic acid.

As used herein, “allele” means one of a pair of copies of a geneexisting at a particular locus or marker on a specific chromosome, orone member of a pair of nucleobases existing at a particular locus ormarker on a specific chromosome, or one member of a pair of nucleobasesequences existing at a particular locus or marker on a specificchromosome. For a diploid organism or cell or for autosomal chromosomes,each allelic pair will normally occupy corresponding positions (loci) ona pair of homologous chromosomes, one inherited from the mother and oneinherited from the father. If these alleles are identical, the organismor cell is said to be “homozygous” for that allele; if they differ, theorganism or cell is said to be “heterozygous” for that allele.“Wild-type allele” refers to the genotype typically not associated withdisease or dysfunction of the gene product. “Mutant allele” refers tothe genotype associated with disease or dysfunction of the gene product.

As used herein, “allelic variant” means a particular identity of anallele, where more than one identity occurs. For example, an allelicvariant may refer to either the mutant allele or the wild-type allele.

As used herein, “single nucleotide polymorphism” or “SNP” means a singlenucleotide variation between the genomes of individuals of the samespecies. In some cases, a SNP may be a single nucleotide deletion orinsertion. In general, SNPs occur relatively frequently in genomes andthus contribute to genetic diversity. The location of a SNP is generallyflanked by highly conserved sequences. An individual may be homozygousor heterozygous for an allele at each SNP site.

As used herein, “single nucleotide polymorphism site” or “SNP site”refers to the nucleotides surrounding a SNP contained in a targetnucleic acid to which an antisense compound is targeted.

As used herein, “targeting” or “targeted to” means the association of anantisense compound to a particular target nucleic acid molecule or aparticular region of a target nucleic acid molecule. An antisensecompound targets a target nucleic acid if it is sufficientlycomplementary to the target nucleic acid to allow hybridization underphysiological conditions.

As used herein, “nucleobase complementarity” or “complementarity” whenin reference to nucleobases means a nucleobase that is capable of basepairing with another nucleobase. For example, in DNA, adenine (A) iscomplementary to thymine (T). For example, in RNA, adenine (A) iscomplementary to uracil (U). In certain embodiments, complementarynucleobase means a nucleobase of an antisense compound that is capableof base pairing with a nucleobase of its target nucleic acid. Forexample, if a nucleobase at a certain position of an antisense compoundis capable of hydrogen bonding with a nucleobase at a certain positionof a target nucleic acid, then the position of hydrogen bonding betweenthe oligonucleotide and the target nucleic acid is considered to becomplementary at that nucleobase pair. Nucleobases comprising certainmodifications may maintain the ability to pair with a counterpartnucleobase and thus, are still capable of nucleobase complementarity.

As used herein, “non-complementary” in reference to nucleobases means apair of nucleobases that do not form hydrogen bonds with one another.

As used herein, “complementary” in reference to oligomeric compounds(e.g., linked nucleosides, oligonucleotides, or nucleic acids) means thecapacity of such oligomeric compounds or regions thereof to hybridize toanother oligomeric compound or region thereof through nucleobasecomplementarity under stringent conditions. Complementary oligomericcompounds need not have nucleobase complementarity at each nucleoside.Rather, some mismatches are tolerated. In certain embodiments,complementary oligomeric compounds or regions are complementary at 70%of the nucleobases (70% complementary). In certain embodiments,complementary oligomeric compounds or regions are 80% complementary. Incertain embodiments, complementary oligomeric compounds or regions are90% complementary. In certain embodiments, complementary oligomericcompounds or regions are 95% complementary. In certain embodiments,complementary oligomeric compounds or regions are 100% complementary.

As used herein, “mismatch” means a nucleobase of a first oligomericcompound that is not capable of pairing with a nucleobase at acorresponding position of a second oligomeric compound, when the firstand second oligomeric compound are aligned. Either or both of the firstand second oligomeric compounds may be oligonucleotides.

As used herein, “hybridization” means the pairing of complementaryoligomeric compounds (e.g., an antisense compound and its target nucleicacid). While not limited to a particular mechanism, the most commonmechanism of pairing involves hydrogen bonding, which may beWatson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, betweencomplementary nucleobases.

As used herein, “specifically hybridizes” means the ability of anoligomeric compound to hybridize to one nucleic acid site with greateraffinity than it hybridizes to another nucleic acid site. In certainembodiments, an antisense oligonucleotide specifically hybridizes tomore than one target site.

As used herein, “fully complementary” in reference to an oligonucleotideor portion thereof means that each nucleobase of the oligonucleotide orportion thereof is capable of pairing with a nucleobase of acomplementary nucleic acid or contiguous portion thereof. Thus, a fullycomplementary region comprises no mismatches or unhybridized nucleobasesin either strand.

As used herein, “percent complementarity” means the percentage ofnucleobases of an oligomeric compound that are complementary to anequal-length portion of a target nucleic acid. Percent complementarityis calculated by dividing the number of nucleobases of the oligomericcompound that are complementary to nucleobases at correspondingpositions in the target nucleic acid by the total length of theoligomeric compound.

As used herein, “percent identity” means the number of nucleobases in afirst nucleic acid that are the same type (independent of chemicalmodification) as nucleobases at corresponding positions in a secondnucleic acid, divided by the total number of nucleobases in the firstnucleic acid.

As used herein, “modulation” means a change of amount or quality of amolecule, function, or activity when compared to the amount or qualityof a molecule, function, or activity prior to modulation. For example,modulation includes the change, either an increase (stimulation orinduction) or a decrease (inhibition or reduction) in gene expression.As a further example, modulation of expression can include a change insplice site selection of pre-mRNA processing, resulting in a change inthe absolute or relative amount of a particular splice-variant comparedto the amount in the absence of modulation.

As used herein, “modification motif” means a pattern of chemicalmodifications in an oligomeric compound or a region thereof. Motifs maybe defined by modifications at certain nucleosides and/or at certainlinking groups of an oligomeric compound.

As used herein, “nucleoside motif” means a pattern of nucleosidemodifications in an oligomeric compound or a region thereof. Thelinkages of such an oligomeric compound may be modified or unmodified.Unless otherwise indicated, motifs herein describing only nucleosidesare intended to be nucleoside motifs. Thus, in such instances, thelinkages are not limited.

As used herein, “sugar motif” means a pattern of sugar modifications inan oligomeric compound or a region thereof.

As used herein, “linkage motif” means a pattern of linkage modificationsin an oligomeric compound or region thereof. The nucleosides of such anoligomeric compound may be modified or unmodified. Unless otherwiseindicated, motifs herein describing only linkages are intended to belinkage motifs. Thus, in such instances, the nucleosides are notlimited.

As used herein, “nucleobase modification motif” means a pattern ofmodifications to nucleobases along an oligonucleotide. Unless otherwiseindicated, a nucleobase modification motif is independent of thenucleobase sequence.

As used herein, “sequence motif” means a pattern of nucleobases arrangedalong an oligonucleotide or portion thereof. Unless otherwise indicated,a sequence motif is independent of chemical modifications and thus mayhave any combination of chemical modifications, including no chemicalmodifications.

As used herein, “type of modification” in reference to a nucleoside or anucleoside of a “type” means the chemical modification of a nucleosideand includes modified and unmodified nucleosides. Accordingly, unlessotherwise indicated, a “nucleoside having a modification of a firsttype” may be an unmodified nucleoside.

As used herein, “differently modified” mean chemical modifications orchemical substituents that are different from one another, includingabsence of modifications. Thus, for example, a MOE nucleoside and anunmodified DNA nucleoside are “differently modified,” even though theDNA nucleoside is unmodified. Likewise, DNA and RNA are “differentlymodified,” even though both are naturally-occurring unmodifiednucleosides. Nucleosides that are the same but for comprising differentnucleobases are not differently modified. For example, a nucleosidecomprising a 2′-OMe modified sugar and an unmodified adenine nucleobaseand a nucleoside comprising a 2′-OMe modified sugar and an unmodifiedthymine nucleobase are not differently modified.

As used herein, “the same type of modifications” refers to modificationsthat are the same as one another, including absence of modifications.Thus, for example, two unmodified DNA nucleoside have “the same type ofmodification,” even though the DNA nucleoside is unmodified. Suchnucleosides having the same type modification may comprise differentnucleobases.

As used herein, “pharmaceutically acceptable carrier or diluent” meansany substance suitable for use in administering to an animal. In certainembodiments, a pharmaceutically acceptable carrier or diluent is sterilesaline. In certain embodiments, such sterile saline is pharmaceuticalgrade saline.

As used herein, “substituent” and “substituent group,” means an atom orgroup that replaces the atom or group of a named parent compound. Forexample a substituent of a modified nucleoside is any atom or group thatdiffers from the atom or group found in a naturally occurring nucleoside(e.g., a modified 2′-substuent is any atom or group at the 2′-positionof a nucleoside other than H or OH). Substituent groups can be protectedor unprotected. In certain embodiments, compounds of the presentinvention have substituents at one or at more than one position of theparent compound. Substituents may also be further substituted with othersubstituent groups and may be attached directly or via a linking groupsuch as an alkyl or hydrocarbyl group to a parent compound.

Likewise, as used herein, “substituent” in reference to a chemicalfunctional group means an atom or group of atoms differs from the atomor a group of atoms normally present in the named functional group. Incertain embodiments, a substituent replaces a hydrogen atom of thefunctional group (e.g., in certain embodiments, the substituent of asubstituted methyl group is an atom or group other than hydrogen whichreplaces one of the hydrogen atoms of an unsubstituted methyl group).Unless otherwise indicated, groups amenable for use as substituentsinclude without limitation, halogen, hydroxyl, alkyl, alkenyl, alkynyl,acyl (—C(O)R_(aa)), carboxyl (—C(O)O—R_(aa)), aliphatic groups,alicyclic groups, alkoxy, substituted oxy (—O—R_(aa)), aryl, aralkyl,heterocyclic radical, heteroaryl, heteroarylalkyl, amino(—N(R_(bb))(R_(cc))), imino(═NR_(bb)), amido (—C(O)N(R_(bb))(R_(cc)) or—N(R_(bb))C(O)R_(aa)), azido (—N₃), nitro (—NO₂), cyano (—CN), carbamido(—OC(O)N(R_(bb))(R_(cc)) or —N(R_(bb))C(O)OR_(aa)), ureido(—N(R_(bb))C(O)N(R_(bb))(R_(cc))), thioureido(—N(R_(bb))C(S)N(R_(bb))—(R_(cc))), guanidinyl(—N(R_(bb))C(═NR_(bb))N(R_(bb))(R_(cc))), amidinyl(—C(═NR_(bb))N(R_(bb))(R_(cc)) or —N(R_(bb))C(═NR_(bb))(R_(aa))), thiol(—SR_(bb)), sulfinyl (—S(O)R_(bb)), sulfonyl (—S(O)₂R_(bb)) andsulfonamidyl (—S(O)₂N(R_(bb))(R_(cc)) or —N(R_(bb))S—(O)₂R_(bb)).Wherein each R_(aa), R_(bb) and R_(cc) is, independently, H, anoptionally linked chemical functional group or a further substituentgroup with a preferred list including without limitation, alkyl,alkenyl, alkynyl, aliphatic, alkoxy, acyl, aryl, aralkyl, heteroaryl,alicyclic, heterocyclic and heteroarylalkyl. Selected substituentswithin the compounds described herein are present to a recursive degree.

As used herein, “alkyl,” as used herein, means a saturated straight orbranched hydrocarbon radical containing up to twenty four carbon atoms.Examples of alkyl groups include without limitation, methyl, ethyl,propyl, butyl, isopropyl, n-hexyl, octyl, decyl, dodecyl and the like.Alkyl groups typically include from 1 to about 24 carbon atoms, moretypically from 1 to about 12 carbon atoms (C₁-C₁₂ alkyl) with from 1 toabout 6 carbon atoms being more preferred.

As used herein, “alkenyl,” means a straight or branched hydrocarbonchain radical containing up to twenty four carbon atoms and having atleast one carbon-carbon double bond. Examples of alkenyl groups includewithout limitation, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl,dienes such as 1,3-butadiene and the like. Alkenyl groups typicallyinclude from 2 to about 24 carbon atoms, more typically from 2 to about12 carbon atoms with from 2 to about 6 carbon atoms being morepreferred. Alkenyl groups as used herein may optionally include one ormore further substituent groups.

As used herein, “alkynyl,” means a straight or branched hydrocarbonradical containing up to twenty four carbon atoms and having at leastone carbon-carbon triple bond. Examples of alkynyl groups include,without limitation, ethynyl, 1-propynyl, 1-butynyl, and the like.Alkynyl groups typically include from 2 to about 24 carbon atoms, moretypically from 2 to about 12 carbon atoms with from 2 to about 6 carbonatoms being more preferred. Alkynyl groups as used herein may optionallyinclude one or more further substituent groups.

As used herein, “acyl,” means a radical formed by removal of a hydroxylgroup from an organic acid and has the general Formula —C(O)—X where Xis typically aliphatic, alicyclic or aromatic. Examples includealiphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromaticsulfinyls, aliphatic sulfinyls, aromatic phosphates, aliphaticphosphates and the like. Acyl groups as used herein may optionallyinclude further substituent groups.

As used herein, “alicyclic” means a cyclic ring system wherein the ringis aliphatic. The ring system can comprise one or more rings wherein atleast one ring is aliphatic. Preferred alicyclics include rings havingfrom about 5 to about 9 carbon atoms in the ring. Alicyclic as usedherein may optionally include further substituent groups.

As used herein, “aliphatic” means a straight or branched hydrocarbonradical containing up to twenty four carbon atoms wherein the saturationbetween any two carbon atoms is a single, double or triple bond. Analiphatic group preferably contains from 1 to about 24 carbon atoms,more typically from 1 to about 12 carbon atoms with from 1 to about 6carbon atoms being more preferred. The straight or branched chain of analiphatic group may be interrupted with one or more heteroatoms thatinclude nitrogen, oxygen, sulfur and phosphorus. Such aliphatic groupsinterrupted by heteroatoms include without limitation, polyalkoxys, suchas polyalkylene glycols, polyamines, and polyimines. Aliphatic groups asused herein may optionally include further substituent groups.

As used herein, “alkoxy” means a radical formed between an alkyl groupand an oxygen atom wherein the oxygen atom is used to attach the alkoxygroup to a parent molecule. Examples of alkoxy groups include withoutlimitation, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy,tert-butoxy, n-pentoxy, neopentoxy, n-hexoxy and the like. Alkoxy groupsas used herein may optionally include further substituent groups.

As used herein, “aminoalkyl” means an amino substituted C₁-C₁₂ alkylradical. The alkyl portion of the radical forms a covalent bond with aparent molecule. The amino group can be located at any position and theaminoalkyl group can be substituted with a further substituent group atthe alkyl and/or amino portions.

As used herein, “aralkyl” and “arylalkyl” mean an aromatic group that iscovalently linked to a C₁-C₁₂ alkyl radical. The alkyl radical portionof the resulting aralkyl (or arylalkyl) group forms a covalent bond witha parent molecule. Examples include without limitation, benzyl,phenethyl and the like. Aralkyl groups as used herein may optionallyinclude further substituent groups attached to the alkyl, the aryl orboth groups that form the radical group.

As used herein, “aryl” and “aromatic” mean a mono- or polycycliccarbocyclic ring system radicals having one or more aromatic rings.Examples of aryl groups include without limitation, phenyl, naphthyl,tetrahydronaphthyl, indanyl, idenyl and the like. Preferred aryl ringsystems have from about 5 to about 20 carbon atoms in one or more rings.Aryl groups as used herein may optionally include further substituentgroups.

As used herein, “halo” and “halogen,” mean an atom selected fromfluorine, chlorine, bromine and iodine.

As used herein, “heteroaryl,” and “heteroaromatic,” mean a radicalcomprising a mono- or polycyclic aromatic ring, ring system or fusedring system wherein at least one of the rings is aromatic and includesone or more heteroatoms. Heteroaryl is also meant to include fused ringsystems including systems where one or more of the fused rings containno heteroatoms. Heteroaryl groups typically include one ring atomselected from sulfur, nitrogen or oxygen. Examples of heteroaryl groupsinclude without limitation, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl,pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl,oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl,benzimidazolyl, benzooxazolyl, quinoxalinyl and the like. Heteroarylradicals can be attached to a parent molecule directly or through alinking moiety such as an aliphatic group or hetero atom. Heteroarylgroups as used herein may optionally include further substituent groups.

As used herein, “huntingtin transcript” means a transcript transcribedfrom a huntingtin gene.

B. Oligomeric Compounds

In certain embodiments, the present invention provides oligomericcompounds. In certain embodiments, such oligomeric compounds compriseoligonucleotides optionally comprising one or more conjugate and/orterminal groups. In certain embodiments, an oligomeric compound consistsof an oligonucleotide. In certain embodiments, oligonucleotides compriseone or more chemical modifications. Such chemical modifications includemodifications of one or more nucleoside (including modifications to thesugar moiety and/or the nucleobase) and/or modifications to one or moreinternucleoside linkage.

a. Certain Modified Nucleosides

In certain embodiments, provided herein are oligomeric compoundscomprising or consisting of oligonuleotides comprising at least onemodified nucleoside. Such modified nucleosides comprise a modified sugarmoeity, a modified nucleobase, or both a modified sugar moiety and amodified nucleobase.

i. Certain Modified Sugar Moieties

In certain embodiments, compounds of the invention comprise one or moremodifed nucleosides comprising a modifed sugar moiety. Such compoundscomprising one or more sugar-modified nucleosides may have desirableproperties, such as enhanced nuclease stability or increased bindingaffinity with a target nucleic acid relative to an oligonucleotidecomprising only nucleosides comprising naturally occurring sugarmoieties. In certain embodiments, modified sugar moieties aresubstituted sugar moieties. In certain embodiments, modified sugarmoieties are sugar surrogates. Such sugar surogates may comprise one ormore substitutions corresponding to those of substituted sugar moieties.

In certain embodiments, modified sugar moieties are substituted sugarmoieties comprising one or more non-bridging sugar substituent,including but not limited to substituents at the 2′ and/or 5′ positions.Examples of sugar substituents suitable for the 2′-position, include,but are not limited to: 2′-F, 2′-OCH₃ (“OMe” or “O-methyl”), and2′-O(CH₂)₂OCH₃ (“MOE”). In certain embodiments, sugar substituents atthe 2′ position is selected from allyl, amino, azido, thio, O-allyl,O—C₁-C₁₀ alkyl, O—C₁-C₁₀ substituted alkyl; OCF₃, O(CH₂)₂SCH₃,O(CH₂)₂—O—N(Rm)(Rn), and O—CH₂—C(═O)—N(Rm)(Rn), where each Rm and Rn is,independently, H or substituted or unsubstituted C₁-C₁₀ alkyl. Examplesof sugar substituents at the 5′-position, include, but are not limitedto: 5′-methyl (R or S); 5′-vinyl, and 5′-methoxy. In certainembodiments, substituted sugars comprise more than one non-bridgingsugar substituent, for example, 2′-F-5′-methyl sugar moieties (see,e.g., PCT International Application WO 2008/101157, for additional 5′,2′-bis substituted sugar moieties and nucleosides).

Nucleosides comprising 2′-substituted sugar moieties are referred to as2′-substituted nucleosides. In certain embodiments, a 2′-substitutednucleoside comprises a 2′-substituent group selected from halo, allyl,amino, azido, SH, CN, OCN, CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, orN(R_(m))-alkenyl; O, S or N(R_(m))-alkynyl; O-alkylenyl-O-alkyl,alkynyl, alkaryl, aralkyl, O-alkaryl, O-aralkyl, O(CH₂)₂SCH₃,O—(CH₂)₂—O—N(R_(m))(R_(n)) or O—CH₂—C(═O)—N(R_(m))(R_(n)), where eachR_(m) and R_(n) is, independently, H, an amino protecting group orsubstituted or unsubstituted C₁-C₁₀ alkyl. These 2′-substituent groupscan be further substituted with one or more substituent groupsindependently selected from hydroxyl, amino, alkoxy, carboxy, benzyl,phenyl, nitro (NO₂), thiol, thioalkoxy (S-alkyl), halogen, alkyl, aryl,alkenyl and alkynyl.

In certain embodiments, a 2′-substituted nucleoside comprises a2′-substituent group selected from F, NH₂, N₃, OCF₃, O—CH₃, O(CH₂)₃NH₂,CH₂—CH═CH₂, O—CH₂—CH═CH₂, OCH₂CH₂OCH₃, O(CH₂)₂SCH₃,O—(CH₂)₂—O—N(R_(m))(R_(n)), O(CH₂)₂O(CH₂)₂N(CH₃)₂, and N-substitutedacetamide (O—CH₂—C(═O)—N(R_(m))(R_(n)) where each R_(m) and R_(n) is,independently, H, an amino protecting group or substituted orunsubstituted C₁-C₁₀ alkyl.

In certain embodiments, a 2′-substituted nucleoside comprises a sugarmoiety comprising a 2′-substituent group selected from F, OCF₃, O—CH₃,OCH₂CH₂OCH₃, O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(CH₃)₂, —O(CH₂)₂O(CH₂)₂N(CH₃)₂,and O—CH₂—C(═O)—N(H)CH₃.

In certain embodiments, a 2′-substituted nucleoside comprises a sugarmoiety comprising a 2′-substituent group selected from F, O—CH₃, andOCH₂CH₂OCH₃.

Certain modifed sugar moieties comprise a bridging sugar substituentthat forms a second ring resulting in a bicyclic sugar moiety. Incertain such embodiments, the bicyclic sugar moiety comprises a bridgebetween the 4′ and the 2′ furanose ring atoms. Examples of such 4′ to 2′sugar substituents, include, but are not limited to:—[C(R_(a))(R_(b))]_(n)—, —[C(R_(a))(R_(b))]_(n)—O—,—C(R_(a)R_(b))—N(R)—O— or, —C(R_(a)R_(b))—O—N(R)—; 4′- CH₂-2′,4′-(CH₂)₂-2′, 4′-(CH₂)₃-2′, 4′-(CH₂)—O-2′ (LNA); 4′-(CH₂)—S-2;4′-(CH₂)₂—O-2′ (ENA); 4′-CH(CH₃)—O-2′ (cEt) and 4′-CH(CH₂OCH₃)—O-2′, andanalogs thereof (see, e.g., U.S. Pat. No. 7,399,845, issued on Jul. 15,2008); 4′-C(CH₃)(CH₃)—O-2′ and analogs thereof, (see, e.g.,WO2009/006478, published Jan. 8, 2009); 4′-CH₂—N(OCH₃)-2′ and analogsthereof (see, e.g., WO2008/150729, published Dec. 11, 2008);4′-CH₂—O—N(CH₃)-2′ (see, e.g., US2004/0171570, published Sep. 2, 2004);4′-CH₂—O—N(R)-2′, and 4′-CH₂—N(R)—O-2′-, wherein each R is,independently, H, a protecting group, or C₁-C₁₂ alkyl; 4′-CH₂—N(R)—O-2′,wherein R is H, C₁-C₁₂ alkyl, or a protecting group (see, U.S. Pat. No.7,427,672, issued on Sep. 23, 2008); 4′-CH₂—C(H)(CH₃)-2′ (see, e.g.,Chattopadhyaya, et al., J. Org. Chem., 2009, 74, 118-134); and4′-CH₂—C(═CH₂)-2′ and analogs thereof (see, published PCT InternationalApplication WO 2008/154401, published on Dec. 8, 2008).

In certain embodiments, such 4′ to 2′ bridges independently comprisefrom 1 to 4 linked groups independently selected from—[C(R_(a))(R_(b))]_(n)—, —C(R_(a))═C(R_(b))—, —C(R_(a))═N—,—C(═NR_(a))—, —C(═O)—, —C(═S)—, —O—, —Si(R_(a))₂—, —S(═O)_(x)—, and—N(R_(a))—;

wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_(a) and R_(b) is, independently, H, a protecting group, hydroxyl,C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substitutedC₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl,substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycleradical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical,substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃,COOJ₁, acyl (C(═O)—H), substituted acyl, CN, sulfonyl (S(═O)₂-J₁), orsulfoxyl (S(═O)-J₁); and

each J₁ and J₂ is, independently, H, C₁-C₁₂ alkyl, substituted C₁-C₁₂alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl,substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, acyl(C(═O)—H), substituted acyl, a heterocycle radical, a substitutedheterocycle radical, C₁-C₁₂ aminoalkyl, substituted C₁-C₁₂ aminoalkyl,or a protecting group.

Nucleosides comprising bicyclic sugar moieties are referred to asbicyclic nucleosides or BNAs. Bicyclic nucleosides include, but are notlimited to, (A) α-L-Methyleneoxy (4′-CH₂—O-2′) BNA, (B) β-D-Methyleneoxy(4′-CH₂—O-2′) BNA (also referred to as locked nucleic acid or LNA), (C)Ethyleneoxy (4′-(CH₂)₂—O-2′) BNA, (D) Aminooxy (4′-CH₂—O—N(R)-2′) BNA,(E) Oxyamino (4′-CH₂—N(R)—O-2′) BNA, (F) Methyl(methyleneoxy)(4′-CH(CH₃)—O-2′) BNA (also referred to as constrained ethyl or cEt),(G) methylene-thio (4′-CH₂—S-2′) BNA, (H) methylene-amino(4′-CH₂—N(R)-2′) BNA, (I) methyl carbocyclic (4′-CH₂—CH(CH₃)-2′) BNA,(J) propylene carbocyclic (4′-(CH₂)3-2′) BNA, and (K) Ethylene(methoxy)(4′-(CH(CH₂OMe)-O-2′) BNA (also referred to as constrained MOE or cMOE)as depicted below.

wherein Bx is a nucleobase moiety and R is, independently, H, aprotecting group, or C₁-C₁₂ alkyl.

Additional bicyclic sugar moieties are known in the art, for example:Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al.,Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad.Sci. U.S.A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem.Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63,10035-10039; Srivastava et al., J. Am. Chem. Soc., 129(26) 8362-8379(Jul. 4, 2007); Elayadi et al., Curr. Opinion Invens. Drugs, 2001, 2,558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; Orum et al., Curr.Opinion Mol. Ther., 2001, 3, 239-243; U.S. Pat. Nos. 7,053,207,6,268,490, 6,770,748, 6,794,499, 7,034,133, 6,525,191, 6,670,461, and7,399,845; WO 2004/106356, WO 1994/14226, WO 2005/021570, and WO2007/134181; U.S. Patent Publication Nos. US2004/0171570,US2007/0287831, and US2008/0039618; U.S. patent Ser. Nos. 12/129,154,60/989,574, 61/026,995, 61/026,998, 61/056,564, 61/086,231, 61/097,787,and 61/099,844; and PCT International Applications Nos.PCT/US2008/064591, PCT/US2008/066154, and PCT/US2008/068922.

In certain embodiments, bicyclic sugar moieties and nucleosidesincorporating such bicyclic sugar moieties are further defined byisomeric configuration. For example, a nucleoside comprising a 4′-2′methylene-oxy bridge, may be in the α-L configuration or in the β-Dconfiguration. Previously, α-L-methyleneoxy (4′-CH₂—O-2′) bicyclicnucleosides have been incorporated into antisense oligonucleotides thatshowed antisense activity (Frieden et al., Nucleic Acids Research, 2003,21, 6365-6372).

In certain embodiments, substituted sugar moieties comprise one or morenon-bridging sugar substituent and one or more bridging sugarsubstituent (e.g., 5′-substituted and 4′-2′ bridged sugars). (see, PCTInternational Application WO 2007/134181, published on Nov. 22, 2007,wherein LNA is substituted with, for example, a 5′-methyl or a 5′-vinylgroup).

In certain embodiments, modified sugar moieties are sugar surrogates. Incertain such embodiments, the oxygen atom of the naturally occuringsugar is substituted, e.g., with a sulfer, carbon or nitrogen atom. Incertain such embodiments, such modified sugar moiety also comprisesbridging and/or non-bridging substituents as described above. Forexample, certain sugar surogates comprise a 4′-sulfer atom and asubstitution at the 2′-position (see, e.g., published U.S. PatentApplication US2005/0130923, published on Jun. 16, 2005) and/or the 5′position. By way of additional example, carbocyclic bicyclic nucleosideshaving a 4′-2′ bridge have been described (see, e.g., Freier et al.,Nucleic Acids Research, 1997, 25(22), 4429-4443 and Albaek et al., J.Org. Chem., 2006, 71, 7731-7740).

In certain embodiments, sugar surrogates comprise rings having otherthan 5-atoms. For example, in certain embodiments, a sugar surrogatecomprises a six-membered tetrahydropyran. Such tetrahydropyrans may befurther modified or substituted. Nucleosides comprising such modifiedtetrahydropyrans include, but are not limited to, hexitol nucleic acid(HNA), anitol nucleic acid (ANA), manitol nucleic acid (MNA) (seeLeumann, C J. Bioorg. & Med. Chem. (2002) 10:841-854), fluoro HNA(F-HNA), and those compounds having Formula VII:

wherein independently for each of said at least one tetrahydropyrannucleoside analog of Formula VII:

Bx is a nucleobase moiety;

T₃ and T₄ are each, independently, an internucleoside linking grouplinking the tetrahydropyran nucleoside analog to the antisense compoundor one of T₃ and T₄ is an internucleoside linking group linking thetetrahydropyran nucleoside analog to the antisense compound and theother of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugategroup, or a 5′ or 3′-terminal group;

q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each, independently, H, C₁-C₆ alkyl,substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆alkynyl, or substituted C₂-C₆ alkynyl; and

each of R₁ and R₂ is independently selected from among: hydrogen,halogen, substituted or unsubstituted alkoxy, NJ₁J₂, SJ₁, N₃, OC(═X)J₁,OC(═X)NJ₁J₂, NJ₃C(═X)NJ₁J₂, and CN, wherein X is O, S or NJ₁, and eachJ₁, J₂, and J₃ is, independently, H or C₁-C₆ alkyl.

In certain embodiments, the modified THP nucleosides of Formula VII areprovided wherein q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each H. In certainembodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is other thanH. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇is methyl. In certain embodiments, THP nucleosides of Formula VII areprovided wherein one of R₁ and R₂ is F. In certain embodiments, R₁ isfluoro and R₂ is H, R₁ is methoxy and R₂ is H, and R₁ is methoxyethoxyand R₂ is H.

Many other bicyclo and tricyclo sugar surrogate ring systems are alsoknown in the art that can be used to modify nucleosides forincorporation into antisense compounds (see, e.g., review article:Leumann, J. C, Bioorganic & Medicinal Chemistry, 2002, 10, 841-854).

Combinations of modifications are also provided without limitation, suchas 2′-F-5′-methyl substituted nucleosides (see PCT InternationalApplication WO 2008/101157 Published on Aug. 21, 2008 for otherdisclosed 5′, 2′-bis substituted nucleosides) and replacement of theribosyl ring oxygen atom with S and further substitution at the2′-position (see published U.S. Patent Application US2005-0130923,published on Jun. 16, 2005) or alternatively 5′-substitution of abicyclic nucleic acid (see PCT International Application WO 2007/134181,published on Nov. 22, 2007 wherein a 4′-CH₂—O-2′ bicyclic nucleoside isfurther substituted at the 5′ position with a 5′-methyl or a 5′-vinylgroup). The synthesis and preparation of carbocyclic bicyclicnucleosides along with their oligomerization and biochemical studieshave also been described (see, e.g., Srivastava et al., J. Am. Chem.Soc. 2007, 129(26), 8362-8379).

In certain embodiments, the present invention provides oligonucleotidescomprising modified nucleosides. Those modified nucleotides may includemodified sugars, modified nucleobases, and/or modified linkages. Thespecific modifications are selected such that the resultingoligonucleotides possess desirable characteristics. In certainembodiments, oligonucleotides comprise one or more RNA-like nucleosides.In certain embodiments, oligonucleotides comprise one or more DNA-likenucleotides.

ii. Certain Modified Nucleobases

In certain embodiments, nucleosides of the present invention compriseone or more unmodified nucleobases. In certain embodiments, nucleosidesof the present invention comprise one or more modifed nucleobases.

In certain embodiments, modified nucleobases are selected from:universal bases, hydrophobic bases, promiscuous bases, size-expandedbases, and fluorinated bases as defined herein. 5-substitutedpyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines,including 2-aminopropyladenine, 5-propynyluracil; 5-propynylcytosine;5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine,6-methyl and other alkyl derivatives of adenine and guanine, 2-propyland other alkyl derivatives of adenine and guanine, 2-thiouracil,2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl(—C≡C—CH₃) uracil and cytosine and other alkynyl derivatives ofpyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil(pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl,8-hydroxyl and other 8-substituted adenines and guanines, 5-haloparticularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracilsand cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine,2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and7-deazaadenine, 3-deazaguanine and 3-deazaadenine, universal bases,hydrophobic bases, promiscuous bases, size-expanded bases, andfluorinated bases as defined herein. Further modified nucleobasesinclude tricyclic pyrimidines such as phenoxazinecytidine([5,4-b][1,4]benzoxazin-2(3H)-one), phenothiazine cytidine(1H-pyrimido[5,4-b][1,4]benzothiazin-2(3H)-one), G-clamps such as asubstituted phenoxazine cytidine (e.g.9-(2-aminoethoxy)-H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one), carbazolecytidine (2H-pyrimido[4,5-b]indol-2-one), pyridoindole cytidine(H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified nucleobasesmay also include those in which the purine or pyrimidine base isreplaced with other heterocycles, for example 7-deaza-adenine,7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobasesinclude those disclosed in U.S. Pat. No. 3,687,808, those disclosed inThe Concise Encyclopedia Of Polymer Science And Engineering, Kroschwitz,J. I., Ed., John Wiley & Sons, 1990, 858-859; those disclosed byEnglisch et al., Angewandte Chemie, International Edition, 1991, 30,613; and those disclosed by Sanghvi, Y. S., Chapter 15, AntisenseResearch and Applications, Crooke, S. T. and Lebleu, B., Eds., CRCPress, 1993, 273-288.

Representative United States patents that teach the preparation ofcertain of the above noted modified nucleobases as well as othermodified nucleobases include without limitation, U.S. Pat. Nos.3,687,808; 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066;5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711;5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985;5,681,941; 5,750,692; 5,763,588; 5,830,653 and 6,005,096, certain ofwhich are commonly owned with the instant application, and each of whichis herein incorporated by reference in its entirety.

b. Certain Internucleoside Linkages

In certain embodiments, nucleosides may be linked together using anyinternucleoside linkage to form oligonucleotides. The two main classesof internucleoside linking groups are defined by the presence or absenceof a phosphorus atom. Representative phosphorus containinginternucleoside linkages include, but are not limited to,phosphodiesters (P═O), phosphotriesters, methylphosphonates,phosphoramidate, and phosphorothioates (P═S). Representativenon-phosphorus containing internucleoside linking groups include, butare not limited to, methylenemethylimino (—CH₂—N(CH₃)—O—CH₂—),thiodiester (—O—C(O)—S—), thionocarbamate (—O—C(O)(NH)—S—); siloxane(—O—Si(H)₂—O—); and N,N′-dimethylhydrazine (—CH₂—N(CH₃)—N(CH₃)—).Modified linkages, compared to natural phosphodiester linkages, can beused to alter, typically increase, nuclease resistance of theoligonucleotide. In certain embodiments, internucleoside linkages havinga chiral atom can be prepared as a racemic mixture, or as separateenantiomers. Representative chiral linkages include, but are not limitedto, alkylphosphonates and phosphorothioates. Methods of preparation ofphosphorous-containing and non-phosphorous-containing internucleosidelinkages are well known to those skilled in the art.

The oligonucleotides described herein contain one or more asymmetriccenters and thus give rise to enantiomers, diastereomers, and otherstereoisomeric configurations that may be defined, in terms of absolutestereochemistry, as (R) or (S), α or β such as for sugar anomers, or as(D) or (L) such as for amino acids etc. Included in the antisensecompounds provided herein are all such possible isomers, as well astheir racemic and optically pure forms.

Neutral internucleoside linkages include without limitation,phosphotriesters, methylphosphonates, MMI (3′-CH₂—N(CH₃)—O-5′), amide-3(3′-CH₂—C(═O)—N(H)-5′), amide-4 (3′-CH₂—N(H)—C(═O)-5′), formacetal(3′-O—CH₂—O-5′), and thioformacetal (3′-S—CH₂—O-5′). Further neutralinternucleoside linkages include nonionic linkages comprising siloxane(dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonateester and amides (See for example: Carbohydrate Modifications inAntisense Research; Y. S. Sanghvi and P. D. Cook, Eds., ACS SymposiumSeries 580; Chapters 3 and 4, 40-65). Further neutral internucleosidelinkages include nonionic linkages comprising mixed N, O, S and CH₂component parts.

i. 3′-Endo Modifications

In one aspect of the present disclosure, oligomeric compounds includenucleosides synthetically modified to induce a 3′-endo sugarconformation. A nucleoside can incorporate synthetic modifications ofthe heterocyclic base moiety, the sugar moiety or both to induce adesired 3′-endo sugar conformation. These modified nucleosides are usedto mimic RNA like nucleosides so that particular properties of anoligomeric compound can be enhanced while maintaining the desirable3′-endo conformational geometry. There is an apparent preference for anRNA type duplex (A form helix, predominantly 3′-endo) as a requirementof RNA interference which is supported in part by the fact that duplexescomposed of 2′-deoxy-2′-F-nucleosides appear efficient in triggeringRNAi response in the C. elegans system. Properties that are enhanced byusing more stable 3′-endo nucleosides include but aren't limited tomodulation of pharmacokinetic properties through modification of proteinbinding, protein off-rate, absorption and clearance; modulation ofnuclease stability as well as chemical stability; modulation of thebinding affinity and specificity of the oligomer (affinity andspecificity for enzymes as well as for complementary sequences); andincreasing efficacy of RNA cleavage. The present invention providesoligomeric compounds having one or more nucleosides modified in such away as to favor a C3′-endo type conformation.

Nucleoside conformation is influenced by various factors includingsubstitution at the 2′, 3′ or 4′-positions of the pentofuranosyl sugar.Electronegative substituents generally prefer the axial positions, whilesterically demanding substituents generally prefer the equatorialpositions (Principles of Nucleic Acid Structure, Wolfgang Sanger, 1984,Springer-Verlag.) Modification of the 2′ position to favor the 3′-endoconformation can be achieved while maintaining the 2′-OH as arecognition element, as exemplified in Example 35, below (Gallo et al.,Tetrahedron (2001), 57, 5707-5713. Harry-O'kuru et al., J. Org. Chem.,(1997), 62(6), 1754-1759 and Tang et al., J. Org. Chem. (1999), 64,747-754.) Alternatively, preference for the 3′-endo conformation can beachieved by deletion of the 2′-OH as exemplified by2′deoxy-2′F-nucleosides (Kawasaki et al., J. Med. Chem. (1993), 36,831-841), which adopts the 3′-endo conformation positioning theelectronegative fluorine atom in the axial position. Other modificationsof the ribose ring, for example substitution at the 4′-position to give4′-F modified nucleosides (Guillerm et al., Bioorganic and MedicinalChemistry Letters (1995), 5, 1455-1460 and Owen et al., J. Org. Chem.(1976), 41, 3010-3017), or for example modification to yieldmethanocarba nucleoside analogs (Jacobson et al., J. Med. Chem. Lett.(2000), 43, 2196-2203 and Lee et al., Bioorganic and Medicinal ChemistryLetters (2001), 11, 1333-1337) also induce preference for the 3′-endoconformation. Some modifications actually lock the conformationalgeometry by formation of a bicyclic sugar moiety e.g. locked nucleicacid (LNA, Singh et al, Chem. Commun. (1998), 4, 455-456), and ethylenebridged nucleic acids (ENA, Morita et al, Bioorganic & MedicinalChemistry Letters (2002), 12, 73-76.)

c. Certain Motifs

In certain embodiments, oligomeric compounds comprise or consist ofoligonucleotides. In certain embodiments, such oligonucleotides compriseone or more chemical modification. In certain embodiments, chemicallymodified oligonucleotides comprise one or more modified sugars. Incertain embodiments, chemically modified oligonucleotides comprise oneor more modified nucleobases. In certain embodiments, chemicallymodified oligonucleotides comprise one or more modified internucleosidelinkages. In certain embodiments, the chemical modifications (sugarmodifications, nucleobase modifications, and/or linkage modifications)define a pattern or motif. In certain embodiments, the patterns ofchemical modifications of sugar moieties, internucleoside linkages, andnucleobases are each independent of one another. Thus, anoligonucleotide may be described by its sugar modification motif,internucleoside linkage motif and/or nucleobase modification motif (asused herein, nucleobase modification motif describes the chemicalmodifications to the nucleobases independent of the sequence ofnucleobases).

i. Certain Sugar Motifs

In certain embodiments, oligonucleotides comprise one or more type ofmodified sugar moieties and/or naturally occurring sugar moietiesarranged along an oligonucleotide or region thereof in a defined patternor sugar motif. Such sugar motifs include but are not limited to any ofthe sugar modifications discussed herein.

In certain embodiments, the oligonucleotides comprise or consist of aregion having a gapmer sugar motif, which comprises two external regionsor “wings” and a central or internal region or “gap.” The three regionsof a gapmer sugar motif (the 5′-wing, the gap, and the 3′-wing) form acontiguous sequence of nucleosides wherein at least some of the sugarmoieties of the nucleosides of each of the wings differ from at leastsome of the sugar moieties of the nucleosides of the gap. Specifically,at least the sugar moieties of the nucleosides of each wing that areclosest to the gap (the 3′-most nucleoside of the 5′-wing and the5′-most nucleoside of the 3′-wing) differ from the sugar moiety of theneighboring gap nucleosides, thus defining the boundary between thewings and the gap. In certain embodiments, the sugar moieties within thegap are the same as one another. In certain embodiments, the gapincludes one or more nucleoside having a sugar moiety that differs fromthe sugar moiety of one or more other nucleosides of the gap. In certainembodiments, the sugar motifs of the two wings are the same as oneanother (symmetric sugar gapmer). In certain embodiments, the sugarmotifs of the 5′-wing differs from the sugar motif of the 3′-wing(asymmetric sugar gapmer).

ii. Certain Nucleobase Modification Motifs

In certain embodiments, oligonucleotides comprise chemical modificationsto nucleobases arranged along the oligonucleotide or region thereof in adefined pattern or nucleobases modification motif. In certainembodiments, each nucleobase is modified. In certain embodiments, noneof the nucleobases is chemically modified.

In certain embodiments, oligonucleotides comprise a block of modifiednucleobases. In certain such embodiments, the block is at the 3′-end ofthe oligonucleotide. In certain embodiments the block is within 3nucleotides of the 3′-end of the oligonucleotide. In certain suchembodiments, the block is at the 5′-end of the oligonucleotide. Incertain embodiments the block is within 3 nucleotides of the 5′-end ofthe oligonucleotide.

In certain embodiments, nucleobase modifications are a function of thenatural base at a particular position of an oligonucleotide. Forexample, in certain embodiments each purine or each pyrimidine in anoligonucleotide is modified. In certain embodiments, each adenine ismodified. In certain embodiments, each guanine is modified. In certainembodiments, each thymine is modified. In certain embodiments, eachcytosine is modified. In certain embodiments, each uracil is modified.

In certain embodiments, oligonucleotides comprise one or morenucleosides comprising a modified nucleobase. In certain embodiments,oligonucleotides having a gapmer sugar motif comprise a nucleosidecomprising a modified nucleobase. In certain such embodiments, onenucleoside comprising a modified nucleobases is in the central gap of anoligonucleotide having a gapmer sugar motif. In certain embodiments, thesugar is an unmodified 2′deoxynucleoside. In certain embodiments, themodified nucleobase is selected from: a 2-thio pyrimidine and a5-propyne pyrimidine

In certain embodiments, some, all, or none of the cytosine moieties inan oligonucleotide are 5-methyl cytosine moieties. Herein, 5-methylcytosine is not a “modified nucleobase.” Accordingly, unless otherwiseindicated, unmodified nucleobases include both cytosine residues havinga 5-methyl and those lacking a 5 methyl. In certain embodiments, themethylation state of all or some cytosine nucleobases is specified.

iii. Certain Nucleoside Motifs

In certain embodiments, oligonucleotides comprise nucleosides comprisingmodified sugar moieties and/or nucleosides comprising modifiednucleobases. Such motifs can be described by their sugar motif and theirnucleobase motif separately or by their nucleoside motif, which providespositions or patterns of modified nucleosides (whether modified sugar,nucleobase, or both sugar and nucleobase) in an oligonucleotide.

In certain embodiments, the oligonucleotides comprise or consist of aregion having a gapmer nucleoside motif, which comprises two externalregions or “wings” and a central or internal region or “gap.” The threeregions of a gapmer nucleoside motif (the 5′-wing, the gap, and the3′-wing) form a contiguous sequence of nucleosides wherein at least someof the sugar moieties and/or nucleobases of the nucleosides of each ofthe wings differ from at least some of the sugar moieties and/ornucleobase of the nucleosides of the gap. Specifically, at least thenucleosides of each wing that are closest to the gap (the 3′-mostnucleoside of the 5′-wing and the 5′-most nucleoside of the 3′-wing)differ from the neighboring gap nucleosides, thus defining the boundarybetween the wings and the gap. In certain embodiments, the nucleosideswithin the gap are the same as one another. In certain embodiments, thegap includes one or more nucleoside that differs from one or more othernucleosides of the gap. In certain embodiments, the nucleoside motifs ofthe two wings are the same as one another (symmetric gapmer). In certainembodiments, the nucleoside motifs of the 5′-wing differs from thenucleoside motif of the 3′-wing (asymmetric gapmer).

iv. Certain 5′-Wings

In certain embodiments, the 5′-wing of a gapmer consists of 1 to 6linked nucleosides. In certain embodiments, the 5′-wing of a gapmerconsists of 1 to 5 linked nucleosides. In certain embodiments, the5′-wing of a gapmer consists of 2 to 5 linked nucleosides. In certainembodiments, the 5′-wing of a gapmer consists of 3 to 5 linkednucleosides. In certain embodiments, the 5′-wing of a gapmer consists of4 or 5 linked nucleosides. In certain embodiments, the 5′-wing of agapmer consists of 1 to 4 linked nucleosides. In certain embodiments,the 5′-wing of a gapmer consists of 1 to 3 linked nucleosides. Incertain embodiments, the 5′-wing of a gapmer consists of 1 or 2 linkednucleosides. In certain embodiments, the 5′-wing of a gapmer consists of2 to 4 linked nucleosides. In certain embodiments, the 5′-wing of agapmer consists of 2 or 3 linked nucleosides. In certain embodiments,the 5′-wing of a gapmer consists of 3 or 4 linked nucleosides. Incertain embodiments, the 5′-wing of a gapmer consists of 1 nucleoside.In certain embodiments, the 5′-wing of a gapmer consists of 2 linkednucleosides. In certain embodiments, the 5′-wing of a gapmer consists of3 linked nucleosides. In certain embodiments, the 5′-wing of a gapmerconsists of 4 linked nucleosides. In certain embodiments, the 5′-wing ofa gapmer consists of 5 linked nucleosides. In certain embodiments, the5′-wing of a gapmer consists of 6 linked nucleosides.

In certain embodiments, the 5′-wing of a gapmer comprises at least onebicyclic nucleoside. In certain embodiments, the 5′-wing of a gapmercomprises at least two bicyclic nucleosides. In certain embodiments, the5′-wing of a gapmer comprises at least three bicyclic nucleosides. Incertain embodiments, the 5′-wing of a gapmer comprises at least fourbicyclic nucleosides. In certain embodiments, the 5′-wing of a gapmercomprises at least one constrained ethyl nucleoside. In certainembodiments, the 5′-wing of a gapmer comprises at least one LNAnucleoside. In certain embodiments, each nucleoside of the 5′-wing of agapmer is a bicyclic nucleoside. In certain embodiments, each nucleosideof the 5′-wing of a gapmer is a constrained ethyl nucleoside. In certainembodiments, each nucleoside of the 5′-wing of a gapmer is a LNAnucleoside.

In certain embodiments, the 5′-wing of a gapmer comprises at least onenon-bicyclic modified nucleoside. In certain embodiments, the 5′-wing ofa gapmer comprises at least one 2′-substituted nucleoside. In certainembodiments, the 5′-wing of a gapmer comprises at least one 2′-MOEnucleoside. In certain embodiments, the 5′-wing of a gapmer comprises atleast one 2′-OMe nucleoside. In certain embodiments, each nucleoside ofthe 5′-wing of a gapmer is a non-bicyclic modified nucleoside. Incertain embodiments, each nucleoside of the 5′-wing of a gapmer is a2′-substituted nucleoside. In certain embodiments, each nucleoside ofthe 5′-wing of a gapmer is a 2′-MOE nucleoside. In certain embodiments,each nucleoside of the 5′-wing of a gapmer is a 2′-OMe nucleoside.

In certain embodiments, the 5′-wing of a gapmer comprises at least one2′-deoxynucleoside. In certain embodiments, each nucleoside of the5′-wing of a gapmer is a 2′-deoxynucleoside. In a certain embodiments,the 5′-wing of a gapmer comprises at least one ribonucleoside. Incertain embodiments, each nucleoside of the 5′-wing of a gapmer is aribonucleoside. In certain embodiments, one, more than one, or each ofthe nucleosides of the 5′-wing is an RNA-like nucleoside.

In certain embodiments, the 5′-wing of a gapmer comprises at least onebicyclic nucleoside and at least one non-bicyclic modified nucleoside.In certain embodiments, the 5′-wing of a gapmer comprises at least onebicyclic nucleoside and at least one 2′-substituted nucleoside. Incertain embodiments, the 5′-wing of a gapmer comprises at least onebicyclic nucleoside and at least one 2′-MOE nucleoside. In certainembodiments, the 5′-wing of a gapmer comprises at least one bicyclicnucleoside and at least one 2′-OMe nucleoside. In certain embodiments,the 5′-wing of a gapmer comprises at least one bicyclic nucleoside andat least one 2′-deoxynucleoside.

In certain embodiments, the 5′-wing of a gapmer comprises at least oneconstrained ethyl nucleoside and at least one non-bicyclic modifiednucleoside. In certain embodiments, the 5′-wing of a gapmer comprises atleast one constrained ethyl nucleoside and at least one 2′-substitutednucleoside. In certain embodiments, the 5′-wing of a gapmer comprises atleast one constrained ethyl nucleoside and at least one 2′-MOEnucleoside. In certain embodiments, the 5′-wing of a gapmer comprises atleast one constrained ethyl nucleoside and at least one 2′-OMenucleoside. In certain embodiments, the 5′-wing of a gapmer comprises atleast one constrained ethyl nucleoside and at least one2′-deoxynucleoside.

In certain embodiments, the 5′-wing of a gapmer has a nucleoside motifselected from among the following: ADDA; ABDAA; ABBA; ABB; ABAA; AABAA;AAABAA; AAAABAA; AAAAABAA; AAABAA; AABAA; ABAB; ABADB; ABADDB; AAABB;AAAAA; ABBDC; ABDDC; ABBDCC; ABBDDC; ABBDCC; ABBC; AA; AAA; AAAA; AAAAB;AAAAAAA; AAAAAAAA; ABBB; AB; ABAB; AAAAB; AABBB; AAAAB; and AABBB,wherein each A is a modified nucleoside of a first type, each B is amodified nucleoside of a second type, each C is a modified nucleoside ofa third type, and each D is an unmodified deoxynucleoside.

In certain embodiments, the 5′-wing of a gapmer has a nucleoside motifselected from among the following: AB, ABB, AAA, BBB, BBBAA, AAB, BAA,BBAA, AABB, AAAB, ABBW, ABBWW, ABBB, ABBBB, ABAB, ABABAB, ABABBB,ABABAA, AAABB, AAAABB, AABB, AAAAB, AABBB, ABBBB, BBBBB, AAABW, AAAAA,BBBBAA, and AAABW; wherein each A is a modified nucleoside of a firsttype, each B is a modified nucleoside of a second type, and each W is amodified nucleoside of either the first type, the second type or a thirdtype.

In certain embodiments, the 5′-wing of a gapmer has a nucleoside motifselected from among the following: ABB; ABAA; AABAA; AAABAA; ABAB;ABADB; AAABB; AAAAA; AA; AAA; AAAA; AAAAB; ABBB; AB; and ABAB; whereineach A is a modified nucleoside of a first type, each B is a modifiednucleoside of a second type, and each W is a modified nucleoside ofeither the first type, the second type or a third type.

In certain embodiments, an oligonucleotide comprises any 5′-wing motifprovided herein. In certain such embodiments, the oligonucleotide is a5′-hemimer (does not comprise a 3′-wing). In certain embodiments, suchan oligonucleotide is a gapmer. In certain such embodiments, the 3′-wingof the gapmer may comprise any nucleoside motif.

In certain embodiments, the 5′-wing of a gapmer has a sugar motifselected from among those listed in the following non-limiting tables:

TABLE 1 Certain 5′-Wing Sugar Motifs Certain 5′-Wing Sugar Motifs AAAAAABCBB BABCC BCBBA CBACC AAAAB ABCBC BACAA BCBBB CBBAA AAAAC ABCCA BACABBCBBC CBBAB AAABA ABCCB BACAC BCBCA CBBAC AAABB ABCCC BACBA BCBCB CBBBAAAABC ACAAA BACBB BCBCC CBBBB AAACA ACAAB BACBC BCCAA CBBBC AAACB ACAACBACCA BCCAB CBBCA AAACC ACABA BACCB BCCAC CBBCB AABAA ACABB BACCC BCCBACBBCC AABAB ACABC BBAAA BCCBB CBCAA AABAC ACACA BBAAB BCCBC CBCAB AABBAACACB BBAAC BCCCA CBCAC AABBB ACACC BBABA BCCCB CBCBA AABBC ACBAA BBABBBCCCC CBCBB AABCA ACBAB BBABC CAAAA CBCBC AABCB ACBAC BBACA CAAAB CBCCAAABCC ACBBA BBACB CAAAC CBCCB AACAA ACBBB BBACC CAABA CBCCC AACAB ACBBCBBBAA CAABB CCAAA AACAC ACBCA BBBAB CAABC CCAAB AACBA ACBCB BBBAC CAACACCAAC AACBB ACBCC BBBBA CAACB CCABA AACBC ACCAA BBBBB CAACC CCABB AACCAACCAB BBBBC CABAA CCABC AACCB ACCAC BBBCA CABAB CCACA AACCC ACCBA BBBCBCABAC CCACB ABAAA ACCBB BBBCC CABBA CCACC ABAAB ACCBC BBCAA CABBB CCBAAABAAC ACCCA BBCAB CABBC CCBAB ABABA ACCCB BBCAC CABCA CCBAC ABABB ACCCCBBCBA CABCB CCBBA ABABC BAAAA BBCBB CABCC CCBBB ABACA BAAAB BBCBC CACAACCBBC ABACB BAAAC BBCCA CACAB CCBCA ABACC BAABA BBCCB CACAC CCBCB ABBAABAABB BBCCC CACBA CCBCC ABBAB BAABC BCAAA CACBB CCCAA ABBAC BAACA BCAABCACBC CCCAB ABBBA BAACB BCAAC CACCA CCCAC ABBBB BAACC BCABA CACCB CCCBAABBBC BABAA BCABB CACCC CCCBB ABBCA BABAB BCABC CBAAA CCCBC ABBCB BABACBCACA CBAAB CCCCA ABBCC BABBA BCACB CBAAC CCCCB ABCAA BABBB BCACC CBABACCCCC ABCAB BABBC BCBAA CBABB ABCAC BABCA BCBAB CBABC ABCBA BABCB BCBACCBACA

TABLE 2 Certain 5′-Wing Sugar Motifs Certain 5′-Wing Sugar Motifs AAAAABABC CBAB ABBB BAA AAAAB BACA CBAC BAAA BAB AAABA BACB CBBA BAAB BBAAAABB BACC CBBB BABA BBB AABAA BBAA CBBC BABB AA AABAB BBAB CBCA BBAA ABAABBA BBAC CBCB BBAB AC AABBB BBBA CBCC BBBA BA ABAAA BBBB CCAA BBBB BBABAAB BBBC CCAB AAA BC ABABA BBCA CCAC AAB CA ABABB BBCB CCBA AAC CBABBAA BBCC CCBB ABA CC ABBAB BCAA CCBC ABB AA ABBBA BCAB CCCA ABC ABABBBB BCAC CCCB ACA BA BAAAA ABCB BCBA ACB BAAAB ABCC BCBB ACC BAABAACAA BCBC BAA BAABB ACAB BCCA BAB BABAA ACAC BCCB BAC BABAB ACBA BCCCBBA BABBA ACBB CAAA BBB BABBB ACBC CAAB BBC BBAAA ACCA CAAC BCA BBAABACCB CABA BCB BBABA ACCC CABB BCC BBABB BAAA CABC CAA BBBAA BAAB CACACAB BBBAB BAAC CACB CAC BBBBA BABA CACC CBA BBBBB BABB CBAA CBB AAAAAACC CCCC CBC AAAB ABAA AAAA CCA AAAC ABAB AAAB CCB AABA ABAC AABA CCCAABB ABBA AABB AAA AABC ABBB ABAA AAB AACA ABBC ABAB ABA AACB ABCA ABBAABB

In certain embodiments, each A, each B, and each C located at the3′-most 5′-wing nucleoside is a modified nucleoside. For example, incertain embodiments the 5′-wing motif is selected from among ABB, BBB,and CBB, wherein the underlined nucleoside represents the 3′-most5′-wing nucleoside and wherein the underlined nucleoside is a modifiednucleoside. In certain embodiments, the the 3′-most 5′-wing nucleosidecomprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA,α-L-LNA, ENA and 2′-thio LNA. In certain embodiments, the the 3′-most5′-wing nucleoside comprises a bicyclic sugar moiety selected from amongcEt and LNA. In certain embodiments, the the 3′-most 5′-wing nucleosidecomprises cEt. In certain embodiments, the the 3′-most 5′-wingnucleoside comprises LNA.

In certain embodiments, each A comprises an unmodified 2′-deoxyfuranosesugar moiety. In certain embodiments, each A comprises a modified sugarmoiety. In certain embodiments, each A comprises a 2′-substituted sugarmoiety. In certain embodiments, each A comprises a 2′-substituted sugarmoiety selected from among F, ara-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each A comprises a bicyclic sugar moiety. In certainembodiments, each A comprises a bicyclic sugar moiety selected fromamong cEt, cMOE, LNA, α-L-LNA, ENA and 2′-thio LNA. In certainembodiments, each A comprises a modified nucleobase. In certainembodiments, each A comprises a modified nucleobase selected from among2-thio-thymidine nucleoside and 5-propyne uridine nucleoside. In certainembodiments, each A comprises an HNA. In certain embodiments, each Acomprises a F-HNA. In certain embodiments, each A comprises a5′-substituted sugar moiety selected from among 5′-Me DNA, and 5′-(R)-MeDNA.

In certain embodiments, each B comprises an unmodified 2′-deoxyfuranosesugar moiety. In certain embodiments, each B comprises a modified sugarmoiety. In certain embodiments, each B comprises a 2′-substituted sugarmoiety. In certain embodiments, each B comprises a 2′-substituted sugarmoiety selected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each B comprises a bicyclic sugar moiety. In certainembodiments, each B comprises a bicyclic sugar moiety selected fromamong cEt, cMOE, LNA, α-L-LNA, ENA and 2′-thio LNA. In certainembodiments, each B comprises a modified nucleobase. In certainembodiments, each B comprises a modified nucleobase selected from among2-thio-thymidine nucleoside and 5-propyne urindine nucleoside. Incertain embodiments, each B comprises an HNA. In certain embodiments,each B comprises a F-HNA. In certain embodiments, each B comprises a5′-substituted sugar moiety selected from among 5′-Me DNA, and 5′-(R)-MeDNA.

In certain embodiments, each A comprises a 2′-substituted sugar moietyselected from among F, ara-F, OCH₃ and O(CH₂)₂—OCH₃ and each B comprisesa bicyclic sugar moiety selected from among cEt, cMOE, LNA, α-L-LNA, ENAand 2′-thio LNA. In certain embodiments, each A comprises O(CH₂)₂—OCH₃and each B comprises cEt.

In certain embodiments, each C comprises an unmodified 2′-deoxyfuranosesugar moiety. In certain embodiments, each C comprises a modified sugarmoiety. In certain embodiments, each C comprises a 2′-substituted sugarmoiety. In certain embodiments, each C comprises a 2′-substituted sugarmoiety selected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each C comprises a 5′-substituted sugar moiety. In certainembodiments, each C comprises a 5′-substituted sugar moiety selectedfrom among 5′-Me DNA, and 5′-(R)-Me DNA. In certain embodiments, each Ccomprises a bicyclic sugar moiety. In certain embodiments, each Ccomprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA,α-L-LNA, ENA and 2′-thio LNA. In certain embodiments, each C comprises amodified nucleobase. In certain embodiments, each C comprises a modifiednucleobase selected from among 2-thio-thymidine and 5-propyne uridine.In certain embodiments, each C comprises a 2-thio-thymidine nucleoside.In certain embodiments, each C comprises an HNA. In certain embodiments,each C comprises an F-HNA.

v. Certain 3′-Wings

In certain embodiments, the 3′-wing of a gapmer consists of 1 to 6linked nucleosides. In certain embodiments, the 3′-wing of a gapmerconsists of 1 to 5 linked nucleosides. In certain embodiments, the3′-wing of a gapmer consists of 2 to 5 linked nucleosides. In certainembodiments, the 3′-wing of a gapmer consists of 3 to 5 linkednucleosides. In certain embodiments, the 3′-wing of a gapmer consists of4 or 5 linked nucleosides. In certain embodiments, the 3′-wing of agapmer consists of 1 to 4 linked nucleosides. In certain embodiments,the 3′-wing of a gapmer consists of 1 to 3 linked nucleosides. Incertain embodiments, the 3′-wing of a gapmer consists of 1 or 2 linkednucleosides. In certain embodiments, the 3′-wing of a gapmer consists of2 to 4 linked nucleosides. In certain embodiments, the 3′-wing of agapmer consists of 2 or 3 linked nucleosides. In certain embodiments,the 3′-wing of a gapmer consists of 3 or 4 linked nucleosides. Incertain embodiments, the 3′-wing of a gapmer consists of 1 nucleoside.In certain embodiments, the 3′-wing of a gapmer consists of 2 linkednucleosides. In certain embodiments, the 3′-wing of a gapmer consists of3linked nucleosides. In certain embodiments, the 3′-wing of a gapmerconsists of 4 linked nucleosides. In certain embodiments, the 3′-wing ofa gapmer consists of 5 linked nucleosides. In certain embodiments, the3′-wing of a gapmer consists of 6 linked nucleosides.

In certain embodiments, the 3′-wing of a gapmer comprises at least onebicyclic nucleoside. In certain embodiments, the 3′-wing of a gapmercomprises at least one constrained ethyl nucleoside. In certainembodiments, the 3′-wing of a gapmer comprises at least one LNAnucleoside. In certain embodiments, each nucleoside of the 3′-wing of agapmer is a bicyclic nucleoside. In certain embodiments, each nucleosideof the 3′-wing of a gapmer is a constrained ethyl nucleoside. In certainembodiments, each nucleoside of the 3′-wing of a gapmer is a LNAnucleoside.

In certain embodiments, the 3′-wing of a gapmer comprises at least onenon-bicyclic modified nucleoside. In certain embodiments, the 3′-wing ofa gapmer comprises at least two non-bicyclic modified nucleosides. Incertain embodiments, the 3′-wing of a gapmer comprises at least threenon-bicyclic modified nucleosides. In certain embodiments, the 3′-wingof a gapmer comprises at least four non-bicyclic modified nucleosides.In certain embodiments, the 3′-wing of a gapmer comprises at least one2′-substituted nucleoside. In certain embodiments, the 3′-wing of agapmer comprises at least one 2′-MOE nucleoside. In certain embodiments,the 3′-wing of a gapmer comprises at least one 2′-OMe nucleoside. Incertain embodiments, each nucleoside of the 3′-wing of a gapmer is anon-bicyclic modified nucleoside. In certain embodiments, eachnucleoside of the 3′-wing of a gapmer is a 2′-substituted nucleoside. Incertain embodiments, each nucleoside of the 3′-wing of a gapmer is a2′-MOE nucleoside. In certain embodiments, each nucleoside of the3′-wing of a gapmer is a 2′-OMe nucleoside.

In certain embodiments, the 3′-wing of a gapmer comprises at least one2′-deoxynucleoside. In certain embodiments, each nucleoside of the3′-wing of a gapmer is a 2′-deoxynucleoside. In a certain embodiments,the 3′-wing of a gapmer comprises at least one ribonucleoside. Incertain embodiments, each nucleoside of the 3′-wing of a gapmer is aribonucleoside. In certain embodiments, one, more than one, or each ofthe nucleosides of the 5′-wing is an RNA-like nucleoside.

In certain embodiments, the 3′-wing of a gapmer comprises at least onebicyclic nucleoside and at least one non-bicyclic modified nucleoside.In certain embodiments, the 3′-wing of a gapmer comprises at least onebicyclic nucleoside and at least one 2′-substituted nucleoside. Incertain embodiments, the 3′-wing of a gapmer comprises at least onebicyclic nucleoside and at least one 2′-MOE nucleoside. In certainembodiments, the 3′-wing of a gapmer comprises at least one bicyclicnucleoside and at least one 2′-OMe nucleoside. In certain embodiments,the 3′-wing of a gapmer comprises at least one bicyclic nucleoside andat least one 2′-deoxynucleoside.

In certain embodiments, the 3′-wing of a gapmer comprises at least oneconstrained ethyl nucleoside and at least one non-bicyclic modifiednucleoside. In certain embodiments, the 3′-wing of a gapmer comprises atleast one constrained ethyl nucleoside and at least one 2′-substitutednucleoside. In certain embodiments, the 3′-wing of a gapmer comprises atleast one constrained ethyl nucleoside and at least one 2′-MOEnucleoside. In certain embodiments, the 3′-wing of a gapmer comprises atleast one constrained ethyl nucleoside and at least one 2′-OMenucleoside. In certain embodiments, the 3′-wing of a gapmer comprises atleast one constrained ethyl nucleoside and at least one2′-deoxynucleoside.

In certain embodiments, the 3′-wing of a gapmer comprises at least oneLNA nucleoside and at least one non-bicyclic modified nucleoside. Incertain embodiments, the 3′-wing of a gapmer comprises at least one LNAnucleoside and at least one 2′-substituted nucleoside. In certainembodiments, the 3′-wing of a gapmer comprises at least one LNAnucleoside and at least one 2′-MOE nucleoside. In certain embodiments,the 3′-wing of a gapmer comprises at least one LNA nucleoside and atleast one 2′-OMe nucleoside. In certain embodiments, the 3′-wing of agapmer comprises at least one LNA nucleoside and at least one2′-deoxynucleoside.

In certain embodiments, the 3′-wing of a gapmer comprises at least onebicyclic nucleoside, at least one non-bicyclic modified nucleoside, andat least one 2′-deoxynucleoside. In certain embodiments, the 3′-wing ofa gapmer comprises at least one constrained ethyl nucleoside, at leastone non-bicyclic modified nucleoside, and at least one2′-deoxynucleoside. In certain embodiments, the 3′-wing of a gapmercomprises at least one LNA nucleoside, at least one non-bicyclicmodified nucleoside, and at least one 2′-deoxynucleoside.

In certain embodiments, the 3′-wing of a gapmer comprises at least onebicyclic nucleoside, at least one 2′-substituted nucleoside, and atleast one 2′-deoxynucleoside. In certain embodiments, the 3′-wing of agapmer comprises at least one constrained ethyl nucleoside, at least one2′-substituted nucleoside, and at least one 2′-deoxynucleoside. Incertain embodiments, the 3′-wing of a gapmer comprises at least one LNAnucleoside, at least one 2′-substituted nucleoside, and at least one2′-deoxynucleoside.

In certain embodiments, the 3′-wing of a gapmer comprises at least onebicyclic nucleoside, at least one 2′-MOE nucleoside, and at least one2′-deoxynucleoside. In certain embodiments, the 3′-wing of a gapmercomprises at least one constrained ethyl nucleoside, at least one 2′-MOEnucleoside, and at least one 2′-deoxynucleoside. In certain embodiments,the 3′-wing of a gapmer comprises at least one LNA nucleoside, at leastone 2′-MOE nucleoside, and at least one 2′-deoxynucleoside.

In certain embodiments, the 3′-wing of a gapmer comprises at least onebicyclic nucleoside, at least one 2′-OMe nucleoside, and at least one2′-deoxynucleoside. In certain embodiments, the 3′-wing of a gapmercomprises at least one constrained ethyl nucleoside, at least one 2′-OMenucleoside, and at least one 2′-deoxynucleoside. In certain embodiments,the 3′-wing of a gapmer comprises at least one LNA nucleoside, at leastone 2′-OMe nucleoside, and at least one 2′-deoxynucleoside.

In certain embodiments, the 3′-wing of a gapmer has a nucleoside motifselected from among the following: ABB, ABAA, AAABAA, AAAAABAA, AABAA,AAAABAA, AAABAA, ABAB, AAAAA, AAABB, AAAAAAAA, AAAAAAA, AAAAAA, AAAAB,AAAA, AAA, AA, AB, ABBB, ABAB, AABBB; wherein each A is a modifiednucleoside of a first type, each B is a modified nucleoside of a secondtype. In certain embodiments, an oligonucleotide comprises any 3′-wingmotif provided herein. In certain such embodiments, the oligonucleotideis a 3′-hemimer (does not comprise a 5′-wing). In certain embodiments,such an oligonucleotide is a gapmer. In certain such embodiments, the5′-wing of the gapmer may comprise any nucleoside motif.

In certain embodiments, the 3′-wing of a gapmer has a nucleoside motifselected from among the following: BBA, AAB, AAA, BBB, BBAA, AABB, WBBA,WAAB, BBBA, BBBBA, BBBB, BBBBBA, ABBBBB, BBAAA, AABBB, BBBAA, BBBBA,BBBBB, BABA, AAAAA, BBAAAA, AABBBB, BAAAA, and ABBBB, wherein each A isa modified nucleoside of a first type, each B is a modified nucleosideof a second type, and each W is a modified nucleoside of either thefirst type, the second type or a third type.

In certain embodiments, the 3′-wing of a gapmer has a nucleoside motifselected from among the following: ABB; AAABAA; AABAA; AAAABAA; AAAAA;AAABB; AAAAAAAA; AAAAAAA; AAAAAA; AAAAB; AB; ABBB; and ABAB, whereineach A is a modified nucleoside of a first type, each B is a modifiednucleoside of a second type, and each W is a modified nucleoside ofeither the first type, the second type or a third type.

In certain embodiments, the 3′-wing of a gapmer has a sugar motifselected from among those listed in the following non-limiting tables:

TABLE 3 Certain 3′-Wing Sugar Motifs Certain 3′-Wing Sugar Motifs AAAAAABCBB BABCC BCBBA CBACC AAAAB ABCBC BACAA BCBBB CBBAA AAAAC ABCCA BACABBCBBC CBBAB AAABA ABCCB BACAC BCBCA CBBAC AAABB ABCCC BACBA BCBCB CBBBAAAABC ACAAA BACBB BCBCC CBBBB AAACA ACAAB BACBC BCCAA CBBBC AAACB ACAACBACCA BCCAB CBBCA AAACC ACABA BACCB BCCAC CBBCB AABAA ACABB BACCC BCCBACBBCC AABAB ACABC BBAAA BCCBB CBCAA AABAC ACACA BBAAB BCCBC CBCAB AABBAACACB BBAAC BCCCA CBCAC AABBB ACACC BBABA BCCCB CBCBA AABBC ACBAA BBABBBCCCC CBCBB AABCA ACBAB BBABC CAAAA CBCBC AABCB ACBAC BBACA CAAAB CBCCAAABCC ACBBA BBACB CAAAC CBCCB AACAA ACBBB BBACC CAABA CBCCC AACAB ACBBCBBBAA CAABB CCAAA AACAC ACBCA BBBAB CAABC CCAAB AACBA ACBCB BBBAC CAACACCAAC AACBB ACBCC BBBBA CAACB CCABA AACBC ACCAA BBBBB CAACC CCABB AACCAACCAB BBBBC CABAA CCABC AACCB ACCAC BBBCA CABAB CCACA AACCC ACCBA BBBCBCABAC CCACB ABAAA ACCBB BBBCC CABBA CCACC ABAAB ACCBC BBCAA CABBB CCBAAABAAC ACCCA BBCAB CABBC CCBAB ABABA ACCCB BBCAC CABCA CCBAC ABABB ACCCCBBCBA CABCB CCBBA ABABC BAAAA BBCBB CABCC CCBBB ABACA BAAAB BBCBC CACAACCBBC ABACB BAAAC BBCCA CACAB CCBCA ABACC BAABA BBCCB CACAC CCBCB ABBAABAABB BBCCC CACBA CCBCC ABBAB BAABC BCAAA CACBB CCCAA ABBAC BAACA BCAABCACBC CCCAB ABBBA BAACB BCAAC CACCA CCCAC ABBBB BAACC BCABA CACCB CCCBAABBBC BABAA BCABB CACCC CCCBB ABBCA BABAB BCABC CBAAA CCCBC ABBCB BABACBCACA CBAAB CCCCA ABBCC BABBA BCACB CBAAC CCCCB ABCAA BABBB BCACC CBABACCCCC ABCAB BABBC BCBAA CBABB ABCAC BABCA BCBAB CBABC ABCBA BABCB BCBACCBACA

TABLE 4 Certain 3′-Wing Sugar Motifs Certain 3′-Wing Sugar Motifs AAAAABABC CBAB ABBB BAA AAAAB BACA CBAC BAAA BAB AAABA BACB CBBA BAAB BBAAAABB BACC CBBB BABA BBB AABAA BBAA CBBC BABB AA AABAB BBAB CBCA BBAA ABAABBA BBAC CBCB BBAB AC AABBB BBBA CBCC BBBA BA ABAAA BBBB CCAA BBBB BBABAAB BBBC CCAB AAA BC ABABA BBCA CCAC AAB CA ABABB BBCB CCBA AAC CBABBAA BBCC CCBB ABA CC ABBAB BCAA CCBC ABB AA ABBBA BCAB CCCA ABC ABABBBB BCAC CCCB ACA BA BAAAA ABCB BCBA ACB BAAAB ABCC BCBB ACC BAABAACAA BCBC BAA BAABB ACAB BCCA BAB BABAA ACAC BCCB BAC BABAB ACBA BCCCBBA BABBA ACBB CAAA BBB BABBB ACBC CAAB BBC BBAAA ACCA CAAC BCA BBAABACCB CABA BCB BBABA ACCC CABB BCC BBABB BAAA CABC CAA BBBAA BAAB CACACAB BBBAB BAAC CACB CAC BBBBA BABA CACC CBA BBBBB BABB CBAA CBB AAAAAACC CCCC CBC AAAB ABAA AAAA CCA AAAC ABAB AAAB CCB AABA ABAC AABA CCCAABB ABBA AABB AAA AABC ABBB ABAA AAB AACA ABBC ABAB ABA AACB ABCA ABBAABB

In certain embodiments, each A, each B, and each C located at the5′-most 3′-wing region nucleoside is a modified nucleoside. For example,in certain embodiments the 3′-wing motif is selected from among ABB,BBB, and CBB, wherein the underlined nucleoside represents the the5′-most 3′-wing region nucleoside and wherein the underlined nucleosideis a modified nucleoside.

In certain embodiments, each A comprises an unmodified 2′-deoxyfuranosesugar moiety. In certain embodiments, each A comprises a modified sugarmoiety. In certain embodiments, each A comprises a 2′-substituted sugarmoiety. In certain embodiments, each A comprises a 2′-substituted sugarmoiety selected from among F, ara-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each A comprises a bicyclic sugar moiety. In certainembodiments, each A comprises a bicyclic sugar moiety selected fromamong cEt, cMOE, LNA, α-L-LNA, ENA and 2′-thio LNA. In certainembodiments, each A comprises a modified nucleobase. In certainembodiments, each A comprises a modified nucleobase selected from among2-thio-thymidine nucleoside and 5-propyne uridine nucleoside. In certainembodiments, each A comprises a 5′-substituted sugar moiety selectedfrom among 5′-Me DNA, and 5′-(R)-Me DNA.

In certain embodiments, each B comprises an unmodified 2′-deoxyfuranosesugar moiety. In certain embodiments, each B comprises a modified sugarmoiety. In certain embodiments, each B comprises a 2′-substituted sugarmoiety. In certain embodiments, each B comprises a 2′-substituted sugarmoiety selected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each B comprises a bicyclic sugar moiety. In certainembodiments, each B comprises a bicyclic sugar moiety selected fromamong cEt, cMOE, LNA, α-L-LNA, ENA and 2′-thio LNA. In certainembodiments, each B comprises a modified nucleobase. In certainembodiments, each B comprises a modified nucleobase selected from among2-thio-thymidine nucleoside and 5-propyne urindine nucleoside. Incertain embodiments, each B comprises an HNA. In certain embodiments,each B comprises an F-HNA. In certain embodiments, each B comprises a5′-substituted sugar moiety selected from among 5′-Me DNA, and 5′-(R)-MeDNA.

In certain embodiments, each A comprises a 2′-substituted sugar moietyselected from among F, ara-F, OCH₃ and O(CH₂)₂—OCH₃ and each B comprisesa bicyclic sugar moiety selected from among cEt, cMOE, LNA, α-L-LNA, ENAand 2′-thio LNA. In certain embodiments, each A comprises O(CH₂)₂—OCH₃and each B comprises cEt.

In certain embodiments, each C comprises an unmodified 2′-deoxyfuranosesugar moiety. In certain embodiments, each C comprises a modified sugarmoiety. In certain embodiments, each C comprises a 2′-substituted sugarmoiety. In certain embodiments, each C comprises a 2′-substituted sugarmoiety selected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each C comprises a 5′-substituted sugar moiety. In certainembodiments, each C comprises a 5′-substituted sugar moiety selectedfrom among 5′-Me, and 5′-(R)-Me. In certain embodiments, each Ccomprises a bicyclic sugar moiety. In certain embodiments, each Ccomprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA,α-L-LNA, ENA and 2′-thio LNA. In certain embodiments, each C comprises amodified nucleobase. In certain embodiments, each C comprises a modifiednucleobase selected from among 2-thio-thymidine and 5-propyne uridine.In certain embodiments, each C comprises a 2-thio-thymidine nucleoside.In certain embodiments, each C comprises an HNA. In certain embodiments,each C comprises an F-HNA.

vi. Certain Central Regions (Gaps)

In certain embodiments, the gap of a gapmer consists of 6 to 20 linkednucleosides. In certain embodiments, the gap of a gapmer consists of 6to 15 linked nucleosides. In certain embodiments, the gap of a gapmerconsists of 6 to 12 linked nucleosides. In certain embodiments, the gapof a gapmer consists of 6 to 10 linked nucleosides. In certainembodiments, the gap of a gapmer consists of 6 to 9 linked nucleosides.In certain embodiments, the gap of a gapmer consists of 6 to 8 linkednucleosides. In certain embodiments, the gap of a gapmer consists of 6or 7 linked nucleosides. In certain embodiments, the gap of a gapmerconsists of 7 to 10 linked nucleosides. In certain embodiments, the gapof a gapmer consists of 7 to 9 linked nucleosides. In certainembodiments, the gap of a gapmer consists of 7 or 8 linked nucleosides.In certain embodiments, the gap of a gapmer consists of 8 to 10 linkednucleosides. In certain embodiments, the gap of a gapmer consists of 8or 9 linked nucleosides. In certain embodiments, the gap of a gapmerconsists of 6 linked nucleosides. In certain embodiments, the gap of agapmer consists of 7 linked nucleosides. In certain embodiments, the gapof a gapmer consists of 8 linked nucleosides. In certain embodiments,the gap of a gapmer consists of 9 linked nucleosides. In certainembodiments, the gap of a gapmer consists of 10 linked nucleosides. Incertain embodiments, the gap of a gapmer consists of 11 linkednucleosides. In certain embodiments, the gap of a gapmer consists of 12linked nucleosides.

In certain embodiments, each nucleoside of the gap of a gapmer is a2′-deoxynucleoside. In certain embodiments, the gap comprises one ormore modified nucleosides. In certain embodiments, each nucleoside ofthe gap of a gapmer is a 2′-deoxynucleoside or is a modified nucleosidethat is “DNA-like.” In such embodiments, “DNA-like” means that thenucleoside has similar characteristics to DNA, such that a duplexcomprising the gapmer and an RNA molecule is capable of activating RNaseH. For example, under certain conditions, 2′-(ara)-F have been shown tosupport RNase H activation, and thus is DNA-like. In certainembodiments, one or more nucleosides of the gap of a gapmer is not a2′-deoxynucleoside and is not DNA-like. In certain such embodiments, thegapmer nonetheless supports RNase H activation (e.g., by virtue of thenumber or placement of the non-DNA nucleosides).

In certain embodiments, gaps comprise a stretch of unmodified2′-deoxynucleoside interrupted by one or more modified nucleosides, thusresulting in three sub-regions (two stretches of one or more2′-deoxynucleosides and a stretch of one or more interrupting modifiednucleosides). In certain embodiments, no stretch of unmodified2′-deoxynucleosides is longer than 5, 6, or 7 nucleosides. In certainembodiments, such short stretches is achieved by using short gapregions. In certain embodiments, short stretches are achieved byinterrupting a longer gap region.

In certain embodiments, the gap comprises one or more modifiednucleosides. In certain embodiments, the gap comprises one or moremodified nucleosides selected from among cEt, FHNA, LNA, and2-thio-thymidine. In certain embodiments, the gap comprises one modifiednucleoside. In certain embodiments, the gap comprises a 5′-substitutedsugar moiety selected from among 5′-Me, and 5′-(R)-Me. In certainembodiments, the gap comprises two modified nucleosides. In certainembodiments, the gap comprises three modified nucleosides. In certainembodiments, the gap comprises four modified nucleosides. In certainembodiments, the gap comprises two or more modified nucleosides and eachmodified nucleoside is the same. In certain embodiments, the gapcomprises two or more modified nucleosides and each modified nucleosideis different.

In certain embodiments, the gap comprises one or more modified linkages.In certain embodiments, the gap comprises one or more methyl phosphonatelinkages. In certain embodiments the gap comprises two or more modifiedlinkages. In certain embodiments, the gap comprises one or more modifiedlinkages and one or more modified nucleosides. In certain embodiments,the gap comprises one modified linkage and one modified nucleoside. Incertain embodiments, the gap comprises two modified linkages and two ormore modified nucleosides.

In certain embodiments, the gap comprises a nucleoside motif selectedfrom among the following: DDDDXDDDDD; DDDDDXDDDDD; DDDXDDDDD;DDDDXDDDDDD; DDDDXDDDD; DDXDDDDDD; DDDXDDDDDD; DXDDDDDD; DDXDDDDDDD;DDXDDDDD; DDXDDDXDDD; DDDXDDDXDDD; DXDDDXDDD; DDXDDDXDD; DDXDDDDXDDD;DDXDDDDXDD; DXDDDDXDDD; DDDDXDDD; DDDXDDD; DXDDDDDDD; DDDDXXDDD; andDXXDXXDXX; wherein each D is an unmodified deoxynucleoside; and each Xis a modified nucleoside or a substituted sugar moiety.

In certain embodiments, the gap comprises a nucleoside motif selectedfrom among the following: DDDDDDDDD; DXDDDDDDD; DDXDDDDDD; DDDXDDDDD;DDDDXDDDD; DDDDDXDDD; DDDDDDXDD; DDDDDDDXD; DXXDDDDDD; DDDDDDXXD;DDXXDDDDD; DDDXXDDDD; DDDDXXDDD; DDDDDXXDD; DXDDDDDXD; DXDDDDXDD;DXDDDXDDD; DXDDXDDDD; DXDXDDDDD; DDXDDDDXD; DDXDDDXDD; DDXDDXDDD;DDXDXDDDD; DDDXDDDXD; DDDXDDXDD; DDDXDXDDD; DDDDXDDXD; DDDDXDXDD; andDDDDDXDXD, wherein each D is an unmodified deoxynucleoside; and each Xis a modified nucleoside or a substituted sugar moiety.

In certain embodiments, the gap comprises a nucleoside motif selectedfrom among the following: DDDDXDDDD, DXDDDDDDD, DXXDDDDDD, DDXDDDDDD,DDDXDDDDD, DDDDXDDDD, DDDDDXDDD, DDDDDDXDD, and DDDDDDDXD, wherein eachD is an unmodified deoxynucleoside; and each X is a modified nucleosideor a substituted sugar moiety.

In certain embodiments, the gap comprises a nucleoside motif selectedfrom among the following: DDDDDDDD, DXDDDDDD, DDXDDDDD, DDDXDDDD,DDDDXDDD, DDDDDXDD, DDDDDDXD, DXDDDDXD, DXDDDXDD, DXDDXDDD, DXDXDDDD,DXXDDDDD, DDXXDDDD, DDXDXDDD, DDXDDXDD, DXDDDDXD, DDDXXDDD, DDDXDXDD,DDDXDDXD, DDDDXXDD, DDDDXDXD, and DDDDDXXD, wherein each D is anunmodified deoxynucleoside; and each X is a modified nucleoside or asubstituted sugar moiety.

In certain embodiments, the gap comprises a nucleoside motif selectedfrom among the following: DXDDDDD, DDXDDDD, DDDXDDD, DDDDXDD, DDDDDXD,DXDDDXD, DXDDXDD, DXDXDDD, DXXDDDD, DDXXDDD, DDXDXDD, DDXDDXD, DDDXXDD,DDDXDXD, and DDDDXXD, wherein each D is an unmodified deoxynucleoside;and each X is a modified nucleoside or a substituted sugar moiety.

In certain embodiments, the gap comprises a nucleoside motif selectedfrom among the following: DXDDDD, DDXDDD, DDDXDD, DDDDXD, DXXDDD,DXDXDD, DXDDXD, DDXXDD, DDXDXD, and DDDXXD, wherein each D is anunmodified deoxynucleoside; and each X is a modified nucleoside or asubstituted sugar moiety.

In certain embodiments, the gap comprises a nucleoside motif selectedfrom among the following: DXDDDD, DDXDDD, DDDXDD, DDDDXD, DXDDDDD,DDXDDDD, DDDXDDD, DDDDXDD, DDDDDXD, DXDDDDDD, DDXDDDDD, DDDXDDDD,DDDDXDDD, DDDDDXDD, DDDDDDXD, DXDDDDDDD; DDXDDDDDD, DDDXDDDDD,DDDDXDDDD, DDDDDXDDD, DDDDDDXDD, DDDDDDDXD, DXDDDDDDDD, DDXDDDDDDD,DDDXDDDDDD, DDDDXDDDDD, DDDDDXDDDD, DDDDDDXDDD, DDDDDDDXDD, andDDDDDDDDXD, wherein each D is an unmodified deoxynucleoside; and each Xis a modified nucleoside or a substituted sugar moiety.

In certain embodiments, each X comprises an unmodified 2′-deoxyfuranosesugar moiety. In certain embodiments, each X comprises a modified sugarmoiety. In certain embodiments, each X comprises a 2′-substituted sugarmoiety. In certain embodiments, each X comprises a 2′-substituted sugarmoiety selected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each X comprises a 5′-substituted sugar moiety. In certainembodiments, each X comprises a 5′-substituted sugar moiety selectedfrom among 5′-Me, and 5′-(R)-Me. In certain embodiments, each Xcomprises a bicyclic sugar moiety. In certain embodiments, each Xcomprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA,α-L-LNA, ENA and 2′-thio LNA. In certain embodiments, each X comprises amodified nucleobase. In certain embodiments, each X comprises a modifiednucleobase selected from among 2-thio-thymidine and 5-propyne uridine.In certain embodiments, each X comprises a 2-thio-thymidine nucleoside.In certain embodiments, each X comprises an HNA. In certain embodiments,each C comprises an F-HNA. In certain embodiments, X represents thelocation of a single differentiating nucleobase.

vii. Certain Gapmer Motifs

In certain embodiments, a gapmer comprises a 5′-wing, a gap, and a 3′wing, wherein the 5′-wing, gap, and 3′ wing are independently selectedfrom among those discussed above. For example, in certain embodiments, agapmer has a 5′-wing, a gap, and a 3′-wing having features selected fromamong any of those listed in the tables above and any 5′-wing may bepaired with any gap and any 3′-wing. For example, in certainembodiments, a 5′-wing may comprise AAABB, a 3′-wing may comprise BBA,and the gap may comprise DDDDDDD. For example, in certain embodiments, agapmer has a 5′-wing, a gap, and a 3′-wing having features selected fromamong those listed in the following non-limiting table, wherein eachmotif is represented as (5′-wing)-(gap)-(3′-wing), wherein each numberrepresents the number of linked nucleosides in each portion of themotif, for example, a 5-10-5 motif would have a 5′-wing comprising 5nucleosides, a gap comprising 10 nucleosides, and a 3′-wing comprising 5nucleosides:

TABLE 5 Certain Gapmer Sugar Motifs Certain Gapmer Sugar Motifs 2-10-23-10-2 4-10-2 5-10-2 2-10-3 3-10-3 4-10-3 5-10-3 2-10-4 3-10-4 4-10-45-10-4 2-10-5 3-10-5 4-10-5 5-10-5 2-9-2 3-9-2 4-9-2 5-9-2 2-9-3 3-9-34-9-3 5-9-3 2-9-4 3-9-4 4-9-4 5-9-4 2-9-5 3-9-5 4-9-5 5-9-5 2-11-23-11-2 4-11-2 5-11-2 2-11-3 3-11-3 4-11-3 5-11-3 2-11-4 3-11-4 4-11-45-11-4 2-11-5 3-11-5 4-11-5 5-11-5 2-8-2 3-8-2 4-8-2 5-8-2 2-8-3 3-8-34-8-3 5-8-3 2-8-4 3-8-4 4-8-4 5-8-4 2-8-5 3-8-5 4-8-5 5-8-5

In certain embodiments, a gapmer comprises a 5′-wing, a gap, and a 3′wing, wherein the 5′-wing, gap, and 3′ wing are independently selectedfrom among those discussed above. For example, in certain embodiments, agapmer has a 5′-wing, a gap, and a 3′-wing having features selected fromamong those listed in the following non-limiting tables:

TABLE 6 Certain Gapmer Nucleoside Motifs 5′-wing region Central gapregion 3′-wing region ADDA DDDDDD ABB ABBA DDDADDDD ABAA AAAAAAADDDDDDDDDDD AAA AAAAABB DDDDDDDD BBAAAAA ABB DDDDADDDD ABB ABB DDDDBDDDDBBA ABB DDDDDDDDD BBA AABAA DDDDDDDDD AABAA ABB DDDDDD AABAA AAABAADDDDDDDDD AAABAA AAABAA DDDDDDDDD AAB ABAB DDDDDDDDD ABAB AAABB DDDDDDDBBA ABADB DDDDDDD BBA ABA DBDDDDDDD BBA ABA DADDDDDDD BBA ABAB DDDDDDDDBBA AA DDDDDDDD BBBBBBBB ABB DDDDDD ABADB AAAAB DDDDDDD BAAAA ABBBDDDDDDDDD AB AB DDDDDDDDD BBBA ABBB DDDDDDDDD BBBA AB DDDDDDDD ABA ABBDDDDWDDDD BBA AAABB DDDWDDD BBAAA ABB DDDDWWDDD BBA ABADB DDDDDDD BBAABBDC DDDDDDD BBA ABBDDC DDDDDD BBA ABBDCC DDDDDD BBA ABB DWWDWWDWW BBAABB DWDDDDDDD BBA ABB DDWDDDDDD BBA ABB DWWDDDDDD BBA AAABB DDWDDDDDD AABB DDWDWDDDD BBABBBB ABB DDDD(^(N)D)DDDD BBA AAABB DDD(^(N)D)DDD BBAAAABB DDDD(^(N)D)(^(N)D)DDD BBA ABBD(^(N)D)(^(N)D)D(^(N)D)(^(N)D)D(^(N)D)(^(N)D) BBA ABB D(^(N)D)DDDDDDDBBA ABB DD(^(N)D)DDDDDD BBA ABB D(^(N)D)(^(N)D)DDDDDD BBA AAABBDD(^(N)D)DDDDDD AA BB DD(^(N)D)D(^(N)D)DDDD BBABBBB ABAB DDDDDDDDD BABA

TABLE 7 Certain Gapmer Nucleoside Motifs 5′-wing region Central gapregion 3′-wing region ABBW DDDDDDDD BBA ABB DWDDDDDDD BBA ABB DDWDDDDDDBBA ABB DDDWDDDDD BBA ABB DDDDWDDDD BBA ABB DDDDDWDDD BBA ABB DDDDDDWDDBBA ABB DDDDDDDWD BBA ABB DDDDDDDD WBBA ABBWW DDDDDDD BBA ABB DWWDDDDDDBBA ABB DDWWDDDDD BBA ABB DDDWWDDDD BBA ABB DDDDWWDDD BBA ABB DDDDDWWDDBBA ABB DDDDDDWWD BBA ABB DDDDDDD WWBBA ABBW DDDDDDD WBBA ABBW DDDDDDWDBBA ABBW DDDDDWDD BBA ABBW DDDDWDDD BBA ABBW DDDWDDDD BBA ABBW DDWDDDDDBBA ABBW DWDDDDDD BBA ABB DWDDDDDD WBBA ABB DWDDDDDWD BBA ABB DWDDDDWDDBBA ABB DWDDDWDDD BBA ABB DWDDWDDDD BBA ABB DWDWDDDDD BBA ABB DDWDDDDDWBBA ABB DDWDDDDWD BBA ABB DDWDDDWDD BBA ABB DDWDDWDDD BBA ABB DDWDWDDDDBBA ABB DDWWDDDDD BBA ABB DDDWDDDD WBBA ABB DDDWDDDWD BBA ABB DDDWDDWDDBBA ABB DDDWDWDDD BBA ABB DDDWWDDDD BBA ABB DDDDWDDD WBBA ABB DDDDWDDWDBBA ABB DDDDWDWDD BBA ABB DDDDWWDDD BBA ABB DDDDDWDD WBBA ABB DDDDDWDWDBBA ABB DDDDDWWDD BBA ABB DDDDDDWD WBBA

TABLE 8 Certain Gapmer Nucleoside Motifs 5′-wing region Central gapregion 3′-wing region ABBB DDDDDDDD BBA ABB DBDDDDDDD BBA ABB DDBDDDDDDBBA ABB DDDBDDDDD BBA ABB DDDDBDDDD BBA ABB DDDDDBDDD BBA ABB DDDDDDBDDBBA ABB DDDDDDDBD BBA ABB DDDDDDDD BBBA ABBBB DDDDDDD BBA ABB DBBDDDDDDBBA ABB DDBBDDDDD BBA ABB DDDBBDDDD BBA ABB DDDDBBDDD BBA ABB DDDDDBBDDBBA ABB DDDDDDBBD BBA ABB DDDDDDD BBBBA ABBB DDDDDDD BBBA ABB DDDDDDBDBBA ABBB DDDDDBDD BBA ABBB DDDDBDDD BBA ABBB DDDBDDDD BBA ABBB DDBDDDDDBBA ABBB DBDDDDDD BBA ABB DBDDDDDD BBBA ABB DBDDDDDBD BBA ABB DBDDDDBDDBBA ABB DBDDDBDDD BBA ABB DBDDBDDDD BBA ABB DBDBDDDDD BBA ABB DDBDDDDDBBBA ABB DDBDDDDBD BBA ABB DDBDDDBDD BBA ABB DDBDDBDDD BBA ABB DDBDBDDDDBBA ABB DDBBDDDDD BBA ABB DDDBDDDD BBBA ABB DDDBDDDBD BBA ABB DDDBDDBDDBBA ABB DDDBDBDDD BBA ABB DDDBBDDDD BBA ABB DDDDBDDD BBBA ABB DDDDBDDBDBBA ABB DDDDBDBDD BBA ABB DDDDBBDDD BBA ABB DDDDDBDD BBBA ABB DDDDDBDBDBBA ABB DDDDDBBDD BBA ABB DDDDDDBD BBBA

TABLE 9 Certain Gapmer Nucleoside Motifs 5′-wing region Central gapregion 3′-wing region ABB DDDDDDDDD BBA AB DBDDDDDDDD BBA AB DDBDDDDDDDBBA AB DDDBDDDDDD BBA AB DDDDBDDDDD BBA AB DDDDDBDDDD BBA AB DDDDDDBDDDBBA AB DDDDDDDBDD BBA AB DDDDDDDDBD BBA AB DDDDDDDDD BBBA ABBB DDDDDDDDBBA AB DBBDDDDDDD BBA AB DDBBDDDDDD BBA AB DDDBBDDDDD BBA AB DDDDBBDDDDBBA AB DDDDDBBDDD BBA AB DDDDDDBBDD BBA AB DDDDDDDBBD BBA AB DDDDDDDDBBBBA ABBBB DDDDDDD BBA AB DBBBDDDDDD BBA AB DDBBBDDDDD BBA ABDDDBBBDDDD BBA AB DDDDBBBDDD BBA AB DDDDDBBBDD BBA AB DDDDDDBBBD BBA ABDDDDDDD BBBBBA AB DDDDDDDDD BBBA AB DDDDDDDBD BBBA AB DDDDDBDD BBBA ABDDDDBDDD BBBA AB DDDBDDDD BBBA AB DDBDDDDD BBBA AB DBDDDDDD BBBA ABDDDDDBD BBBBA AB DDDDBDD BBBBA AB DDDBDDD BBBBA AB DDBDDDD BBBBA ABDBDDDDD BBBBA AB DDDDBD BBBBBA AB DDDBDD BBBBBA AB DDBDDD BBBBBA ABDBDDDD BBBBBA

TABLE 10 Certain Gapmer Nucleoside Motifs 5′-wing region Central gapregion 3′-wing region AAAAAA DDDDDDD BABA AAAAAB DDDDDDD BABA AAAABADDDDDDD BABA AAABAA DDDDDDD BABA AABAAA DDDDDDD BABA ABAAAA DDDDDDD BABABAAAAA DDDDDDD BABA ABAAAB DDDDDDD BABA ABAABA DDDDDDD BABA ABABAADDDDDDD BABA ABBAAA DDDDDDD BABA AABAAB DDDDDDD BABA AABABA DDDDDDD BABAAABBAA DDDDDDD BABA AAABAB DDDDDDD BABA AAABBA DDDDDDD BABA AAAABBDDDDDDD BABA BAAAAB DDDDDDD BABA BAAABA DDDDDDD BABA BAABAA DDDDDDD BABABABAAA DDDDDDD BABA BBAAAA DDDDDDD BABA BBBAAA DDDDDDD BABA BBABAADDDDDDD BABA BBAABA DDDDDDD BABA BBAAAB DDDDDDD BABA ABABAB DDDDDDD BABABBBBAA DDDDDDD BABA BBBABA DDDDDDD BABA BBBAAB DDDDDDD BABA BBBBBADDDDDDD BABA BBBBAB DDDDDDD BABA AAABBB DDDDDDD BABA AABABB DDDDDDD BABAABAABB DDDDDDD BABA BAAABB DDDDDDD BABA AABBBB DDDDDDD BABA ABABBBDDDDDDD BABA BAABBB DDDDDDD BABA ABBBBB DDDDDDD BABA BABBBB DDDDDDD BABABBBBBB DDDDDDD BABA

TABLE 11 Certain Gapmer Nucleoside Motifs 5′-wing region Central gapregion 3′-wing region AAAAA DDDDDDD AAAAA AAAAB DDDDDDD AAAAA AAABADDDDDDD AAAAA AAABB DDDDDDD AAAAA AABAA DDDDDDD AAAAA AABAB DDDDDDDAAAAA AABBA DDDDDDD AAAAA AABBB DDDDDDD AAAAA ABAAA DDDDDDD AAAAA ABAABDDDDDDD AAAAA ABABA DDDDDDD AAAAA ABABB DDDDDDD AAAAA ABBAA DDDDDDDAAAAA ABBAB DDDDDDD AAAAA ABBBA DDDDDDD AAAAA ABBBB DDDDDDD AAAAA BAAAADDDDDDD AAAAA BAAAB DDDDDDD AAAAA BAABA DDDDDDD AAAAA BAABB DDDDDDDAAAAA BABAA DDDDDDD AAAAA BABAB DDDDDDD AAAAA BABBA DDDDDDD AAAAA BABBBDDDDDDD AAAAA BBAAA DDDDDDD AAAAA BBAAB DDDDDDD AAAAA BBABA DDDDDDDAAAAA BBABB DDDDDDD AAAAA BBBAA DDDDDDD AAAAA BBBAB DDDDDDD AAAAA BBBBADDDDDDD AAAAA BBBBB DDDDDDD AAAAA AAAAA DDDDDDD BAAAA AAAAB DDDDDDDBAAAA AAABA DDDDDDD BAAAA AAABB DDDDDDD BAAAA AABAA DDDDDDD BAAAA AABABDDDDDDD BAAAA AABBA DDDDDDD BAAAA AABBB DDDDDDD BAAAA ABAAA DDDDDDDBAAAA ABAAB DDDDDDD BAAAA ABABA DDDDDDD BAAAA ABABB DDDDDDD BAAAA ABBAADDDDDDD BAAAA ABBAB DDDDDDD BAAAA ABBBA DDDDDDD BAAAA ABBBB DDDDDDDBAAAA BAAAA DDDDDDD BAAAA BAAAB DDDDDDD BAAAA BAABA DDDDDDD BAAAA BAABBDDDDDDD BAAAA BABAA DDDDDDD BAAAA BABAB DDDDDDD BAAAA BABBA DDDDDDDBAAAA BABBB DDDDDDD BAAAA BBAAA DDDDDDD BAAAA BBAAB DDDDDDD BAAAA BBABADDDDDDD BAAAA BBABB DDDDDDD BAAAA BBBAA DDDDDDD BAAAA BBBAB DDDDDDDBAAAA BBBBA DDDDDDD BAAAA BBBBB DDDDDDD BAAAA AAAAA DDDDDDD BBAAA AAAABDDDDDDD BBAAA AAABA DDDDDDD BBAAA AAABB DDDDDDD BBAAA AABAA DDDDDDDBBAAA AABAB DDDDDDD BBAAA AABBA DDDDDDD BBAAA AABBB DDDDDDD BBAAA ABAAADDDDDDD BBAAA ABAAB DDDDDDD BBAAA ABABA DDDDDDD BBAAA ABABB DDDDDDDBBAAA ABBAA DDDDDDD BBAAA ABBAB DDDDDDD BBAAA ABBBA DDDDDDD BBAAA ABBBBDDDDDDD BBAAA BAAAA DDDDDDD BBAAA BAAAB DDDDDDD BBAAA BAABA DDDDDDDBBAAA BAABB DDDDDDD BBAAA BABAA DDDDDDD BBAAA BABAB DDDDDDD BBAAA BABBADDDDDDD BBAAA BABBB DDDDDDD BBAAA BBAAA DDDDDDD BBAAA BBAAB DDDDDDDBBAAA BBABA DDDDDDD BBAAA BBABB DDDDDDD BBAAA BBBAA DDDDDDD BBAAA BBBABDDDDDDD BBAAA BBBBA DDDDDDD BBAAA BBBBB DDDDDDD BBAAA AAAAA DDDDDDDBBBAA AAAAB DDDDDDD BBBAA AAABA DDDDDDD BBBAA AAABB DDDDDDD BBBAA AABAADDDDDDD BBBAA AABAB DDDDDDD BBBAA AABBA DDDDDDD BBBAA AABBB DDDDDDDBBBAA ABAAA DDDDDDD BBBAA ABAAB DDDDDDD BBBAA ABABA DDDDDDD BBBAA ABABBDDDDDDD BBBAA ABBAA DDDDDDD BBBAA ABBAB DDDDDDD BBBAA ABBBA DDDDDDDBBBAA ABBBB DDDDDDD BBBAA BAAAA DDDDDDD BBBAA BAAAB DDDDDDD BBBAA BAABADDDDDDD BBBAA BAABB DDDDDDD BBBAA BABAA DDDDDDD BBBAA BABAB DDDDDDDBBBAA BABBA DDDDDDD BBBAA BABBB DDDDDDD BBBAA BBAAA DDDDDDD BBBAA BBAABDDDDDDD BBBAA BBABA DDDDDDD BBBAA BBABB DDDDDDD BBBAA BBBAA DDDDDDDBBBAA BBBAB DDDDDDD BBBAA BBBBA DDDDDDD BBBAA BBBBB DDDDDDD BBBAA AAAAADDDDDDD BBBBA AAAAB DDDDDDD BBBBA AAABA DDDDDDD BBBBA AAABB DDDDDDDBBBBA AABAA DDDDDDD BBBBA AABAB DDDDDDD BBBBA AABBA DDDDDDD BBBBA AABBBDDDDDDD BBBBA ABAAA DDDDDDD BBBBA ABAAB DDDDDDD BBBBA ABABA DDDDDDDBBBBA ABABB DDDDDDD BBBBA ABBAA DDDDDDD BBBBA ABBAB DDDDDDD BBBBA ABBBADDDDDDD BBBBA ABBBB DDDDDDD BBBBA BAAAA DDDDDDD BBBBA BAAAB DDDDDDDBBBBA BAABA DDDDDDD BBBBA BAABB DDDDDDD BBBBA BABAA DDDDDDD BBBBA BABABDDDDDDD BBBBA BABBA DDDDDDD BBBBA BABBB DDDDDDD BBBBA BBAAA DDDDDDDBBBBA BBAAB DDDDDDD BBBBA BBABA DDDDDDD BBBBA BBABB DDDDDDD BBBBA BBBAADDDDDDD BBBBA BBBAB DDDDDDD BBBBA BBBBA DDDDDDD BBBBA BBBBB DDDDDDDBBBBA AAAAA DDDDDDD BBBBB AAAAB DDDDDDD BBBBB AAABA DDDDDDD BBBBB AAABBDDDDDDD BBBBB AABAA DDDDDDD BBBBB AABAB DDDDDDD BBBBB AABBA DDDDDDDBBBBB AABBB DDDDDDD BBBBB ABAAA DDDDDDD BBBBB ABAAB DDDDDDD BBBBB ABABADDDDDDD BBBBB ABABB DDDDDDD BBBBB ABBAA DDDDDDD BBBBB ABBAB DDDDDDDBBBBB ABBBA DDDDDDD BBBBB ABBBB DDDDDDD BBBBB BAAAA DDDDDDD BBBBB BAAABDDDDDDD BBBBB BAABA DDDDDDD BBBBB BAABB DDDDDDD BBBBB BABAA DDDDDDDBBBBB BABAB DDDDDDD BBBBB BABBA DDDDDDD BBBBB BABBB DDDDDDD BBBBB BBAAADDDDDDD BBBBB BBAAB DDDDDDD BBBBB BBABA DDDDDDD BBBBB BBABB DDDDDDDBBBBB BBBAA DDDDDDD BBBBB BBBAB DDDDDDD BBBBB BBBBA DDDDDDD BBBBB BBBBBDDDDDDD BBBBB

TABLE 12 Certain Gapmer Nucleoside Motifs 5′-wing region Central gapregion 3′-wing region AAAW DDDDDDDD BBA AABW DDDDDDDD BBA ABAW DDDDDDDDBBA ABBW DDDDDDDD BBA BAAW DDDDDDDD BBA BABW DDDDDDDD BBA BBAW DDDDDDDDBBA BBBW DDDDDDDD BBA ABB DDDDDDDD WAAA ABB DDDDDDDD WAAB ABB DDDDDDDDWABA ABB DDDDDDDD WABB ABB DDDDDDDD WBAA ABB DDDDDDDD WBAB ABB DDDDDDDDWBBA ABB DDDDDDDD WBBB AAAWW DDDDDDD BBA AABWW DDDDDDD BBA ABAWW DDDDDDDBBA ABBWW DDDDDDD BBA BAAWW DDDDDDD BBA BABWW DDDDDDD BBA BBAWW DDDDDDDBBA BBBWW DDDDDDD BBA ABB DDDDDDD WWAAA ABB DDDDDDD WWAAB ABB DDDDDDDWWABA ABB DDDDDDD WWABB ABB DDDDDDD WWBAA ABB DDDDDDD WWBAB ABB DDDDDDDWWBBA ABB DDDDDDD WWBBB AAAAW DDDDDDD BBA AAABW DDDDDDD BBA AABAWDDDDDDD BBA AABBW DDDDDDD BBA ABAAW DDDDDDD BBA ABABW DDDDDDD BBA ABBAWDDDDDDD BBA ABBBW DDDDDDD BBA BAAAW DDDDDDD BBA BAABW DDDDDDD BBA BABAWDDDDDDD BBA BABBW DDDDDDD BBA BBAAW DDDDDDD BBA BBABW DDDDDDD BBA BBBAWDDDDDDD BBA BBBBW DDDDDDD WAAAA ABB DDDDDDD WAAAB ABB DDDDDDD WAABA ABBDDDDDDD WAABB ABB DDDDDDD WABAA ABB DDDDDDD WABAB ABB DDDDDDD WABBA ABBDDDDDDD WABBB ABB DDDDDDD WBAAA ABB DDDDDDD WBAAB ABB DDDDDDD WBABA ABBDDDDDDD WBABB ABB DDDDDDD WBBAA ABB DDDDDDD WBBAB ABB DDDDDDD WBBBA ABBDDDDDDD WBBBBwherein each A is a modified nucleoside of a first type, each B is amodified nucleoside of a second type and each W is a modified nucleosideor nucleobase of either the first type, the second type or a third type,each D is a nucleoside comprising an unmodified 2′deoxy sugar moiety andunmodified nucleobase, and ^(N)D is modified nucleoside comprising amodified nucleobase and an unmodified 2′deoxy sugar moiety.

In certain embodiments, each A comprises a modified sugar moiety. Incertain embodiments, each A comprises a 2′-substituted sugar moiety. Incertain embodiments, each A comprises a 2′-substituted sugar moietyselected from among F, ara-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each A comprises a bicyclic sugar moiety. In certainembodiments, each A comprises a bicyclic sugar moiety selected fromamong cEt, cMOE, LNA, α-L-LNA, ENA and 2′-thio LNA. In certainembodiments, each A comprises a modified nucleobase. In certainembodiments, each A comprises a modified nucleobase selected from among2-thio-thymidine nucleoside and 5-propyne uridine nucleoside. In certainembodiments, each A comprises an HNA. In certain embodiments, each Acomprises an F-HNA. In certain embodiments, each A comprises a5′-substituted sugar moiety selected from among 5′-Me, and 5′-(R)-Me.

In certain embodiments, each B comprises a modified sugar moiety. Incertain embodiments, each B comprises a 2′-substituted sugar moiety. Incertain embodiments, each B comprises a 2′-substituted sugar moietyselected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each B comprises a bicyclic sugar moiety. In certainembodiments, each B comprises a bicyclic sugar moiety selected fromamong cEt, cMOE, LNA, α-L-LNA, ENA and 2′-thio LNA. In certainembodiments, each B comprises a modified nucleobase. In certainembodiments, each B comprises a modified nucleobase selected from among2-thio-thymidine nucleoside and 5-propyne urindine nucleoside. Incertain embodiments, each B comprises an HNA. In certain embodiments,each B comprises an F-HNA. In certain embodiments, each B comprises a5′-substituted sugar moiety selected from among 5′-Me, and 5′-(R)-Me.

In certain embodiments, each C comprises a modified sugar moiety. Incertain embodiments, each C comprises a 2′-substituted sugar moiety. Incertain embodiments, each C comprises a 2′-substituted sugar moietyselected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each C comprises a 5′-substituted sugar moiety. In certainembodiments, each C comprises a 5′-substituted sugar moiety selectedfrom among 5′-Me, and 5′-(R)-Me. In certain embodiments, each Ccomprises a bicyclic sugar moiety. In certain embodiments, each Ccomprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA,α-L-LNA, ENA and 2′-thio LNA. In certain embodiments, each C comprises amodified nucleobase. In certain embodiments, each C comprises a modifiednucleobase selected from among 2-thio-thymidine and 5-propyne uridine.In certain embodiments, each C comprises a 2-thio-thymidine nucleoside.In certain embodiments, each C comprises an HNA. In certain embodiments,each C comprises an F-HNA.

In certain embodiments, each W comprises a modified sugar moiety. Incertain embodiments, each W comprises a 2′-substituted sugar moiety. Incertain embodiments, each W comprises a 2′-substituted sugar moietyselected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each W comprises a 5′-substituted sugar moiety. In certainembodiments, each W comprises a 5′-substituted sugar moiety selectedfrom among 5′-Me, and 5′-(R)-Me. In certain embodiments, each Wcomprises a bicyclic sugar moiety. In certain embodiments, each Wcomprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA,α-L-LNA, ENA and 2′-thio LNA. In certain embodiments, each W comprises asugar surrogate. In certain embodiments, each W comprises a sugarsurrogate selected from among HNA and F-HNA. In certain embodiments,each W comprises a 2-thio-thymidine nucleoside.

In certain embodiments, at least one of A or B comprises a bicyclicsugar moiety, and the other comprises a 2′-substituted sugar moiety. Incertain embodiments, one of A or B is an LNA nucleoside and the other ofA or B comprises a 2′-substituted sugar moiety. In certain embodiments,one of A or B is a cEt nucleoside and the other of A or B comprises a2′-substituted sugar moiety. In certain embodiments, one of A or B is anα-L-LNA nucleoside and the other of A or B comprises a 2′-substitutedsugar moiety. In certain embodiments, one of A or B is an LNA nucleosideand the other of A or B comprises a 2′-MOE sugar moiety. In certainembodiments, one of A or B is a cEt nucleoside and the other of A or Bcomprises a 2′-MOE sugar moiety. In certain embodiments, one of A or Bis an α-L-LNA nucleoside and the other of A or B comprises a 2′-MOEsugar moiety. In certain embodiments, one of A or B is an LNA nucleosideand the other of A or B comprises a 2′-F sugar moiety. In certainembodiments, one of A or B is a cEt nucleoside and the other of A or Bcomprises a 2′-F sugar moiety. In certain embodiments, one of A or B isan α-L-LNA nucleoside and the other of A or B comprises a 2′-F sugarmoiety. In certain embodiments, one of A or B is an LNA nucleoside andthe other of A or B comprises a 2′-(ara)-F sugar moiety. In certainembodiments, one of A or B is a cEt nucleoside and the other of A or Bcomprises a 2′-(ara)-F sugar moiety. In certain embodiments, one of A orB is an α-L-LNA nucleoside and the other of A or B comprises a2′-(ara)-F sugar moiety.

In certain embodiments, A comprises a bicyclic sugar moiety, and Bcomprises a 2′-substituted sugar moiety. In certain embodiments, A is anLNA nucleoside and B comprises a 2′-substituted sugar moiety. In certainembodiments, A is a cEt nucleoside and B comprises a 2′-substitutedsugar moiety. In certain embodiments, A is an α-L-LNA nucleoside and Bcomprises a 2′-substituted sugar moiety.

In certain embodiments, A comprises a bicyclic sugar moiety, and Bcomprises a 2′-MOE sugar moiety. In certain embodiments, A is an LNAnucleoside and B comprises a 2′-MOE sugar moiety. In certainembodiments, A is a cEt nucleoside and B comprises a 2′-MOE sugarmoiety. In certain embodiments, A is an α-L-LNA nucleoside and Bcomprises a 2′-MOE sugar moiety.

In certain embodiments, A comprises a bicyclic sugar moiety, and Bcomprises a 2′-F sugar moiety. In certain embodiments, A is an LNAnucleoside and B comprises a 2′-F sugar moiety. In certain embodiments,A is a cEt nucleoside and B comprises a 2′-F sugar moiety. In certainembodiments, A is an α-L-LNA nucleoside and B comprises a 2′-F sugarmoiety.

In certain embodiments, A comprises a bicyclic sugar moiety, and Bcomprises a 2′-(ara)-F sugar moiety. In certain embodiments, A is an LNAnucleoside and B comprises a 2′-(ara)-F sugar moiety. In certainembodiments, A is a cEt nucleoside and B comprises a 2′-(ara)-F sugarmoiety. In certain embodiments, A is an α-L-LNA nucleoside and Bcomprises a 2′-(ara)-F sugar moiety.

In certain embodiments, B comprises a bicyclic sugar moiety, and Acomprises a 2′-MOE sugar moiety. In certain embodiments, B is an LNAnucleoside and A comprises a 2′-MOE sugar moiety. In certainembodiments, B is a cEt nucleoside and A comprises a 2′-MOE sugarmoiety. In certain embodiments, B is an α-L-LNA nucleoside and Acomprises a 2′-MOE sugar moiety.

In certain embodiments, B comprises a bicyclic sugar moiety, and Acomprises a 2′-F sugar moiety. In certain embodiments, B is an LNAnucleoside and A comprises a 2′-F sugar moiety. In certain embodiments,B is a cEt nucleoside and A comprises a 2′-F sugar moiety. In certainembodiments, B is an α-L-LNA nucleoside and A comprises a 2′-F sugarmoiety.

In certain embodiments, B comprises a bicyclic sugar moiety, and Acomprises a 2′-(ara)-F sugar moiety. In certain embodiments, B is an LNAnucleoside and A comprises a 2′-(ara)-F sugar moiety. In certainembodiments, B is a cEt nucleoside and A comprises a 2′-(ara)-F sugarmoiety. In certain embodiments, B is an α-L-LNA nucleoside and Acomprises a 2′-(ara)-F sugar moiety.

In certain embodiments, at least one of A or B comprises a bicyclicsugar moiety, another of A or B comprises a 2′-substituted sugar moietyand W comprises a modified nucleobase. In certain embodiments, one of Aor B is an LNA nucleoside, another of A or B comprises a 2′-substitutedsugar moiety, and W comprises a modified nucleobase. In certainembodiments, one of A or B is a cEt nucleoside, another of A or Bcomprises a 2′-substituted sugar moiety, and C comprises a modifiednucleobase. In certain embodiments, one of A or B is an α-L-LNAnucleoside, another of A or B comprises a 2′-substituted sugar moiety,and W comprises a modified nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises amodified nucleobase. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a modified nucleobase. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and W comprises a modified nucleobase. In certain embodiments, one of Aor B is an α-L-LNA nucleoside, another of A or B comprises a 2′-MOEsugar moiety, and W comprises a modified nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises amodified nucleobase. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a modified nucleobase. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-F sugar moiety,and W comprises a modified nucleobase. In certain embodiments, one of Aor B is an α-L-LNA nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a modified nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises amodified nucleobase. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a modified nucleobase. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a modified nucleobase. In certain embodiments,one of A or B is an α-L-LNA nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a modified nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-substituted sugar moiety, and Wcomprises a 2-thio-thymidine nucleobase. In certain embodiments, one ofA or B is an LNA nucleoside, another of A or B comprises a2′-substituted sugar moiety, and W comprises a 2-thio-thymidinenucleobase. In certain embodiments, one of A or B is a cEt nucleoside,another of A or B comprises a 2′-substituted sugar moiety, and Wcomprises a 2-thio-thymidine nucleobase. In certain embodiments, one ofA or B is an α-L-LNA nucleoside, another of A or B comprises a2′-substituted sugar moiety, and W comprises a 2-thio-thymidinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a2-thio-thymidine nucleobase. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a 2-thio-thymidine nucleobase. In certain embodiments, one ofA or B is a cEt nucleoside, another of A or B comprises a 2′-MOE sugarmoiety, and W comprises a 2-thio-thymidine nucleobase. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-MOE sugar moiety, and W comprises a 2-thio-thymidinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a2-thio-thymidine nucleobase. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a 2-thio-thymidine nucleobase. In certain embodiments, one ofA or B is a cEt nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a 2-thio-thymidine nucleobase. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-F sugar moiety, and W comprises a 2-thio-thymidinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a2-thio-thymidine nucleobase. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety,and W comprises a 2-thio-thymidine nucleobase. In certain embodiments,one of A or B is a cEt nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase.In certain embodiments, one of A or B is an α-L-LNA nucleoside, anotherof A or B comprises a 2′-(ara)-F sugar moiety, and W comprises2-thio-thymidine nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a5-propyne uridine nucleobase. In certain embodiments, one of A or B isan LNA nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and C comprises a 5-propyne uridine nucleobase. In certain embodiments,one of A or B is a cEt nucleoside, another of A or B comprises a 2′-MOEsugar moiety, and W comprises a 5-propyne uridine nucleobase. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-MOE sugar moiety, and C comprises a 5-propyne uridinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a5-propyne uridine nucleobase. In certain embodiments, one of A or B isan LNA nucleoside, another of A or B comprises a 2′-F sugar moiety, andC comprises a 5-propyne uridine nucleobase. In certain embodiments, oneof A or B is a cEt nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a 5-propyne uridine nucleobase. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-F sugar moiety, and W comprises a 5-propyne uridinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a5-propyne uridine nucleobase. In certain embodiments, one of A or B isan LNA nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a 5-propyne uridine nucleobase. In certainembodiments, one of A or B is a cEt nucleoside, another of A or Bcomprises a 2′-(ara)-F sugar moiety, and W comprises a 5-propyne uridinenucleobase. In certain embodiments, one of A or B is an α-L-LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a 5-propyne uridine nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises asugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a sugar surrogate. In certain embodiments, one of A or B is acEt nucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a sugar surrogate. In certain embodiments, one of A or B is anα-L-LNA nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and W comprises a sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a sugarsurrogate. In certain embodiments, one of A or B is an LNA nucleoside,another of A or B comprises a 2′-F sugar moiety, and W comprises a sugarsurrogate. In certain embodiments, one of A or B is a cEt nucleoside,another of A or B comprises a 2′-F sugar moiety, and W comprises a sugarsurrogate. In certain embodiments, one of A or B is an α-L-LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises asugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a sugar surrogate. In certain embodiments, one of A or B is acEt nucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety,and W comprises a sugar surrogate. In certain embodiments, one of A or Bis an α-L-LNA nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a HNAsugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and W comprises a HNA sugar surrogate. In certain embodiments, one of Aor B is an α-L-LNA nucleoside, another of A or B comprises a 2′-MOEsugar moiety, and W comprises a HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a HNAsugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-F sugar moiety,and W comprises a HNA sugar surrogate. In certain embodiments, one of Aor B is an α-L-LNA nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a sugar HNA surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises aHNA sugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a HNA sugar surrogate. In certain embodiments,one of A or B is an α-L-LNA nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises aF-HNA sugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a F-HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and W comprises a F-HNA sugar surrogate. In certain embodiments, one ofA or B is an α-L-LNA nucleoside, another of A or B comprises a 2′-MOEsugar moiety, and W comprises a F-HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a F-HNAsugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a F-HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-F sugar moiety,and W comprises a F-HNA sugar surrogate. In certain embodiments, one ofA or B is an α-L-LNA nucleoside, another of A or B comprises a 2′-Fsugar moiety, and W comprises a F-HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises aF-HNA sugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a F-HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a F-HNA sugar surrogate. In certain embodiments,one of A or B is an α-L-LNA nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a 5‘-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2’-MOE sugar moiety, and Wcomprises a 5′-Me DNA sugar moiety. In certain embodiments, one of A orB is a cEt nucleoside, another of A or B comprises a 2′-MOE sugarmoiety, and W comprises a 5 ‘-Me DNA sugar moiety. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2’-MOE sugar moiety, and W comprises a 5′-Me DNA sugarmoiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a 5′-MeDNA sugar moiety. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a 5′-Me DNA sugar moiety. In certain embodiments, one of A orB is a cEt nucleoside, another of A or B comprises a 2′-F sugar moiety,and W comprises a 5′-Me DNA sugar moiety. In certain embodiments, one ofA or B is an α-L-LNA nucleoside, another of A or B comprises a 2′-Fsugar moiety, and W comprises a 5′-Me DNA sugar moiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a5′-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a 5′-Me DNA sugar moiety. In certain embodiments, one of A orB is a cEt nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a 5′-Me DNA sugar moiety. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-(ara)-F sugar moiety, and W comprises a 5′-Me DNA sugarmoiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a5′-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a 5′-(R)-Me DNA sugar moiety. In certain embodiments, one of Aor B is a cEt nucleoside, another of A or B comprises a 2′-MOE sugarmoiety, and W comprises a 5′-(R)-Me DNA sugar moiety. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-MOE sugar moiety, and W comprises a 5′-(R)-Me DNA sugarmoiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a5′-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a 5′-(R)-Me DNA sugar moiety. In certain embodiments, one of Aor B is a cEt nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a 5′-(R)-Me DNA sugar moiety. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-F sugar moiety, and W comprises a 5′-(R)-Me DNA sugarmoiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a5′-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety,and W comprises a 5′-(R)-Me DNA sugar moiety. In certain embodiments,one of A or B is a cEt nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a 5′-(R)-Me DNA sugar moiety.In certain embodiments, one of A or B is an α-L-LNA nucleoside, anotherof A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a5′-(R)-Me DNA sugar moiety.

In certain embodiments, at least two of A, B or W comprises a2′-substituted sugar moiety, and the other comprises a bicyclic sugarmoiety. In certain embodiments, at least two of A, B or W comprises abicyclic sugar moiety, and the other comprises a 2′-substituted sugarmoiety. In certain embodiments, a gapmer has a sugar motif other than:E-K-K-(D)₉-K-K-E; E-E-E-E-K-(D)₉-E-E-E-E-E; E-K-K-K-(D)₉-K-K-K-E;K-E-E-K-(D)₉-K-E-E-K; K-D-D-K-(D)₉-K-D-D-K; K-E-K-E-K-(D)₉-K-E-K-E-K;K-D-K-D-K-(D)₉-K-D-K-D-K; E-K-E-K-(D)₉-K-E-K-E;E-E-E-E-E-K-(D)s-E-E-E-E-E; or E-K-E-K-E-(D)₉-E-K-E-K-E,E-E-E-K-K-(D)₇-E-E-K, E-K-E-K-K-K-(D)₇-K-E-K-E,E-K-E-K-E-K-(D)₇-K-E-K-E, wherein K is a nucleoside comprising a cEtsugar moiety and E is a nucleoside comprising a 2′-MOE sugar moiety.

In certain embodiments a gapmer comprises a A-(D)₄-A-(D)₄-A-(D)₄-AAmotif. In certain embodiments a gapmer comprises aB-(D)₄-A-(D)₄-A-(D)₄-AA motif In certain embodiments a gapmer comprisesa A-(D)₄-B-(D)₄-A-(D)₄-AA motif. In certain embodiments a gapmercomprises a A-(D)₄-A-(D)₄-B-(D)₄-AA motif. In certain embodiments agapmer comprises a A-(D)₄-A-(D)₄-A-(D)₄-BA motif. In certain embodimentsa gapmer comprises a A-(D)₄-A-(D)₄-A-(D)₄-BB motif. In certainembodiments a gapmer comprises a K-(D)₄-K-(D)₄-K-(D)₄-K-E motif

viii. Certain Internucleoside Linkage Motifs

In certain embodiments, oligonucleotides comprise modifiedinternucleoside linkages arranged along the oligonucleotide or regionthereof in a defined pattern or modified internucleoside linkage motif.In certain embodiments, internucleoside linkages are arranged in agapped motif, as described above for nucleoside motif. In suchembodiments, the internucleoside linkages in each of two wing regionsare different from the internucleoside linkages in the gap region. Incertain embodiments the internucleoside linkages in the wings arephosphodiester and the internucleoside linkages in the gap arephosphorothioate. The nucleoside motif is independently selected, sosuch oligonucleotides having a gapped internucleoside linkage motif mayor may not have a gapped nucleoside motif and if it does have a gappednucleoside motif, the wing and gap lengths may or may not be the same.

In certain embodiments, oligonucleotides comprise a region having analternating internucleoside linkage motif. In certain embodiments,oligonucleotides of the present invention comprise a region of uniformlymodified internucleoside linkages. In certain such embodiments, theoligonucleotide comprises a region that is uniformly linked byphosphorothioate internucleoside linkages. In certain embodiments, theoligonucleotide is uniformly linked by phosphorothioate. In certainembodiments, each internucleoside linkage of the oligonucleotide isselected from phosphodiester and phosphorothioate. In certainembodiments, each internucleoside linkage of the oligonucleotide isselected from phosphodiester and phosphorothioate and at least oneinternucleoside linkage is phosphorothioate.

In certain embodiments, the oligonucleotide comprises at least 6phosphorothioate internucleoside linkages. In certain embodiments, theoligonucleotide comprises at least 8 phosphorothioate internucleosidelinkages. In certain embodiments, the oligonucleotide comprises at least10 phosphorothioate internucleoside linkages. In certain embodiments,the oligonucleotide comprises at least one block of at least 6consecutive phosphorothioate internucleoside linkages. In certainembodiments, the oligonucleotide comprises at least one block of atleast 8 consecutive phosphorothioate internucleoside linkages. Incertain embodiments, the oligonucleotide comprises at least one block ofat least 10 consecutive phosphorothioate internucleoside linkages. Incertain embodiments, the oligonucleotide comprises at least block of atleast one 12 consecutive phosphorothioate internucleoside linkages. Incertain such embodiments, at least one such block is located at the 3′end of the oligonucleotide. In certain such embodiments, at least onesuch block is located within 3 nucleosides of the 3′ end of theoligonucleotide.

In certain embodiments, oligonucleotides comprise one or moremethylphosponate linkages. In certain embodiments, oligonucleotideshaving a gapmer nucleoside motif comprise a linkage motif comprising allphosphorothioate linkages except for one or two methylphosponatelinkages. In certain embodiments, one methylphosponate linkage is in thecentral gap of an oligonucleotide having a gapmer nucleoside motif

ix. Certain Modification Motifs

Modification motifs define oligonucleotides by nucleoside motif (sugarmotif and nucleobase motif) and linkage motif. For example, certainoligonucleotides have the following modification motif:

A_(s)A_(s)A_(s)D_(s)D_(s)D_(s)D_(s)(^(N)D)_(s)D_(s)D_(s)D_(s)D_(s)B_(s)B_(s)B;

wherein each A is a modified nucleoside comprising a 2′-substitutedsugar moiety; each D is an unmodified 2′-deoxynucleoside; each B is amodified nucleoside comprising a bicyclic sugar moiety; ^(N)D is amodified nucleoside comprising a modified nucleobase; and s is aphosphorothioate internucleoside linkage. Thus, the sugar motif is agapmer motif. The nucleobase modification motif is a single modifiednucleobase at 8^(th) nucleoside from the 5′-end. Combining the sugarmotif and the nucleobase modification motif, the nucleoside motif is aninterrupted gapmer where the gap of the sugar modified gapmer isinterrupted by a nucleoside comprising a modified nucleobase. Thelinkage motif is uniform phosphorothioate. The following non-limitingTable further illustrates certain modification motifs:

TABLE 13 Certain Modification Motifs 5′-wing region Central gap region3′-wing region B_(s)B_(s)_(s)D_(s)D_(s)D_(s)D_(s)D_(s)D_(s)D_(s)D_(s)D_(s)A_(s)A_(s)A_(s)A_(s)A_(s)A_(s)A_(s)A AsBsBs DsDsDsDsDsDsDsDsDs BsBsAAsBsBs DsDsDsDs(^(N)D)sDsDsDsDs BsBsA AsBsBs DsDsDsDsAsDsDsDsDs BsBsAAsBsBs DsDsDsDsBsDsDsDsDs BsBsA AsBsBs DsDsDsDsWsDsDsDsDs BsBsA AsBsBsBsDsDsDsDsDsDsDsDsDs BsBsAsBsB AsBsBs DsDsDsDsDsDsDsDsDs BsBsAsBsBBsBsAsBsBs DsDsDsDsDsDsDsDsDs BsBsA AsBsBs DsDsDsDsDsDsDsDsDsBsBsAsBsBsBsB AsAsBsAsAs DsDsDsDsDsDsDsDsDs BsBsA AsAsAsBsAsAsDsDsDsDsDsDsDsDsDs BsBsA AsAsBsAsAs DsDsDsDsDsDsDsDsDs AsAsBsAsAAsAsAsBsAsAs DsDsDsDsDsDsDsDsDs AsAsBsAsAsA AsAsAsAsBsAsAsDsDsDsDsDsDsDsDsDs BsBsA AsBsAsBs DsDsDsDsDsDsDsDsDs BsAsBsA AsBsAsBsDsDsDsDsDsDsDsDsDs AsAsBsAsAs AsBsBs DsDsDsDsDsDsDsDsDs BsAsBsABsBsAsBsBsBsB DsDsDsDsDsDsDsDsDs BsAsBsA AsAsAsAsAs DsDsDsDsDsDsDsDsDsAsAsAsAsA AsAsAsAsAs DsDsDsDsDsDsDs AsAsAsAsA AsAsAsAsAsDsDsDsDsDsDsDsDsDs BsBsAsBsBsBsB AsAsAsBsBs DsDsDsDsDsDsDs BsBsAAsBsAsBs DsDsDsDsDsDsDsDs BsBsA AsBsAsBs DsDsDsDsDsDsDs AsAsAsBsBsAsAsAsAsBs DsDsDsDsDsDsDs BsAsAsAsA BsBs DsDsDsDsDsDsDsDs AsA AsAsDsDsDsDsDsDsDs AsAsAsAsAsAsAsA AsAsAs DsDsDsDsDsDsDs AsAsAsAsAsAsAAsAsAs DsDsDsDsDsDsDs AsAsAsAsAsA AsBs DsDsDsDsDsDsDs BsBsBsA AsBsBsBsDsDsDsDsDsDsDsDsDs BsA AsBs DsDsDsDsDsDsDsDsDs BsBsBsA AsAsAsBsBsDsDsDs(^(N)D)sDsDsDs BsBsAsAsA AsAsAsBsBs DsDsDsAsDsDsDs BsBsAsAsAAsAsAsBsBs DsDsDsBsDsDsDs BsBsAsAsA AsAsAsAsBs DsDsDsDsDsDsDs BsAsAsAsAAsAsBsBsBs DsDsDsDsDsDsDs BsBsBsAsA AsAsAsAsBs DsDsDsDsDsDsDs AsAsAsAsAsAsAsAsBsBs DsDsDsDsDsDsDs AsAsAsAsAs AsAsBsBsBs DsDsDsDsDsDsDsAsAsAsAsAs AsAsAsAsAs DsDsDsDsDsDsDs BsAsAsAsAs AsAsAsAsAsDsDsDsDsDsDsDs BsBsAsAsAs AsAsAsAsAs DsDsDsDsDsDsDs BsBsBsAsAs AsBsBsDsDsDsDs(^(N)D)s(^(N)D)sDsDsDs BsBsA AsBsBsDs(^(N)D)s(^(N)D)sDs(^(N)D)s(^(N)D)sDs(^(N)D)s(^(N)D)s BsBsA AsBsBsDs(^(N)D)sDsDsDsDsDsDsDs BsBsA AsBsBs DsDs(^(N)D)sDsDsDsDsDsDs BsBsAAsBsBs Ds(^(N)D)s(^(N)D)sDsDsDsDsDsDs BsBsA AsBsBs DsDs(D)zDsDsDsDsDsDsBsBsA AsBsBs Ds(D)zDsDsDsDsDsDsDs BsBsA AsBsBs (D)zDsDsDsDsDsDsDsDsBsBsA AsBsBs DsDsAsDsDsDsDsDsDs BsBsA AsBsBs DsDsBsDsDsDsDsDsDs BsBsAAsBsBs AsDsDsDsDsDsDsDsDs BsBsA AsBsBs BsDsDsDsDsDsDsDsDs BsBsA AsBsAsBsDsDs(D)zDsDsDsDsDsDs BsBsBsAsAs AsAsAsBsBs DsDs(^(N)D)sDsDsDsDsDsDs AsAAsBsBsBs Ds(D)zDsDsDsDsDsDsDs AsAsAsBsBs AsBsBs DsDsDsDsDsDsDsDs(D)zBsBsA AsAsBsBsBs DsDsDsAsDsDsDs BsBsBsAsA AsAsBsBsBs DsDsDsBsDsDsDsBsBsBsAsA AsBsAsBs DsDsDsAsDsDsDs BsBsAsBsBsBsB AsBsBsBsDsDsDsDs(D)zDsDsDsDs BsA AsAsBsBsBs DsDsAsAsDsDsDs BsBsA AsBsBsDsDsDsDs(D)zDsDsDsDs BsBsBsA BsBs DsDs(^(N)D)sDs(^(N)D)sDsDsDsDsBsBsAsBsBsBsBwherein each A and B are nucleosides comprising differently modifiedsugar moieties, each D is a nucleoside comprising an unmodified 2′deoxysugar moiety, each W is a modified nucleoside of either the first type,the second type or a third type, each ^(N)D is a modified nucleosidecomprising a modified nucleobase, s is a phosphorothioateinternucleoside linkage, and z is a non-phosphorothioate internucleosidelinkage.

In certain embodiments, each A comprises a modified sugar moiety. Incertain embodiments, each A comprises a 2′-substituted sugar moiety. Incertain embodiments, each A comprises a 2′-substituted sugar moietyselected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each A comprises a bicyclic sugar moiety. In certainembodiments, each A comprises a bicyclic sugar moiety selected fromamong cEt, cMOE, LNA, α-L-LNA, ENA and 2′-thio LNA. In certainembodiments, each A comprises a modified nucleobase. In certainembodiments, each A comprises a modified nucleobase selected from among2-thio-thymidine nucleoside and 5-propyne uridine nucleoside. In certainembodiments, each B comprises a modified sugar moiety. In certainembodiments, each B comprises a 2′-substituted sugar moiety. In certainembodiments, each B comprises a 2′-substituted sugar moiety selectedfrom among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certain embodiments,each B comprises a bicyclic sugar moiety. In certain embodiments, each Bcomprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA,α-L-LNA, ENA and 2′-thio LNA. In certain embodiments, each B comprises amodified nucleobase. In certain embodiments, each B comprises a modifiednucleobase selected from among 2-thio-thymidine nucleoside and 5-propyneurindine nucleoside. In certain embodiments, each A comprises an HNA. Incertain embodiments, each A comprises an F-HNA.

In certain embodiments, each W comprises a modified sugar moiety. Incertain embodiments, each W comprises a 2′-substituted sugar moiety. Incertain embodiments, each W comprises a 2′-substituted sugar moietyselected from among F, (ara)-F, OCH₃ and O(CH₂)₂—OCH₃. In certainembodiments, each W comprises a 5′-substituted sugar moiety. In certainembodiments, each W comprises a 5′-substituted sugar moiety selectedfrom among 5′-Me, and 5′-(R)-Me. In certain embodiments, each Wcomprises a bicyclic sugar moiety. In certain embodiments, each Wcomprises a bicyclic sugar moiety selected from among cEt, cMOE, LNA,α-L-LNA, ENA and 2′-thio LNA. In certain embodiments, each W comprises asugar surrogate. In certain embodiments, each W comprises a sugarsurrogate selected from among HNA and F-HNA.

In certain embodiments, at least one of A or B comprises a bicyclicsugar moiety, and the other comprises a 2′-substituted sugar moiety. Incertain embodiments, one of A or B is an LNA nucleoside and the other ofA or B comprises a 2′-substituted sugar moiety. In certain embodiments,one of A or B is a cEt nucleoside and the other of A or B comprises a2′-substituted sugar moiety. In certain embodiments, one of A or B is anα-L-LNA nucleoside and the other of A or B comprises a 2′-substitutedsugar moiety. In certain embodiments, one of A or B is an LNA nucleosideand the other of A or B comprises a 2′-MOE sugar moiety. In certainembodiments, one of A or B is a cEt nucleoside and the other of A or Bcomprises a 2′-MOE sugar moiety. In certain embodiments, one of A or Bis an α-L-LNA nucleoside and the other of A or B comprises a 2′-MOEsugar moiety. In certain embodiments, one of A or B is an LNA nucleosideand the other of A or B comprises a 2′-F sugar moiety. In certainembodiments, one of A or B is a cEt nucleoside and the other of A or Bcomprises a 2′-F sugar moiety. In certain embodiments, one of A or B isan α-L-LNA nucleoside and the other of A or B comprises a 2′-F sugarmoiety. In certain embodiments, one of A or B is an LNA nucleoside andthe other of A or B comprises a 2′-(ara)-F sugar moiety. In certainembodiments, one of A or B is a cEt nucleoside and the other of A or Bcomprises a 2′-(ara)-F sugar moiety. In certain embodiments, one of A orB is an α-L-LNA nucleoside and the other of A or B comprises a2′-(ara)-F sugar moiety.

In certain embodiments, A comprises a bicyclic sugar moiety, and Bcomprises a 2′-substituted sugar moiety. In certain embodiments, A is anLNA nucleoside and B comprises a 2′-substituted sugar moiety. In certainembodiments, A is a cEt nucleoside and B comprises a 2′-substitutedsugar moiety. In certain embodiments, A is an α-L-LNA nucleoside and Bcomprises a 2′-substituted sugar moiety.

In certain embodiments, A comprises a bicyclic sugar moiety, and Bcomprises a 2′-MOE sugar moiety. In certain embodiments, A is an LNAnucleoside and B comprises a 2′-MOE sugar moiety. In certainembodiments, A is a cEt nucleoside and B comprises a 2′-MOE sugarmoiety. In certain embodiments, A is an α-L-LNA nucleoside and Bcomprises a 2′-MOE sugar moiety.

In certain embodiments, A comprises a bicyclic sugar moiety, and Bcomprises a 2′-F sugar moiety. In certain embodiments, A is an LNAnucleoside and B comprises a 2′-F sugar moiety. In certain embodiments,A is a cEt nucleoside and B comprises a 2′-F sugar moiety. In certainembodiments, A is an α-L-LNA nucleoside and B comprises a 2′-F sugarmoiety.

In certain embodiments, A comprises a bicyclic sugar moiety, and Bcomprises a 2′-(ara)-F sugar moiety. In certain embodiments, A is an LNAnucleoside and B comprises a 2′-(ara)-F sugar moiety. In certainembodiments, A is a cEt nucleoside and B comprises a 2′-(ara)-F sugarmoiety. In certain embodiments, A is an α-L-LNA nucleoside and Bcomprises a 2′-(ara)-F sugar moiety.

In certain embodiments, B comprises a bicyclic sugar moiety, and Acomprises a 2′-MOE sugar moiety. In certain embodiments, B is an LNAnucleoside and A comprises a 2′-MOE sugar moiety. In certainembodiments, B is a cEt nucleoside and A comprises a 2′-MOE sugarmoiety. In certain embodiments, B is an α-L-LNA nucleoside and Acomprises a 2′-MOE sugar moiety.

In certain embodiments, B comprises a bicyclic sugar moiety, and Acomprises a 2′-F sugar moiety. In certain embodiments, B is an LNAnucleoside and A comprises a 2′-F sugar moiety. In certain embodiments,B is a cEt nucleoside and A comprises a 2′-F sugar moiety. In certainembodiments, B is an α-L-LNA nucleoside and A comprises a 2′-F sugarmoiety.

In certain embodiments, B comprises a bicyclic sugar moiety, and Acomprises a 2′-(ara)-F sugar moiety. In certain embodiments, B is an LNAnucleoside and A comprises a 2′-(ara)-F sugar moiety. In certainembodiments, B is a cEt nucleoside and A comprises a 2′-(ara)-F sugarmoiety. In certain embodiments, B is an α-L-LNA nucleoside and Acomprises a 2′-(ara)-F sugar moiety.

In certain embodiments, at least one of A or B comprises a bicyclicsugar moiety, another of A or B comprises a 2′-substituted sugar moietyand W comprises a modified nucleobase. In certain embodiments, one of Aor B is an LNA nucleoside, another of A or B comprises a 2′-substitutedsugar moiety, and W comprises a modified nucleobase. In certainembodiments, one of A or B is a cEt nucleoside, another of A or Bcomprises a 2′-substituted sugar moiety, and C comprises a modifiednucleobase. In certain embodiments, one of A or B is an α-L-LNAnucleoside, another of A or B comprises a 2′-substituted sugar moiety,and W comprises a modified nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises amodified nucleobase. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a modified nucleobase. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and W comprises a modified nucleobase. In certain embodiments, one of Aor B is an α-L-LNA nucleoside, another of A or B comprises a 2′-MOEsugar moiety, and W comprises a modified nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises amodified nucleobase. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a modified nucleobase. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-F sugar moiety,and W comprises a modified nucleobase. In certain embodiments, one of Aor B is an α-L-LNA nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a modified nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises amodified nucleobase. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a modified nucleobase. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a modified nucleobase. In certain embodiments,one of A or B is an α-L-LNA nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a modified nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-substituted sugar moiety, and Wcomprises a 2-thio-thymidine nucleobase. In certain embodiments, one ofA or B is an LNA nucleoside, another of A or B comprises a2′-substituted sugar moiety, and W comprises a 2-thio-thymidinenucleobase. In certain embodiments, one of A or B is a cEt nucleoside,another of A or B comprises a 2′-substituted sugar moiety, and Wcomprises a 2-thio-thymidine nucleobase. In certain embodiments, one ofA or B is an α-L-LNA nucleoside, another of A or B comprises a2′-substituted sugar moiety, and W comprises a 2-thio-thymidinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a2-thio-thymidine nucleobase. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a 2-thio-thymidine nucleobase. In certain embodiments, one ofA or B is a cEt nucleoside, another of A or B comprises a 2′-MOE sugarmoiety, and W comprises a 2-thio-thymidine nucleobase. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-MOE sugar moiety, and W comprises a 2-thio-thymidinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a2-thio-thymidine nucleobase. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a 2-thio-thymidine nucleobase. In certain embodiments, one ofA or B is a cEt nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a 2-thio-thymidine nucleobase. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-F sugar moiety, and W comprises a 2-thio-thymidinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a2-thio-thymidine nucleobase. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety,and W comprises a 2-thio-thymidine nucleobase. In certain embodiments,one of A or B is a cEt nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a 2-thio-thymidine nucleobase.In certain embodiments, one of A or B is an α-L-LNA nucleoside, anotherof A or B comprises a 2′-(ara)-F sugar moiety, and W comprises2-thio-thymidine nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a5-propyne uridine nucleobase. In certain embodiments, one of A or B isan LNA nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and C comprises a 5-propyne uridine nucleobase. In certain embodiments,one of A or B is a cEt nucleoside, another of A or B comprises a 2′-MOEsugar moiety, and W comprises a 5-propyne uridine nucleobase. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-MOE sugar moiety, and C comprises a 5-propyne uridinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a5-propyne uridine nucleobase. In certain embodiments, one of A or B isan LNA nucleoside, another of A or B comprises a 2′-F sugar moiety, andC comprises a 5-propyne uridine nucleobase. In certain embodiments, oneof A or B is a cEt nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a 5-propyne uridine nucleobase. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-F sugar moiety, and W comprises a 5-propyne uridinenucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a5-propyne uridine nucleobase. In certain embodiments, one of A or B isan LNA nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a 5-propyne uridine nucleobase. In certainembodiments, one of A or B is a cEt nucleoside, another of A or Bcomprises a 2′-(ara)-F sugar moiety, and W comprises a 5-propyne uridinenucleobase. In certain embodiments, one of A or B is an α-L-LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a 5-propyne uridine nucleobase.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises asugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a sugar surrogate. In certain embodiments, one of A or B is acEt nucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a sugar surrogate. In certain embodiments, one of A or B is anα-L-LNA nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and W comprises a sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a sugarsurrogate. In certain embodiments, one of A or B is an LNA nucleoside,another of A or B comprises a 2′-F sugar moiety, and W comprises a sugarsurrogate. In certain embodiments, one of A or B is a cEt nucleoside,another of A or B comprises a 2′-F sugar moiety, and W comprises a sugarsurrogate. In certain embodiments, one of A or B is an α-L-LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises asugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a sugar surrogate. In certain embodiments, one of A or B is acEt nucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety,and W comprises a sugar surrogate. In certain embodiments, one of A or Bis an α-L-LNA nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a HNAsugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and W comprises a HNA sugar surrogate. In certain embodiments, one of Aor B is an α-L-LNA nucleoside, another of A or B comprises a 2′-MOEsugar moiety, and W comprises a HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a HNAsugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-F sugar moiety,and W comprises a HNA sugar surrogate. In certain embodiments, one of Aor B is an α-L-LNA nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a sugar HNA surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises aHNA sugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a HNA sugar surrogate. In certain embodiments,one of A or B is an α-L-LNA nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises aF-HNA sugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a F-HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-MOE sugar moiety,and W comprises a F-HNA sugar surrogate. In certain embodiments, one ofA or B is an α-L-LNA nucleoside, another of A or B comprises a 2′-MOEsugar moiety, and W comprises a F-HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a F-HNAsugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a F-HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-F sugar moiety,and W comprises a F-HNA sugar surrogate. In certain embodiments, one ofA or B is an α-L-LNA nucleoside, another of A or B comprises a 2′-Fsugar moiety, and W comprises a F-HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises aF-HNA sugar surrogate. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a F-HNA sugar surrogate. In certain embodiments, one of A or Bis a cEt nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a F-HNA sugar surrogate. In certain embodiments,one of A or B is an α-L-LNA nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a F-HNA sugar surrogate.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a5′-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a 5′-Me DNA sugar moiety. In certain embodiments, one of A orB is a cEt nucleoside, another of A or B comprises a 2′-MOE sugarmoiety, and W comprises a 5′-Me DNA sugar moiety. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-MOE sugar moiety, and W comprises a 5′-Me DNA sugarmoiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a 5′-MeDNA sugar moiety. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a 5′-Me DNA sugar moiety. In certain embodiments, one of A orB is a cEt nucleoside, another of A or B comprises a 2′-F sugar moiety,and W comprises a 5′-Me DNA sugar moiety. In certain embodiments, one ofA or B is an α-L-LNA nucleoside, another of A or B comprises a 2′-Fsugar moiety, and W comprises a 5′-Me DNA sugar moiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a5′-Me DNA sugar moiety. In certain embodiments, one of A or B is an LNAnucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety, and Wcomprises a 5′-Me DNA sugar moiety. In certain embodiments, one of A orB is a cEt nucleoside, another of A or B comprises a 2′-(ara)-F sugarmoiety, and W comprises a 5′-Me DNA sugar moiety. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-(ara)-F sugar moiety, and W comprises a 5′-Me DNA sugarmoiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a5′-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-MOE sugar moiety, and Wcomprises a 5′-(R)-Me DNA sugar moiety. In certain embodiments, one of Aor B is a cEt nucleoside, another of A or B comprises a 2′-MOE sugarmoiety, and W comprises a 5′-(R)-Me DNA sugar moiety. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-MOE sugar moiety, and W comprises a 5′-(R)-Me DNA sugarmoiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-F sugar moiety, and W comprises a5′-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-F sugar moiety, and Wcomprises a 5′-(R)-Me DNA sugar moiety. In certain embodiments, one of Aor B is a cEt nucleoside, another of A or B comprises a 2′-F sugarmoiety, and W comprises a 5′-(R)-Me DNA sugar moiety. In certainembodiments, one of A or B is an α-L-LNA nucleoside, another of A or Bcomprises a 2′-F sugar moiety, and W comprises a 5′-(R)-Me DNA sugarmoiety.

In certain embodiments, one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a5′-(R)-Me DNA sugar moiety. In certain embodiments, one of A or B is anLNA nucleoside, another of A or B comprises a 2′-(ara)-F sugar moiety,and W comprises a 5′-(R)-Me DNA sugar moiety. In certain embodiments,one of A or B is a cEt nucleoside, another of A or B comprises a2′-(ara)-F sugar moiety, and W comprises a 5′-(R)-Me DNA sugar moiety.In certain embodiments, one of A or B is an α-L-LNA nucleoside, anotherof A or B comprises a 2′-(ara)-F sugar moiety, and W comprises a5′-(R)-Me DNA sugar moiety.

In certain embodiments, at least two of A, B or W comprises a2′-substituted sugar moiety, and the other comprises a bicyclic sugarmoiety. In certain embodiments, at least two of A, B or W comprises abicyclic sugar moiety, and the other comprises a 2′-substituted sugarmoiety.

d. Certain Overall Lengths

In certain embodiments, the present invention provides oligomericcompounds including oligonucleotides of any of a variety of ranges oflengths. In certain embodiments, the invention provides oligomericcompounds or oligonucleotides consisting of X to Y linked nucleosides,where X represents the fewest number of nucleosides in the range and Yrepresents the largest number of nucleosides in the range. In certainsuch embodiments, X and Y are each independently selected from 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,47, 48, 49, and 50; provided that X≤Y. For example, in certainembodiments, the invention provides oligomeric compounds which compriseoligonucleotides consisting of 8 to 9, 8 to 10, 8 to 11, 8 to 12, 8 to13, 8 to 14, 8 to 15, 8 to 16, 8 to 17, 8 to 18, 8 to 19, 8 to 20, 8 to21, 8 to 22, 8 to 23, 8 to 24, 8 to 25, 8 to 26, 8 to 27, 8 to 28, 8 to29, 8 to 30, 9 to 10, 9 to 11, 9 to 12, 9 to 13, 9 to 14, 9 to 15, 9 to16, 9 to 17, 9 to 18, 9 to 19, 9 to 20, 9 to 21, 9 to 22, 9 to 23, 9 to24, 9 to 25, 9 to 26, 9 to 27, 9 to 28, 9 to 29, 9 to 30, 10 to 11, 10to 12, 10 to 13, 10 to 14, 10 to 15, 10 to 16, 10 to 17, 10 to 18, 10 to19, 10 to 20, 10 to 21, 10 to 22, 10 to 23, 10 to 24, 10 to 25, 10 to26, 10 to 27, 10 to 28, 10 to 29, 10 to 30, 11 to 12, 11 to 13, 11 to14, 11 to 15, 11 to 16, 11 to 17, 11 to 18, 11 to 19, 11 to 20, 11 to21, 11 to 22, 11 to 23, 11 to 24, 11 to 25, 11 to 26, 11 to 27, 11 to28, 11 to 29, 11 to 30, 12 to 13, 12 to 14, 12 to 15, 12 to 16, 12 to17, 12 to 18, 12 to 19, 12 to 20, 12 to 21, 12 to 22, 12 to 23, 12 to24, 12 to 25, 12 to 26, 12 to 27, 12 to 28, 12 to 29, 12 to 30, 13 to14, 13 to 15, 13 to 16, 13 to 17, 13 to 18, 13 to 19, 13 to 20, 13 to21, 13 to 22, 13 to 23, 13 to 24, 13 to 25, 13 to 26, 13 to 27, 13 to28, 13 to 29, 13 to 30, 14 to 15, 14 to 16, 14 to 17, 14 to 18, 14 to19, 14 to 20, 14 to 21, 14 to 22, 14 to 23, 14 to 24, 14 to 25, 14 to26, 14 to 27, 14 to 28, 14 to 29, 14 to 30, 15 to 16, 15 to 17, 15 to18, 15 to 19, 15 to 20, 15 to 21, 15 to 22, 15 to 23, 15 to 24, 15 to25, 15 to 26, 15 to 27, 15 to 28, 15 to 29, 15 to 30, 16 to 17, 16 to18, 16 to 19, 16 to 20, 16 to 21, 16 to 22, 16 to 23, 16 to 24, 16 to25, 16 to 26, 16 to 27, 16 to 28, 16 to 29, 16 to 30, 17 to 18, 17 to19, 17 to 20, 17 to 21, 17 to 22, 17 to 23, 17 to 24, 17 to 25, 17 to26, 17 to 27, 17 to 28, 17 to 29, 17 to 30, 18 to 19, 18 to 20, 18 to21, 18 to 22, 18 to 23, 18 to 24, 18 to 25, 18 to 26, 18 to 27, 18 to28, 18 to 29, 18 to 30, 19 to 20, 19 to 21, 19 to 22, 19 to 23, 19 to24, 19 to 25, 19 to 26, 19 to 29, 19 to 28, 19 to 29, 19 to 30, 20 to21, 20 to 22, 20 to 23, 20 to 24, 20 to 25, 20 to 26, 20 to 27, 20 to28, 20 to 29, 20 to 30, 21 to 22, 21 to 23, 21 to 24, 21 to 25, 21 to26, 21 to 27, 21 to 28, 21 to 29, 21 to 30, 22 to 23, 22 to 24, 22 to25, 22 to 26, 22 to 27, 22 to 28, 22 to 29, 22 to 30, 23 to 24, 23 to25, 23 to 26, 23 to 27, 23 to 28, 23 to 29, 23 to 30, 24 to 25, 24 to26, 24 to 27, 24 to 28, 24 to 29, 24 to 30, 25 to 26, 25 to 27, 25 to28, 25 to 29, 25 to 30, 26 to 27, 26 to 28, 26 to 29, 26 to 30, 27 to28, 27 to 29, 27 to 30, 28 to 29, 28 to 30, or 29 to 30 linkednucleosides. In embodiments where the number of nucleosides of anoligomeric compound or oligonucleotide is limited, whether to a range orto a specific number, the oligomeric compound or oligonucleotide may,nonetheless further comprise additional other substituents. For example,an oligonucleotide comprising 8-30 nucleosides excludes oligonucleotideshaving 31 nucleosides, but, unless otherwise indicated, such anoligonucleotide may further comprise, for example one or moreconjugates, terminal groups, or other substituents. In certainembodiments, a gapmer oligonucleotide has any of the above lengths.

Further, where an oligonucleotide is described by an overall lengthrange and by regions having specified lengths, and where the sum ofspecified lengths of the regions is less than the upper limit of theoverall length range, the oligonucleotide may have additionalnucleosides, beyond those of the specified regions, provided that thetotal number of nucleosides does not exceed the upper limit of theoverall length range.

e. Certain Oligonucleotides

In certain embodiments, oligonucleotides of the present invention arecharacterized by their modification motif and overall length. In certainembodiments, such parameters are each independent of one another. Thus,unless otherwise indicated, each internucleoside linkage of anoligonucleotide having a gapmer sugar motif may be modified orunmodified and may or may not follow the gapmer modification pattern ofthe sugar modifications. For example, the internucleoside linkageswithin the wing regions of a sugar-gapmer may be the same or differentfrom one another and may be the same or different from theinternucleoside linkages of the gap region. Likewise, such sugar-gapmeroligonucleotides may comprise one or more modified nucleobaseindependent of the gapmer pattern of the sugar modifications. One ofskill in the art will appreciate that such motifs may be combined tocreate a variety of oligonucleotides. Herein if a description of anoligonucleotide or oligomeric compound is silent with respect to one ormore parameter, such parameter is not limited. Thus, an oligomericcompound described only as having a gapmer sugar motif without furtherdescription may have any length, internucleoside linkage motif, andnucleobase modification motif. Unless otherwise indicated, all chemicalmodifications are independent of nucleobase sequence.

f. Certain Conjugate Groups

In certain embodiments, oligomeric compounds are modified by attachmentof one or more conjugate groups. In general, conjugate groups modify oneor more properties of the attached oligomeric compound including but notlimited to pharmacodynamics, pharmacokinetics, stability, binding,absorption, cellular distribution, cellular uptake, charge andclearance. Conjugate groups are routinely used in the chemical arts andare linked directly or via an optional conjugate linking moiety orconjugate linking group to a parent compound such as an oligomericcompound, such as an oligonucleotide. Conjugate groups includes withoutlimitation, intercalators, reporter molecules, polyamines, polyamides,polyethylene glycols, thioethers, polyethers, cholesterols,thiocholesterols, cholic acid moieties, folate, lipids, phospholipids,biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine,fluoresceins, rhodamines, coumarins and dyes. Certain conjugate groupshave been described previously, for example: cholesterol moiety(Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556),cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4,1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al.,Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med.Chem. Let., 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al.,Nucl. Acids Res., 1992, 20, 533-538), an aliphatic chain, e.g.,do-decan-diol or undecyl residues (Saison-Behmoaras et al., EMBO J.,1991, 10, 1111-1118; Kabanov et al., FEBS Lett., 1990, 259, 327-330;Svinarchuk et al., Biochimie, 1993, 75, 49-54), a phospholipid, e.g.,di-hexadecyl-rac-glycerol or triethyl-ammonium1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al.,Tetrahedron Lett., 1995, 36, 3651-3654; Shea et al., Nucl. Acids Res.,1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain(Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), oradamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36,3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta,1995, 1264, 229-237), or an octadecylamine orhexylamino-carbonyl-oxycholesterol moiety (Crooke et al., J. Pharmacol.Exp. Ther., 1996, 277, 923-937).

In certain embodiments, a conjugate group comprises an active drugsubstance, for example, aspirin, warfarin, phenylbutazone, ibuprofen,suprofen, fen-bufen, ketoprofen, (S)-(+)-pranoprofen, carprofen,dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinicacid, a benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, abarbiturate, a cephalosporin, a sulfa drug, an antidiabetic, anantibacterial or an antibiotic.

In certain embodiments, conjugate groups are directly attached tooligonucleotides in oligomeric compounds. In certain embodiments,conjugate groups are attached to oligonucleotides by a conjugate linkinggroup. In certain such embodiments, conjugate linking groups, including,but not limited to, bifunctional linking moieties such as those known inthe art are amenable to the compounds provided herein. Conjugate linkinggroups are useful for attachment of conjugate groups, such as chemicalstabilizing groups, functional groups, reporter groups and other groupsto selective sites in a parent compound such as for example anoligomeric compound. In general a bifunctional linking moiety comprisesa hydrocarbyl moiety having two functional groups. One of the functionalgroups is selected to bind to a parent molecule or compound of interestand the other is selected to bind essentially any selected group such aschemical functional group or a conjugate group. In some embodiments, theconjugate linker comprises a chain structure or an oligomer of repeatingunits such as ethylene glycol or amino acid units. Examples offunctional groups that are routinely used in a bifunctional linkingmoiety include, but are not limited to, electrophiles for reacting withnucleophilic groups and nucleophiles for reacting with electrophilicgroups. In some embodiments, bifunctional linking moieties includeamino, hydroxyl, carboxylic acid, thiol, unsaturations (e.g., double ortriple bonds), and the like.

Some nonlimiting examples of conjugate linking moieties includepyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and6-aminohexanoic acid (AHEX or AHA). Other linking groups include, butare not limited to, substituted C₁-C₁₀ alkyl, substituted orunsubstituted C₂-C₁₀ alkenyl or substituted or unsubstituted C₂-C₁₀alkynyl, wherein a nonlimiting list of preferred substituent groupsincludes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol,thioalkoxy, halogen, alkyl, aryl, alkenyl and alkynyl.

Conjugate groups may be attached to either or both ends of anoligonucleotide (terminal conjugate groups) and/or at any internalposition.

In certain embodiments, conjugate groups are at the 3′-end of anoligonucleotide of an oligomeric compound. In certain embodiments,conjugate groups are near the 3′-end. In certain embodiments, conjugatesare attached at the 3′end of an oligomeric compound, but before one ormore terminal group nucleosides. In certain embodiments, conjugategroups are placed within a terminal group. In certain embodiments, thepresent invention provides oligomeric compounds. In certain embodiments,oligomeric compounds comprise an oligonucleotide. In certainembodiments, an oligomeric compound comprises an oligonucleotide and oneor more conjugate and/or terminal groups. Such conjugate and/or terminalgroups may be added to oligonucleotides having any of the motifsdiscussed above. Thus, for example, an oligomeric compound comprising anoligonucleotide having region of alternating nucleosides may comprise aterminal group.

C. Antisense Compounds

In certain embodiments, oligomeric compounds provided herein areantisense compounds. Such antisense compounds are capable of hybridizingto a target nucleic acid, resulting in at least one antisense activity.In certain embodiments, antisense compounds specifically hybridize toone or more target nucleic acid. In certain embodiments, a specificallyhybridizing antisense compound has a nucleobase sequence comprising aregion having sufficient complementarity to a target nucleic acid toallow hybridization and result in antisense activity and insufficientcomplementarity to any non-target so as to avoid non-specifichybridization to any non-target nucleic acid sequences under conditionsin which specific hybridization is desired (e.g., under physiologicalconditions for in vivo or therapeutic uses, and under conditions inwhich assays are performed in the case of in vitro assays).

In certain embodiments, the present invention provides antisensecompounds comprising oligonucleotides that are fully complementary tothe target nucleic acid over the entire length of the oligonucleotide.In certain embodiments, oligonucleotides are 99% complementary to thetarget nucleic acid. In certain embodiments, oligonucleotides are 95%complementary to the target nucleic acid. In certain embodiments, sucholigonucleotides are 90% complementary to the target nucleic acid.

In certain embodiments, such oligonucleotides are 85% complementary tothe target nucleic acid. In certain embodiments, such oligonucleotidesare 80% complementary to the target nucleic acid. In certainembodiments, an antisense compound comprises a region that is fullycomplementary to a target nucleic acid and is at least 80% complementaryto the target nucleic acid over the entire length of theoligonucleotide. In certain such embodiments, the region of fullcomplementarity is from 6 to 14 nucleobases in length.

a. Certain Antisense Activities and Mechanisms

In certain antisense activities, hybridization of an antisense compoundresults in recruitment of a protein that cleaves of the target nucleicacid. For example, certain antisense compounds result in RNase Hmediated cleavage of target nucleic acid. RNase H is a cellularendonuclease that cleaves the RNA strand of an RNA:DNA duplex. The “DNA”in such an RNA:DNA duplex, need not be unmodified DNA. In certainembodiments, the invention provides antisense compounds that aresufficiently “DNA-like” to elicit RNase H activity. Such DNA-likeantisense compounds include, but are not limited to gapmers havingunmodified deoxyfuronose sugar moieties in the nucleosides of the gapand modified sugar moieties in the nucleosides of the wings.

Antisense activities may be observed directly or indirectly. In certainembodiments, observation or detection of an antisense activity involvesobservation or detection of a change in an amount of a target nucleicacid or protein encoded by such target nucleic acid; a change in theratio of splice variants of a nucleic acid or protein; and/or aphenotypic change in a cell or animal.

In certain embodiments, compounds comprising oligonucleotides having agapmer nucleoside motif described herein have desirable propertiescompared to non-gapmer oligonucleotides or to gapmers having othermotifs. In certain circumstances, it is desirable to identify motifsresulting in a favorable combination of potent antisense activity andrelatively low toxicity. In certain embodiments, compounds of thepresent invention have a favorable therapeutic index (measure ofactivity divided by measure of toxicity).

b. Certain Selective Antisense Compounds

In certain embodiments, antisense compounds provided are selective for atarget relative to a non-target nucleic acid. In certain embodiments,the nucleobase sequences of the target and non-target nucleic acidsdiffer by no more than 4 differentiating nucleobases in the targetedregion. In certain embodiments, the nucleobase sequences of the targetand non-target nucleic acids differ by no more than 3 differentiatingnucleobases in the targeted region. In certain embodiments, thenucleobase sequences of the target and non-target nucleic acids differby no more than 2 differentiating nucleobases in the targeted region. Incertain embodiments, the nucleobase sequences of the target andnon-target nucleic acids differ by a single differentiating nucleobasein the targeted region. In certain embodiments, the target andnon-target nucleic acids are transcripts from different genes. Incertain embodiments, the target and non-target nucleic acids aredifferent alleles for the same gene. In certain embodiments, theintroduction of a mismatch between an antisense compound and anon-target nucleic acid may alter the RNase H cleavage site of a targetnucleic acid compared to a non-target nucleic acid. In certainembodiments, the target and non-target nucleic acids are notfunctionally related to one another (e.g., are transcripts fromdifferent genes). In certain embodiments, the target and not-targetnucleic acids are allelic variants of one another. In certainembodiments, the allelic variant contains a single nucleotidepolymorphism (SNP). In certain embodiments, a SNP is associated with amutant allele. In certain embodiments, a mutant SNP is associated with adisease. In certain embodiments a mutant SNP is associated with adisease, but is not causative of the disease. In certain embodiments,mRNA and protein expression of a mutant allele is associated withdisease.

Selectivity of antisense compounds is achieved, principally, bynucleobase complementarity. For example, if an antisense compound has nomismatches for a target nucleic acid and one or more mismatches for anon-target nucleic acid, some amount of selectivity for the targetnucleic acid will result. In certain embodiments, provided herein areantisense compounds with enhanced selectivity (i.e. the ratio ofactivity for the target to the activity for non-target is greater). Forexample, in certain embodiments, a selective nucleoside comprises aparticular feature or combination of features (e.g., chemicalmodification, motif, placement of selective nucleoside, and/orself-complementary region) that increases selectivity of an antisensecompound compared to an antisense compound not having that feature orcombination of features. In certain embodiments, such feature orcombination of features increases antisense activity for the target. Incertain embodiments, such feature or combination of features decreasesactivity for the target, but decreases activity for the non-target by agreater amount, thus resulting in an increase in selectivity.

Without being limited by mechanism, enhanced selectivity may result froma larger difference in the affinity of an antisense compound for itstarget compared to its affinity for the non-target and/or a largerdifference in RNase H activity for the resulting duplexes. For example,in certain embodiments, a selective antisense compound comprises amodified nucleoside at that same position as a differentiatingnucleobase (i.e., the selective nucleoside is modified). Thatmodification may increase the difference in binding affinity of theantisense compound for the target relative to the non-target. Inaddition or in the alternative, the chemical modification may increasethe difference in RNAse H activity for the duplex formed by theantisense compound and its target compared to the RNase activity for theduplex formed by the antisense compound and the non-target. For example,the modification may exaggerate a structure that is less compatible forRNase H to bind, cleave and/or release the non-target.

In certain embodiments, an antisense compound binds its intended targetto form a target duplex. In certain embodiments, RNase H cleaves thetarget nucleic acid of the target duplex. In certain such embodiments,there is a primary cleavage site between two particular nucleosides ofthe target nucleic acid (the primary target cleavage site), whichaccounts for the largest amount of cleavage of the target nucleic acid.In certain embodiments, there are one or more secondary target cleavagesites. In certain embodiments, the same antisence compound hybridizes toa non-target to form a non-target duplex. In certain such embodiments,the non-target differs from the target by a single nucleobase within thetarget region, and so the antisense compound hybridizes with a singlemismatch. Because of the mismatch, in certain embodiments, RNase Hcleavage of the non-target may be reduced compared to cleavage of thetarget, but still occurs. In certain embodiments, though, the primarysite of that cleavage of the non-target nucleic acid (primary non-targetcleavage site) is different from that of the target. That is; theprimary site is shifted due to the mismatch. In such a circumstance, onemay use a modification placed in the antisense compound to disrupt RNaseH cleavage at the primary non-target cleavage site. Such modificationwill result in reduced cleavage of the non-target, but will resultlittle or no decrease in cleavage of the target. In certain embodiments,the modification is a modified sugar, nucleobase and/or linkage.

In certain embodiments, the primary non-target cleavage site is towardsthe 5′-end of the antisense compound, and the 5′-end of an antisensecompound may be modified to prevent RNaseH cleavage. In this manner, itis thought that one having skill in the art may modify the 5′-end of anantisense compound, or modify the nucleosides in the gap region of the5′-end of the antisense compound, or modify the the 3′-most 5′-regionnucleosides of the antisense compound to selectively inhibit RNaseHcleavage of the non-target nucleic acid duplex while retaining RNase Hcleavage of the target nucleic acid duplex. In certain embodiments, 1-3of the 3′-most 5′-region nucleosides of the antisense compound comprisesa bicyclic sugar moiety.

For example, in certain embodiments the target nucleic acid may have anallelic variant, e.g. a non-target nucleic acid, containing a singlenucleotide polymorphism. An antisense compound may be designed having asingle nucleobase mismatch from the non-target nucleic acid, but whichhas full complementarity to the target nucleic acid. The mismatchbetween the antisense compound and the non-target nucleic acid maydestabilize the antisense compound non-target nucleic acid duplex, andconsequently the cleavage site of RNaseH may shift upstream towards the5′-end of the antisense compound. Modification of the 5′-end of theantisense compound or the gap region near the 5′-end of the antisensecompound, or one or more of the 3′-most nucleosides of the 5′-wingregion, will then prevent RNaseH cleavage of the non-target nucleicacid. Since the target nucleic acid is fully complementary to theantisense compound, the antisense compound and the target nucleic acidwill form a more stabilized antisense compound-target nucleic acidduplex and the cleavage site of RnaseH will be more downstream, towardsthe 3′ end of the antisense compound. Accordingly, modifications at the5′-end of the antisense compound will prevent RNaseH cleavage of thenon-target nucleic acid, but will not substantially effect RNaseHcleavage of the target nucleic acid, and selectivity between a targetnucleic acid and its allelic variant may be achieved. In certainembodiments, one or more of the 3′-most nucleosides of the 5′-wingregion comprises a bicyclic sugar moiety. In certain embodiments, one ormore of the 3′-most nucleosides of the 5′-wing region comprises abicyclic sugar moiety selected from cEt and LNA. In certain embodiments,one or more of the 3′-most nucleosides of the 5′-wing region comprisescEt. In certain embodiments, one or more of the 3′-most nucleosides ofthe 5′-wing region comprises LNA.

In certain embodiments, the introduction of a mismatch between anantisense compound and a target nucleic acid may alter the RNase Hcleavage site of a target nucleic acid compared to a non-target nucleicacid by shifting the RNaseH cleavage site downstream from the mismatchsite and towards the 3′-end of the antisense compound. In certainembodiments where the cleavage site of a target nucleic acid compared toa non-target nucleic acid has shifted downstream towards the 3′-end ofthe antisense compound, the 3′-end of an antisense compound may bemodified to prevent RNaseH cleavage. In this manner, it is thought thatone having skill in the art may modify the 3′-end of an antisensecompound, or modify the nucleosides in the gap region near the 3′-end ofantisense compound, to selectively inhibit RNaseH cleavage of thenon-target nucleic acid while retaining RNase H cleavage of the targetnucleic acid.

For example, in certain embodiments the target nucleic acid may have anallelic variant, e.g. a non-target nucleic acid, containing a singlenucleotide polymorphism. An antisense compound may be designed having asingle nucleobase mismatch from the non-target nucleic acid, but whichhas full complementarity to target nucleic acid. The mismatch betweenthe antisense compound and the non-target nucleic acid may destabilizethe antisense compound-non-target nucleic acid duplex, and consequentlythe cleavage site of RNaseH may shift downstream towards the 3′-end ofthe antisense compound. Modification of the 3′-end of the antisensecompound, or one or more of the the 5′-most nucleosides of the 3′-wingregion, or the gap region of the antisense compound near the 3′-end willthen prevent RNaseH cleavage of the non-target nucleic acid. Since thetarget nucleic acid is fully complementary to the antisense compound,the antisense compound and the target nucleic acid will form a morestabilized antisense compound-target nucleic acid duplex and thecleavage site of RnaseH will be more upstream, towards the 5′ end of theantisense compound. Accordingly, modifications at the 3′-end of theantisense compound will prevent RNaseH cleavage of the non-targetnucleic acid, but will not substantially effect RNaseH cleavage of thetarget nucleic acid, and selectivity between a target nucleic acid andits allelic variant may be achieved. In certain embodiments, one or moreof the 5′-most nucleosides of the 3′-wing region comprises a bicyclicsugar moiety. In certain embodiments, one or more of the 5′-mostnucleosides of the 3′-wing region comprises a bicyclic sugar moietyselected from cEt and LNA. In certain embodiments, one or more of the5′-most nucleosides of the 3′-wing region comprises cEt. In certainembodiments, one or more of the 5′-most nucleosides of the 3′-wingregion comprises LNA.

In certain embodiments, the selectivity of antisense compounds havingcertain gaps, e.g. gaps of 7 nucleosides or longer, may be improved bythe addition of one or more bicyclic nucleosides at the 3′-most 5′-wingnucleoside. In certain embodiments, the selectivity of antisensecompounds having certain gaps, e.g. gaps of 7 nucleosides or longer, maybe improved by the addition of two or more bicyclic nucleosides at the3′-most 5′-wing nucleoside. In certain embodiments, the selectivity ofantisense compounds having certain gaps, e.g. gaps of 7 nucleosides orlonger, may be improved by the addition of one bicyclic nucleoside atthe 3′-most 5′-wing nucleoside. In certain embodiments, the selectivityof antisense compounds having certain gaps, e.g. gaps of 7 nucleosidesor longer, may be improved by the addition of two bicyclic nucleosidesat the 3′-most 5′-wing nucleoside. In certain embodiments, theselectivity of antisense compounds having certain gaps, e.g. gaps of 7nucleosides or longer, may be improved by the addition of three bicyclicnucleosides at the 3′-most 5′-wing nucleoside. In certain embodiments,the selectivity of antisense compounds having certain gaps, e.g. gaps of7 nucleosides or longer, may be improved by the addition of fourbicyclic nucleosides at the 3′-most 5′-wing nucleoside. In certainembodiments, the selectivity of antisense compounds having certain gaps,e.g. gaps of 7 nucleosides or longer, may be improved by the addition offive bicyclic nucleosides at the 3′-most 5′-wing nucleoside. In certainembodiments discussed above, the bicyclic nucleosides at the 3′-most5′-wing nucleoside are selected from among cEt, cMOE, LNA, α-LNA, ENAand 2′-thio LNA. In certain embodiments discussed above, the bicyclicnucleosides at the 3′-most 5′-wing nucleoside comprise cEt. In certainembodiments discussed above, the bicyclic nucleosides at the 3′-most5′-wing nucleoside comprise LNA.

In certain embodiments, the selectivity of antisense compounds havingcertain gaps, e.g. gaps of 7 nucleosides or longer, may be improved bythe addition of one or more bicyclic nucleosides at the 3′-most 5′-wingnucleoside and the addition of one or more bicylic nucleosides at the5′-most 3′-wing nucleoside. In certain embodiments, the selectivity ofantisense compounds having certain gaps, e.g. gaps of 7 nucleosides orlonger, may be improved by the addition of two or more bicyclicnucleosides at the 3′-most 5′-wing nucleoside and the addition of one ormore bicylic nucleosides at the 5′-most 3′-wing nucleoside. In certainembodiments, the selectivity of antisense compounds having certain gaps,e.g. gaps of 7 nucleosides or longer, may be improved by the addition ofone bicyclic nucleoside at the 3′-most 5′-wing nucleoside and theaddition of one or more bicylic nucleosides at the 5′-most 3′-wingnucleoside. In certain embodiments, the selectivity of antisensecompounds having certain gaps, e.g. gaps of 7 nucleosides or longer, maybe improved by the addition of two bicyclic nucleosides at the 3′-most5′-wing nucleoside and the addition of one or more bicylic nucleosidesat the 5′-most 3′-wing nucleoside. In certain embodiments, theselectivity of antisense compounds having certain gaps, e.g. gaps of 7nucleosides or longer, may be improved by the addition of three bicyclicnucleosides at the 3′-most 5′-wing nucleoside and the addition of one ormore bicylic nucleosides at the 5′-most 3′-wing nucleoside. In certainembodiments, the selectivity of antisense compounds having certain gaps,e.g. gaps of 7 nucleosides or longer, may be improved by the addition offour bicyclic nucleosides at the 3′-most 5′-wing nucleoside and theaddition of one or more bicylic nucleosides at the 5′-most 3′-wingnucleoside. In certain embodiments, the selectivity of antisensecompounds having certain gaps, e.g. gaps of 7 nucleosides or longer, maybe improved by the addition of four bicyclic nucleosides at the 3′-most5′-wing nucleoside and the addition of one or more bicylic nucleosidesat the 5′-most 3′-wing nucleoside.

In certain embodiments, the selectivity of antisense compounds havingcertain gaps, e.g. gaps of 7 nucleosides or shorter, may be improved bythe addition of one or more bicyclic nucleosides at the 3′-most 5′-wingnucleoside. In certain embodiments, the selectivity of antisensecompounds having certain gaps, e.g. gaps of 7 nucleosides or shorter,may be improved by the addition of two or more bicyclic nucleosides atthe 3′-most 5′-wing nucleoside. In certain embodiments, the selectivityof antisense compounds having certain gaps, e.g. gaps of 7 nucleosidesor shorter, may be improved by the addition of one bicyclic nucleosideat the 3′-most 5′-wing nucleoside. In certain embodiments, theselectivity of antisense compounds having certain gaps, e.g. gaps of 7nucleosides or shorter, may be improved by the addition of two bicyclicnucleosides at the 3′-most 5′-wing nucleoside. In certain embodiments,the selectivity of antisense compounds having certain gaps, e.g. gaps of7 nucleosides or shorter, may be improved by the addition of threebicyclic nucleosides at the 3′-most 5′-wing nucleoside. In certainembodiments, the selectivity of antisense compounds having certain gaps,e.g. gaps of 7 nucleosides or shorter, may be improved by the additionof four bicyclic nucleosides at the 3′-most 5′-wing nucleoside. Incertain embodiments, the selectivity of antisense compounds havingcertain gaps, e.g. gaps of 7 nucleosides or shorter, may be improved bythe addition of five bicyclic nucleosides at the 3′-most 5′-wingnucleoside. In certain embodiments discussed above, the bicyclicnucleosides at the 3′-most 5′-wing nucleoside are selected from amongcEt, cMOE, LNA, α-LNA, ENA and 2′-thio LNA. In certain embodimentsdiscussed above, the bicyclic nucleosides at the 3′-most 5′-wingnucleoside comprise cEt. In certain embodiments discussed above, thebicyclic nucleosides at the 3′-most 5′-wing nucleoside comprise LNA.

Antisense compounds having certain specified motifs have enhancedselectivity, including, but not limited to motifs described above. Incertain embodiments, enhanced selectivity is achieved byoligonucleotides comprising any one or more of:

a modification motif comprising a long 5′-wing (longer than 5, 6, or 7nucleosides);

a modification motif comprising a long 3′-wing (longer than 5, 6, or 7nucleosides);

a modification motif comprising a short gap region (shorter than 8, 7,or 6 nucleosides); and

a modification motif comprising an interrupted gap region (having nouninterrupted stretch of unmodified 2′-deoxynucleosides longer than 7, 6or 5).

i. Certain Selective Nucleobase Sequence Elements

In certain embodiments, selective antisense compounds comprisenucleobase sequence elements. Such nucleobase sequence elements areindependent of modification motifs. Accordingly, oligonucleotides havingany of the motifs (modification motifs, nucleoside motifs, sugar motifs,nucleobase modification motifs, and/or linkage motifs) may also compriseone or more of the following nucleobase sequence elements.

ii. Alignment of Differentiating Nucleobase/Target-Selective Nucleoside

In certain embodiments, a target region and a region of a non-targetnucleic acid differ by 1-4 differentiating nucleobase. In suchembodiments, selective antisense compounds have a nucleobase sequencethat aligns with the non-target nucleic acid with 1-4 mismatches. Anucleoside of the antisense compound that corresponds to adifferentiating nucleobase of the target nucleic acid is referred toherein as a target-selective nucleoside. In certain embodiments,selective antisense compounds having a gapmer motif align with anon-target nucleic acid, such that a target-selective nucleoside ispositioned in the gap. In certain embodiments, a target-selectivenucleoside is the 1^(st) nucleoside of the gap from the 5′ end. Incertain embodiments, a target-selective nucleoside is the 2^(nd)nucleoside of the gap from the 5′ end. In certain embodiments, atarget-selective nucleoside is the 3^(rd) nucleoside of the gap from the5′-end. In certain embodiments, a target-selective nucleoside is the4^(th) nucleoside of the gap from the 5′-end. In certain embodiments, atarget-selective nucleoside is the 5^(th) nucleoside of the gap from the5′-end. In certain embodiments, a target-selective nucleoside is the6^(rd) nucleoside of the gap from the 5′-end. In certain embodiments, atarget-selective nucleoside is the 8^(th) nucleoside of the gap from the3′-end. In certain embodiments, a target-selective nucleoside is the7^(th) nucleoside of the gap from the 3′-end. In certain embodiments, atarget-selective nucleoside is the 6^(th) nucleoside of the gap from the3′-end. In certain embodiments, a target-selective nucleoside is the5^(th) nucleoside of the gap from the 3′-end. In certain embodiments, atarget-selective nucleoside is the 4^(th) nucleoside of the gap from the3′-end. In certain embodiments, a target-selective nucleoside is the3^(rd) nucleoside of the gap from the 3′-end. In certain embodiments, atarget-selective nucleoside is the 2^(nd) nucleoside of the gap from the3′-end.

In certain embodiments, a target-selective nucleoside comprises amodified nucleoside. In certain embodiments, a target-selectivenucleoside comprises a modified sugar. In certain embodiments, atarget-selective nucleoside comprises a sugar surrogate. In certainembodiments, a target-selective nucleoside comprises a sugar surrogateselected from among HNA and F-HNA. In certain embodiments, atarget-selective nucleoside comprises a 2′-substituted sugar moiety. Incertain embodiments, a target-selective nucleoside comprises a2′-substituted sugar moiety selected from among MOE, F and (ara)-F. Incertain embodiments, a target-selective nucleoside comprises a5′-substituted sugar moiety. In certain embodiments, a target-selectivenucleoside comprises a 5′-substituted sugar moiety selected from5′-(R)-Me DNA. In certain embodiments, a target-selective nucleosidecomprises a bicyclic sugar moiety. In certain embodiments, atarget-selective nucleoside comprises a bicyclic sugar moiety selectedfrom among cEt, and α-L-LNA. In certain embodiments, a target-selectivenucleoside comprises a modified nucleobase. In certain embodiments, atarget-selective nucleoside comprises a modified nucleobase selectedfrom among 2-thio-thymidine and 5-propyne uridine.

iii. Mismatches to the Target Nucleic Acid

In certain embodiments, selective antisense compounds comprise one ormore mismatched nucleobases relative to the target nucleic acid. Incertain such embodiments, antisense activity against the target isreduced by such mismatch, but activity against the non-target is reducedby a greater amount. Thus, in certain embodiments selectivity isimproved. Any nucleobase other than the differentiating nucleobase issuitable for a mismatch. In certain embodiments, however, the mismatchis specifically positioned within the gap of an oligonucleotide having agapmer motif. In certain embodiments, a mismatch relative to the targetnucleic acid is at positions 1, 2, 3, 4, 5, 6, 7, or 8 from the 5′-endof the gap region. In certain embodiments, a mismatch relative to thetarget nucleic acid is at positions 9, 8, 7, 6, 5, 4, 3, 2, 1 of theantisense compounds from the 3′-end of the gap region. In certainembodiments, a mismatch relative to the target nucleic acid is atpositions 1, 2, 3, or 4 of the antisense compounds from the 5′-end ofthe wing region. In certain embodiments, a mismatch relative to thetarget nucleic acid is at positions 4, 3, 2, or 1 of the antisensecompounds from the 3′-end of the wing region.

iv. Self Complementary Regions

In certain embodiments, selective antisense compounds comprise a regionthat is not complementary to the target. In certain embodiments, suchregion is complementary to another region of the antisense compound.Such regions are referred to herein as self-complementary regions. Forexample, in certain embodiments, an antisense compound has a firstregion at one end that is complementary to a second region at the otherend. In certain embodiments, one of the first and second regions iscomplementary to the target nucleic acid. Unless the target nucleic acidalso includes a self-complementary region, the other of the first andsecond region of the antisense compound will not be complementary to thetarget nucleic acid. For illustrative purposes, certain antisensecompounds have the following nucleobase motif:

ABCXXXXXXXXXC′B′A′;

ABCXXXXXXX(X/C′)(X/B′)(X/A′);

(X/A)(X/B)(X/C)XXXXXXXXXC′B′A′

where each of A, B, and C are any nucleobase; A′, B′, and C′ are thecomplementary bases to A, B, and C, respectively; each X is a nucleobasecomplementary to the target nucleic acid; and two letters in parentheses(e.g., (X/C′)) indicates that the nucleobase is complementary to thetarget nucleic acid and to the designated nucleoside within theantisense oligonucleotide.

Without being bound to any mechanism, in certain embodiments, suchantisense compounds are expected to form self-structure, which isdisrupted upon contact with a target nucleic acid. Contact with anon-target nucleic acid is expected to disrupt the self-structure to alesser degree, thus increasing selectivity compared to the sameantisense compound lacking the self-complementary regions.

v. Combinations of Features

Though it is clear to one of skill in the art, the above motifs andother elements for increasing selectivity may be used alone or incombination. For example, a single antisense compound may include anyone, two, three, or more of: self-complementary regions, a mismatchrelative to the target nucleic acid, a short nucleoside gap, aninterrupted gap, and specific placement of the selective nucleoside.

D. Certain Target Nucleic Acids

In certain embodiments, antisense compounds comprise or consist of anoligonucleotide comprising a region that is complementary to a targetnucleic acid. In certain embodiments, the target nucleic acid is anendogenous RNA molecule. In certain embodiments, the target nucleic acidis a non-coding RNA. In certain such embodiments, the target non-codingRNA is selected from: a long-non-coding RNA, a short non-coding RNA, anintronic RNA molecule, a snoRNA, a scaRNA, a microRNA (includingpre-microRNA and mature microRNA), a ribosomal RNA, and promoterdirected RNA. In certain embodiments, the target nucleic acid encodes aprotein. In certain such embodiments, the target nucleic acid isselected from: an mRNA and a pre-mRNA, including intronic, exonic anduntranslated regions. In certain embodiments, oligomeric compounds areat least partially complementary to more than one target nucleic acid.For example, antisense compounds of the present invention may mimicmicroRNAs, which typically bind to multiple targets.

In certain embodiments, the target nucleic acid is a nucleic acid otherthan a mature mRNA. In certain embodiments, the target nucleic acid is anucleic acid other than a mature mRNA or a microRNA. In certainembodiments, the target nucleic acid is a non-coding RNA other than amicroRNA. In certain embodiments, the target nucleic acid is anon-coding RNA other than a microRNA or an intronic region of apre-mRNA. In certain embodiments, the target nucleic acid is a longnon-coding RNA. In certain embodiments, the target RNA is an mRNA. Incertain embodiments, the target nucleic acid is a pre-mRNA. In certainsuch embodiments, the target region is entirely within an intron. Incertain embodiments, the target region spans an intron/exon junction. Incertain embodiments, the target region is at least 50% within an intron.In certain embodiments, the target nucleic acid is selected from amongnon-coding RNA, including exonic regions of pre-mRNA. In certainembodiments, the target nucleic acid is a ribosomal RNA (rRNA). Incertain embodiments, the target nucleic acid is a non-coding RNAassociated with splicing of other pre-mRNAs. In certain embodiments, thetarget nucleic acid is a nuclear-retained non-coding RNA.

In certain embodiments, antisense compounds described herein arecomplementary to a target nucleic acid comprising a single-nucleotidepolymorphism. In certain such embodiments, the antisense compound iscapable of modulating expression of one allele of the single-nucleotidepolymorphism-containing-target nucleic acid to a greater or lesserextent than it modulates another allele. In certain embodiments anantisense compound hybridizes to a single-nucleotidepolymorphism-containing-target nucleic acid at the single-nucleotidepolymorphism site. In certain embodiments, the target nucleic acid is aHuntingtin gene transcript. In certain embodiments, the target nucleicacid is a single-nucleotide polymorphism-containing-target nucleic acidof a Huntingtin gene transcript. In certain embodiments, the targetnucleic acid is not a Huntingtin gene transcript. In certainembodiments, the target nucleic acid is a single-nucleotidepolymorphism-containing-target nucleic acid of a gene transcript otherthan Huntingtin. In certain embodiments, the target nucleic acid is anynucleic acid other than a Huntingtin gene transcript.

a. Single-Nucleotide Polymorphism

In certain embodiments, the invention provides selective antisensecompounds that have greater activity for a target nucleic acid than fora homologous or partially homologous non-target nucleic acid. In certainsuch embodiments, the target and non-target nucleic acids are notfunctionally related to one another (e.g., are transcripts fromdifferent genes). In certain embodiments, the target and not-targetnucleic acids are allelic variants of one another. Certain embodimentsof the present invention provide methods, compounds, and compositionsfor selectively inhibiting mRNA and protein expression of an allelicvariant of a particular gene or DNA sequence. In certain embodiments,the allelic variant contains a single nucleotide polymorphism (SNP). Incertain embodiments, a SNP is associated with a mutant allele. Incertain embodiments, a mutant SNP is associated with a disease. Incertain embodiments a mutant SNP is associated with a disease, but isnot causative of the disease. In certain embodiments, mRNA and proteinexpression of a mutant allele is associated with disease.

In certain embodiments, the expressed gene product of a mutant alleleresults in aggregation of the mutant proteins causing disease. Incertain embodiments, the expressed gene product of a mutant alleleresults in gain of function causing disease. In certain embodiments,genes with an autosomal dominant mutation resulting in a toxic gain offunction of the protein are the APP gene encoding amyloid precursorprotein involved in Alzheimer's disease (Gene, 371: 68, 2006); the PrPgene encoding prion protein involved in Creutzfeldt-Jakob disease and infatal familial insomnia (Nat. Med. 1997, 3: 1009); GFAP gene encodingglial fibrillary acidic protein involved in Alexander disease (J.Neurosci. 2006, 26:111623); alpha-synuclein gene encodingalpha-synuclein protein involved in Parkinson's disease (J. Clin.Invest. 2003, 111: 145); SOD-1 gene encoding the SOD-1 protein involvedin amyotrophic lateral sclerosis (Science 1998, 281: 1851); atrophin-1gene encoding atrophin-1 protein involved in dentato-rubral andpallido-luysian atrophy (DRPA) (Trends Mol. Med. 2001, 7: 479); SCA1gene encoding ataxin-1 protein involved in spino-cerebellar ataxia-1(SCA1) (Protein Sci. 2003, 12: 953); PLP gene encoding proteolipidprotein involved in Pelizaeus-Merzbacher disease (NeuroMol Med. 2007, 4:73); DYT1 gene encoding torsinA protein involved in Torsion dystonia(Brain Res. 2000, 877: 379); and alpha-B crystalline gene encodingalpha-B crystalline protein involved in protein aggregation diseases,including cardiomyopathy (Cell 2007, 130: 427); alpha1-antitrypsin geneencoding alpha1-antitrypsin protein involved in chronic obstructivepulmonary disease (COPD), liver disease and hepatocellular carcinoma(New Engl J Med. 2002, 346: 45); Ltk gene encoding leukocyte tyrosinekinase protein involved in systemic lupus erythematosus (Hum. Mol. Gen.2004, 13: 171); PCSK9 gene encoding PCSK9 protein involved inhypercholesterolemia (Hum Mutat. 2009, 30: 520); prolactin receptor geneencoding prolactin receptor protein involved in breast tumors (Proc.Natl. Assoc. Sci. 2008, 105: 4533); CCLS gene encoding the chemokineCCLS involved in COPD and asthma (Eur. Respir. J. 2008, 32: 327); PTPN22gene encoding PTPN22 protein involved in Type 1 diabetes, Rheumatoidarthritis, Graves disease, and SLE (Proc. Natl. Assoc. Sci. 2007, 104:19767); androgen receptor gene encoding the androgen receptor proteininvolved in spinal and bulbar muscular atrophy or Kennedy's disease (JSteroid Biochem. Mol. Biol. 2008, 108: 245); CHMP4B gene encodingchromatin modifying protein-4B involved in progressive childhoodposterior subcapsular cataracts (Am. J. Hum. Genet 2007, 81: 596);FXR/NR1H4 gene encoding Farnesoid X receptor protein involved incholesterol gallstone disease, arthrosclerosis and diabetes (Mol.Endocrinol. 2007, 21: 1769); ABCA1 gene encoding ABCA1 protein involvedin cardiovascular disease (Transl. Res. 2007, 149: 205); CaSR geneencoding the calcium sensing receptor protein involved in primaryhypercalciuria (Kidney Int. 2007, 71: 1155); alpha-globin gene encodingalpha-globin protein involved in alpha-thallasemia (Science 2006, 312:1215); httlpr gene encoding HTTLPR protein involved in obsessivecompulsive disorder (Am. J. Hum. Genet. 2006, 78: 815); AVP geneencoding arginine vasopressin protein in stress-related disorders suchas anxiety disorders and comorbid depression (CNS Neurol. Disord. DrugTargets 2006, 5: 167); GNAS gene encoding G proteins involved incongenital visual defects, hypertension, metabolic syndrome (TrendsPharmacol. Sci. 2006, 27: 260); APAF1 gene encoding APAF1 proteininvolved in a predisposition to major depression (Mol. Psychiatry 2006,11: 76); TGF-beta1 gene encoding TGF-beta1 protein involved in breastcancer and prostate cancer (Cancer Epidemiol. Biomarkers Prev. 2004, 13:759); AChR gene encoding acetylcholine receptor involved in congentialmyasthenic syndrome (Neurology 2004, 62: 1090); P2Y12 gene encodingadenosine diphosphate (ADP) receptor protein involved in risk ofperipheral arterial disease (Circulation 2003, 108: 2971); LQT1 geneencoding LQT1 protein involved in atrial fibrillation (Cardiology 2003,100: 109); RET protooncogene encoding RET protein involved in sporadicpheochromocytoma (J. Clin. Endocrinol. Metab. 2003, 88: 4911); filamin Agene encoding filamin A protein involved in various congenitalmalformations (Nat. Genet. 2003, 33: 487); TARDBP gene encoding TDP-43protein involved in amyotrophic lateral sclerosis (Hum. Mol. Gene.t2010, 19: 671); SCA3 gene encoding ataxin-3 protein involved inMachado-Joseph disease (PLoS One 2008, 3: e3341); SCAT gene encodingataxin-7 protein involved in spino-cerebellar ataxia-7 (PLoS One 2009,4: e7232); and HTT gene encoding huntingtin protein involved inHuntington's disease (Neurobiol Dis. 1996, 3:183); and the CA4 geneencoding carbonic anhydrase 4 protein, CRX gene encoding cone-rodhomeobox transcription factor protein, FSCN2 gene encoding retinalfascin homolog 2 protein, IMPDH1 gene encoding inosine monophosphatedehydrogenase 1 protein, NR2E3 gene encoding nuclear receptor subfamily2 group E3 protein, NRL gene encoding neural retina leucine zipperprotein, PRPF3 (RP18) gene encoding pre-mRNA splicing factor 3 protein,PRPF8 (RP13) gene encoding pre-mRNA splicing factor 8 protein, PRPF31(RP11) gene encoding pre-mRNA splicing factor 31 protein, RDS geneencoding peripherin 2 protein, ROM1 gene encoding rod outer membraneprotein 1 protein, RHO gene encoding rhodopsin protein, RP1 geneencoding RP1 protein, RPGR gene encoding retinitis pigmentosa GTPaseregulator protein, all of which are involved in Autosomal DominantRetinitis Pigmentosa disease (Adv Exp Med Biol. 2008, 613:203)

In certain embodiments, the mutant allele is associated with any diseasefrom the group consisting of Alzheimer's disease, Creutzfeldt-Jakobdisease, fatal familial insomnia, Alexander disease, Parkinson'sdisease, amyotrophic lateral sclerosis, dentato-rubral andpallido-luysian atrophy DRPA, spino-cerebellar ataxia, Torsion dystonia,cardiomyopathy, chronic obstructive pulmonary disease (COPD), liverdisease, hepatocellular carcinoma, systemic lupus erythematosus,hypercholesterolemia, breast cancer, asthma, Type 1 diabetes, Rheumatoidarthritis, Graves disease, SLE, spinal and bulbar muscular atrophy,Kennedy's disease, progressive childhood posterior subcapsularcataracts, cholesterol gallstone disease, arthrosclerosis,cardiovascular disease, primary hypercalciuria, alpha-thallasemia,obsessive compulsive disorder, Anxiety, comorbid depression, congenitalvisual defects, hypertension, metabolic syndrome, prostate cancer,congential myasthenic syndrome, peripheral arterial disease, atrialfibrillation, sporadic pheochromocytoma, congenital malformations,Machado-Joseph disease, Huntington's disease, and Autosomal DominantRetinitis Pigmentosa disease.

i. Certain Huntingtin Targets

In certain embodiments, an allelic variant of huntingtin is selectivelyreduced. Nucleotide sequences that encode huntingtin include, withoutlimitation, the following: GENBANK Accession No. NT_006081.18, truncatedfrom nucleotides 1566000 to 1768000 (replaced by GENBANK Accession No.NT_006051), incorporated herein as SEQ ID NO: 1, and NM_002111.6,incorporated herein as SEQ ID NO: 2.

Table 14 provides SNPs found in the GM04022, GM04281, GM02171, andGM02173B cell lines. Also provided are the allelic variants found ateach SNP position, the genotype for each of the cell lines, and thepercentage of HD patients having a particular allelic variant. Forexample, the two allelic variants for SNP rs6446723 are T and C. TheGM04022 cell line is heterozygous TC, the GM02171 cell line ishomozygous CC, the GM02173 cell line is heterozygous TC, and the GM04281cell line is homozygous TT. Fifty percent of HD patients have a T at SNPposition rs6446723.

TABLE 14 Allelic Variations for SNPs Associated with HD SNP VariationGM04022 GM02171 GM02173 GM04281 TargetPOP allele rs6446723 T/C TC CC TCTT 0.50 T rs3856973 A/G AG AA AG GG 0.50 G rs2285086 A/G AG GG AG AA0.50 A rs363092 A/C AC AA AC CC 0.49 C rs916171 C/G GC GG GC CC 0.49 Crs6844859 T/C TC CC TC TT 0.49 T rs7691627 A/G AG AA AG GG 0.49 Grs4690073 A/G AG AA AG GG 0.49 G rs2024115 A/G AG GG AG AA 0.48 Ars11731237 T/C CC CC TC TT 0.43 T rs362296 A/C CC AC AC AC 0.42 Crs10015979 A/G AA AA AG GG 0.42 G rs7659144 C/G CG CG CG CC 0.41 Crs363096 T/C CC CC TC TT 0.40 T rs362273 A/G AA AG AG AA 0.39 Ars16843804 T/C CC TC TC CC 0.38 C rs362271 A/G GG AG AG GG 0.38 Grs362275 T/C CC TC TC CC 0.38 C rs3121419 T/C CC TC TC CC 0.38 Crs362272 A/G GG — AG GG 0.38 G rs3775061 A/G AA AG AG AA 0.38 Ars34315806 T/C CC TC TC CC 0.38 C rs363099 T/C CC TC TC CC 0.38 Crs2298967 T/C TT TC TC TT 0.38 T rs363088 A/T AA TA TA AA 0.38 Ars363064 T/C CC TC TC CC 0.35 C rs363102 A/G AG AA AA AA 0.23 Grs2798235 A/G AG GG GG GG 0.21 A rs363080 T/C TC CC CC CC 0.21 Trs363072 A/T TA TA AA AA 0.13 A rs363125 A/C AC AC CC CC 0.12 C rs362303T/C TC TC CC CC 0.12 C rs362310 T/C TC TC CC CC 0.12 C rs10488840 A/G AGAG GG GG 0.12 G rs362325 T/C TC TC TT TT 0.11 T rs35892913 A/G GG GG GGGG 0.10 A rs363102 A/G AG AA AA AA 0.09 A rs363096 T/C CC CC TC TT 0.09C rs11731237 T/C CC CC TC TT 0.09 C rs10015979 A/G AA AA AG GG 0.08 Ars363080 T/C TC CC CC CC 0.07 C rs2798235 A/G AG GG GG GG 0.07 Grs1936032 C/G GC CC CC CC 0.06 C rs2276881 A/G GG GG GG GG 0.06 Grs363070 A/G AA AA AA AA 0.06 A rs35892913 A/G GG GG GG GG 0.04 Grs12502045 T/C CC CC CC CC 0.04 C rs6446723 T/C TC CC TC TT 0.04 Crs7685686 A/G AG GG AG AA 0.04 G rs3733217 T/C CC CC CC CC 0.03 Crs6844859 T/C TC CC TC TT 0.03 C rs362331 T/C TC CC TC TT 0.03 C

E. Certain Indications

In certain embodiments, provided herein are methods of treating ananimal or individual comprising administering one or more pharmaceuticalcompositions as described herein. In certain embodiments, the individualor animal has Huntington's disease.

In certain embodiments, compounds targeted to huntingtin as describedherein may be administered to reduce the severity of physiologicalsymptoms of Huntington's disease. In certain embodiments, compoundstargeted to huntingtin as described herein may be administered to reducethe rate of degeneration in an individual or an animal havingHuntington's disease. In certain embodiments, compounds targeted tohuntingtin as described herein may be administered regeneration functionin an individual or an animal having Huntington's disease. In certainembodiments, symptoms of Huntingtin's disease may be reversed bytreatment with a compound as described herein.

In certain embodiments, compounds targeted to huntingtin as describedherein may be administered to ameliorate one or more symptoms ofHuntington's disease. In certain embodiments administration of compoundstargeted to huntingtin as described herein may improve the symptoms ofHuntington's disease as measured by any metric known to those havingskill in the art. In certain embodiments, administration of compoundstargeted to huntingtin as described herein may improve a rodent'srotaraod assay performance. In certain embodiments, administration ofcompounds targeted to huntingtin as described herein may improve arodent's plus maze assay. In certain embodiments, administration ofcompounds targeted to huntingtin as described herein may improve arodent's open field assay performance.

Accordingly, provided herein are methods for ameliorating a symptomassociated with Huntington's disease in a subject in need thereof. Incertain embodiments, provided is a method for reducing the rate of onsetof a symptom associated with Huntington's disease. In certainembodiments, provided is a method for reducing the severity of a symptomassociated with Huntington's disease. In certain embodiments, providedis a method for regenerating neurological function as shown by animprovement of a symptom associated with Huntington's disease. In suchembodiments, the methods comprise administering to an individual oranimal in need thereof a therapeutically effective amount of a compoundtargeted to a huntingtin nucleic acid.

Huntington's disease is characterized by numerous physical,neurological, psychiatric, and/or peripheral symptoms. Any symptom knownto one of skill in the art to be associated with Huntington's diseasecan be ameliorated or otherwise modulated as set forth above in themethods described above. In certain embodiments, the symptom is aphysical symptom selected from the group consisting of restlessness,lack of coordination, unintentionally initiated motions, unintentionallyuncompleted motions, unsteady gait, chorea, rigidity, writhing motions,abnormal posturing, instability, abnormal facial expressions, difficultychewing, difficulty swallowing, difficulty speaking, seizure, and sleepdisturbances. In certain embodiments, the symptom is a cognitive symptomselected from the group consisting of impaired planning, impairedflexibility, impaired abstract thinking, impaired rule acquisition,impaired initiation of appropriate actions, impaired inhibition ofinappropriate actions, impaired short-term memory, impaired long-termmemory, paranoia, disorientation, confusion, hallucination and dementia.In certain embodiments, the symptom is a psychiatric symptom selectedfrom the group consisting of anxiety, depression, blunted affect,egocentrisms, aggression, compulsive behavior, irritability and suicidalideation. In certain embodiments, the symptom is a peripheral symptomselected from the group consisting of reduced brain mass, muscleatrophy, cardiac failure, impaired glucose tolerance, weight loss,osteoporosis, and testicular atrophy.

In certain embodiments, the symptom is restlessness. In certainembodiments, the symptom is lack of coordination. In certainembodiments, the symptom is unintentionally initiated motions. Incertain embodiments, the symptom is unintentionally uncompleted motions.In certain embodiments, the symptom is unsteady gait. In certainembodiments, the symptom is chorea. In certain embodiments, the symptomis rigidity. In certain embodiments, the symptom is writhing motions. Incertain embodiments, the symptom is abnormal posturing. In certainembodiments, the symptom is instability. In certain embodiments, thesymptom is abnormal facial expressions. In certain embodiments, thesymptom is difficulty chewing. In certain embodiments, the symptom isdifficulty swallowing. In certain embodiments, the symptom is difficultyspeaking. In certain embodiments, the symptom is seizures. In certainembodiments, the symptom is sleep disturbances.

In certain embodiments, the symptom is impaired planning. In certainembodiments, the symptom is impaired flexibility. In certainembodiments, the symptom is impaired abstract thinking. In certainembodiments, the symptom is impaired rule acquisition. In certainembodiments, the symptom is impaired initiation of appropriate actions.In certain embodiments, the symptom is impaired inhibition ofinappropriate actions. In certain embodiments, the symptom is impairedshort-term memory. In certain embodiments, the symptom is impairedlong-term memory. In certain embodiments, the symptom is paranoia. Incertain embodiments, the symptom is disorientation. In certainembodiments, the symptom is confusion. In certain embodiments, thesymptom is hallucination. In certain embodiments, the symptom isdementia.

In certain embodiments, the symptom is anxiety. In certain embodiments,the symptom is depression. In certain embodiments, the symptom isblunted affect. In certain embodiments, the symptom is egocentrism. Incertain embodiments, the symptom is aggression. In certain embodiments,the symptom is compulsive behavior. In certain embodiments, the symptomis irritability. In certain embodiments, the symptom is suicidalideation.

In certain embodiments, the symptom is reduced brain mass. In certainembodiments, the symptom is muscle atrophy. In certain embodiments, thesymptom is cardiac failure. In certain embodiments, the symptom isimpaired glucose tolerance. In certain embodiments, the symptom isweight loss. In certain embodiments, the symptom is osteoporosis. Incertain embodiments, the symptom is testicular atrophy.

In certain embodiments, symptoms of Huntington's disease may bequantifiable. For example, osteoporosis may be measured and quantifiedby, for example, bone density scans. For such symptoms, in certainembodiments, the symptom may be reduced by about 15, 20, 25, 30, 35, 40,45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%, or a range defined byany two of these values.

In certain embodiments, provided are methods of treating an individualcomprising administering one or more pharmaceutical compositions asdescribed herein. In certain embodiments, the individual hasHuntington's disease.

In certain embodiments, administration of an antisense compound targetedto a huntingtin nucleic acid results in reduction of huntingtinexpression by at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65,70, 75, 80, 85, 90, 95 or 99%, or a range defined by any two of thesevalues.

In certain embodiments, pharmaceutical compositions comprising anantisense compound targeted to huntingtin are used for the preparationof a medicament for treating a patient suffering or susceptible toHuntington's disease.

F. Certain Pharmaceutical Compositions

In certain embodiments, the present invention provides pharmaceuticalcompositions comprising one or more antisense compound. In certainembodiments, such pharmaceutical composition comprises a suitablepharmaceutically acceptable diluent or carrier. In certain embodiments,a pharmaceutical composition comprises a sterile saline solution and oneor more antisense compound. In certain embodiments, such pharmaceuticalcomposition consists of a sterile saline solution and one or moreantisense compound. In certain embodiments, the sterile saline ispharmaceutical grade saline. In certain embodiments, a pharmaceuticalcomposition comprises one or more antisense compound and sterile water.In certain embodiments, a pharmaceutical composition consists of one ormore antisense compound and sterile water. In certain embodiments, thesterile saline is pharmaceutical grade water. In certain embodiments, apharmaceutical composition comprises one or more antisense compound andphosphate-buffered saline (PBS). In certain embodiments, apharmaceutical composition consists of one or more antisense compoundand sterile phosphate-buffered saline (PBS). In certain embodiments, thesterile saline is pharmaceutical grade PBS.

In certain embodiments, antisense compounds may be admixed withpharmaceutically acceptable active and/or inert substances for thepreparation of pharmaceutical compositions or formulations. Compositionsand methods for the formulation of pharmaceutical compositions depend ona number of criteria, including, but not limited to, route ofadministration, extent of disease, or dose to be administered.

Pharmaceutical compositions comprising antisense compounds encompass anypharmaceutically acceptable salts, esters, or salts of such esters. Incertain embodiments, pharmaceutical compositions comprising antisensecompounds comprise one or more oligonucleotide which, uponadministration to an animal, including a human, is capable of providing(directly or indirectly) the biologically active metabolite or residuethereof. Accordingly, for example, the disclosure is also drawn topharmaceutically acceptable salts of antisense compounds, prodrugs,pharmaceutically acceptable salts of such prodrugs, and otherbioequivalents. Suitable pharmaceutically acceptable salts include, butare not limited to, sodium and potassium salts.

A prodrug can include the incorporation of additional nucleosides at oneor both ends of an oligomeric compound which are cleaved by endogenousnucleases within the body, to form the active antisense oligomericcompound.

Lipid moieties have been used in nucleic acid therapies in a variety ofmethods. In certain such methods, the nucleic acid is introduced intopreformed liposomes or lipoplexes made of mixtures of cationic lipidsand neutral lipids. In certain methods, DNA complexes with mono- orpoly-cationic lipids are formed without the presence of a neutral lipid.In certain embodiments, a lipid moiety is selected to increasedistribution of a pharmaceutical agent to a particular cell or tissue.In certain embodiments, a lipid moiety is selected to increasedistribution of a pharmaceutical agent to fat tissue. In certainembodiments, a lipid moiety is selected to increase distribution of apharmaceutical agent to muscle tissue.

In certain embodiments, pharmaceutical compositions provided hereincomprise one or more modified oligonucleotides and one or moreexcipients. In certain such embodiments, excipients are selected fromwater, salt solutions, alcohol, polyethylene glycols, gelatin, lactose,amylase, magnesium stearate, talc, silicic acid, viscous paraffin,hydroxymethylcellulose and polyvinylpyrrolidone.

In certain embodiments, a pharmaceutical composition provided hereincomprises a delivery system. Examples of delivery systems include, butare not limited to, liposomes and emulsions. Certain delivery systemsare useful for preparing certain pharmaceutical compositions includingthose comprising hydrophobic compounds. In certain embodiments, certainorganic solvents such as dimethylsulfoxide are used.

In certain embodiments, a pharmaceutical composition provided hereincomprises one or more tissue-specific delivery molecules designed todeliver the one or more pharmaceutical agents of the present inventionto specific tissues or cell types. For example, in certain embodiments,pharmaceutical compositions include liposomes coated with atissue-specific antibody.

In certain embodiments, a pharmaceutical composition provided hereincomprises a co-solvent system. Certain of such co-solvent systemscomprise, for example, benzyl alcohol, a nonpolar surfactant, awater-miscible organic polymer, and an aqueous phase. In certainembodiments, such co-solvent systems are used for hydrophobic compounds.A non-limiting example of such a co-solvent system is the VPD co-solventsystem, which is a solution of absolute ethanol comprising 3% w/v benzylalcohol, 8% w/v of the nonpolar surfactant Polysorbate 80™ and 65% w/vpolyethylene glycol 300. The proportions of such co-solvent systems maybe varied considerably without significantly altering their solubilityand toxicity characteristics. Furthermore, the identity of co-solventcomponents may be varied: for example, other surfactants may be usedinstead of Polysorbate 80™; the fraction size of polyethylene glycol maybe varied; other biocompatible polymers may replace polyethylene glycol,e.g., polyvinyl pyrrolidone; and other sugars or polysaccharides maysubstitute for dextrose.

In certain embodiments, a pharmaceutical composition provided herein isprepared for oral administration. In certain embodiments, pharmaceuticalcompositions are prepared for buccal administration.

In certain embodiments, a pharmaceutical composition is prepared foradministration by injection (e.g., intravenous, subcutaneous,intramuscular, etc.). In certain of such embodiments, a pharmaceuticalcomposition comprises a carrier and is formulated in aqueous solution,such as water or physiologically compatible buffers such as Hanks'ssolution, Ringer's solution, or physiological saline buffer. In certainembodiments, other ingredients are included (e.g., ingredients that aidin solubility or serve as preservatives). In certain embodiments,injectable suspensions are prepared using appropriate liquid carriers,suspending agents and the like. Certain pharmaceutical compositions forinjection are presented in unit dosage form, e.g., in ampoules or inmulti-dose containers. Certain pharmaceutical compositions for injectionare suspensions, solutions or emulsions in oily or aqueous vehicles, andmay contain formulatory agents such as suspending, stabilizing and/ordispersing agents. Certain solvents suitable for use in pharmaceuticalcompositions for injection include, but are not limited to, lipophilicsolvents and fatty oils, such as sesame oil, synthetic fatty acidesters, such as ethyl oleate or triglycerides, and liposomes. Aqueousinjection suspensions may contain.

G. Administration

In certain embodiments, the compounds and compositions as describedherein are administered parenterally.

In certain embodiments, parenteral administration is by infusion.Infusion can be chronic or continuous or short or intermittent. Incertain embodiments, infused pharmaceutical agents are delivered with apump. In certain embodiments, parenteral administration is by injection.

In certain embodiments, compounds and compositions are delivered to theCNS. In certain embodiments, compounds and compositions are delivered tothe cerebrospinal fluid. In certain embodiments, compounds andcompositions are administered to the brain parenchyma. In certainembodiments, compounds and compositions are delivered to an animal byintrathecal administration, or intracerebroventricular administration.Broad distribution of compounds and compositions, described herein,within the central nervous system may be achieved with intraparenchymaladministration, intrathecal administration, or intracerebroventricularadministration.

In certain embodiments, parenteral administration is by injection. Theinjection may be delivered with a syringe or a pump. In certainembodiments, the injection is a bolus injection. In certain embodiments,the injection is administered directly to a tissue, such as striatum,caudate, cortex, hippocampus and cerebellum.

Therefore, in certain embodiments, delivery of a compound or compositiondescribed herein can affect the pharmacokinetic profile of the compoundor composition. In certain embodiments, injection of a compound orcomposition described herein, to a targeted tissue improves thepharmacokinetic profile of the compound or composition as compared toinfusion of the compound or composition. In a certain embodiment, theinjection of a compound or composition improves potency compared tobroad diffusion, requiring less of the compound or composition toachieve similar pharmacology. In certain embodiments, similarpharmacology refers to the amount of time that a target mRNA and/ortarget protein is down-regulated (e.g. duration of action). In certainembodiments, methods of specifically localizing a pharmaceutical agent,such as by bolus injection, decreases median effective concentration(EC50) by a factor of about 50 (e.g. 50 fold less concentration intissue is required to achieve the same or similar pharmacodynamiceffect). In certain embodiments, methods of specifically localizing apharmaceutical agent, such as by bolus injection, decreases medianeffective concentration (EC50) by a factor of 20, 25, 30, 35, 40, 45 or50. In certain embodiments the pharmaceutical agent in an antisensecompound as further described herein. In certain embodiments, thetargeted tissue is brain tissue. In certain embodiments the targetedtissue is striatal tissue. In certain embodiments, decreasing EC50 isdesirable because it reduces the dose required to achieve apharmacological result in a patient in need thereof.

In certain embodiments, an antisense oligonucleotide is delivered byinjection or infusion once every month, every two months, every 90 days,every 3 months, every 6 months, twice a year or once a year.

H. Certain Combination Therapies

In certain embodiments, one or more pharmaceutical compositions areco-administered with one or more other pharmaceutical agents. In certainembodiments, such one or more other pharmaceutical agents are designedto treat the same disease, disorder, or condition as the one or morepharmaceutical compositions described herein. In certain embodiments,such one or more other pharmaceutical agents are designed to treat adifferent disease, disorder, or condition as the one or morepharmaceutical compositions described herein. In certain embodiments,such one or more other pharmaceutical agents are designed to treat anundesired side effect of one or more pharmaceutical compositions asdescribed herein. In certain embodiments, one or more pharmaceuticalcompositions are co-administered with another pharmaceutical agent totreat an undesired effect of that other pharmaceutical agent. In certainembodiments, one or more pharmaceutical compositions are co-administeredwith another pharmaceutical agent to produce a combinational effect. Incertain embodiments, one or more pharmaceutical compositions areco-administered with another pharmaceutical agent to produce asynergistic effect.

In certain embodiments, one or more pharmaceutical compositions and oneor more other pharmaceutical agents are administered at the same time.In certain embodiments, one or more pharmaceutical compositions and oneor more other pharmaceutical agents are administered at different times.In certain embodiments, one or more pharmaceutical compositions and oneor more other pharmaceutical agents are prepared together in a singleformulation. In certain embodiments, one or more pharmaceuticalcompositions and one or more other pharmaceutical agents are preparedseparately.

In certain embodiments, pharmaceutical agents that may beco-administered with a pharmaceutical composition of includeantipsychotic agents, such as, e.g., haloperidol, chlorpromazine,clozapine, quetapine, and olanzapine; antidepressant agents, such as,e.g., fluoxetine, sertraline hydrochloride, venlafaxine andnortriptyline; tranquilizing agents such as, e.g., benzodiazepines,clonazepam, paroxetine, venlafaxin, and beta-blockers; mood-stabilizingagents such as, e.g., lithium, valproate, lamotrigine, andcarbamazepine; paralytic agents such as, e.g., Botulinum toxin; and/orother experimental agents including, but not limited to, tetrabenazine(Xenazine), creatine, conezyme Q10, trehalose, docosahexanoic acids,ACR16, ethyl-EPA, atomoxetine, citalopram, dimebon, memantine, sodiumphenylbutyrate, ramelteon, ursodiol, zyprexa, xenasine, tiapride,riluzole, amantadine, [123I]MNI-420, atomoxetine, tetrabenazine,digoxin, detromethorphan, warfarin, alprozam, ketoconazole, omeprazole,and minocycline.

NONLIMITING DISCLOSURE AND INCORPORATION BY REFERENCE

While certain compounds, compositions and methods described herein havebeen described with specificity in accordance with certain embodiments,the following examples serve only to illustrate the compounds describedherein and are not intended to limit the same. Each of the references,GenBank accession numbers, and the like recited in the presentapplication is incorporated herein by reference in its entirety.

Although the sequence listing accompanying this filing identifies eachsequence as either “RNA” or “DNA” as required, in reality, thosesequences may be modified with any combination of chemicalmodifications. One of skill in the art will readily appreciate that suchdesignation as “RNA” or “DNA” to describe modified oligonucleotides is,in certain instances, arbitrary. For example, an oligonucleotidecomprising a nucleoside comprising a 2′-OH sugar moiety and a thyminebase could be described as a DNA having a modified sugar (2′-OH for thenatural 2′-H of DNA) or as an RNA having a modified base (thymine(methylated uracil) for natural uracil of RNA).

Accordingly, nucleic acid sequences provided herein, including, but notlimited to those in the sequence listing, are intended to encompassnucleic acids containing any combination of natural or modified RNAand/or DNA, including, but not limited to such nucleic acids havingmodified nucleobases. By way of further example and without limitation,an oligomeric compound having the nucleobase sequence “ATCGATCG”encompasses any oligomeric compounds having such nucleobase sequence,whether modified or unmodified, including, but not limited to, suchcompounds comprising RNA bases, such as those having sequence “AUCGAUCG”and those having some DNA bases and some RNA bases such as “AUCGATCG”and oligomeric compounds having other modified or naturally occurringbases, such as “AT^(me)CGAUCG,” wherein ^(me)C indicates a cytosine basecomprising a methyl group at the 5-position.

EXAMPLES

The following examples illustrate certain embodiments of the presentinvention and are not limiting. Moreover, where specific embodiments areprovided, the inventors have contemplated generic application of thosespecific embodiments. For example, disclosure of an oligonucleotidehaving a particular motif provides reasonable support for additionaloligonucleotides having the same or similar motif. And, for example,where a particular high-affinity modification appears at a particularposition, other high-affinity modifications at the same position areconsidered suitable, unless otherwise indicated.

To allow assessment of the relative effects of nucleobase sequence andchemical modification, throughout the examples, oligomeric compounds areassigned a “Sequence Code.” Oligomeric compounds having the sameSequence Code have the same nucleobase sequence. Oligomeric compoundshaving different Sequence Codes have different nucleobase sequences.

Example 1 Single Nucleotide Polymorphisms (SNPs) in the Huntingtin (HTT)Gene Sequence

SNP positions (identified by Hayden et al, WO/2009/135322) associatedwith the HTT gene were mapped to the HTT genomic sequence, designatedherein as SEQ ID NO: 1 (NT_006081.18 truncated from nucleotides 1566000to 1768000). Table 15 provides SNP positions associated with the HTTgene. Table 15 provides a reference SNP ID number from the Entrez SNPdatabase at the National Center for Biotechnology Information (NCBI,http://www.ncbi.nlm.nih.gov/sites/entrez?db=snp), incorporated herein byreference. Table 15 furnishes further details on each SNP. The‘Reference SNP ID number’ or ‘RS number’ is the number designated toeach SNP from the Entrez SNP database at NCBI, incorporated herein byreference. ‘SNP position’ refers to the nucleotide position of the SNPon SEQ ID NO: 1. ‘Polymorphism’ indicates the nucleotide variants atthat SNP position. ‘Major allele’ indicates the nucleotide associatedwith the major allele, or the nucleotide present in a statisticallysignificant proportion of individuals in the human population. ‘Minorallele’ indicates the nucleotide associated with the minor allele, orthe nucleotide present in a relatively small proportion of individualsin the human population.

TABLE 15 Single Nuclear Polymorphisms (SNPs) and their positions on SEQID NO: 1 SNP Major Minor RS No. position Polymorphism allele allelers2857936 1963 C/T C T rs12506200 3707 A/G G A rs762855 14449 A/G G Ars3856973 19826 G/A G A rs2285086 28912 G/A A G rs7659144 37974 C/G C Grs16843804 44043 C/T C T rs2024115 44221 G/A A G rs10015979 49095 A/G AG rs7691627 51063 A/G G A rs2798235 54485 G/A G A rs4690072 62160 G/T TG rs6446723 66466 C/T T C rs363081 73280 G/A G A rs363080 73564 T/C C Trs363075 77327 G/A G A rs363064 81063 T/C C T rs3025849 83420 A/G A Grs6855981 87929 A/G G A rs363102 88669 G/A A G rs11731237 91466 C/T C Trs4690073 99803 A/G G A rs363144 100948 T/G T G rs3025838 101099 C/T C Trs34315806 101687 A/G G A rs363099 101709 T/C C T rs363096 119674 T/C TC rs2298967 125400 C/T T C rs2298969 125897 A/G G A rs6844859 130139 C/TT C rs363092 135682 C/A C A rs7685686 146795 A/G A G rs363088 149983 A/TA T rs362331 155488 C/T T C rs916171 156468 G/C C G rs362322 161018 A/GA G rs362275 164255 T/C C T rs362273 167080 A/G A G rs2276881 171314 G/AG A rs3121419 171910 T/C C T rs362272 174633 G/A G A rs362271 175171 G/AG A rs3775061 178407 C/T C T rs362310 179429 A/G G A rs362307 181498 T/CC T rs362306 181753 G/A G A rs362303 181960 T/C C T rs362296 186660 C/AC A rs1006798 198026 A/G A G

Example 2 Modified Oligonucleotides Targeting Huntingtin (HTT) SingleNucleotide Polymorphism (SNP)

A series of modified oligonucleotides were designed based on the parentgapmer, ISIS 460209 wherein the central gap region contains nine2′-deoxyribonucleosides. These modified oligonucleotides were designedby introducing various chemical modifications in the central gap regionand were tested for their ability to selectively inhibit mutant (mut)HTT mRNA expression levels targeting rs7685686 while leaving theexpression of the wild-type (wt) intact. The activity and selectivity ofthe modified oligonucleotides were evaluated and compared to the parentgapmer, ISIS 460209.

The modified oligonucleotides were created with a 3-9-3 motif and aredescribed in Table 16. The internucleoside linkages throughout eachgapmer are phosphorothioate (P═S) linkages. All cytosine nucleobasesthroughout each gapmer are 5-methyl cytosines. Nucleosides without asubscript are β-D-2′-deoxyribonucleosides. Nucleosides followed by asubscript “e”, “k”, “y”, or “z” are sugar modified nucleosides. Asubscript “e” indicates a 2′-O-methoxyethyl (MOE) modified nucleoside, asubscript “k” indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt), asubscript “y” indicates an α-L-LNA bicyclic nucleoside and a subscript“z” indicates a F-HNA modified nucleoside. ^(p)U indicates a 5-propyneuridine nucleoside and ^(x)T indicates a 2-thio-thymidine nucleoside.

The number in parentheses indicates the position on the modifiedoligonucleotide opposite to the SNP position, as counted from the5′-terminus.

Cell Culture and Transfection

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used (from Coriell Institute). CulturedGM04022 cells at a density of 25,000 cells per well were transfectedusing electroporation with 0.12, 0.37, 1.1, 3.3 and 10 μM concentrationsof modified oligonucleotides. After a treatment period of approximately24 hours, cells were washed with DPBS buffer and lysed. RNA wasextracted using Qiagen RNeasy purification and mRNA levels were measuredby quantitative real-time PCR using ABI assay C_2229297_10 whichmeasures at dbSNP rs362303. RT-PCR method in short; A mixture was madeusing 2020 uL 2×PCR buffer, 101 uL primers (300 uM from ABI), 1000 uLwater and 40.4 uL RT MIX. To each well was added 15 uL of this mixtureand 5 uL of purified RNA. The mutant and wild-type HTT mRNA levels weremeasured simultaneously by using two different fluorophores, FAM formutant allele and VIC for wild-type allele. The HTT mRNA levels wereadjusted according to total RNA content, as measured by RIBOGREEN andthe results are presented below.

Analysis of IC₅₀'s

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotideis presented in Table 17 and was calculated by plotting theconcentrations of oligonucleotides used versus the percent inhibition ofHTT mRNA expression achieved at each concentration, and noting theconcentration of oligonucleotide at which 50% inhibition of HTT mRNAexpression was achieved compared to the control. The IC₅₀ at which eacholigonucleotide inhibits the mutant HTT mRNA expression is denoted as‘mut IC₅₀’. The IC₅₀ at which each oligonucleotide inhibits thewild-type HTT mRNA expression is denoted as ‘wt IC₅₀’. Selectivity wascalculated by dividing the IC₅₀ for inhibition of the wild-type HTTversus the IC₅₀ for inhibiting expression of the mutant HTT mRNA.

The parent gapmer, ISIS 460209 is marked with an asterisk (*) in thetable and was included in the study as a benchmark oligonucleotideagainst which the activity and selectivity of the modifiedoligonucleotides targeting nucleotides overlapping the SNP positioncould be compared.

As illustrated in Table 17, modified oligonucleotides having chemicalmodifications in the central gap region at the SNP position exhibitedsimilar activity with an increase in selectivity comparing to the parentgapmer, wherein the central gap region contains fulldeoxyribonucleosides.

TABLE 16 Modified oligonucleotides targeting HTT rs7685686Wing chemistry SEQ ID ISIS NO Sequence (5′ to 3′) Gap chemistry 5′ 3′NO. 460209* (8) T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) Full Deoxy ekkkke 10 539560 (8) T_(e)A_(k)A_(k)ATTG^(p)UCATCA_(k)C_(k)C_(e)Deoxy/5-Propyne ekk kke 11 539563 (8)T_(e)A_(k)A_(k)ATTG^(x)TCATCA_(k)C_(k)C_(e) Deoxy/2-Thio ekk kke 10539554 (8) T_(e)A_(k)A_(k)ATTGU_(y)CATCA_(k)C_(k)C_(e) Deoxy/α-L-LNA ekkkke 11 542686 (8) T_(e)A_(k)A_(k)ATTGT_(z)CATCA_(k)C_(k)C_(e)Deoxy/F-HNA ekk kke 10 e = 2′-MOE, k = cEt

TABLE 17 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeted to rs7685686 inGM04022 cells Mut Wt Selectivity Wing ISIS IC₅₀ IC₅₀ (mut Gap chemistryNO (μM) (μM) vs wt) chemistry 5′ 3′ 460209* (8)  0.41 2.0 4.9 Full Deoxyekk kke 539560 (8) 0.29 1.1 3.8 Deoxy/5- ekk kke Propyne 539563 (8) 0.453.1 6.9 Deoxy/2-Thio ekk kke 539554 (8) 3.5 >10 >3 Deoxy/α-L- ekk kkeLNA 542686 (8) 0.5 3.1 6.0 Deoxy/F-HNA ekk kke

Example 3 Modified Oligonucleotides Comprising Chemical Modifications inthe Gap Region Targeting Huntingtin (HTT) Single Nucleotide Polymorphism(SNP)

Additional modified oligonucleotides were designed in a similar manneras the antisense oligonucleotides described in Table 16. Variouschemical modifications were introduced in the central gap region at theSNP position in an effort to improve selectivity while maintainingactivity in reducing mutant HTT mRNA levels.

The modified oligonucleotides were created with a 3-9-3 motif and aredescribed in Table 18. The internucleoside linkages throughout eachgapmer are phosphorothioate (P═S) linkages. All cytosine nucleobasesthroughout each gapmer are 5-methyl cytosines. Nucleosides without asubscript are τ-D-2′-deoxyribonucleosides. Nucleosides followed by asubscript “a”, “e”, “f”, “h”, “k”, “l”, “R”, “w” are sugar modifiednucleosides. A subscript “a” indicates a 2′-(ara)-F modified nucleoside,a subscript “e” indicates a 2′-O-methoxyethyl (MOE) modified nucleoside,a subscript “f” indicates a 2′-F modified nucleoside, a subscript “h”indicates a HNA modified nucleoside, a subscript “k” indicates a6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt), a subscript “1” indicates aLNA modified nucleoside, a subscript “R” indicates a 5′-(R)-Me DNA, asubscript “w” indicates an unlocked nucleic acid (UNA) modifiednucleoside. ^(n)T indicates an N3-ethylcyano thymidine nucleoside and^(b)N indicates an abasic nucleoside (e.g. 2′-deoxyribonucleosidecomprising a H in place of a nucleobase). Underlined nucleoside or thenumber in parentheses indicates the position on the modifiedoligonucleotide opposite to the SNP position, as counted from the5′-terminus.

Thermal Stability Assay

The modified oligonucleotides were evaluated in thermal stability(T_(m)) assay. The T_(m)'s were measured using the method describedherein. A Cary 100 Bio spectrophotometer with the Cary Win UV Thermalprogram was used to measure absorbance vs. temperature. For the T_(m)experiments, oligonucleotides were prepared at a concentration of 8 μMin a buffer of 100 mM Na+, 10 mM phosphate, 0.1 mM EDTA, pH 7.Concentration of oligonucleotides were determined at 85° C. Theoligonucleotide concentration was 4 μM with mixing of equal volumes oftest oligonucleotide and mutant or wild-type RNA strand.Oligonucleotides were hybridized with the mutant or wild-type RNA strandby heating duplex to 90° C. for 5 min and allowed to cool at roomtemperature. Using the spectrophotometer, T_(m) measurements were takenby heating duplex solution at a rate of 0.5 C/min in cuvette starting @15° C. and heating to 85° C. T_(m) values were determined using VantHoff calculations (A₂₆₀ vs temperature curve) using nonself-complementary sequences where the minimum absorbance which relatesto the duplex and the maximum absorbance which relates to the non-duplexsingle strand are manually integrated into the program.

Presented in Table 19 is the T_(m) for the modified oligonucleotideswhen duplexed to mutant or wild-type RNA complement. The T_(m) of themodified oligonucleotides duplexed with mutant RNA complement is denotedas “T_(m) (° C.) mut”. The T_(m) of the modified oligonucleotidesduplexed with wild-type RNA complement is denoted as “T_(m) (° C.) wt”.

Cell Culture, Transfection and Selectivity Analysis

The modified oligonucleotides were also tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith a single dose at 2 μM concentration of the modifiedoligonucleotide. After a treatment period of approximately 24 hours,cells were washed with DPBS buffer and lysed. RNA was extracted usingQiagen RNeasy purification and mRNA levels were measured by quantitativereal-time PCR using ABI assay C_2229297_10 which measures at dbSNPrs362303. RT-PCR method in short; A mixture was made using 2020 uL 2×PCRbuffer, 101 uL primers (300 uM from ABI), 1000 uL water and 40.4 uL RTMIX. To each well was added 15 uL of this mixture and 5 uL of purifiedRNA. The mutant and wild-type HTT mRNA levels were measuredsimultaneously by using two different fluorophores, FAM for mutantallele and VIC for wild-type allele. The HTT mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN. The results inTable 19 are presented as percent of HTT mRNA expression, relative tountreated control levels and is denoted as “% UTC”. Selectivity as wasalso evaluated and measured by dividing the percent of wild-type HTTmRNA levels vs. the percent of mutant HTT mRNA levels.

The parent gapmer, ISIS 460209 is marked with an asterisk (*) in thetable and was included in the study as a benchmark oligonucleotideagainst which the selectivity of the modified oligonucleotides targetingnucleotides overlapping the SNP position could be compared.

As illustrated in Table 19, improvement in selectivity was observed forantisense oligonucleotides comprising chemical modifications in thecentral gap region at the SNP site such as 5′-(R)-Me (ISIS 539558), HNA(ISIS 539559), and 2′-(ara)-F (ISIS 539565) in comparison to the parentfull deoxy gapmer, ISIS 460209. Modified oligonucleotides comprising LNA(ISIS 539553) or 2′-F (ISIS 539570) showed comparable selectivity whileUNA modification (ISIS 539556 or 543909) showed no selectivity. Modifiedoligonucleotides comprising modified nucleobase, N₃-ethylcyano (ISIS539564) or abasic nucleobase (ISIS 543525) showed little to noimprovement in selectivity.

TABLE 18 Modified oligonucleotides comprising chemical modificationsin the central gap region Wing SEQ chemistry ID ISIS NOSequence (5′ to 3′) Gap chemistry 5′ 3′ NO. 460209* (8)T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) Full Deoxy ekk kke 10 539553 (8)T_(e)A_(k)A_(k)ATTGT₁ CATCA_(k)C_(k)C_(e) Deoxy/LNA ekk kke 10539556 (8) T_(e)A_(k)A_(k)ATTGU_(w) CATCA_(k)C_(k)C_(e) Deoxy/UNA ekkkke 11 539558 (8) T_(e)A_(k)A_(k)ATTGT_(R) CATCA_(k)C_(k)C_(e)Deoxy/5′-(R)-Me DNA ekk kke 10 539559 (8) T_(e)A_(k)A_(k)ATTGT_(h)CATCA_(k)C_(k)C_(e) Deoxy/HNA ekk kke 10 539564 (8) T_(e)A_(k)A_(k)ATTG^(n)TCATCA_(k)C_(k)C_(e) Deoxy/deoxy with N3- ekk kke 10Ethylcyano nucleobase 539565 (8) T_(e)A_(k)A_(k)ATTGT_(a)CATCA_(k)C_(k)C_(e) Deoxy/2′-(ara)-F ekk kke 10 539570 (8)T_(e)A_(k)A_(k)ATTGT_(f) CATCA_(k)C_(k)C_(e) Deoxy/2′-F ekk kke 10543525 (8) T_(e)A_(k)A_(k)ATTG ^(b)NCATCA_(k)C_(k)C_(e)Deoxy/Deoxy-Abasic ekk kke 12 543909 (5) T_(e)A_(k)A_(k)AU_(w)TGTCATCA_(k)C_(k)C_(e) Deoxy/UNA ekk kke 13 e = 2′-MOE, k = cEt, d= 2′-deoxyribonucleoside

TABLE 19 Comparison of selectivity in inhibition of HTT mRNA levels andTm of modified oligonucleotides with ISIS 460209 targeted to rs7685686in GM04022 cells Wing Tm (° C.) % UTC Selectivity Gap chemistry ISIS NOmutant wt mutant wt (wt vs mut) chemistry 5′ 3′ 460209* (8)  53.7 52.223 57 2.4 Full Deoxy ekk kke 539553 (8) 57.7 55.3 54 102 1.9 Deoxy/LNAekk kke 539556 (8) 43.7 44.1 90 105 1.2 Deoxy/UNA ekk kke 539558 (8)51.2 49.7 25 83 3.3 Deoxy/5′-(R)-Me DNA ekk kke 539559 (8) 55.4 50.5 1862 3.5 Deoxy/HNA ekk kke 539564 (8) 42.8 43.1 86 135 1.6 Deoxy/Deoxy N3-ekk kke ethylcyano nucleobase 539565 (8) 53.8 52.5 14 46 3.4Deoxy/2′-(ara)-F ekk kke 539570 (8) 54.4 51.8 25 50 2.0 Deoxy/2′-F ekkkke 543525 (8) 43.1 43.8 87 97 1.1 Deoxy/Deoxy Abasic ekk kke 543909 (5)44.7 42.1 68 79 1.2 Deoxy/UNA ekk kke e = 2′-MOE, k = cEt, d =2′-deoxyribonucleoside

Example 4 Chimeric Oligonucleotides Comprising Self-ComplementaryRegions Targeting Huntingtin (HTT) Single Nucleotide Polymorphism (SNP)

Chimeric oligonucleotides were designed based on the parent gapmer, ISIS460209. These gapmers comprise self-complementary regions flanking thecentral gap region, wherein the central gap region contains ninedeoxyribonucleosides and the self-complementary regions arecomplementary to one another. The underlined nucleosides indicate theportion of the 5′-end that is self-complement to the portion of the3′-end.

The gapmers and their motifs are described in Table 20. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt).

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith a single dose at 2 μM concentration of the modifiedoligonucleotide. After a treatment period of approximately 24 hours,cells were washed with DPBS buffer and lysed. RNA was extracted usingQiagen RNeasy purification and mRNA levels were measured by quantitativereal-time PCR using ABI assay C_2229297_10 which measures at dbSNPrs362303. RT-PCR method in short; A mixture was made using 2020 uL 2×PCRbuffer, 101 uL primers (300 uM from ABI), 1000 uL water and 40.4 uL RTMIX. To each well was added 15 uL of this mixture and 5 uL of purifiedRNA. The mutant and wild-type HTT mRNA levels were measuredsimultaneously by using two different fluorophores, FAM for mutantallele and VIC for wild-type allele. HTT mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN. The results inTable 21 are presented as percent of HTT mRNA expression, relative tountreated control levels and is denoted as “% UTC”. Selectivity was alsoevaluated and measured by dividing the percent of wild-type HTT mRNAlevels vs. the percent of the mutant HTT mRNA levels.

The parent gapmer, ISIS 460209 is marked with an asterisk (*) in thetable and was included in the study as a benchmark oligonucleotideagainst which the selectivity of the modified oligonucleotides targetingnucleotides overlapping the SNP position could be compared.

As illustrated in Table 21, improvement in selectivity was observed forchimeric oligonucleotides comprising 5-9-5 (ISIS 550913), 6-9-6 (ISIS550912), 6-9-3 (ISIS 550907) or 3-9-7 (ISIS 550904) in comparison to theparent gapmer motif, 3-9-3 (ISIS 460209). The remaining gapmers showedmoderate to little improvement in selectivity.

TABLE 20 Chimeric oligonucleotides comprising various wing motifstargeted to HTT rs7685686 Wing chemistry SEQ ID ISIS NOSequence (5′ to 3′) Motif 5′ 3′ NO.  460209*T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) 3-9-3 ekk kke 10 544838 T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) A_(k) 3-9-4 ekk kkek 14 544840T_(e)A_(k)A_(k) ATTGTCATCA_(k)C_(k)C_(e) T_(k)T_(k)A_(k) 3-9-6 ekkkkekkk 15 544842 T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e)A_(k)T_(k)T_(k)T_(k)A_(k) 3-9-8 ekk kkekkkkk 16 550903 T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) T_(k)A_(k) 3-9-5 ekk kkekk 17 550904T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) T_(k)T_(k)T_(k)A_(k) 3-9-7 ekkkkekkkk 18 550905 G_(k) T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k) C_(e) 4-9-3kekk kke 19 550906 G_(k)G_(k) T_(e)A_(k)A_(k)ATTGTCATCA_(k) C_(k)C_(e)5-9-3 kkekk kke 20 550907 G_(k)G_(k)T_(k)T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) 6-9-3 kkkekk kke 21 550908G_(k)G_(k)T_(k)G_(k) T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) 7-9-3kkkkekk kke 22 550909 G_(k)G_(k)T_(k)G_(k)A_(k)T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) 8-9-3 kkkkkekk kke 23 550910G_(k)G_(k)C_(k) T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) G_(k)C_(k)C_(k)6-9-6 kkkekk kkekkk 24 550911 G_(k)C_(k)T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) G_(k)C_(k) 5-9-5 kkekk kkekk 25550912 T_(k)A_(k)A_(k) T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e)T_(k)T_(k)A_(k) 6-9-6 kkkekk kkekkk 26 550913 A_(k)A_(k)T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) T_(k)T_(k) 5-9-5 kkekk kkekk 27550914 T_(k)C_(k)T_(k) T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e)A_(k)G_(k)A_(k) 6-9-6 kkkekk kkekkk 28 550915 C_(k)T_(k)T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) A_(k)G_(k) 5-9-5 kkekk kkekk 29e = 2′-MOE, k = cEt

TABLE 21 Comparison of selectivity in inhibition of HTT mRNA levels ofchimeric oligonucleotides with ISIS 460209 targeted to rs7685686 inGM04022 cells Selectivity wing ISIS % UTC (wt vs. chemistry NO mut wtmut) Motif 5′ 3′  460209* 23 57 2.4 3-9-3 ekk kke 544838 13 25 2.0 3-9-4ekk kkek 544840 17 31 1.8 3-9-6 ekk kkekkk 544842 55 102 1.9 3-9-8 ekkkkekkkkk 550903 13 36 2.7 3-9-5 ekk kkekk 550904 23 67 3.0 3-9-7 ekkkkekkkk 550905 21 51 2.4 4-9-3 kekk kke 550906 23 67 2.9 5-9-3 kkekk kke550907 30 93 3.1 6-9-3 kkkekk kke 550908 60 80 2.4 7-9-3 kkkkekk kke550909 42 101 2.4 8-9-3 kkkkkekk kke 550910 57 102 1.8 6-9-6 kkkekkkkekkk 550911 18 40 2.2 5-9-5 kkekk kkekk 550912 14 51 3.6 6-9-6 kkkekkkkekkk 550913 8 36 4.5 5-9-5 kkekk kkekk 550914 29 45 1.5 6-9-6 kkkekkkkekkk 550915 13 28 2.1 5-9-5 kkekk kkekk e = 2′-MOE, k = cEt

Example 5 Chimeric Antisense Oligonucleotides ComprisingNon-Self-Complementary Regions Targeting Huntingtin (HTT) SingleNucleotide Polymorphism (SNP)

Additional gapmers are designed based on the most selective gapmers fromstudies described in Tables 61 and 62 (ISIS 550912 and 550913). Thesegapmers are created such that they cannot form self-structure in theeffort to evaluate if the increased activity simply is due to higherbinding affinity. Gapmers are designed by deleting two or threenucleotides at the 3′-terminus and are created with 6-9-3 or 5-9-3motif.

The chimeric oligonucleotides and their motifs are described in Table22. The internucleoside linkages throughout each gapmer arephosphorothioate (P═S) linkages. All cytosine nucleobases throughouteach gapmer are 5-methyl cytosines. Nucleosides without a subscript areτ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt).

The gapmers, ISIS 550912 and ISIS 550913, from which the newly designedgapmers are derived from, are marked with an asterisk (*) in the table.

TABLE 22 Non-self-complementary chimericoligonucleotides targeting HTT SNP SEQ ISIS Sequence Wing chemistry IDNO (5′ to 3′) Motif 5′ 3′ NO. 550912*T_(k)A_(k)A_(k)T_(e)A_(k)A_(k)ATTGTC 6-9-6 kkkekk kkekk 26ATCA_(k)C_(k)C_(e)T_(k)T_(k)A_(k) 550913*A_(k)A_(k)T_(e)A_(k)A_(k)ATTGTCAT 5-9-5 kkekk kkekk 27CA_(k)C_(k)C_(e)T_(k)T_(k) 556879 T_(k)A_(k)A_(k)T_(e)A_(k)A_(k)ATTGTC6-9-3 kkkekk kkekk 30 ATCA_(k)C_(k)C_(e) 556880A_(k)A_(k)T_(e)A_(k)A_(k)ATTGTCAT 5-9-3 kkekk kke 31 CA_(k)C_(k)C_(e) e= 2′-MOE, k = cEt

Example 6 Chimeric Oligonucleotides Containing Mismatches TargetingHuntingtin (HTT) Single Nucleotide Polymorphism (SNP)

A series of chimeric antisense oligonucleotides were designed based onthe parent gapmer, ISIS 460209, wherein the central gap region containsnine 2′-deoxyribonucleosides. These gapmers were designed by introducingmodified nucleosides at both 5′ and 3′ termini. Gapmers were alsocreated with a single mismatch shifted slightly upstream and downstream(i.e. “microwalk”) within the central gap region and with the SNPposition opposite position 5 of the parent gapmer, as counted from the5′-gap terminus.

The gapmers and their motifs are described in Table 23. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt). Underlinednucleosides indicate the mismatch position, as counted from the 5′-gapterminus.

These gapmers were evaluated for thermal stability (T_(m)) using methodsdescribed in Example 3. Presented in Table 24 are the T_(m) measurementsfor chimeric antisense oligonucleotides when duplexed to mutant orwild-type RNA complement. The T_(m) of chimeric antisenseoligonucleotides duplexed with mutant RNA complement is denoted as“T_(m) (° C.) mut”. The T_(m) of chimeric antisense oligonucleotidesduplexed with wild-type RNA complement is denoted as “T_(m) (° C.) wt”.

These gapmers were also tested in vitro. Heterozygous fibroblast GM04022cell line was used. Cultured GM04022 cells at a density of 25,000 cellsper well were transfected using electroporation with a single dose at 2μM concentration of the modified oligonucleotide. After a treatmentperiod of approximately 24 hours, cells were washed with DPBS buffer andlysed. RNA was extracted using Qiagen RNeasy purification and mRNAlevels were measured by quantitative real-time PCR using ABI assayC_2229297_10 which measures at dbSNP rs362303. RT-PCR method in short; Amixture was made using 2020 uL 2×PCR buffer, 101 uL primers (300 uM fromABI), 1000 uL water and 40.4 uL RT MIX. To each well was added 15 uL ofthis mixture and 5 uL of purified RNA. The mutant and wild-type HTT mRNAlevels were measured simultaneously by using two different fluorophores,FAM for mutant allele and VIC for wild-type allele. HTT mRNA levels wereadjusted according to total RNA content, as measured by RIBOGREEN. Theresults in Table 24 are presented as percent of HTT mRNA expression,relative to untreated control levels and is denoted as “% UTC”.Selectivity was also evaluated and measured by dividing the percent ofwild-type HTT mRNA levels vs. the percent of mutant HTT mRNA levels.

The parent gapmer, ISIS 460209 is marked with an asterisk (*) in thetable and was included in the study as a benchmark oligonucleotideagainst which the selectivity of the modified oligonucleotides targetingnucleotides overlapping the SNP position could be compared.

As illustrated in Table 24, improvement in selectivity was observed forgapmers comprising a 4-9-4 motif with a central deoxy gap region (ISIS476333) or a single mismatch at position 8 within the gap region (ISIS543531) in comparison to the parent gapmer. The remaining gapmers showedmoderate to little improvement in selectivity.

TABLE 23 Chimeric oligonucleotides containing a singlemismatch targeting mutant HTT SNP Mismatch Wing chemistry SEQ ID ISIS NOSequence (5′ to 3′) position Motif 5′ 3′ NO. 460209*T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) — 3-9-3 ekk kke 10 476333A_(e)T_(k)A_(e)A_(k)ATTGTCATCA_(k)C_(e)C_(k)A_(e) — 4-9-4 ekek keke 32543526 A_(e)T_(k)A_(e)A_(k)ATTCTCATCA_(k)C_(e)C_(k)A_(e) 4 4-9-4 ekekkeke 33 543527 A_(e)T_(k)A_(e)A_(k)ATAGTCATCA_(k)C_(e)C_(k)A_(e) 3 4-9-4ekek keke 34 543529 A_(e)T_(k)A_(e)A_(k)ATTGTGATCA_(k)C_(e)C_(k)A_(e) 64-9-4 ekek keke 35 543530A_(e)T_(k)A_(e)A_(k)ATTGTCTTCA_(k)C_(e)C_(k)A_(e) 7 4-9-4 ekek keke 36543531 A_(e)T_(k)A_(e)A_(k)ATTGTCAACA_(k)C_(e)C_(k)A_(e) 8 4-9-4 ekkkeke 37 543532 T_(e)A_(k)A_(k)ATTCTCATCA_(k)C_(k)C_(e) 4 3-9-3 ekk kke38 543534 T_(e)A_(k)A_(k)AATGTCATCA_(k)C_(k)C_(e) 2 3-9-3 ekk kke 39543535 T_(e)A_(k)A_(k)ATTGTGATCA_(k)C_(k)C_(e) 6 3-9-3 ekk kke 40 543536T_(e)A_(k)A_(k)ATTGTCTTCA_(k)C_(k)C_(e) 7 3-9-3 ekk kke 41 543537T_(e)A_(k)A_(k)ATTGTCAACA_(k)C_(k)C_(e) 8 3-9-3 ekk kke 42 e = 2′-MOE, k= cEt

TABLE 24 Comparison of selectivity and T_(m) of chimericoligonucleotides with ISIS 460209 targeted to rs7685686 in GM04022 cellsWing Tm (° C.) % UTC Selectivity Mismatch chemistry ISIS NO mut wt mutwt (wt vs mut) position Motif 5′ 3′  460209* 53.7 52.2 23 57 2.4 — 3-9-3ekk kke 476333 60.2 58.4 10 37 3.6 — 4-9-4 ekek keke 543526 47.9 46.6 7086 1.2 4 4-9-4 ekek keke 543527 52.6 49.9 40 103 2.6 3 4-9-4 ekek keke543529 50.3 49.0 66 102 1.5 6 4-9-4 ekek keke 543530 52.9 50.9 67 1101.6 7 4-9-4 ekek keke 543531 53.3 50.3 46 136 3.0 8 4-9-4 ekk keke543532 43.6 42.8 127 151 1.2 4 3-9-3 ekk kke 543534 45.9 43.8 67 95 1.42 3-9-3 ekk kke 543535 44.0 43.3 96 113 1.2 6 3-9-3 ekk kke 543536 46.844.6 106 104 1.0 7 3-9-3 ekk kke 543537 45.9 44.3 77 81 1.1 8 3-9-3 ekkkke e = 2′-MOE, k = cEt

Example 7 Chimeric Oligonucleotides Comprising Mismatches TargetingHuntingtin (HTT) Single Nucleotide Polymorphism (SNP)

Additional chimeric antisense oligonucleotides are designed based on twogapmers selected from studies described in Tables 64 and 65 (ISIS 476333and ISIS 460209) wherein the central gap region contains nine2′-deoxyribonucleosides. These gapmers are designed by introducing asingle mismatch, wherein the mismatch will be shifted throughout theantisense oligonucleotide (i.e. “microwalk”). Gapmers are also createdwith 4-9-4 or 3-9-3 motifs and with the SNP position opposite position 8of the original gapmers, as counted from the 5′-terminus.

The gapmers and their motifs are described in Table 25. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt). Underlinednucleosides indicate the mismatch position, as counted from the5′-terminus.

The gapmers, ISIS 476333 and ISIS 460209, in which the newly designedantisense oligonucleotides are derived from, are marked with an asterisk(*) in the table.

TABLE 25 Chimeric oligonucleotides comprising mismatchestargeting HTT SNP Mismatch Wing chemistry SEQ ID ISIS NOSequence (5′ to 3′) position Motif 5′ 3′ NO 476333*A_(e)T_(k)A_(e)AkATTGTCATCA_(k)C_(e)C_(k)A_(e) — 4-9-4 ekek keke 32554209 T_(e) T_(k)A_(e)A_(k)ATTGTCATCA_(k)C_(e)C_(k)A_(e) 1 4-9-4 ekekkeke 43 554210 A_(e) A_(k) A_(e)A_(k)ATTGTCATCA_(k)C_(e)C_(k)A_(e) 24-9-4 ekek keke 44 554211 A_(e)T_(k) T_(e)A_(k)ATTGTCATCA_(k)C_(e)C_(k)A_(e) 3 4-9-4 ekek keke 45 554212A_(e)T_(k)A_(e) T_(k) ATTGTCATCA_(k)C_(e)CkA_(e) 4 4-9-4 ekek keke 46554213 A_(e)T_(k)A_(e)A_(k) TTTGTCATCA_(k)C_(e)CkA_(e) 5 4-9-4 ekek keke47 554214 A_(e)T_(k)A_(e)A_(k)ATTGTCATGA_(k)C_(e)C_(k)A_(e) 13 4-9-4ekek keke 48 554215 A_(e)T_(k)A_(e)A_(k)ATTGTCATCT _(k)C_(e)C_(k)A_(e)14 4-9-4 ekek keke 49 554216 A_(e)T_(k)A_(e)A_(k)ATTGTCATCA_(k) G_(e)C_(k)A_(e) 15 4-9-4 ekek keke 50 554217A_(e)T_(k)A_(e)A_(k)ATTGTCATCA_(k)C_(e) G_(k) A_(e) 16 4-9-4 ekek keke51 554218 A_(e)T_(k)A_(e)A_(k)ATTGTCATCA_(k)C_(e)C_(k) T_(e) 17 4-9-4ekek keke 52 460209* T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) — 3-9-3 ekkkke 10 562481 T_(e)A_(k)A_(k) GTTGTCATCA_(k)C_(k)C_(e) 4 3-9-3 ekk kke53 554482 T_(e)A_(k)A_(k)AGTGTCATCA_(k)C_(k)C_(e) 5 3-9-3 ekk kke 54554283 T_(e)A_(k)A_(k)ATGGTCATCA_(k)C_(k)C_(e) 6 3-9-3 ekk kke 55 e= 2′-MOE, k = cEt

Example 8 Short-Gap Chimeric Oligonucleotides Targeting Huntingtin (HTT)Single Nucleotide Polymorphism (SNP)

Chimeric antisense oligonucleotides were designed based on the parentgapmer, ISIS 460209, wherein the central gap region contains nine2′-deoxyribonucleosides. These gapmers were designed by shortening thecentral gap region to seven 2′-deoxyribonuclosides. Gapmers were alsocreated with 5-7-5 motif and with the SNP position opposite position 8or 9 of the parent gapmer, as counted from the 5′-terminus.

The gapmers and their motifs are described in Table 26. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt). Underlinednucleoside or the number in parentheses indicates the position on themodified oligonucleotide opposite to the SNP position, as counted fromthe 5′-terminus.

The chimeric antisense oligonucleotides were tested in vitro. ISIS141923 was included in the study as a negative control and is denoted as“neg control”. A non-allele specific antisense oligonucleotide, ISIS387916 was used as a positive control and is denoted as “pos control”.ISIS 460209 was included in the study for comparison. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.12, 0.37, 1.1, 3.3, and 10 μM concentration of the modifiedoligonucleotide. After a treatment period of approximately 24 hours,cells were washed with DPBS buffer and lysed. RNA was extracted usingQiagen RNeasy purification and mRNA levels were measured by quantitativereal-time PCR using ABI assay C_2229297_10 which measures at dbSNPrs362303. RT-PCR method in short; A mixture was made using 2020 uL 2×PCRbuffer, 101 uL primers (300 uM from ABI), 1000 uL water and 40.4 uL RTMIX. To each well was added 15 uL of this mixture and 5 uL of purifiedRNA. The mutant and wild-type HTT mRNA levels were measuredsimultaneously by using two different fluorophores, FAM for mutantallele and VIC for wild-type allele. HTT mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN and the resultsare presented in Table 27.

The IC₅₀ and selectivity were calculated using methods describedpreviously in Example 2. As illustrated in Table 27, no improvement inpotency and selectivity was observed for the chimeric antisenseoligonucleotides as compared to ISIS 460209.

TABLE 26 Chimeric antisense oligonucleotides targeting HTT rs7685686Wing Chemistry SEQ ID ISIS NO Sequence (5′ to 3′) Motif 5′ 3′ NO.460209* (8) T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) 3-9-3 ekk kke 10460085 (9) A_(e)T_(e)A_(e)A_(e)A_(e)TTGTCATC_(e)A_(e)C_(e)C_(e)A_(e)5-7-5 eeeee eeeee 32 540108 (9)A_(e)T_(e)A_(e)A_(k)A_(k)TTGTCATC_(k)A_(k)C_(e)C_(e)A_(e) 5-7-5 eeekkkkeee 32 387916T_(e)C_(e)T_(e)C_(e)T_(e)ATTGCACATTC_(e)C_(e)A_(e)A_(e)G_(e) 5-10-5eeeee eeeee 56 (pos control) 141923C_(e)C_(e)T_(e)T_(e)C_(e)CCTGAAGGTTC_(e)C_(e)T_(e)C_(e)C_(e) 5-10-5eeeee eeeee 57 (neg control) e = 2′-MOE, k = cEt

TABLE 27 Comparison of inhibition of HTT mRNA levels and selectivity ofchimeric antisense oligonucleotides with ISIS 460209 targeted tors7685686 in GM04022 cells Mut Wt Selectivity Wing ISIS IC₅₀ IC₅₀ (mutchemistry NO (μM) (μM) vs wt) Motif 5′ 3′ 460209* (8)  0.41 2.0 4.93-9-3 ekk kke 460085 (9) 3.5 >10 >3 5-7-5 eeeee eeeee 540108 (9) 0.41 —— 5-7-5 eeekk kkeee 387916 0.39 0.34 1.0 5-10-5 eeeee eeeee (poscontrol) 141923 >10 >10 — 5-10-5 eeeee eeeee (neg control) e = 2′-MOE, k= cEt

Example 9 Short-Gap Chimeric Oligonucleotides Targeting Huntingtin (HTT)Single Nucleotide Polymorphism (SNP)

Additional chimeric antisense oligonucleotides were designed based onthe parent gapmer, ISIS 460209, wherein the central gap region containsnine 2′-deoxyribonucleosides. These gapmers were designed with thecentral gap region shortened or interrupted by introducing variousmodifications either within the gap or by adding one or more modifiednucleosides to the 3′-most 5′-region or to the 5′-most 3′-region.Gapmers were created with the SNP position opposite position 8 of theparent gapmer, as counted from the 5′-terminus.

The gapmers and their motifs are described in Table 28. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt).

The chimeric antisense oligonucleotides were tested in vitro.Heterozygous fibroblast GM04022 cell line was used. Cultured GM04022cells at a density of 25,000 cells per well were transfected usingelectroporation with 2 μM concentration of the modified oligonucleotide.After a treatment period of approximately 24 hours, cells were washedwith DPBS buffer and lysed. RNA was extracted using Qiagen RNeasypurification and mRNA levels were measured by quantitative real-time PCRusing ABI assay C_2229297_10 which measures at dbSNP rs362303. RT-PCRmethod in short; A mixture was made using 2020 uL 2×PCR buffer, 101 uLprimers (300 uM from ABI), 1000 uL water and 40.4 uL RT MIX. To eachwell was added 15 uL of this mixture and 5 uL of purified RNA. Themutant and wild-type HTT mRNA levels were measured simultaneously byusing two different fluorophores, FAM for mutant allele and VIC forwild-type allele. HTT mRNA levels were adjusted according to total RNAcontent, as measured by RIBOGREEN. The results in Table 29 are presentedas percent of HTT mRNA expression, relative to untreated control levelsand is denoted as “% UTC”. Selectivity was also evaluated and measuredby dividing the percent of wild-type HTT mRNA levels vs. the percent ofmutant HTT mRNA levels. ISIS 460209 marked with an asterisk (*) in thetable was included in the study for comparison.

As illustrated in Table 29, modifications to the 3′-most 5′-regionnucleosides that shorten the gap from 9 to 7 or 8 nucleotides (ISIS551429 and ISIS 551426) improved selectivity and potency comparing tothe parent gapmer (ISIS 460209). The remaining chimeric antisenseoligonucleotides showed moderate to little improvement in selectivity.

TABLE 28 Short-gap antisense oligonucleotides targeting HTT rs7685686ISIS Sequence Wing Chemistry SEQ ID NO (5′ to 3′) Motif 5′ 3′ NO.460209* T_(e)A_(k)A_(k)ATTGT 3-9-3 ekk kke 10 CATCA_(k)C_(k)C_(e) 551426T_(e)A_(k)A_(e)A_(k)TTG 4-8-3 ekek kke 10 TCATCA_(k)C_(k)C_(e) 551427T_(e)A_(k)A_(e)AT_(k)TGT 3-9-3 or eke or kke 10 CATCA_(k)C_(k)C_(e)5-7-3 ekedk 551428 T_(e)A_(k)A_(e)ATT_(k)GT 3-9-3 or eke or kke 10CATCA_(k)C_(k)C_(e) 6-6-3 ekeddk 551429 T_(e)A_(e)A_(e)AkT_(k)TG 5-7-3eeekk kke 10 TCATCA_(k)C_(k)C_(e) e = 2′-MOE, k = cEt, d= 2′-deoxyribonucleoside

TABLE 29 Comparison of selectivity in inhition of HTT mRNA levels ofantisense oligonucleotides with ISIS 460209 targeted to rs7685686 inGM4022 cells Selectivity Wing ISIS % UTC (wt vs. chemistry NO mut wtmut) Motif 5′ 3′  460209* 23 57 2.4 3-9-3 ekk kke 551426 14 66 4.8 4-8-3ekek kke 551427 35 97 2.8 3-9-3 or eke or kke 5-7-3 ekedk 551428 61 1101.8 3-9-3 or eke or kke 6-6-3 ekeddk 551429 19 94 5.0 5-7-3 eeekk kke e= 2′-MOE, k = cEt, d = 2′-deoxyribonucleoside

Example 10 Modified Oligonucleotides Targeting HTT SNP

A series of modified antisense oligonucleotides are designed based onthe parent gapmer, ISIS 460209, wherein the central gap region containsnine 2′-deoxynucleosides and is marked with an asterisk (*) in thetable. These modified oligonucleotides are designed by shortening orinterrupting the gap with a single mismatch or various chemicalmodifications within the central gap region. The modifiedoligonucleotides are created with the SNP position opposite position 8of the parent gapmer, as counted from the 5′-terminus.

The gapmers and their motifs are described in Table 30. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages, except for the internucleoside linkage with a subscript“p”, “pz” or “pw”. Subscript “p” indicates methyl phosphonateinternucleoside linkage. Subscript “pz” indicates (R)-methyl phosphonateinternucleoside linkage. Subscript “pw” indicates (S)-methyl phosphonateinternucleoside linkage. All cytosine nucleobases throughout each gapmerare 5-methyl cytosines. ^(x)T indicates a 2-thio thymidine nucleoside.Nucleosides without a subscript are β-D-2′-deoxyribonucleosides.Nucleosides followed by a subscript “e”, “k” or “b” are sugar modifiednucleosides. A subscript “e” indicates a 2′-O-methoxyethyl (MOE)modified nucleoside, a subscript “k” indicates a 6′-(S)—CH₃ bicyclicnucleoside (e.g. cEt) and a subscript “b” indicates a 5′-Me DNA modifiednucleoside. Underlined nucleosides indicate the position ofmodification. Bold and underlined nucleosides indicate the mismatchposition.

TABLE 30 Short-gap chimeric oligonucleotides targeting HTT SNP SEQSequence Wing Chemistry ID ISIS NO (5′ to 3′) Motif Gap Chemistry 5′ 3′NO. 460209* T_(e)A_(k)A_(k)ATTGTC 3-9-3 — ekk kke 10 ATCA_(k)C_(k)C_(e)XXXX16 T_(e)A_(k)A_(k)A ^(x)TTGT 3-9-3 Deoxy/2-thio ekk kke 10CATCA_(k)C_(k)C_(e) XXXX17 T_(e)A_(k)A_(k)AT ^(x)TGT 3-9-3 Deoxy/2-thioekk kke 10 CATCA_(k)C_(k)C_(e) XXXX18 T_(e)A_(k)A_(k)A ^(x)T^(x)TGT3-9-3 Deoxy/2-thio ekk kke 10 CATCA_(k)C_(k)C_(e) XXXX19T_(e)A_(k)A_(k)AT_(p) GT 3-9-3 Deoxy/Methyl ekk kke 10 (558257)CATCA_(k)C_(k)C_(e) phosphonate XXXX20 T_(e)A_(k)A_(k)AT_(p) TGT 3-9-3Deoxy/Methyl ekk kke 10 (558256) CATCA_(k)C_(k)C_(e) phosphonate XXXX20aT_(e)A_(k)A_(k)AT_(pz) TGT 3-9-3 Deoxy/(R)- ekk kke 10CATCA_(k)C_(k)C_(e) Methyl phosphonate XXXX20b T_(e)A_(k)A_(k)AT_(pw) TG3-9-3 Deoxy/(S)- ekk kke 10 TCATCA_(k)C_(k)C_(e) Methyl phosphonateXXXX21 T_(e)A_(k)A_(k) A_(p) TTGT 3-9-3 Methyl ekk kke 10 (558255)CATCA_(k)C_(k)C_(e) phosphonate XXXX22 T_(e)A_(k)A_(k)ATT_(b) GT 3-9-35′-Me-DNA ekk kke 10 CATCA_(k)C_(k)C_(e) XXXX23 T_(e)A_(k)A_(k)AT_(b)TGT 3-9-3 5′-Me-DNA ekk kke 10 CATCA_(k)C_(k)C_(e) XXXX24T_(e)A_(k)A_(k) A_(b) TTGT 3-9-3 5′-Me-DNA ekk kke 10CATCA_(k)C_(k)C_(e) XXXX25 T_(e)A_(k)A_(k) G TTGTC 4-8-3 Mismatch at ekkkke 53 ATCA_(k)C_(k)C_(e) position 4 XXXX26 T_(e)A_(k)A_(k)A G TGT 5-7-3Mismatch at ekk kke 54 CATCA_(k)C_(k)C_(e) position 5 XXXX27T_(e)A_(k)A_(k)AT G GT 6-6-3 Mismatch at ekk kke 55 CATCA_(k)C_(k)C_(e)position 6 e = 2′-M0E, k = cEt

Example 11 Short-Gap Chimeric Oligonucleotides Comprising Modificationsat the Wing Regions Targeting Huntingtin (HTT) Single NucleotidePolymorphism (SNP)

Additional chimeric antisense oligonucleotides were designed based onthe parent gapmer, ISIS 460209, wherein the central gap region containsnine 2′-deoxynucleosides. These gapmers were designed by shortening thecentral gap region to seven 2′-deoxynucleosides and introducing variousmodifications at the wing regions.

The gapmers and their motifs are described in Table 31. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt).

The number in parentheses indicates the position on the chimericoligonucleotide opposite to the SNP position, as counted from the5′-terminus.

These gapmers were evaluated for thermal stability (T_(m)) using methodsdescribed in Example 3. Presented in Table 32 is the T_(m) measurementsfor chimeric antisense oligonucleotides when duplexed to mutant orwild-type RNA complement. The T_(m) of chimeric antisenseoligonucleotides duplexed with mutant RNA complement is denoted as“T_(m) (° C.) mut”. The T_(m) of chimeric antisense oligonucleotidesduplexed with wild-type RNA complement is denoted as “T_(m) (° C.) wt”.

These gapmers were also tested in vitro. Heterozygous fibroblast GM04022cell line was used. Cultured GM04022 cells at a density of 25,000 cellsper well were transfected using electroporation with a single dose at 2μM concentration of the modified oligonucleotide. After a treatmentperiod of approximately 24 hours, cells were washed with DPBS buffer andlysed. RNA was extracted using Qiagen RNeasy purification and mRNAlevels were measured by quantitative real-time PCR using ABI assayC_2229297_10 which measures at dbSNP rs362303. RT-PCR method in short; Amixture was made using 2020 uL 2×PCR buffer, 101 uL primers (300 uM fromABI), 1000 uL water and 40.4 uL RT MIX. To each well was added 15 uL ofthis mixture and 5 uL of purified RNA. The mutant and wild-type HTT mRNAlevels were measured simultaneously by using two different fluorophores,FAM for mutant allele and VIC for wild-type allele. HTT mRNA levels wereadjusted according to total RNA content, as measured by RIBOGREEN. Theresults in Table 32 are presented as percent of HTT mRNA expression,relative to untreated control levels and is denoted as “% UTC”.Selectivity was also evaluated and measured by dividing the percent ofwild-type HTT mRNA levels vs. the percent of mutant HTT mRNA levels.ISIS 460209 marked with an asterisk (*) in the table was included in thestudy for comparison.

As illustrated in Table 32, improvement in selectivity was observed forgapmers comprising 2-7-8 or 5-7-5 motifs having cEt subunits at the wingregions in comparison to the parent gapmer, ISIS 460209. The remaininggapmers showed moderate to little improvement in selectivity.

TABLE 31 Short-gap chimeric oligonucleotides comprisingwing modifications wing SEQ Sequence chemistry ID ISIS NO (5′ to 3′)Motif 5′ 3′ NO. 460209* (8) T_(e)A_(k)A_(k)ATTGTCA 3-9-3 ekk kke 10TCA_(k)C_(k)C_(e) 540103 (6) A_(k)A_(k)TTGTCATC_(e) 2-7-8 kk e8 58A_(e)C_(e)C_(e)A_(e)G_(e)A_(e)A_(e) 540104 (6) A_(e)A_(e)TTGTCATC_(e)2-7-8 ee e8 59 A_(e)C_(e)C_(e)A_(e)G_(e)A_(e)A_(e) 540105 (7)A_(e)A_(e)A_(e)TTGTCAT 3-7-7 eee e7 60C_(e)A_(e)C_(e)C_(e)A_(e)G_(e)A_(e) 540106 (8) T_(e)A_(e)A_(e)A_(e)TTGTC4-7-6 eeee e6 61 ATC_(e)A_(e)C_(e)C_(e)A_(e)G_(e) 540107 (9)A_(e)T_(e)A_(e)A_(e)AkTTGT 5-7-5 eeeek keeee 32CATC_(k)A_(e)C_(e)C_(e)A_(e) 540109 (10)A_(e)A_(e)T_(e)A_(e)A_(e)A_(e)TTG 6-7-4 e6 e4 62TCATC_(e)A_(e)C_(e)C_(e) 540110 (11)T_(e)A_(e)A_(e)T_(e)A_(e)A_(e)A_(e)T 7-7-3 e7 eee 63TGTCATC_(e)A_(e)C_(e) 540111 (12)T_(e)T_(e)A_(e)A_(e)T_(e)A_(e)A_(e)A_(e) 8-7-2 e8 ee 64TTGTCATC_(e)A_(e) 540112 (12) T_(e)T_(e)A_(e)A_(e)T_(e)A_(e)A_(e)A_(e)8-7-2 e8 kk 64 TTGTCATC_(k)A_(k) e = 2′-MOE (e.g. e6 = eeeeee), and k= cEt

TABLE 32 Comparison of selectivity in inhibition of HTT mRNA levels ofantisense oligonucleotides with ISIS 460209 targeted to RS7685686 inGM04022 cells wing Tm (° C.) % UTC Selectivity chemistry ISIS NO mut wtmut wt (wt vs mut) Motif 5′ 3′ 460209* (8)  53.7 52.2 23 57 2.4 3-9-3ekk kke 540103 (6) 57.6 56.4 23 74 3.3 2-7-8 kk e8 540104 (6) 54.8 52.836 91 2.5 2-7-8 ee e8 540105 (7) 54.2 52.2 53 135 2.6 3-7-7 eee e7540106 (8) 52.4 50.8 30 77 2.6 4-7-6 eeee e6 540107 (9) 56.6 54.7 19 623.3 5-7-5 eeeek keeee  540109 (10) 49.1 47.3 78 127 1.6 6-7-4 e6 e4 540110 (11) 42.8 41.2 89 112 1.3 7-7-3 e7 eee  540111 (12) 39.0 36.9111 128 1.1 8-7-2 e8 ee  540112 (12) 44.2 42.4 86 102 1.2 8-7-2 e8 kk

Example 12

Chimeric Oligonucleotides with SNP Site Shifting within the Central GapRegion

Chimeric antisense oligonucleotides were designed based on the parentgapmer, ISIS 460209 wherein the SNP site aligns with position 5 of theparent gapmer, as counted from the 5′-gap terminus. These gapmers weredesigned by shifting the SNP site upstream or downstream (i.e.microwalk) within the central gap region of the parent gapmer.

The gapmers and their motifs are described in Table 33. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt). Underlinenucleosides indicate the position on the chimeric oligonucleotide alignswith the SNP site.

The SNP site indicates the position on the chimeric antisenseoligonucleotide opposite to the SNP position, as counted from the 5′-gapterminus and is denoted as “SNP site”.

The chimeric oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations of modifiedoligonucleotides. After a treatment period of approximately 16 hours,RNA was isolated from the cells and mRNA levels were measured byquantitative real-time PCR using ABI assay C_2229297_10 which measuresat dbSNP rs362303. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN. ISIS 460209 marked with anasterisk (*) in the table was included in the study for comparison.

The IC₅₀ and selectivity were calculated using the methods previouslydescribed in Example 2. As illustrated in Table 34, chimericoligonucleotides comprising 4-9-2 (ISIS 540082) or 2-9-4 (ISIS 540095)motif with the SNP site at position 1 or 3 showed comparable activityand 2.5 fold selectivity as compared to their counterparts.

TABLE 33 Chimeric oligonucleotides designed by microwalk wing SEQ ISISSequence SNP chemistry ID NO (5′ to 3′) Motif site 5′ 3′ NO. 460209*T_(e)A_(k)A_(k)ATTGTCA 3-9-3 5 ekk kke 10 TCA_(k)C_(k)C_(e) 540082A_(e)T_(k)T_(k)G_(k) TCATC 4-9-2 1 ekkk ke 65 ACCAG_(k)A_(e) 540089T_(e)T_(k)A_(k)A_(k)TAAAT 4-9-2 8 ekkk ke 66 TGTCA_(k)T_(e) 540095A_(e)T_(k)TGTCATCA 2-9-4 3 ek kkke 65 CC_(k)A_(k)G_(k)A_(e) e = 2′-MOE,and k = cEt

TABLE 34 Comparison of inhibition of HTT mRNA levels and selectivity ofchimeric oligonucleotides with ISIS 460209 targeted to HTT SNP Mut WtSelectivity Wing ISIS IC₅₀ IC₅₀ (wt vs SNP Chemistry NO (μM) (μM) mut)Motif site 5′ 3′ 460209 0.41 2.0 4.9 3-9-3 5 ekk kke 540082 0.45 5.6 124-9-2 1 ekkk ke 540089 >10 >10 — 4-9-2 8 ekkk ke 540095 0.69 8.4 122-9-4 3 ek kkke e = 2′-MOE, and k = cEt

Example 13

Chimeric Oligonucleotides with SNP Site Shifting at Various Positions

Chimeric antisense oligonucleotides were designed based on the parentgapmer, ISIS 460209 wherein the SNP site aligns with position 8 of theparent gapmer, as counted from the 5′-terminus. These gapmers weredesigned by shifting the SNP site upstream or downstream (i.e.microwalk) of the original oligonucleotide.

The gapmers and their motifs are described in Table 35. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areτ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt). Underlinenucleosides indicate the SNP site.

The SNP site indicates the position on the chimeric antisenseoligonucleotide opposite to the SNP position, as counted from the5′-terminus and is denoted as “SNP site”.

The chimeric oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations of modifiedoligonucleotides. After a treatment period of approximately 16 hours,cells were washed with DPBS buffer and lysed. RNA was extracted usingQiagen RNeasy purification and mRNA levels were measured by quantitativereal-time PCR using ABI assay C_2229297_10 which measures at dbSNPrs362303. RT-PCR method in short; A mixture was made using 2020 uL 2×PCRbuffer, 101 uL primers (300 uM from ABI), 1000 uL water and 40.4 uL RTMIX. To each well was added 15 uL of this mixture and 5 uL of purifiedRNA. The mutant and wild-type HTT mRNA levels were measuredsimultaneously by using two different fluorophores, FAM for mutantallele and VIC for wild-type allele. HTT mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN. The results inTable 36 are presented as percent of HTT mRNA expression, relative tountreated control levels and is denoted as “% UTC”. Selectivity was alsoevaluated and measured by dividing the percent of wild-type HTT mRNAlevels vs. the percent of mutant HTT mRNA levels.

The parent gapmer, ISIS 460209 is marked with an asterisk (*) in thetable and was included in the study as a benchmark oligonucleotideagainst which the selectivity of the modified oligonucleotides targetingnucleotides overlapping the SNP position could be compared.

As illustrated in Table 36, improvement in potency and selectivity wasobserved for chimeric oligonucleotides comprising 4-9-2 or 2-9-4 motifhaving the target SNP site at positions 3, 4, 6, 7 and 8 (ISIS540083,ISIS540084, ISIS 540085, ISIS 540094, ISIS 540096, ISIS 540097 and ISIS540098) in comparison to position 8 of the parent gapmer (ISIS 460209).The remaining gapmers showed little to no improvement in potency orselectivity.

TABLE 35 Chimeric oligonucleotides designed by microwalk SEQ SNP IDISIS NO Sequence (5′ to 3′) site Motif NO. 460209*T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) 8 3-9-3 10 (ekk-d9-kke) 543887T_(e)T_(k)G_(k) T_(k) CATCACCAGA_(k)A_(e) 4 4-9-2 67 (ekkk-d9-ke) 540083A_(e)A_(k)T_(k)T_(k)GTCATCACCA_(k)G_(e) 6 4-9-2 68 (ekkk-d9-ke) 540084A_(e)A_(k)A_(k)T_(k)TGTCATCACC_(k)A_(e) 7 4-9-2 69 (ekkk-d9-ke) 540085T_(e)A_(k)A_(k)A_(k)TTGTCATCAC_(k)C_(e) 8 4-9-2 10 (ekkk-d9-ke) 540087A_(e)A_(k)T_(k)A_(k)AATTGTCATC_(k)A_(e) 10 4-9-2 70 (ekkk-d9-ke) 540090A_(e)T_(k)T_(k)A_(k)ATAAATTGTC_(k)A_(e) 13 4-9-2 71 (ekkk-d9-ke) 540091T_(e)A_(k)T_(k)T_(k)AATAAATTGT_(k) C_(e) 14 4-9-2 72 (ekkk-d9-ke) 540092G_(e) T_(k) CATCACCAGA_(k)A_(k)A_(k)A_(e) 2 2-9-4 73 (ek-d9-kkke) 540093T_(e)G_(k) TCATCACCAG_(k)A_(k)A_(k)A_(e) 3 2-9-4 74 (ek-d9-kkke) 540094T_(e)T_(k)GTCATCACCA_(k)G_(k)A_(k)A_(e) 4 2-9-4 67 (ek-d9-kkke) 540096A_(e)A_(k)TTGTCATCAC_(k)C_(k)A_(k)G_(e) 6 2-9-4 68 (ek-d9-kkke) 540097A_(e)A_(k)ATTGTCATCA_(k)C_(k)C_(k)A_(e) 8 2-9-4 69 (ek-d9-kkke) 540098T_(e)A_(k)AATTGTCATC_(k)A_(k)C_(k)C_(e) 8 2-9-4 10 (ek-d9-kkke) 540099A_(e)T_(k)AAATTGTCAT_(k)C_(k)A_(k)C_(e) 9 2-9-4 75 (ek-d9-kkke) 540100A_(e)A_(k)TAAATTGTCA_(k)T_(k)C_(k)A_(e) 10 2-9-4 70 (ek-d9-kkke) 540101T_(e)A_(k)ATAAATTGTC_(k)A_(k)T_(k)C_(e) 11 2-9-4 76 (ek-d9-kkke) 540102T_(e)T_(k)AATAAATTGT_(k) C_(k)A_(k)T_(e) 12 2-9-4 66 (ek-d9-kkke) e= 2′-MOE; k = cEt; d = 2′-deoxyribonucleoside

TABLE 36 Comparison of selectivity in HTT SNP inhibition of chimericoligonucleotides with ISIS 460209 % UTC Selectivity SNP ISIS NO mut wt(wt vs. mut) site Motif  460209* 23 57 2.4 8 3-9-3 (ekk-d9-kke) 54388718 43 2.3 4 4-9-2 (ekkk-d9-ke) 540083 18 67 3.7 6 4-9-2 (ekkk-d9-ke)540084 10 49 4.9 7 4-9-2 (ekkk-d9-ke) 540085 21 86 4.1 8 4-9-2(ekkk-d9-ke) 540087 60 98 1.6 10 4-9-2 (ekkk-d9-ke) 540090 129 137 1.113 4-9-2 (ekkk-d9-ke) 540091 93 105 1.1 14 4-9-2 (ekkk-d9-ke) 540092 2855 2.0 2 2-9-4 (ek-d9-kkke) 540093 18 62 3.4 3 2-9-4 (ek-d9-kkke) 54009413 45 3.4 4 2-9-4 (ek-d9-kkke) 540096 17 68 4.0 6 2-9-4 (ek-d9-kkke)540097 8 35 4.2 8 2-9-4 (ek-d9-kkke) 540098 12 45 3.9 8 2-9-4(ek-d9-kkke) 540099 62 91 1.5 9 2-9-4 (ek-d9-kkke) 540100 80 106 1.3 102-9-4 (ek-d9-kkke) 540101 154 152 1.0 11 2-9-4 (ek-d9-kkke) 540102 102106 1.0 12 2-9-4 (ek-d9-kkke) e = 2′-MOE; k = cEt; d =2′-deoxyribonucleoside

Example 14

Selectivity in Inhibition of HTT mRNA Levels Targeting SNP by ChimericOligonucleotides Designed by Microwalk

A series of modified oligonucleotides were designed based on the parentgapmer, ISIS 460209, wherein the central gap region comprises nine2′-deoxyribonucleosides. These gapmers were created with various motifsand modifications at the wings and/or the central gap region.

The modified oligonucleotides and their motifs are described in Table37. The internucleoside linkages throughout each gapmer arephosphorothioate (P═S) linkages. All cytosine nucleobases throughouteach gapmer are 5-methyl cytosines. Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e”,“k”, “y”, or “z” are sugar modified nucleosides. A subscript “e”indicates a 2′-O-methoxyethyl (MOE) modified nucleoside, a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt), a subscript “y”indicates an α-L-LNA modified nucleoside, and a subscript “z” indicatesa F-HNA modified nucleoside. ^(p)U indicates a 5-propyne uridinenucleoside and ^(x)T indicates a 2-thio-thymidine nucleoside. Underlinednucleosides indicate the mismatch position.

These gapmers were evaluated for thermal stability (T_(m)) using methodsdescribed in Example 3. Presented in Table 38 are the T_(m) measurementsfor chimeric antisense oligonucleotides when duplexed to mutant orwild-type RNA complement. The T_(m) of chimeric antisenseoligonucleotides duplexed with mutant RNA complement is denoted as“T_(m) (° C.) mut”. The T_(m) of chimeric antisense oligonucleotidesduplexed with wild-type RNA complement is denoted as “T_(m) (° C.) wt”.

These gapmers were also tested in vitro. ISIS 141923 was included in thestudy as a negative control and is denoted as “neg control”. Thenon-allele specific antisense oligonucleotides, ISIS 387916 was used asa positive control and is denoted as “pos control”. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith a single dose at 2 μM concentration of the modifiedoligonucleotide. After a treatment period of approximately 24 hours,cells were washed with DPBS buffer and lysed. RNA was extracted usingQiagen RNeasy purification and mRNA levels were measured by quantitativereal-time PCR using ABI assay C_2229297_10 which measures at dbSNPrs362303. RT-PCR method in short; A mixture was made using 2020 uL 2×PCRbuffer, 101 uL primers (300 uM from ABI), 1000 uL water and 40.4 uL RTMIX. To each well was added 15 uL of this mixture and 5 uL of purifiedRNA. The mutant and wild-type HTT mRNA levels were measuredsimultaneously by using two different fluorophores, FAM for mutantallele and VIC for wild-type allele. HTT mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN. ISIS 460209marked with an asterisk (*) in the table was included in the study forcomparison. The results in Table 38 are presented as percent of HTT mRNAexpression, relative to untreated control levels and is denoted as “%UTC”. Selectivity was also evaluated and measured by dividing thepercent of wild-type HTT mRNA levels vs. the percent of mutant HTT mRNAlevels.

As illustrated, several of the newly designed antisense oligonucleotidesshowed improvement in potency and/or selectivity in inhibiting mut HTTmRNA levels comparing to ISIS 460209.

TABLE 37 Modified oligonucleotides comprising various modificationstargeting HTT SNP SEQ Wing Chemistry ID ISIS NO Sequence (5′ to 3′)Modification 5′ 3′ NO. 460209* T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e)3-9-3 ekk kke 10 (ekk-d9-kke) 539560T_(e)A_(k)A_(k)ATTG^(p)UCATCA_(k)C_(k)C_(e) 5-propyne in gap ekk kke 11539563 T_(e)A_(k)A_(k)ATTG^(x)TCATCA_(k)C_(k)C_(e) 2-thio in gap ekk kke10 539554 T_(e)A_(k)A_(k)ATTGU_(y)CATCA_(k)C_(k)C_(e) α-L-LNA in gap ekkkke 11 542686 T_(e)A_(k)A_(k)ATTGT_(z)CATCA_(k)C_(k)C_(e) F-HNA in gapekk kke 10 540108A_(e)T_(e)A_(e)A_(k)A_(k)TTGTCATC_(k)A_(k)C_(e)C_(e)A_(e) 5-7-5 eeekkkkeee 23 (eeekk-d7-kkeee) 544840T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e)T_(k)T_(k)A_(k) 3-9-6 ekk kkekkk15 (ekk-d9-kkekkk) 550904T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e)T_(k)T_(k)T_(k)A_(k) 3-9-7 ekkkkekkkk 18 (ekk-d9-kkekkkk) 540082A_(e)T_(k)T_(k)G_(k)TCATCACCAG_(k)A_(e) 4-9-2 ekkk ke 65 (ekkk-d9-ke)540089 T_(e)T_(k)A_(k)A_(k)TAAATTGTCA_(k)T_(e) 4-9-2 ekkk ke 66(ekkk-d9-ke) 540095 A_(e)T_(k)TGTCATCACC_(k)A_(k)G_(k)A_(e) 2-9-4 ekkkke 67 (ek-d9-kkke) 543528A_(e)T_(k)A_(e)A_(k)AATGTCATCA_(k)C_(e)C_(k)A_(e) Mismatch at ekek keke77 position 2 counting from 5′ gap 543533T_(e)A_(k)A_(k)ATAGTCATCA_(k)C_(k)C_(e) Mismatch at ekk kke 78position 3 counting from 5′ gap 387916T_(e)C_(e)T_(e)C_(e)T_(e)ATTGCACATTC_(e)C_(e)A_(e)A_(e)G_(e) 5-10-5eeeee eeeee 56 (pos control) 141923C_(e)C_(e)T_(e)T_(e)C_(e)CCTGAAGGTTC_(e)C_(e)T_(e)C_(e)C_(e) 5-10-5eeeee eeeee 57 (neg control) e = 2′-MOE; k = cEt; d= 2′-deoxyribonucleoside

TABLE 38 Comparison of selectivity in inhibition of HTT mRNA levels, andTm of modified oligonucleotides with ISIS 460209 targeted to rs7685686in GM04022 cells Wing Tm (° C.) % UTC Selectivity Chemistry ISIS NOmutant wt mut wt (wt vs mut) Modification 5′ 3′  460209* 53.7 52.2 23 572.7 3-9-3 ekk kke (ekk-d9-kke) 539560 54.1 50.8 13 32 2.4 5-propyne ingap ekk kke 539563 53.8 49.1 13 40 3.2 2-thio in gap ekk kke 539554 56.554.5 54 89 1.7 α-L-LNA in gap ekk kke 542686 56.1 50.4 26 62 2.4 F-HNAin gap ekk kke 540108 60.0 57.9 27 63 2.3 5-7-5 eeekk kkeee(eeekk-d7-kkeee) 544840 — — 19 40 2.1 3-9-6 ekk kkekkk (ekk-d9-kkekkk)550904 — — 39 65 1.7 3-9-7 ekk kkekkkk (ekk-d9-kkekkkk) 540082 — — 21 623.0 4-9-2 ekkk ke (ekkk-d9-ke) 540089 — — 78 86 1.1 4-9-2 ekkk ke(ekkk-d9-ke) 540095 — — 22 66 3.1 2-9-4 ek kkke (ek-d9-kkke) 543528 50.549.1 44 90 2.1 Mismatch at ekek keke position 2 counting from 5′ gap543533 47.0 44.8 83 97 1.2 Mismatch at ekk kke position 3 counting from5′ gap 387916 — — 21 19 0.9 5-10-5 eeeee eeeee (pos control) 141923 — —95 99 1.0 5-10-5 eeeee eeeee (neg control) e = 2′-MOE; k = cEt; d =2′-deoxyribonucleoside

Example 15 Chimeric Oligonucleotides Comprising Modifications at the SNPSite of HTT Gene

Additional gapmers are designed based on the gapmer selected fromstudies described in Tables 73 and 74 (ISIS 540108) and is marked withan asterisk (*). These gapmers are designed by introducing modificationsat the SNP site at position 9 of the oligonucleotides, as counted fromthe 5′-terminus and are created with a 5-7-5 motif.

The gapmers are described in Table 39. The internucleoside linkagesthroughout each gapmer are phosphorothioate (P═S) linkages. All cytosinenucleobases throughout each gapmer are 5-methyl cytosines. Nucleosideswithout a subscript are β-D-2′-deoxyribonucleosides. Nucleosidesfollowed by a subscript “a”, “b”, “e”, or “k” are sugar modifiednucleosides. A subscript “a” indicates 2′-(ara)-F modified nucleoside, asubscript “b” indicates a 5′-Me DNA modified nucleoside, a subscript “e”indicates a 2′-O-methoxyethyl (MOE) modified nucleoside, and a subscript“k” indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt). ^(x)Tindicates a 2-thio-thymidine nucleoside. Underline nucleoside or thenumber in parentheses indicates the position on the oligonucleotidesopposite to the SNP position, as counted from the 5′-terminus.

TABLE 39 Modified oligonucleotides targeting HTT SNP Wing SEQ SequenceGap chemistiy ID ISIS NO (5′ to 3′) Chemistry 5′ 3′ NO. 540108* (9)A_(e)T_(e)A_(e)A_(k)A_(k)TTGT Deoxy eeekk kkeee 32CATC_(k)A_(k)C_(e)C_(e)A_(e) XXXX28 (9) A_(e)T_(e)A_(e)A_(k)A_(k)TTG^(x)T Deoxy/2- eeekk kkeee 32 CATC_(k)A_(k)C_(e)C_(e)A_(e) thioXXXX29 (9) A_(e)T_(e)A_(e)A_(k)A_(k)TTGT_(a) Deoxy/2'- eeekk kkeee 32CATC_(k)A_(k)C_(e)C_(e)A_(e) (ara)-F XXXX30 (9)A_(e)T_(e)A_(e)A_(k)A_(k)TTGT_(b) Deoxy/5'- eeekk kkeee 32CATC_(k)A_(k)C_(e)C_(e)A_(e) Me-DNA e = 2′-MOE, k = cEt

Example 16 Chimeric Oligonucleotides Comprising Modifications at theWing Regions Targeting HTT SNP

Additional gapmers are designed based on the gapmer, ISIS 540107selected from Example 11 and is marked with an asterisk (*). Thesegapmers are designed by introducing bicyclic modified nucleosides at the3′ or 5′ terminus and are tested to evaluate if the addition of bicyclicmodified nucleosides at the wing regions improves the activity andselectivity in inhibition of mutant HTT SNP.

The gapmers comprise a 5-7-5 motif and are described in Table 40. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e”, or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside, and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt).

TABLE 40 Modified oligonucleotides targeting HTT SNP ISIS wing chemistrySEQ ID NO Sequence (5′ to 3′) Motif 5′ 3′ NO. 540107*A_(e)T_(e)A_(e)A_(e)A_(k)TTGTCATC_(k)A_(e)C_(e)C_(e)A_(e) 5-7-5 eeeekkeeee 32 (eeeek-d7-keeee) XXXX31A_(e)T_(e)A_(k)A_(k)A_(k)TTGTCATC_(k)A_(k)C_(k)C_(e)A_(e) 5-7-5 eekkkkkkee 32 (eekkk-d7-kkkee) XXXX32A_(e)T_(e)A_(e)A_(e)A_(k)TTGTCATC_(e)A_(e)C_(e)C_(e)A_(e) 5-7-5 eeeekeeeee 32 (eeeek-d7-eeeee) XXXX33A_(e)T_(e)A_(e)A_(k)A_(k)TTGTCATC_(e)A_(e)C_(e)C_(e)A_(e) 5-7-5 eeekkeeeee 32 (eeekk-d7-eeeee) XXXX34A_(e)T_(e)A_(k)A_(k)A_(k)TTGTCATC_(e)A_(e)C_(e)C_(e)A_(e) 5-7-5 eekkkeeeee 32 (eekkk-d7-eeeee) XXXX35A_(e)T_(e)A_(e)A_(e)A_(e)TTGTCATC_(k)A_(e)C_(e)C_(e)A_(e) 5-7-5 eeeeekeeee 32 (eeeee-d7-keeee) XXXX36A_(e)T_(e)A_(e)A_(e)A_(e)TTGTCATC_(k)A_(k)C_(e)C_(e)A_(e) 5-7-5 eeeeekkeee 32 (eeeee-d7-kkeee) XXXX37A_(e)T_(e)A_(e)A_(e)A_(e)TTGTCATC_(k)A_(k)C_(k)C_(e)A_(e) 5-7-5 eeeeekkkee 32 (eeeee-d7-kkkee) e = 2′-MOE; k = cEt; d= 2′-deoxyribonucleoside

Example 17 Chimeric Oligonucleotides Comprising Wing and Central GapModifications Targeting HTT SNP

Additional gapmers are designed based on the parent gapmer, ISIS 460209,wherein the central gap region comprises nine 2′-deoxyribonucleosidesand is marked with an asterisk (*) in the table. These gapmers weredesigned by introducing modifications at the wings or the central gapregion and are created with a 3-9-3 motif.

The gapmers are described in Table 41. The internucleoside linkagesthroughout each gapmer are phosphorothioate (P═S) linkages. All cytosinenucleobases throughout each gapmer are 5-methyl cytosines. Nucleosideswithout a subscript are β-D-2′-deoxyribonucleosides. Nucleosidesfollowed by a subscript “e”, or “k” are sugar modified nucleosides. Asubscript “e” indicates a 2′-O-methoxyethyl (MOE) modified nucleoside,and a subscript “k” indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g.cEt). ^(P)T indicates a 5-propyne thymidine nucleoside. ^(P)C indicatesa 5-propyne cytosine nucleoside. Underline nucleoside or the number inparentheses indicates the position on the oligonucleotides opposite tothe SNP position, as counted from the 5′-terminus.

TABLE 41 Modified oligonucleotides targeting HTT SNP wing chemistiySEQ ID ISIS NO Sequence (5′ to 3′) Modification 5′ 3′ NO 460209* (8)T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) Deoxy gap ekk kke 10 (3-9-3)552103 (8) T_(e)A_(e)A_(e)ATTGTCATCA_(k)C_(k)C_(k) Deoxy gap eee kkk 10(3-9-3) 552104 (8) T_(k)A_(k)A_(k)ATTGTCATCA_(e)C_(e)C_(e) Deoxy gap kkkeee 10 (3-9-3) 552105 (8) T_(e)A_(k)A_(k)ATTG ^(P)T^(P)CATCA_(k)C_(k)C_(e) Deoxy/ ekk kke 10 5-Propyne 552106 (8)T_(e)A_(k)A_(k)A^(P)T^(P)TG ^(P)T ^(P)CA^(P)T^(P)CA_(k)C_(k)C_(e) Deoxy/ekk kke 10 5-Propyne e = 2′-MOE; k = cEt

Example 18 Modified Oligonucleotides Comprising F-HNA Modification atthe Central Gap or Wing Region Targeting HTT SNP

A series of modified oligonucleotides were designed based on ISIS460209, wherein the central gap region contains nine2′-deoxyribonucleosides. These modified oligonucleotides were designedby incorporating one or more F-HNA(s) modification within the centralgap region or on the wing regions. The F-HNA containing oligonucleotideswere tested for their ability to selectively inhibit mutant (mut) HTTmRNA expression levels targeting rs7685686 while leaving the expressionof the wild-type (wt) intact. The activity and selectivity of themodified oligonucleotides were evaluated and compared to ISIS 460209.

The modified oligonucleotides and their motifs are described in Table42. The internucleoside linkages throughout each modifiedoligonucleotide are phosphorothioate linkages (P═S). Nucleosides withouta subscript are β-D-2′-deoxyribonucleosides. Nucleosides followed by asubscript “e” indicate 2′-O-methoxyethyl (MOE) modified nucleosides.Nucleosides followed by a subscript “k” indicate 6′-(S)—CH₃ bicyclicnucleosides (e.g. cEt). Nucleosides followed by a subscript “z” indicateF-HNA modified nucleosides. ^(m)C indicates a 5-methyl cytosinenucleoside. Underlined nucleoside indicates the position on theoligonucleotides opposite to the SNP position, which is position 8 ascounted from the 5′-terminus.

The gap-interrupted antisense oligonucleotides were tested in vitro.Heterozygous fibroblast GM04022 cell line was used. Cultured GM04022cells at a density of 25,000 cells per well were transfected usingelectroporation with 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations ofmodified oligonucleotides. After a treatment period of approximately 16hours, RNA was isolated from the cells and mRNA levels were measured byquantitative real-time PCR using ABI assay C_2229297_10 which measuresat dbSNP rs362303. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN and the results are presented inTable 43.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

The parent gapmer, 460209 is marked with an asterisk (*) in the tableand was included in the study as a benchmark oligonucleotide againstwhich the activity and selectivity of antisense oligonucleotidestargeting nucleotides overlapping the SNP position could be compared.

As illustrated in Table 43, oligonucleotides comprising F-HNAmodification(s) showed improvement in selectivity while maintainingactivity as compared to the parent gapmer, ISIS 460209.

TABLE 42 Gap-interrupted antisense oligonucleotides targeting HTT SNPGap Wing SEQ ISIS Sequence chem- chemistry ID NO. (5′ to 3′) Motif istry5′ 3′ NO. 460209* T_(e)A_(k)A_(k)ATTGT 3-9-3 Full ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) deoxy 566266T_(e)A_(k)A_(k)A_(z)TTGT 3-9-3 Deoxy/ ekk or kke 10 ^(m)CAT^(m)CA_(k)^(m)C_(k) ^(m)C_(e) or F-HNA ekkz 4-8-3 566267 T_(e)A_(k)A_(k)AT_(z)TGT3-9-3 Deoxy/ ekk or kke 10 ^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) orF-HNA ekkdz 5-7-3 566268 T_(e)A_(k)A_(k)ATT_(z)GT 3-9-3 Deoxy/ ekk orkke 10 ^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) or F-HNA ekkddz 6-6-3566269 T_(e)A_(k)A_(k)ATTG_(z) T 3-9-3 Deoxy/ ekk or kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) or F-HNA ekkdddz 7-5-3 567369T_(e)A_(k)A_(k)A_(z)T_(z)TGT 3-9-3 Deoxy/ ekk or kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) or F-HNA ekkzz 5-7-3 e = 2′-MOE, k= cEt, d = 2′-β-deoxyribonucleoside, z = F-HNA

TABLE 43 Comparison of inhibition of HTT mRNA levels and selectivity ofgap-interrupted antisense oligonucleotides with ISIS 460209 targetingHTT SNP Wing IC₅₀ (μM) Selectivity Gap Chemistry ISIS NO Mut Wt (wt vsmut) Motif chemistry 5′ 3′  460209* 0.28 3.1 11 3-9-3 Full deoxy ekk kke566266 0.20 >10 >50 3-9-3 or Deoxy/F-HNA ekk or kke 4-8-3 ekkz 5662670.90 >9.9 >11 3-9-3 or Deoxy/F-HNA ekk or kke 5-7-3 ekkdz 5662681.0 >10 >10 3-9-3 or Deoxy/F-HNA ekk or kke 6-6-3 ekkddz 5662691.7 >10.2 >6 3-9-3 or Deoxy/F-HNA ekk or kke 7-5-3 ekkdddz 5673690.82 >9.8 >12 3-9-3 or Deoxy/F-HNA ekk or kke 5-7-3 ekkzz e = 2′-MOE, k= cEt, d = 2′-β-deoxyribonucleoside, z = F-HNA

Example 19 Modified Oligonucleotides Comprising cEt Modification(s) atthe Central Gap Region Targeting HTT SNP

A series of modified oligonucleotides were designed in the same manneras described in Example 18. These modified oligonucleotides weredesigned by replacing F-HNA(s) with cEt modification(s) in the centralgap region while maintaining the wing configuration. The modifiedoligonucleotides were tested for their ability to selectively inhibitmutant (mut) HTT mRNA expression levels targeting rs7685686 whileleaving the expression of the wild-type (wt) intact. The activity andselectivity of the modified oligonucleotides were evaluated and comparedto ISIS 460209.

The modified oligonucleotides and their motifs are described in Table44. The internucleoside linkages throughout each modifiedoligonucleotide are phosphorothioate linkages (P═S). Nucleosides withouta subscript are β-D-2′-deoxyribonucleosides. Nucleosides followed by asubscript “e” indicate 2′-O-methoxyethyl (MOE) modified nucleosides.Nucleosides followed by a subscript “k” indicate 6′-(S)—CH₃ bicyclicnucleosides (e.g. cEt). ^(m)C indicates a 5-methyl cytosine nucleoside.Underlined nucleoside indicates the position on the oligonucleotidesopposite to the SNP position, which is position 8 as counted from the5′-terminus.

The gap-interrupted antisense oligonucleotides were tested in vitro.Heterozygous fibroblast GM04022 cell line was used. Cultured GM04022cells at a density of 25,000 cells per well were transfected usingelectroporation with 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations ofmodified oligonucleotides. After a treatment period of approximately 16hours, RNA was isolated from the cells and mRNA levels were measured byquantitative real-time PCR using ABI assay C_2229297_10 which measuresat dbSNP rs362303. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN and the results are presentedbelow.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 45, some of the newly designed antisenseoligonucleotides (ISIS 575006, 575007, and 575008) showed improvement inpotency and/or selectivity in inhibiting mut HTT mRNA levels comparingto ISIS 460209.

TABLE 44 Gap-interrupted antisense oligonucleotides targeting HTT SNPGap Wing SEQ ISIS Sequence chem- chemistiy ID NO. (5′ to 3′) Motif istry5′ 3′ NO. 460209* T_(e)A_(k)A_(k)ATTGT 3-9-3 Full ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) deoxy 575006T_(e)A_(k)A_(k)A_(k)TTGT 4-8-3 Full ekkk kke 10 ^(m)CAT^(m)CA_(k)^(m)C_(k) ^(m)C_(e) deoxy 575007 T_(e)A_(k)A_(k)AT_(k)TGT 3-9-3 Fullekk or kke 10 ^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) or deoxy ekkdk 5-7-3or Deoxy/ cEt 575133 T_(e)A_(k)A_(k)ATT_(k)GT 3-9- Full ekk or kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 3or deoxy ekkddk 6-6-3 or Deoxy/cEt 575134 T_(e)A_(k)A_(k)ATTG_(k) T 3-9- Full ekk or kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 3or deoxy ekkdd 7-5-3 or dk Deoxy/cEt 575008 T_(e)A_(k)A_(k)A_(k)T_(k)TGT 5-7-3 Deoxy ekkkk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) e = 2′-MOE, k = cEt, d= 2′-β-deoxyribonucleoside

TABLE 45 Comparison of inhibition of HTT mRNA levels and selectivity ofgap-interrupted antisense oligonucleotides with ISIS 460209 targetingHTT SNP Wing IC₅₀ (μM) Selectivity Gap Chemistry ISIS NO Mut Wt (wt vsmut) Motif chemistry 5′ 3′  460209* 0.28 3.1 11 3-9-3 Full deoxy ekk kke575006 0.27 3.8 14 4-8-3 Full deoxy ekkk kke 575007 0.67 >10.1 >15 3-9-3or Full deoxy or ekk or kke 5-7-3 Deoxy/cEt ekkdk 575133 3.0 >9 >3 3-9-3or Full deoxy or ekk or kke 6-6-3 Deoxy/cEt ekkddk 575134 2.6 >10.4 >43-9-3 or Full deoxy or ekk or kke 7-5-3 Deoxy/cEt ekkdddk 5750080.18 >9.9 >55 5-7-3 Deoxy ekkkk kke e = 2′-MOE, k = cEt, d =2′-β-deoxyribonucleoside

Example 20 Modified Oligonucleotides Comprising F-HNA Modification atthe 3′-End of Central Gap Region Targeting HTT SNP

A series of modified oligonucleotides were designed based on ISIS460209, wherein the central gap region contains nine2′-deoxyribonucleosides. These modified oligonucleotides were designedby incorporating one F-HNA modification at the 3′-end of the central gapregion. The F-HNA containing oligonucleotides were tested for theirability to selectively inhibit mutant (mut) HTT mRNA expression levelstargeting HTT SNP while leaving the expression of the wild-type (wt)intact. The activity and selectivity of the modified oligonucleotideswere evaluated and compared to ISIS 460209.

The modified oligonucleotides and their motifs are described in Table46. The internucleoside linkages throughout each modifiedoligonucleotide are phosphorothioate linkages (P═S). Nucleosides withouta subscript are β-D-2′-deoxyribonucleosides. Nucleosides followed by asubscript “e” indicate 2′-O-methoxyethyl (MOE) modified nucleosides.Nucleosides followed by a subscript “k” indicate 6′-(S)—CH₃ bicyclicnucleosides (e.g. cEt). Nucleosides followed by a subscript “z” indicateF-HNA modified nucleosides. ^(m)C indicates a 5-methyl cytosinenucleoside. Underlined nucleoside indicates the position on theoligonucleotides opposite to the SNP position, which is position 8 ascounted from the 5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations of modifiedoligonucleotides. After a treatment period of approximately 16 hours,RNA was isolated from the cells and mRNA levels were measured byquantitative real-time PCR using ABI assay C_2229297_10 which measuresat dbSNP rs362303. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN and the results are presented inTable 47.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 47, a couple of the newly designed antisenseoligonucleotides (ISIS 575833 and 575834) showed improvement inselectivity while maintaining potency as compared to ISIS 460209. ISIS575836 showed an increase in potency without improvement in selectivitywhile ISIS 575835 showed comparable selectivity without improvement inpotency.

TABLE 46 Modified oligonucleotides targeting HTT SNP Sequence GapWing chemistry SEQ ID ISIS NO. (5′ to 3′) Motif chemistry 5′ 3′ NO.460209* T_(e)A_(k)A_(k)ATTGT 3-9-3 Full deoxy ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 575833 T_(e)A_(k)A_(k)ATTGT3-9-3 or Deoxy/F- ekk kke or 10 ^(m)C_(z)AT^(m)CA_(k) ^(m)C_(k)^(m)C_(e) 3-5-7 HNA zdddkke 575834 T_(e)A_(k)A_(k)ATTGT 3-9-3 orDeoxy/F- ekk kke or 10 ^(m)CA_(z)T^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 3-6-6HNA zddkke 575835 T_(e)A_(k)A_(k)ATTGT 3-9-3 or Deoxy/F- ekk kke or 10^(m)CAT_(z) ^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 3-7-5 HNA zdkke 575836T_(e)A_(k)A_(k)ATTGT 3-9-3 or Deoxy/F- ekk kke or 10^(m)CAT^(m)C_(z)A_(k) ^(m)C_(k)C_(e) 3-8-4 HNA zkke e = 2′-MOE, k = cEt,d = 2′-β-deoxyribonucleoside, z = F-HNA

TABLE 47 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeting HTT SNP SelectivityWing ISIS IC₅₀ (μM) (wt vs Gap Chemistry NO Mut Wt mut) Motif chemistry5′ 3′  460209* 0.28 3.1 11 3-9-3 Full deoxy ekk kke 575833 0.22 4.2 193-9-3 or Deoxy/F- ekk kke or 3-5-7 HNA zdddkke 575834 0.30 6.3 21 3-9-3or Deoxy/F- ekk kke or 3-6-6 HNA zddkke 575835 0.89 9.8 11 3-9-3 orDeoxy/F- ekk kke or 3-7-5 HNA zdkke 575836 0.09 0.4 4.6 3-9-3 orDeoxy/F- ekk kke or 3-8-4 HNA zkke e = 2′-MOE, k = cEt, d =2′-β-deoxyribonucleoside, z = F-HNA

Example 21 Short-Gap Chimeric Oligonucleotides Targeting Huntingtin(HTT) Single Nucleotide Polymorphism (SNP)

Additional chimeric antisense oligonucleotides were designed based onISIS 460209 and ISIS 540094 wherein the central gap region contains nine2′-deoxynucleosides. These gapmers were designed with the central gapregion shortened by introducing cEt modifications to the wing regions,or interrupted by introducing cEt modifications at the 3′-end of the thecentral gap region. The modified oligonucleotides were tested for theirability to selectively inhibit mutant (mut) HTT mRNA expression levelstargeting HTT SNP while leaving the expression of the wild-type (wt)intact. The activity and selectivity of the modified oligonucleotideswere evaluated and compared to ISIS 460209 and 540094.

The gapmers and their motifs are described in Table 48. Theinternucleoside linkages throughout each modified oligonucleotide arephosphorothioate linkages (P═S). Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e”indicate 2′-O-methoxyethyl (MOE) modified nucleosides. Nucleosidesfollowed by a subscript “k” indicate 6′-(S)—CH₃ bicyclic nucleosides(e.g. cEt). ^(m)C indicates a 5-methyl cytosine nucleoside. Underlinednucleoside indicates the position on the oligonucleotides opposite tothe SNP position, which is position 4 or 8 as counted from the5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations of modifiedoligonucleotides. After a treatment period of approximately 16 hours,RNA was isolated from the cells and mRNA levels were measured byquantitative real-time PCR using ABI assay C_2229297_10 which measuresat dbSNP rs362303. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN and the results are presented inTable 49.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 49, the newly designed antisenseoligonucleotides (ISIS 575003) showed improvement in selectivity whilemaintaining potency as compared to ISIS 460209.

TABLE 48 Short-gap antisense oligonucleotides targeting HTT SNP SequenceGap Wing chemistry SEQ ID ISIS NO. (5′ to 3′) Motif chemistry 5′ 3′ NO.460209* T_(e)A_(k)A_(k)ATTGT 3-9-3 Full deoxy ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 540094* T_(e)T_(k)GT ^(m)CAT^(m)CA2-9-4 Full deoxy ek kkke 67 ^(m)C^(m)CA_(k)G_(k)A_(k)A_(e) 575003T_(e)T_(k)GT ^(m)CAT^(m)CA 2-8-5 Full deoxy ek kkkke 67^(m)C^(m)C_(k)A_(k)G_(k)A_(k)A_(e) 575004 T_(e)T_(k)GT ^(m)CAT^(m)CA2-9-4 or Full deoxy or ek kkke or 67 ^(m)C_(k) ^(m)CA_(k)G_(k)A_(k)A_(e)2-7-6 Deoxy/cEt kdkkke 575005 T_(e)T_(k)GT ^(m)CAT^(m)CA 2-7-6Full deoxy ek kkkkke 67 ^(m)C_(k) ^(m)C_(k)A_(k)G_(k)A_(k)A_(e) e= 2′-MOE, k = cEt, d = 2′-deoxyribonucleoside

TABLE 49 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeting HTT SNP Wing IC₅₀(μM) Selectivity Gap Chemistry ISIS NO Mut Wt (wt vs mut) Motifchemistry 5′ 3′  460209* 0.34 3.3 9.7 3-9-3 Full deoxy ekk kke  540094*0.17 2.4 14 2-9-4 Full deoxy ek kkke 575003 0.40 10 25 2-8-5 Full deoxyek kkkke 575004 1.2 >9.6 >8 2-9-4 or Full deoxy or ek kkke or 2-7-6Deoxy/cEt kdkkke 575005 >10 >100 >10 2-7-6 Full deoxy ek kkkkke e =2′-MOE, k = cEt, d = 2′-deoxyribonucleoside

Example 22 Short-Gap Chimeric Oligonucleotides Targeting Huntingtin(HTT) Single Nucleotide Polymorphism (SNP)

Additional chimeric antisense oligonucleotides were designed based on15-mer, ISIS 460209 and 17-mer, ISIS 476333 wherein the central gapregion contains nine 2′-deoxynucleosides. These gapmers were designedwith the central gap region shortened at the 5′-end of the the centralgap region. The gapmers were tested for their ability to selectivelyinhibit mutant (mut) HTT mRNA expression levels targeting HTT SNP whileleaving the expression of the wild-type (wt) intact. The activity andselectivity of the gapmers were evaluated and compared to ISIS 460209and ISIS 476333.

The gapmers and their motifs are described in Table 50. Theinternucleoside linkages throughout each modified oligonucleotide arephosphorothioate linkages (P═S). Nucleosides without a subscript are(3-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e”indicate 2′-O-methoxyethyl (MOE) modified nucleosides. Nucleosidesfollowed by a subscript “k” indicate 6′-(S)—CH₃ bicyclic nucleosides(e.g. cEt). ^(m)C indicates a 5-methyl cytosine nucleoside. Underlinednucleoside indicates the position on the oligonucleotides opposite tothe SNP position, which is position 8 or 9 as counted from the5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations of modifiedoligonucleotides. After a treatment period of approximately 16 hours,RNA was isolated from the cells and mRNA levels were measured byquantitative real-time PCR using ABI assay C_2229297_10 which measuresat dbSNP rs362303. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN and the results are presented inTable 51.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 51, a couple of the newly designed antisenseoligonucleotides (ISIS 571036 and 571037) showed improvement in potencyand selectivity in inhibiting mut HTT mRNA levels as compared to ISIS460209 and 476333.

TABLE 50 Short-gap antisense oligonucleotides targeting HTT SNP SequenceGap Wing chemistiy SEQ ID ISIS NO. (5′ to 3′) Motif chemistry 5′ 3′ NO.460209* T_(e)A_(k)A_(k)ATTGT 3-9-3 Full deoxy ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 476333* A_(e)T_(k)A_(e)A_(k)ATTGT4-9-4 Full deoxy ekek keke 32 ^(m)CAT^(m)CA_(k) ^(m)C_(e) ^(m)C_(k)A_(e)571036 A_(e)T_(k)A_(e)A_(k)A_(e)T_(k)TGT 6-7-4 Full deoxy ekekek keke 32^(m)CAT^(m)CA_(k) ^(m)C_(e) ^(m)C_(k)A_(e) 571037A_(e)T_(e)A_(e)A_(e)A_(k)T_(k)TGT 6-7-4 Full deoxy eeeekk keke 32^(m)CAT^(m)CA_(k) ^(m)C_(e) ^(m)C_(k)A_(e) 571038A_(e)T_(k)A_(e)A_(k)A_(e)T_(e)TGT 6-7-4 Full deoxy ekekee keke 32^(m)CAT^(m)CA_(k) ^(m)C_(e) ^(m)C_(k)A_(e) e = 2′-MOE, k = cEt, d= 2′-deoxyribonucleoside

TABLE 51 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeting HTT SNP SelectivityWing ISIS IC₅₀ (μM) (wt vs Gap Chemistry NO Mut Wt mut) Motif chemistry5′ 3′  460209* 0.34 3.3 9.7 3-9-3 Full deoxy ekk kke  476333* 0.32 1.54.7 4-9-4 Full deoxy ekek keke 571036 0.17 >10.0 >59 6-7-4 Full deoxyekekek keke 571037 0.11 >9.9 >90 6-7-4 Full deoxy eeeekk keke 5710381.5 >10.5 >7 6-7-4 Full deoxy ekekee keke e = 2′-MOE, k = cEt, d =2′-deoxyribonucleoside

Example 23 Short-Gap Chimeric Oligonucleotides Targeting Huntingtin(HTT) Single Nucleotide Polymorphism (SNP)

Additional chimeric antisense oligonucleotides were designed based on15-mer, ISIS 460209 wherein the central gap region contains nine2′-deoxynucleosides. These gapmers were designed by having the centralgap region shortened to seven 2′-deoxynucleosides. The gapmers weretested for their ability to selectively inhibit mutant (mut) HTT mRNAexpression levels targeting HTT SNP while leaving the expression of thewild-type (wt) intact. The activity and selectivity of the gapmers wereevaluated and compared to ISIS 460209.

The gapmers and their motifs are described in Table 52. Theinternucleoside linkages throughout each modified oligonucleotide arephosphorothioate linkages (P═S). Nucleosides without a subscript areβ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e”indicate 2′-O-methoxyethyl (MOE) modified nucleosides. Nucleosidesfollowed by a subscript “k” indicate 6′-(S)—CH₃ bicyclic nucleosides(e.g. cEt). ^(m)C indicates a 5-methyl cytosine nucleoside. Underlinednucleoside indicates the position on the oligonucleotides opposite tothe SNP position, which is position 8 or 9 as counted from the5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations of modifiedoligonucleotides. After a treatment period of approximately 16 hours,RNA was isolated from the cells and mRNA levels were measured byquantitative real-time PCR using ABI assay C_2229297_10 which measuresat dbSNP rs362303. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN and the results are presented inTable 53.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 53, each of the newly designed antisenseoligonucleotides (ISIS 540108 and 571069) showed improvement in potencyand/or selectivity in inhibiting mut HTT mRNA levels as compared to ISIS460209.

TABLE 52 Short-gap antisense oligonucleotides targeting HTT SNP ISISSequence Gap Wing chemistry SEQ ID NO. (5′ to 3′) Motif chemistry 5′ 3′NO. 460209 T_(e)A_(k)A_(k)ATTGT 3-9-3 Full deoxy ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 540108A_(e)T_(e)A_(e)A_(k)A_(k)TTGT 5-7-5 Full deoxy eeekk kkeee 32^(m)CAT^(m)C_(k)A_(k) ^(m)C_(e) ^(m)C_(e)A_(e) 571069A_(e)T_(e)A_(e)A_(e)A_(k)T_(k)TGT 6-7-4 Full deoxy eeeekk kkee 32^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e)A_(e) 571173A_(e)T_(e)A_(k)A_(k)ATTGT 4-7-6 Full deoxy eekk kkeeee 32 ^(m)CAT_(k)^(m)C_(k)A_(e) ^(m)C_(e) ^(m)C_(e)A_(e) 572773 T_(e)A_(e)A_(k)A_(k)TTGT4-7-4 Full deoxy eekk kkee 10 ^(m)CAT^(m)C_(k)A_(k) ^(m)C_(e) ^(m)C_(e)e = 2′-MOE, k = cEt, d = 2′-deoxyribonucleoside

TABLE 53 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeting HTT SNP SelectivityWing ISIS IC₅₀ (μM) (wt vs Gap Chemistry NO Mut Wt mut) Motif chemistry5′ 3′ 460209 0.34 3.3 9.7 3-9-3 Full deoxy ekk kke 540108 0.20 >10 >505-7-5 Full deoxy eeekk kkeee 571069 0.29 >9.9 >34 6-7-4 Full deoxyeeeekk kkee 571173 1.0 >10 >10 4-7-6 Full deoxy eekk kkeeee 5727730.71 >7.8 11 4-7-4 Full deoxy eekk kkee e = 2′-MOE, k = cEt, d =2′-deoxyribonucleoside

Example 24 Short-Gap Chimeric Oligonucleotides Targeting Huntingtin(HTT) Single Nucleotide Polymorphism (SNP)

Additional chimeric antisense oligonucleotides were designed based on15-mer, ISIS 460209 and 17-mer, ISIS 540108 wherein the central gapregion contains nine and seven 2′-deoxynucleosides, respectively. Thesegapmers were designed by introducing one or more cEt modification(s) atthe 5′-end of the central gap region. The gapmers were tested for theirability to selectively inhibit mutant (mut) HTT mRNA expression levelstargeting HTT SNP while leaving the expression of the wild-type (wt)intact. The activity and selectivity of the gapmers were evaluated andcompared to ISIS 460209 and ISIS 540108.

The gapmers and their motifs are described in Table 54. Theinternucleoside linkages throughout each modified oligonucleotide arephosphorothioate linkages (P═S). Nucleosides without a subscript are(3-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e”indicate 2′-O-methoxyethyl (MOE) modified nucleosides. Nucleosidesfollowed by a subscript “k” indicate 6′-(S)—CH₃ bicyclic nucleosides(e.g. cEt). ^(m)C indicates a 5-methyl cytosine nucleoside. Underlinednucleoside indicates the position on the oligonucleotides opposite tothe SNP position, which is position 8 or 9 as counted from the5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations of modifiedoligonucleotides. After a treatment period of approximately 16 hours,RNA was isolated from the cells and mRNA levels were measured byquantitative real-time PCR using ABI assay C_2229297_10 which measuresat dbSNP rs362303. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN and the results are presented inTable 55.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 55, most of the newly designed oligonucleotidesshowed improvement in selectivity while maintaining potency as comparedto 460209.

TABLE 54 Short-gap antisense oligonucleotides targeting HTT SNP Wing SEQISIS Sequence Gap chemistry ID NO. (5′ to 3′) Motif chemistry 5′ 3′ NO.460209 T_(e)A_(k)A_(k)ATTGT 3-9-3 Full deoxy ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 540108A_(e)T_(e)A_(e)A_(k)A_(k)TTGT 5-7-5 Full deoxy eeekk kkeee 32^(m)CAT^(m)C_(k)A_(k) ^(m)C_(e) ^(m)C_(e)A_(e) 556872A_(e)T_(e)A_(e)A_(e)A_(k)TTGT 5-7-5 Full deoxy eeeek eeeee 32^(m)CAT^(m)C_(e)A_(e) ^(m)C_(e) ^(m)C_(e)A_(e) 556873A_(e)T_(e)A_(e)A_(k)A_(k)TTGT 5-7-5 Full deoxy eeekk eeeee 32^(m)CAT^(m)C_(e)A_(e) ^(m)C_(e) ^(m)C_(e)A_(e) 556874A_(e)T_(e)A_(k)A_(k)A_(k)TTGT 5-7-5 Full deoxy eelddc eeeee 32^(m)CAT^(m)C_(e)A_(e) ^(m)C_(em)C_(e)A_(e) 568877A_(e)T_(k)A_(k)A_(k)A_(k)TTGT 5-7-5 Full deoxy eldcick eeeee 32^(m)CAT^(m)C_(e)A_(e) ^(m)C_(e) ^(m)C_(e)A_(e) 568878A_(k)T_(k)A_(k)A_(k)A_(k)TTGT 5-7-5 Full deoxy lddcick eeeee 32^(m)CAT^(m)C_(e)A_(e) ^(m)C_(e) ^(m)C_(e)A_(e) e = 2′-MOE, k = cEt, d= 2′-deoxyribonucleoside

TABLE 55 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeting HTT SNP SelectivityWing ISIS IC₅₀ (μM) (wt vs Gap Chemistry NO Mut Wt mut) Motif chemistry5′ 3′ 460209 0.45 2.3 5.1 3-9-3 Full deoxy ekk kke 540108 0.25 9.5 385-7-5 Full deoxy eeekk kkeee 556872 1.0 9.9 9.9 5-7-5 Full deoxy eeeekeeeee 556873 0.67 3.4 5.1 5-7-5 Full deoxy eeekk eeeee 556874 0.38 1.95.0 5-7-5 Full deoxy eekkk eeeee 568877 0.44 6.2 14 5-7-5 Full deoxyekkkk eeeee 568878 0.41 8.6 21 5-7-5 Full deoxy kkkkk eeeee e = 2′-MOE,k = cEt, d = 2′-deoxyribonucleoside

Example 25 Short-Gap Chimeric Oligonucleotides Targeting Huntingtin(HTT) Single Nucleotide Polymorphism (SNP)

Additional chimeric antisense oligonucleotides were designed based on15-mer, ISIS 460209 and 17-mer, ISIS 540108 wherein the central gapregion contains nine and seven 2′-deoxynucleosides, respectively. Thesegapmers were designed by introducing one or more cEt modification(s) atthe 3′-end of the central gap region. The gapmers were tested for theirability to selectively inhibit mutant (mut) HTT mRNA expression levelstargeting HTT SNP while leaving the expression of the wild-type (wt)intact. The activity and selectivity of the gapmers were evaluated andcompared to ISIS 460209 and ISIS 540108.

The gapmers and their motifs are described in Table 56. Theinternucleoside linkages throughout each modified oligonucleotide arephosphorothioate linkages (P═S). Nucleosides without a subscript are(3-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e”indicate 2′-O-methoxyethyl (MOE) modified nucleosides. Nucleosidesfollowed by a subscript “k” indicate 6′-(S)—CH₃ bicyclic nucleosides(e.g. cEt). ^(m)C indicates a 5-methyl cytosine nucleoside. Underlinednucleoside indicates the position on the oligonucleotides opposite tothe SNP position, which is position 8 or 9 as counted from the5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.12, 0.37, 1.1, 3.3 and 10 μM concentrations of modifiedoligonucleotides. After a treatment period of approximately 16 hours,RNA was isolated from the cells and mRNA levels were measured byquantitative real-time PCR using ABI assay C_2229297_10 which measuresat dbSNP rs362303. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN and the results are presented inTable 57.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 57, each of the newly designed oligonucleotidesshowed improvement in selective inhibition of mutant HTT mRNA levelscompared to ISIS 460209. Comparable potency was observed for ISIS 568879and 568880 while a slight loss in potency was observed for ISIS 556875,556876 and 556877.

TABLE 56 Short-gap antisense oligonucleotides targeting HTT SNP Wing SEQSequence Gap chemistry ID ISIS NO. (5′ to 3′) Motif chemistry 5′ 3′ NO.460209 T_(e)A_(k)A_(k)ATTGT 3-9-3 Full deoxy ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 540108A_(e)T_(e)A_(e)A_(k)A_(k)TTGT 5-7-5 Full deoxy eeekk kkeee 32^(m)CAT^(m)C_(k)A_(k) ^(m)C_(e) ^(m)C_(e)A_(e) 556875A_(e)T_(e)A_(e)A_(e)A_(e)TTGT 5-7-5 Full deoxy eeeee keeee 32^(m)CAT^(m)C_(k)A_(e) ^(m)C_(e) ^(m)C_(e)A_(e) 556876A_(e)T_(e)A_(e)A_(e)A_(e)TTGT 5-7-5 Full deoxy eeeee kkeee 32^(m)CAT^(m)C_(k)A_(k) ^(m)C_(e) ^(m)C_(e)A_(e) 556877A_(e)T_(e)A_(e)A_(e)A_(e)TTGT 5-7-5 Full deoxy eeeee kkkee 32^(m)CAT^(m)C_(k)A_(k) ^(m)C_(k) ^(m)C_(e)A_(e) 568879A_(e)T_(e)A_(e)A_(e)A_(e)TTGT 5-7-5 Full deoxy eeeee ldckke 32^(m)CAT^(m)C_(k)A_(k) ^(m)C_(k) ^(m)C_(k)A_(e) 568880A_(e)T_(e)A_(e)A_(e)A_(e)TTGT 5-7-5 Full deoxy eeeee lddckk 32^(m)CAT^(m)C_(k)A_(k) ^(m)C_(k) ^(m)C_(k)A_(k) e = 2′-MOE, k = cEt, d= 2′-deoxyribonucleoside

TABLE 57 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeting HTT SNP SelectivityWing ISIS IC₅₀ (μM) (wt vs Gap Chemistry NO Mut Wt mut) Motif chemistry5′ 3′ 460209 0.45 2.3 5.1 3-9-3 Full deoxy ekk kke 540108 0.25 9.5 385-7-5 Full deoxy eeekk kkeee 556875 1.9 >9.5 >5 5-7-5 Full deoxy eeeeekeeee 556876 0.99 >9.9 >10 5-7-5 Full deoxy eeeee kkeee 5568771.0 >10 >10 5-7-5 Full deoxy eeeee kkkee 568879 0.44 >10.1 >23 5-7-5Full deoxy eeeee kkkke 568880 0.59 >10 >17 5-7-5 Full deoxy eeeee kkkkke = 2′-MOE, k = cEt, d = 2′-deoxyribonucleoside

Example 26 Modified Oligonucleotides Targeting Huntingtin (HTT) SingleNucleotide Polymorphism (SNP)

A series of modified oligonucleotides were designed based on the parentgapmer, ISIS 460209 wherein the central gap region contains nine2′-deoxyribonucleosides. These modified oligonucleotides were designedby introducing various chemical modifications in the central gap regionand were tested for their ability to selectively inhibit mutant (mut)HTT mRNA expression levels targeting SNP while leaving the expression ofthe wild-type (wt) intact. The activity and selectivity of the modifiedoligonucleotides were evaluated and compared to the parent gapmer, ISIS460209.

The modified oligonucleotides were created with a 3-9-3 motif and aredescribed in Table 58. The internucleoside linkages throughout eachgapmer are phosphorothioate (P═S) linkages, except for theinternucleoside linkage having a subscript “p” which indicates a methylphosphonate internucleoside linkage (—O—P(CH₃)(═O)—O—). Nucleosideswithout a subscript are β-D-2′-deoxyribonucleosides. Nucleosidesfollowed by a subscript “e” indicates a 2′-O-methoxyethyl (MOE) modifiednucleoside. Nucleosides followed by a subscript “k” indicates a6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt). ^(m)C indicates a 5-methylcytosine nucleoside. ^(x)T indicates a 2-thio-thymidine nucleoside.Underlined nucleoside indicates the position on the oligonucleotidesopposite to the SNP position, which is position 8 as counted from the5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used (from Coriell Institute). CulturedGM04022 cells at a density of 25,000 cells per well were transfectedusing electroporation with 0.12, 0.37, 1.1, 3.3 and 10 μM concentrationsof modified oligonucleotides. After a treatment period of approximately24 hours, cells were washed with DPBS buffer and lysed. RNA wasextracted using Qiagen RNeasy purification and mRNA levels were measuredby quantitative real-time PCR using ABI assay C_2229297_10 whichmeasures at dbSNP rs362303. RT-PCR method in short; A mixture was madeusing 2020 uL 2×PCR buffer, 101 uL primers (300 uM from ABI), 1000 uLwater and 40.4 uL RT MIX. To each well was added 15 uL of this mixtureand 5 uL of purified RNA. The mutant and wild-type HTT mRNA levels weremeasured simultaneously by using two different fluorophores, FAM formutant allele and VIC for wild-type allele. The HTT mRNA levels wereadjusted according to total RNA content, as measured by RIBOGREEN andthe results are presented in Table 59.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 59, improvement in selectivity with a slightdecrease in potency was observed for the newly designed oligonucleotidesas compared to ISIS 460209.

TABLE 58 Short-gap antisense oligonucleotides targeting HTT SNP Wing SEQISIS Sequence chemistry ID NO. (5′ to 3′) Gap chemistry 5′ 3′ NO. 460209T_(e)A_(k)A_(k)ATTGT Full deoxy ekk kke 10 ^(m)CAT^(m)CA_(k) ^(m)C_(k)^(m)C_(e) 556845 T_(e)A_(k)A_(k)A^(x)TTGT Deoxy/2-Thio ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 556847T_(e)A_(k)A_(k)A^(x)T^(x)TGT Deoxy/2-Thio ekk kke 10 ^(m)CAT^(m)CA_(k)^(m)C_(k) ^(m)C_(e) 558257 T_(e)A_(k)A_(k)ATT_(p)GT Deoxy/Methyl ekk kke10 ^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C Phosphonate 571125T_(e)A_(k)A_(k)A^(x)TT_(p)GT Deoxy/2-Thio/ ekk kke 10 ^(m)CAT^(m)CA_(k)^(m)C_(k) ^(m)C_(e) Methyl Phosphonate e = 2′-MOE, k = cEt, d= 2′-deoxyribonucleoside

TABLE 59 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeting HTT SNP SelectivityWing ISIS IC₅₀ (μM) (wt vs Gap Chemistry NO Mut Wt mut) chemistry 5′ 3′460209 0.56 3.8 6.8 Full deoxy ekk kke 556845 0.98 >9.8 >10 Deoxy/2-Thioekk kke 556847 1.3 >10.4 >8 Deoxy/2-Thio ekk kke 558257 1.7 >10.2 >6Deoxy/Methyl ekk kke Phosphonate 571125 1.8 >10.8 >6 Deoxy/2- ekk kkeThio/Methyl Phosphonate e = 2′-MOE, k = cEt, d = 2′-deoxyribonucleoside

Example 27 Modified Oligonucleotides Comprising Chemical Modificationsin the Central Gap Region Targeting Huntingtin (HTT) Single NucleotidePolymorphism (SNP)

Additional chimeric antisense oligonucleotides were designed in the samemanner as the antisense oligonucleotides described in Example 26. Thesegapmers were designed by introducing various modifications in thecentral gap region and were tested for their ability to selectivelyinhibit mutant (mut) HTT mRNA expression levels targeting SNP whileleaving the expression of the wild-type (wt) intact. The activity andselectivity of the modified oligonucleotides were evaluated and comparedto the parent gapmer, ISIS 460209.

The modified oligonucleotides and their motifs are described in Table60. The internucleoside linkages throughout each gapmer arephosphorothioate (P═S) linkages, except for the internucleoside linkagehaving a subscript “p” which indicates a methyl phosphonateinternucleoside linkage (—O—P(CH₃)(═O)—O—). Nucleosides without asubscript are β-D-2′-deoxyribonucleosides. Nucleosides followed by asubscript “e” indicates a 2′-O-methoxyethyl (MOE) modified nucleoside.Nucleosides followed by a subscript “k” indicates a 6′-(S)—CH₃ bicyclicnucleoside (e.g. cEt). ^(m)C indicates a 5-methyl cytosine nucleoside.^(x)T indicates a 2-thio-thymidine nucleoside. Underlined nucleosideindicates the position on the oligonucleotides opposite to the SNPposition, which is position 8 as counted from the 5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used (from Coriell Institute). CulturedGM04022 cells at a density of 25,000 cells per well were transfectedusing electroporation with 0.12, 0.37, 1.1, 3.3 and 10 μM concentrationsof modified oligonucleotides. After a treatment period of approximately24 hours, cells were washed with DPBS buffer and lysed. RNA wasextracted using Qiagen RNeasy purification and mRNA levels were measuredby quantitative real-time PCR using ABI assay C_2229297_10 whichmeasures at dbSNP rs362303. RT-PCR method in short; A mixture was madeusing 2020 uL 2×PCR buffer, 101 uL primers (300 uM from ABI), 1000 uLwater and 40.4 uL RT MIX. To each well was added 15 uL of this mixtureand 5 uL of purified RNA. The mutant and wild-type HTT mRNA levels weremeasured simultaneously by using two different fluorophores, FAM formutant allele and VIC for wild-type allele. The HTT mRNA levels wereadjusted according to total RNA content, as measured by RIBOGREEN andthe results are presented in Table 61.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 61, some of the newly designed oligonucleotidesshowed improvement in selectivity while maintaining potency as comparedto 460209.

TABLE 60 Short-gap antisense oligonucleotides targeting HTT SNP Wing SEQISIS Sequence chemistry ID NO. (5′ to 3′) Motif Gap chemistry 5′ 3′ NO.460209 T_(e)A_(k)A_(k)ATTGT 3-9-3 Full deoxy ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 551429T_(e)A_(e)A_(e)A_(k)T_(k)TGT 5-7-3 Full deoxy eeekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 571122 T_(e)A_(e)A_(e)A_(k)^(x)TTGT 4-8-3 Deoxy/2-Thio eeek kke 10 ^(m)CAT^(m)CA_(k) ^(m)C_(k)^(m)C_(e) 571123 T_(e)A_(e)A_(e)A_(k)T_(k)T_(p)GT 5-7-3 Deoxy/Methyleeekk kke 10 ^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) Phosphonate 571124T_(e)A_(e)A_(e)A_(k) ^(x)TT_(p)GT 4-8-3 Deoxy/2- eeek kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) Thio/Methyl Phosphonate 579854T_(e)A_(e)A_(e)A_(k)TT_(p)GT 4-8-3 Deoxy/Methyl eeek kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) Phosphonate 566282T_(e)A_(k)A_(k)A_(dx)T_(dx)T_(d)G_(d)T_(d) ^(m)C_(d) 3-9-3 Deoxy/Methylekk kke 10 A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) Phosphonate e= 2′-MOE, k = cEt, d = 2′-deoxyribonucleoside

TABLE 61 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeting HTT SNP SelectivityWing ISIS IC₅₀ (μM) (wt vs Gap Chemistry NO Mut Wt mut) Motif chemistry5′ 3′ 460209 0.56 3.8 6.8 3-9-3 Full deoxy ekk kke 551429 0.50 >10 >205-7-3 Full deoxy eeekk kke 571122 1.8 >10.8 >6 4-8-3 Deoxy/2-Thio eeekkke 571123 0.96 >9.6 >10 5-7-3 Deoxy/Methyl eeekk kke Phosphonate 5711242.3 >9.2 >4 4-8-3 Deoxy/2- eeek kke Thio/Methyl Phosphonate 5798540.63 >10.1 >16 4-8-3 Deoxy/Methyl eeek kke Phosphonate 566282 0.51 6.312.4 3-9-3 Deoxy/Methyl ekk kke Phosphonate e = 2′-MOE, k = cEt

Example 28 Modified Oligonucleotides Comprising Chemical Modificationsin the Central Gap Region Targeting Huntingtin (HTT) Single NucleotidePolymorphism (SNP)

Additional chimeric antisense oligonucleotides were designed in the samemanner as the antisense oligonucleotides described in Example 26. Thesegapmers were designed by introducing various modifications to thecentral gap region and were tested for their ability to selectivelyinhibit mutant (mut) HTT mRNA expression levels targeting SNP whileleaving the expression of the wild-type (wt) intact. The activity andselectivity of the modified oligonucleotides were evaluated and comparedto the parent gapmer, ISIS 460209.

The modified oligonucleotides and their motifs are described in Table62. The internucleoside linkages throughout each gapmer arephosphorothioate (P═S) linkages, except for the internucleoside linkagehaving a subscript “p” which indicates a methyl phosphonateinternucleoside linkage (—O—P(CH₃)(═O)—O—). Nucleosides without asubscript are β-D-2′-deoxyribonucleosides. Nucleosides followed by asubscript “e” indicates a 2′-O-methoxyethyl (MOE) modified nucleoside.Nucleosides followed by a subscript “k” indicates a 6′-(S)—CH₃ bicyclicnucleoside (e.g. cEt). ^(m)C indicates a 5-methyl cytosine nucleoside.^(x)T indicates a 2-thio-thymidine nucleoside. Underlined nucleosideindicates the position on the oligonucleotides opposite to the SNPposition, which is position 8 or 9 as counted from the 5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used (from Coriell Institute). CulturedGM04022 cells at a density of 25,000 cells per well were transfectedusing electroporation with 0.12, 0.37, 1.1, 3.3 and 10 μM concentrationsof modified oligonucleotides. After a treatment period of approximately24 hours, cells were washed with DPBS buffer and lysed. RNA wasextracted using Qiagen RNeasy purification and mRNA levels were measuredby quantitative real-time PCR using ABI assay C_2229297_10 whichmeasures at dbSNP rs362303. RT-PCR method in short; A mixture was madeusing 2020 uL 2×PCR buffer, 101 uL primers (300 uM from ABI), 1000 uLwater and 40.4 uL RT MIX. To each well was added 15 uL of this mixtureand 5 uL of purified RNA. The mutant and wild-type HTT mRNA levels weremeasured simultaneously by using two different fluorophores, FAM formutant allele and VIC for wild-type allele. The HTT mRNA levels wereadjusted according to total RNA content, as measured by RIBOGREEN andthe results are presented in Table 63.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 63, all but one of the newly designedoligonucleotides showed improvement in selectivity while maintainingpotency as compared to ISIS 460209.

TABLE 62 Short-gap antisense oligonucleotides targeting HTT SNP WingISIS Sequence chemistry SEQ ID NO. (5′ to 3′) Motif Gap chemistry 5′ 3′NO. 460209 T_(e)A_(k)A_(k)ATTGT 3-9-3 Full deoxy ekk kke 10^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 476333 A_(e)T_(k)A_(e)A_(k)ATTGT4-94 Full deoxy ekek keke 32 ^(m)CAT^(m)CA_(k) ^(m)C_(e) ^(m)C_(k)A_(e)571039 A_(e)T_(k)A_(e)A_(k)A^(x)TTGT 4-9-4 Deoxy/2-Thio ekek keke 32^(m)CAT^(m)CA_(k) ^(m)C_(e) ^(m)C_(k)A_(e) 571171A_(e)T_(k)A_(e)A_(k)ATT_(p)GT 4-9-4 Deoxy/Methyl ekek keke 32^(m)CAT^(m)CA_(k) ^(m)C_(e) ^(m)C_(k)A_(e) Phosphonate 571041A_(e)T_(k)A_(e)A_(k)A^(x)TT_(p)GT 4-9-4 Deoxy/2- ekek keke 32^(m)CAT^(m)CA_(k) ^(m)C_(e) ^(m)C_(k)A_(e) Thio/Methyl Phosphonate e= 2′-MOE, k = cEt, d = 2′-deoxyribonucleoside

TABLE 63 Comparison of inhibition of HTT mRNA levels and selectivity ofmodified oligonucleotides with ISIS 460209 targeting HTT SNP SelectivityWing ISIS IC₅₀ (μM) (wt vs Gap Chemistry NO Mut Wt mut) chemistry 5′ 3′460209 0.56 3.8 6.8 Full deoxy ekk kke 476333 0.56 3.4 6.1 Full deoxyekek keke 571039 0.34 >9.9 >29 Deoxy/2-Thio ekek keke 5711710.54 >10.3 >19 Deoxy/Methyl ekek keke Phosphonate 571041 0.75 >9.8 >13Deoxy/2- ekek keke Thio/Methyl Phosphonate e = 2′-MOE, k = cEt, d =2′-deoxyribonucleoside

Example 29

Selectivity in Inhibition of HTT mRNA Levels Targeting SNP byGap-Interrupted Modified Oligonucleotides

Additional modified oligonucleotides were designed based on the parentgapmer, ISIS 460209 wherein the central gap region contains nine2′-deoxyribonucleosides. These modified oligonucleotides were designedby introducing one or more modified nucleobase(s) in the central gapregion and were tested for their ability to selectively inhibit mutant(mut) HTT mRNA expression levels targeting SNP while leaving theexpression of the wild-type (wt) intact. The activity and selectivity ofthe modified oligonucleotides were evaluated and compared to ISIS460209.

The modified oligonucleotides were created with a 3-9-3 motif and aredescribed in Table 64. The internucleoside linkages throughout eachgapmer are phosphorothioate (P═S) linkages. Nucleosides without asubscript are β-D-2′-deoxyribonucleosides. Nucleosides followed by asubscript “e” indicates a 2′O-methoxyethyl (MOE) modified nucleoside.Nucleosides followed by a subscript “k” indicates a 6′-(S)—CH₃ bicyclicnucleoside (e.g. cEt). ^(m)C indicates a 5-methyl cytosine nucleoside.^(x)T indicates a 2-thio-thymidine nucleoside. Underlined nucleosideindicates the position on the oligonucleotides opposite to the SNPposition, which is position 8 as counted from the 5′-terminus.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used (from Coriell Institute). CulturedGM04022 cells at a density of 25,000 cells per well were transfectedusing electroporation with 0.12, 0.37, 1.1, 3.3 and 10 μM concentrationsof modified oligonucleotides. After a treatment period of approximately24 hours, cells were washed with DPBS buffer and lysed. RNA wasextracted using Qiagen RNeasy purification and mRNA levels were measuredby quantitative real-time PCR using ABI assay C_2229297_10 whichmeasures at dbSNP rs362303. RT-PCR method in short; A mixture was madeusing 2020 uL 2×PCR buffer, 101 uL primers (300 uM from ABI), 1000 uLwater and 40.4 uL RT MIX. To each well was added 15 uL of this mixtureand 5 uL of purified RNA. The mutant and wild-type HTT mRNA levels weremeasured simultaneously by using two different fluorophores, FAM formutant allele and VIC for wild-type allele. The HTT mRNA levels wereadjusted according to total RNA content, as measured by RIBOGREEN.

The IC₅₀ and selectivity were calculated using methods previouslydescribed in Example 2. The IC₅₀ at which each oligonucleotide inhibitsthe mutant HTT mRNA expression is denoted as ‘mut IC₅₀’. The IC₅₀ atwhich each oligonucleotide inhibits the wild-type HTT mRNA expression isdenoted as ‘wt IC₅₀’. Selectivity was calculated by dividing the IC₅₀for inhibition of the wild-type HTT versus the IC₅₀ for inhibitingexpression of the mutant HTT mRNA.

As illustrated in Table 65, ISIS 556845 showed improvement inselectivity and potency as compared to ISIS 460209. ISIS 556847 showedimprovement in selectivity with comparable potency while ISIS 556846showed improvement in potency with comparable selectivity.

TABLE 64 Gap-interrupted modified oligonucleotides targeting HTT SNPWing SEQ ISIS Sequence Gap chemistry ID NO. (5′ to 3′) chemistry 5′ 3′NO. 460209 T_(e)A_(k)A_(k)ATTGT Full deoxy ekk kke 10 ^(m)CAT^(m)CA_(k)^(m)C_(k) ^(m)C_(e) 556845 T_(e)A_(k)A_(k)A^(x)TTGT Deoxy/2-Thio ekk kke10 ^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 556846 T_(e)A_(k)A_(k)A_(k)TGTDeoxy/2-Thio ekk kke 10 ^(m)CAT^(m)CA_(k) ^(m)C_(k) ^(m)C_(e) 556847T_(e)A_(k)A_(k)A^(x)T^(x)TGT Deoxy/2-Thio ekk kke 10 ^(m)CAT^(m)CA_(k)^(m)C_(k) ^(m)C_(e) e = 2′-MOE, k = cEt, d = 2′-deoxyribonucleoside

TABLE 65 Comparison of inhibition of HTT mRNA levels and selectivity ofgap-interrupted modified oligonucleotides with ISIS 460209 targeting HTTSNP Selectivity Wing ISIS IC₅₀ (μM) (wt vs Gap Chemistry NO Mut Wt mut)chemistry 5′ 3′ 460209 0.30 0.99 3.3 Full deoxy ekk kke 556845 0.1310.01 >77 Deoxy/2-Thio ekk kke 556846 0.19 0.48 2.5 Deoxy/2-Thio ekk kke556847 0.45 9.9 >22 Deoxy/2-Thio ekk kke e = 2′-MOE, k = cEt, d =2′-deoxyribonucleoside

Example 30 Evaluation of Modified Oligonucleotides Targeting HTT SNP—InVivo Study

Additional modified oligonucleotides were selected and tested for theireffects on mutant and wild type HTT protein levels in vivo targetingvarious SNP sites as illustrated below.

The gapmers and their motifs are described in Table 66. Theinternucleoside linkages throughout each gapmer are phosphorothioate(P═S) linkages. All cytosine nucleobases throughout each gapmer are5-methyl cytosines. Nucleosides without a subscript areτ-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e” or“k” are sugar modified nucleosides. A subscript “e” indicates a2′-O-methoxyethyl (MOE) modified nucleoside and a subscript “k”indicates a 6′-(S)—CH₃ bicyclic nucleoside (e.g. cEt).

The gapmer, ISIS 460209 was included in the study as a benchmarkoligonucleotide against which the potency and selectivity of themodified oligonucletides could be compared. A non-allele specificoligonucleotide, ISIS 387898, was used as a positive control.

Hu97/18 mice, the first murine model of HD that fully geneticallyrecapitulates human HD were used in the study. They were generated inHayden's lab by cross bred BACHD, YAC18 and Hdh (−/−) mice.

Hu97/18 mice were treated with 300 μg of modified oligonucleotides by asingle unilateral intracerebroventricular (ICV) bolus injection. Thistreatment group consisted of 4 animals/oligonucleotide. The controlgroup received a 10 μl bolus injection of sterile PBS and consisted of 4animals.

Animals were sacrificed at 4 weeks post-injection. The second mostanterior 2 mm coronal slab for each brain hemisphere was collected usinga 2 mm rodent brain matrix. The remaining portion of the brain waspost-fixed in 4% paraformaldehyde, cryoprotected in 30% sucrose andsectioned into 25 μm coronal sections for immunohistochemical analysis.

The HTT protein levels were analyzed by high molecular weight westernblot (modified from Invitrogen's NuPAGE Bis-Tris System Protocol). Thetissue was homogenized in ice cold SDP lysis buffer. 40 μg of totalprotein lysate was resolved on 10% low-BIS acrylamide gels (200:1acrylamide:BIS) with tris-glycine running buffer (25 mM Tris, 190 mMGlycince, 0.1% SDS) containing 10.7 mM β-mercaptoethanol added fresh.Gels were run at 90V for 40 min through the stack, then 190V for 2.5 h,or until the 75 kDa molecular weight marker band was at the bottom ofthe gel. Proteins were transferred to nitrocellulose at 24V for 2 h withNuPage transfer buffer (Invitrogen: 25 mM Bicine, 25 mM Bis-Tris, 1.025mM EDTA, 5% MeOH, pH 7.2). Membranes were blocked with 5% milk in PBS,and then blotted for HTT with MAB2166 (1:1000, millipore). Anti-calnexin(Sigma C4731) immunoblotting was used as loading control. Proteins weredetected with IR dye 800CW goat anti-mouse (Rockland 610-131-007) andAlexaFluor 680 goat anti-rabbit (Molecular Probes A21076)-labeledsecondary antibodies, and the LiCor Odyssey Infrared Imaging system.

The results in Table 67 are presented as the average percent of HTTprotein levels for each treatment group, normalized to PBS-treatedcontrol and is denoted as “% UTC”. The percent of mutant HTT proteinlevels is denoted as “mut”. The percent of wild-type HTT protein levelsis denoted as “wt”. Selectivity was also evaluated and measured bydividing the percent of wild-type HTT protein levels vs. the percent ofthe mutant HTT protein levels.

As illustrated in Table 67, treatment with the newly designedoligonucleotides, ISIS 476333 and 460085 showed improvement in potencyand selectivity in inhibiting mutant HTT protein levels as compared tothe parent gapmer, 460209. Comparable or a slight loss in potency and/orselectivity was observed for the remaining oligonucleotides.

TABLE 66 Modified oligonucleotides targeting HTT rs7685686,rs4690072 and rs363088 in Hu97/18 mice Wing ISIS Chemistry SEQ NOSequence (5′ to 3′) Motif 5′ 3′ ID NO. 387898C_(e)T_(e)C_(e)G_(e)A_(e)CTAAAGCAGGA_(e)T_(e)T_(e)T_(e)C_(e) 5-10-5 e5e5 79 460209 T_(e)A_(k)A_(k)ATTGTCATCA_(k)C_(k)C_(e) 3-9-3 ekk kke 10435879 A_(e)A_(e)T_(e)A_(e)A_(e)ATTGTCATCA_(e)C_(e)C_(e)A_(e)G_(e) 5-9-5e5 e5 80 476333 A_(e)T_(k)A_(e)A_(k)ATTGTCATCA_(k)C_(e)C_(k)A_(e) 4-9-4ekek keke 32 435874C_(e)A_(e)C_(e)A_(e)G_(e)TGCTACCCAA_(e)C_(e)C_(e)T_(e)T_(e) 5-9-5 e5 e581 435871 T_(e)C_(e)A_(e)C_(e)A_(e)GCTATCTTCT_(e)C_(e)A_(e)T_(e)C_(e)5-9-5 e5 e5 82 460085A_(e)T_(e)A_(e)A_(e)A_(e)TTGTCATC_(e)A_(e)C_(e)C_(e)A_(e) 5-7-5 e5 e5 32e = 2′-MOE (e.g. e5 = eeeee), k = cEt

TABLE 67 Effects of modified oligonucleotides on mutant and wild typeHTT protein levels in Hu97/18 mice Selectivity Dosage % UTC (wt vs ISISNO SNP site (μg) mut wt mut) PBS — 300 100 100 1 387898 — 300 23.7625.66 1 460209 rs7685686 300 18.16 48.99 2.7 435879 rs7685686 300 41.4873.11 1.8 476333 rs7685686 300 6.35 22.05 3.5 460085 rs7685686 300 2.940.1 13.8 435874 rs4690072 300 44.18 76.63 1.7 435871 rs363088 300 33.0789.30 2.7

Example 31

Evaluation of ISIS 435871 in Central Nervous System (CNS) Targeting HTTrs363088—In Vivo Study

A modified oligonucleotide from Example 29, ISIS 435871 was selected andtested for its effects on mutant and wild type HTT protein levels in theCNS in vivo targeting rs363088.

Hu97/18 mouse was treated with 300 μg of ISIS 435871 by a singleunilateral intracerebroventricular (ICV) bolus injection. The animal wassacrificed at 4 weeks post-injection. Regional CNS structures were thenmicro-dissected including bilateral samples from the most anteriorportion of cortex (Cortex 1), an intermediate section of cortex (Cortex2), the most posterior section of cortex (Cortex 3), the striatum, thehippocampus, the cerebellum, and a 1 cm section of spinal cord directlybelow the brain stem. Tissue was homogenized and assessed for mutant andwild-type HTT levels by Western blotting using the procedures asdescribed in Example 30. The results are presented below. As nountreated or vehicle treated control is shown, HTT intensity of eachallele is expressed as a ratio of calnexin loading control intensity.The ratio of the mutant HTT to the wt HTT in the treated animal wasdetermined and is denoted as “wt/mut”. Having a ratio higher than 1 isindicative of allele-specific silencing.

As illustrated in Table 68, a single unilateral ICV bolus injection ofthe modified antisense oligonucleotide showed selective HTT silencingthroughout the CNS except in the cerebellum, where the antisenseoligonucleotide did not distribute evenly.

TABLE 68 Effects of ISIS 435871 on mutant and wild type HTT proteinlevels in CNS targeting rs363088 in Hu97/18 mice HTT intensity/ calnexinintensity Tissue wt mut wt/mut Cortex 1 0.032 0.014 2.29 Cortex 2 0.0270.009 3 Cortex 3 0.023 0.007 3.29 Striatum 0.030 0.012 2.5 Hippocampus0.016 0.006 2.67 Cerebellum 0.023 0.019 1.21 Spinal Cord 0.014 0.007 2

Example 32

Evaluation of Modified Oligonucleotides Targeting HTT rs7685686—In VivoStudy

Several modified oligonucleotides from Examples 43, 51, 52, 53 and 66were selected and tested for their effects on mutant and wild type HTTprotein levels in vivo targeting HTT rs7685686.

The gapmer, ISIS 460209 was included in the study as a benchmarkoligonucleotide against which the potency and selectivity of themodified oligonucletides could be compared.

Hu97/18 mice were treated with 300 μg of modified oligonucleotides by asingle unilateral intracerebroventricular (ICV) bolus injection. Thistreatment group consisted of 4 animals/oligonucleotide. The controlgroup received a 10 μl bolus injection of sterile PBS and consisted of 4animals.

Animals were sacrificed at 4 weeks post-injection. The second mostanterior 2 mm coronal slab for each brain hemisphere was collected usinga 2 mm rodent brain matrix. The HTT protein levels were analyzed in thesame manner as described in Example 30 and the results are presentedbelow.

The results in Table 69 are presented as the average percent of HTTprotein levels for each allele and treatment group, normalized toPBS-treated control and is denoted as “% UTC”. The percent of mutant HTTprotein levels is denoted as “mut”. The percent of wild-type HTT proteinlevels is denoted as “wt”.

As shown in Table 69, each of the newly designed oligonucleotides showedimprovement in selective inhibition of mutant HTT protein levels ascompared to ISIS 460209. ISIS 550913 and 540095 showed improvement inpotency while the remaining modified oligonucleotides showed comparableor a slight decrease in potency as compared to the parent gapmer.

TABLE 69 Effects of modified oligonucleotides on mutant and wild typeHTT protein levels targeting rs7685686 in Hu97/18 mice Wing SEQ ISIS %UTC chemistry Gap ID NO mut wt Motif 5′ 3′ chemistry NO PBS 100 100 — —— — — 460209 18.16 48.99 3-9-3 ekk kke Full deoxy 10 550913 9.31 34.265-9-5 kkekk kkekk Full deoxy 27 540095 12.75 106.05 2-9-4 ek kkke Fulldeoxy 65 551429 19.07 108.31 5-7-3 eeekk kke Full deoxy 10 540094 24.6887.56 2-9-4 ek kkke Full deoxy 67 540096 24.89 98.26 2-9-4 ek kkke Fulldeoxy 68 540108 28.34 85.62 5-7-5 eeekk kkeee Full deoxy 23 e = 2′-MOE,k = cEt

Example 33

Evaluation of Modified Oligonucleotides Targeting HTT rs7685686—In VivoStudy

Several modified oligonucleotides selected from Examples 57, 58, 61 and62 were tested and evaluated for their effects on mutant and wild typeHTT protein levels in vivo targeting HTT rs7685686.

Hu97/18 mice were treated with 300 μg of modified oligonucleotides by asingle unilateral intracerebroventricular (ICV) bolus injection and thecontrol group received a 10 μl bolus injection of sterile PBS. Eachtreatment group consisted of 4 animals.

Animals were sacrificed at 4 weeks post-injection. The second mostanterior 2 mm coronal slab for each brain hemisphere was collected usinga 2 mm rodent brain matrix. The HTT protein levels were analyzed in thesame manner as described in Example 30. The in vivo study for ISIS575008 and 571069 marked with an asterisk (*) was performedindependently and the results are presented below.

The results in Table 70 are presented as the average percent of HTTprotein levels for each allele and treatment group, normalized toPBS-treated control and is denoted as “% UTC”. The percent of mutant HTTprotein levels is denoted as “mut”. The percent of wild-type HTT proteinlevels is denoted as “wt”.

As illustrated in Table 70, selective inhibition of mut HTT proteinlevels was achieved with the newly designed oligonucleotide treatment ascompared to PBS treated control.

TABLE 70 Effects of modified oligonucleotides on mutant and wild typeHTT protein levels targeting rs7685686 in Hu97/18 mice Wing SEQ ISIS %UTC chemistry Gap ID NO mut wt Motif 5′ 3′ chemistry NO PBS 100 100 — —— — — 575007 26.9 104.5 3-9-3 ekk kke Deoxy/cEt 10  575008* 21.7 105.95-7-3 ekkkk kke Deoxy/cEt or 10 full deoxy 566267 32.8 109.3 3-9-3 ekkkke Deoxy/F-HNA 10 571036 30.3 103.3 6-7-4 ekekek keke Full deoxy 32571037 32.8 111.9 6-7-4 eeeekk keke Full deoxy 32  571069* 29.4 109.86-7-4 eeeekk kkee Full deoxy 32 e = 2′-MOE, k = cEt

Example 34

Evaluation of Modified Oligonucleotides Targeting HTT rs7685686—In VivoDose Response Study

ISIS 476333, 435871, 540108, 575007 and 551429 from previous exampleswere selected and evaluated at various doses for their effect on mutantand wild type HTT protein levels in vivo targeting HTT rs7685686.

Hu97/18 mice were treated with various doses of modifiedoligonucleotides as presented in Table 71 by a single unilateralintracerebroventricular (ICV) bolus injection. This treatment groupconsisted of 4 animals/oligonucleotide. The control group received a 10μl bolus injection of sterile PBS and consisted of 4 animals.

Animals were sacrificed at 4 weeks post-injection. The second mostanterior 2 mm coronal slab for each brain hemisphere was collected usinga 2 mm rodent brain matrix. The HTT protein levels were analyzed in thesame manner as described in Example 30. The dose response study wasperformed independently for each modified oligonucleotide and theresults are presented below.

The results in Table 71 are presented as the average percent of HTTprotein levels for each allele and treatment group, normalized toPBS-treated control and is denoted as “% UTC”. The percent of mutant HTTprotein levels is denoted as “mut”. The percent of wild-type HTT proteinlevels is denoted as “wt”.

As illustrated in Table 71, selective inhibition of mut HTT proteinlevels was achieved in a dose-dependent manner for the newly designedoligonucleotides.

TABLE 71 Dose-dependent effect of modified oligonucleotides on mutantand wild type HTT protein levels targeting rs7685686 in Hu97/18 miceDosage % UTC SEQ ID ISIS NO (μg) mut wt Motif NO. PBS 0 100 100 — 47633350 48.7 115 4-9-4 32 150 23.1 53.3 (ekek-d9-keke) 300 8.8 36.7 435871 75114 118 5-9-5 82 150 47.3 80.3 (e5-d9-e5) 300 33 89.3 500 36 97.5 54010875 30.5 71.7 5-7-5 32 150 22 81 (eeekk-d7-kkeee) 300 8.6 59.6 575007 15041.5 110.7 3-9-3 10 300 29 119.4 (ekk-d-k-d7-kke) (deoxy gap interruptedwith cEt) 551429 75 58 101.3 5-7-3 10 150 36.2 110.4 (eeekk-d7-kke) 30019.7 107.8 e = 2′-MOE (e.g. e5 = eeeee), k = cEt, d =2′-deoxyribonucleoside

Example 35 Modified Oligonucleotides Targeting Huntingtin (HTT) SingleNucleotide Polymorphism (SNP)

A series of modified oligonucleotides was designed based on a parentgapmer, ISIS 460209, wherein the central gap region contains nineβ-D-2′-deoxyribonucleosides. The modified oligonucleotides were designedby introducing a 5′-(R)-Me DNA modification within the central gapregion. The 5′-(R)-Me DNA containing oligonucleotides were tested fortheir ability to selectively inhibit mutant (mut) HTT mRNA expressionlevels targeting rs7685686 while leaving the expression of the wild-type(wt) intact. The potency and selectivity of the modifiedoligonucleotides were evaluated and compared to ISIS 460209.

The position on the oligonucleotides opposite to the SNP position, ascounted from the 5′-terminus is position 8.

The modified oligonucleotides were created with a 3-9-3 motif and aredescribed in Table 72. The internucleoside linkages throughout eachgapmer are phosphorothioate (P═S) linkages. Nucleosides followed by asubscript “d” are β-D-2′-deoxyribonucleosides. Nucleosides followed by asubscript “e” indicates a 2′-O-methoxyethyl (MOE) modified nucleoside.Nucleosides followed by a subscript “k” indicates a 6′-(S)—CH₃ bicyclicnucleoside (e.g. cEt). Nucleosides followed by a subscript “z” indicatesa 5′-(R)-Me DNA. “^(m)C” indicates a 5-methyl cytosine nucleoside.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith a single dose at 2 μM concentration of the modifiedoligonucleotide. After a treatment period of approximately 24 hours,cells were washed with DPBS buffer and lysed. RNA was extracted usingQiagen RNeasy purification and mRNA levels were measured by quantitativereal-time PCR using ABI assay C_2229297_10 which measures at dbSNPrs362303. RT-PCR method in short; A mixture was made using 2020 uL 2×PCRbuffer, 101 uL primers (300 uM from ABI), 1000 uL water and 40.4 uL RTMIX. To each well was added 15 uL of this mixture and 5 uL of purifiedRNA. The mutant and wild-type HTT mRNA levels were measuredsimultaneously by using two different fluorophores, FAM for mutantallele and VIC for wild-type allele. The HTT mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN.

The IC₅₀s and selectivities as expressed in “fold” were measured andcalculated using methods described previously in Example 2. Asillustrated in Table 73, treatment with the newly designedoligonucleotides showed comparable or a slight increase in potencyand/or selectivity as compared to ISIS 460209.

TABLE 72 Gap-interrupted oligonucleotides comprising 5′-(R)-Me DNAtargeting HTT SNP Wing ISIS chemistry SEQ ID NO. Sequence (5′ to 3′)Gap chemistry 5′ 3′ NO. 460209 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e ) Full deoxy ekkkke 10 556848 T_(e)A_(k)A_(k)A_(z)T_(d)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e )Deoxy/5′-(R)-Me DNA ekk kke 10 556849T_(e)A_(k)A_(k)A_(d)T_(z)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e ) Deoxy/5′-(R)-Me DNA ekk kke 10556850 T_(e)A_(k)A_(k)A_(d)T_(d)T_(z)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e ) Deoxy/5′-(R)-Me DNA ekk kke 10 e= 2′-MOE, k = cEt

TABLE 73 Comparison of inhibition of HTT mRNA levels and selectivity ofgap- interrupted oligonucleotides with ISIS 460209 targeting HTT SNPSelectivity Wing ISIS IC₅₀ (μM) (wt vs Gap chemistry NO. Mut Wt mut)chemistry 5′ 3′ 460209 0.30 0.99 3.3 Full deoxy ekk kke 556848 0.15 0.64.0 Deoxy/5′-(R)- ekk kke Me DNA 556849 0.16 0.46 2.9 Deoxy/5′-(R)- ekkkke Me DNA 556850 0.33 0.96 2.9 Deoxy/5′-(R)- ekk kke Me DNA e = 2′-MOE,k = cEt

Example 36 Modified Oligonucleotides Comprising 5′-(R)- or 5′-(S)-Me DNAModification Targeting HTT SNP

A series of modified oligonucleotides was designed based on a parentgapmer, ISIS 460209, wherein the central gap region contains nineβ-D-2′-deoxyribonucleosides. The modified oligonucleotides were designedby introducing 5′-(S)— or 5′-(R)-Me DNA modification slightly upstreamor downstream (i.e. “microwalk”) within the central gap region. Thegapmers were created with a 3-9-3 motif and were tested for theirability to selectively inhibit mutant (mut) HTT mRNA expression. Thepotency and selectivity of the modified oligonucleotides were evaluatedand compared to ISIS 460209.

The position on the oligonucleotides opposite to the SNP position, ascounted from the 5′-terminus is position 8.

The modified oligonucleotides and their motifs are described in Table74. The internucleoside linkages throughout each gapmer arephosphorothioate (P═S) linkages. Nucleosides followed by a subscript “d”are β-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e”indicates a 2′-O-methoxyethyl (MOE) modified nucleoside. Nucleosidesfollowed by a subscript “k” indicates a 6′-(S)—CH₃ bicyclic nucleoside(e.g. cEt). Nucleosides followed by a subscript “v” indicates a5′-(S)-Me DNA. Nucleosides followed by a subscript “z” indicates a5′-(R)-Me DNA. “^(m)C” indicates a 5-methyl cytosine nucleoside.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used. Cultured GM04022 cells at adensity of 25,000 cells per well were transfected using electroporationwith 0.1, 0.4, 1.1, 3.3 and 10 μM concentrations of modifiedoligonucleotides. After a treatment period of approximately 24 hours,cells were washed with DPBS buffer and lysed. RNA was extracted usingQiagen RNeasy purification and mRNA levels were measured by quantitativereal-time PCR using ABI assay C_2229297_10 which measures at dbSNPrs362303. RT-PCR method in short; A mixture was made using 2020 uL 2×PCRbuffer, 101 uL primers (300 uM from ABI), 1000 uL water and 40.4 uL RTMIX. To each well was added 15 uL of this mixture and 5 uL of purifiedRNA. The mutant and wild-type HTT mRNA levels were measuredsimultaneously by using two different fluorophores, FAM for mutantallele and VIC for wild-type allele. The HTT mRNA levels were adjustedaccording to total RNA content, as measured by RIBOGREEN and the resultsare presented below.

The IC₅₀s and selectivities as expressed in “fold” were measured andcalculated using methods described previously in Example 2. The resultsin Table 75 demonstrated that each of the newly designedoligonucleotides comprising 5′-(S)- or 5′-(R)-Me DNA within the centralgap region achieved improvement in potency and selectivity as comparedto the parent gapmer, ISIS 460209.

TABLE 74Gap-interrupted oligonucleotides comprising 5′-(S)- or 5′-(R)-Me DNAtargeting HTT SNP Wing ISIS Gap Chemistry SEQ NO Sequence (5′ to 3′)Motif Chemistry 5′ 3′ ID NO 460209T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Full deoxy ekk kke 10 589429T_(e)A_(k)A_(k)A_(d)T_(v)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k)mC_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)- ekk kke 10 Me DNA589430 T_(e)A_(k)A_(k)A_(d)T_(d)T_(v)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k)mC_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)- ekk kke 10 Me DNA589431 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(v) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k)mC_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)- ekk kke 10 Me DNA589432 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(v)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)- ekk kke 10 Me DNA594588 T_(e)A_(k)A_(k)A_(d)T_(v)T_(v)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)- ekk kke 10 Me DNA556848 T_(e)A_(k)A_(k)A_(z)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)- ekk kke 10 Me DNA556849 T_(e)A_(k)A_(k)A_(d)T_(z)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)- ekk kke 10 Me DNA556850 T_(e)A_(k)A_(k)A_(d)T_(d)T_(z)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)- ekk kke 10 Me DNA539558 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(z) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)- ekk kke 10 Me DNA594160 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(z)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)- ekk kke 10 Me DNA594161 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(z)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)- ekk kke 10 Me DNA589433 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(z)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)- ekk kke 10 Me DNA594162 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(z)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)- ekk kke 10 Me DNA594589 T_(e)A_(k)A_(k)A_(d)T_(z)T_(z)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)- ekk kke 10 Me DNAe = 2′-MOE; k = cEt

TABLE 75 Comparison of inhibition of HTT mRNA levels and selectivity ofgap- interrupted oligonucleotides with ISIS 460209 targeting HTT SNPSelectivity Wing ISIS IC₅₀ (μM) (wt vs. Gap Chemistry NO. Mut Wt mut)Motif chemistry 5′ 3′ 460209 1.2 1.4 1.2 3-9-3 Full deoxy ekk kke 5894290.22 3.3 15 3-9-3 Deoxy/5′-(S)- ekk kke Me DNA 589430 0.22 >10 >45.53-9-3 Deoxy/5′-(S)- ekk kke Me DNA 589431 0.16 1.9 11.9 3-9-3Deoxy/5′-(S)- ekk kke Me DNA 589432 0.23 >10 >43.5 3-9-3 Deoxy/5′-(S)-ekk kke Me DNA 594588 0.81 >10 >12.3 3-9-3 Deoxy/5′-(S)- ekk kke Me DNA556848 0.16 1.8 11.3 3-9-3 Deoxy/5′-(R)- ekk kke Me DNA 556849 0.14 1.17.9 3-9-3 Deoxy/5′-(R)- ekk kke Me DNA 556850 0.22 1.7 7.7 3-9-3Deoxy/5′-(R)- ekk kke Me DNA 539558 0.38 3.8 10 3-9-3 Deoxy/5′-(R)- ekkkke Me DNA 594160 0.28 3.3 11.8 3-9-3 Deoxy/5′-(R)- ekk kke Me DNA594161 0.28 >10 >35.7 3-9-3 Deoxy/5′-(R)- ekk kke Me DNA 589433 0.27 4.416.3 3-9-3 Deoxy/5′-(R)- ekk kke Me DNA 594162 0.27 3.5 13.0 3-9-3Deoxy/5′-(R)- ekk kke Me DNA 594589 0.48 4.4 9.2 3-9-3 Deoxy/5′-(R)- ekkkke Me DNA e = 2′-MOE; k = cEt

Example 37

Inhibition of HTT mRNA Levels Targeting SNP by Modified Oligonucleotides

Additional modified oligonucleotides were designed in a similar manneras the antisense oligonucleotides described in Example 36. Variouschemical modifications were introduced slightly upstream or downstream(i.e. “microwalk”) within the central gap region. The gapmers werecreated with a 3-9-3 motif and were tested for their ability toselectively inhibit mutant (mut) HTT mRNA expression. The position onthe oligonucleotides opposite to the SNP position, as counted from the5′-terminus is position 8. The potency and selectivity of the modifiedoligonucleotides were evaluated and compared to ISIS 460209.

The modified oligonucleotides and their motifs are described in Table76. The internucleoside linkages throughout each gapmer arephosphorothioate (P═S) linkages. Nucleosides followed by a subscript “d”are β-D-2′-deoxyribonucleosides. Nucleosides followed by a subscript “e”indicates a 2′-O-methoxyethyl (MOE) modified nucleoside. Nucleosidesfollowed by a subscript “k” indicates a 6′-(S)—CH₃ bicyclic nucleoside(e.g. cEt). Nucleosides followed by a subscript “b” indicates a5′-(R)-allyl DNA. Nucleosides followed by a subscript “c” indicates a5′-(S)-allyl DNA. Nucleosides followed by a subscript “g” indicates a5′-(R)-hydroxyethyl DNA. Nucleosides followed by a subscript “i”indicates a 5′-(S)-hydroxyethyl DNA. “^(m)C” indicates a 5-methylcytosine nucleoside.

The modified oligonucleotides were tested in vitro using heterozygousfibroblast GM04022 cell line. The transfection method and analysis ofHTT mRNA levels adjusted according to total RNA content, as measured byRIBOGREEN were performed in the same manner as described in Example 37.The IC₅₀s and selectivities as expressed in “fold” were measured andcalculated using methods described previously and the results are shownbelow. As presented in Table 77, several modified oligonucleotidesachieved greater than 4.5 fold selectivity in inhibiting mutant HTT mRNAlevels and, therefore, are more selective than ISIS 460209.

TABLE 76Gap-interrupted oligonucleotides comprising 5′-substituted DNA targeting HTT SNPWing SEQ ISIS Gap Chemistry Chemistry ID NO Sequence (5′ to 3′) Motif(mod position) 5′ 3′ NO 460209 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Full deoxyekk kke 10 589414 T_(e)A_(k)A_(k)A_(d)T_(b)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/5′-(R)-allyl DNA ekk kke 10 (pos 5) 589415T_(e)A_(k)A_(k)A_(d)T_(d)T_(b)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)-allyl DNA ekk kke10 (pos 6) 589416T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(b)mC_(d)A_(d)T_(d) ^(m)C_(d)A_(k)^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)-allyl DNA ekk kke 10 (pos 8)589417 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(b)mC_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/5′-(R)-allyl DNA ekk kke 10 (pos 11) 589418T_(e)A_(k)A_(k)A_(d)T_(c)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)-allyl DNA ekk kke10 (pos 5) 589419 T_(e)A_(k)A_(k)A_(d)T_(d)T_(c)G_(d)T_(d)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/5′-(S)-allyl DNA ekk kke 10 (pos 6) 589420T_(e)A_(k)A_(k)AdT_(d)T_(d)G_(d)T_(c)mC_(d)A_(d)T_(d) ^(m)C_(d)A_(k)^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)-allyl DNA ekk kke 10 (pos 8)589421 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(c)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)-allyl DNA ekk kke10 (pos 11) 589422 T_(e)A_(k)A_(k)A_(d)T_(g)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/5′-(R)-hydroxyethyl ekk kke 10 DNA (pos 5) 589423T_(e)A_(k)A_(k)A_(d)T_(d)T_(g)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)-hydroxyethyl ekkkke 10 DNA (pos 6) 589424 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(g)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/5′-(R)-hydroxyethyl ekk kke 10 DNA (pos 8) 589437T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(g)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(R)-hydroxyethyl ekkkke 10 DNA (pos 11) 589426 T_(e)A_(k)A_(k)A_(d)T_(i)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/5′-(S)-hydroxyethyl ekk kke 10 DNA (pos 5) 589427T_(e)A_(k)A_(k)A_(d)T_(d)T_(i)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)-hydroxyethyl ekkkke 10 DNA (pos 6) 589428 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(i)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/5′-(S)-hydroxyethyl ekk kke 10 DNA (pos 8) 589425T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(i)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/5′-(S)-hydroxyethyl ekkkke 10 DNA (pos 11) e = 2′-MOE; k = cEt

TABLE 77 Comparison of inhibition of HTT mRNA levels and selectivity ofgap- interrupted oligonucleotides with ISIS 460209 targeting HTT SNPSelectivity Wing ISIS IC₅₀ (μM) (wt vs. Gap Chemistry Chemistry NO MutWt mut) (mod position) Motif 5′ 3′ 460209 0.47 2.1 4.5 Full deoxy 3-9-3ekk kke 589414 1.0 7.6 7.6 Deoxy/5′-(R)- 3-9-3 ekk kke Allyl DNA (pos 5)589415 1.4 >10 >7.1 Deoxy/5′-(R)- 3-9-3 ekk kke Allyl DNA (pos 6) 5894162.7 >10 >3.7 Deoxy/5′-(R)- 3-9-3 ekk kke Allyl DNA (pos 8) 5894175.4 >10 >1.9 Deoxy/5′-(R)- 3-9-3 ekk kke Allyl DNA (pos 11) 5894181.2 >10 >8.3 Deoxy/5′-(S)- 3-9-3 ekk kke Allyl DNA (pos 5) 5894191.1 >10 >9.1 Deoxy/5′-(S)- 3-9-3 ekk kke Allyl DNA (pos 6) 5894203.2 >10 >3.1 Deoxy/5′-(S)- 3-9-3 ekk kke Allyl DNA (pos 8) 5894212.0 >10 >5.0 Deoxy/5′-(S)- 3-9-3 ekk kke Allyl DNA (pos 11) 589422 0.733.2 4.4 Deoxy/5′-(R)- 3-9-3 ekk kke Hydroxyethyl DNA (pos 5) 589423 0.929.2 10 Deoxy/5′-(R)- 3-9-3 ekk kke Hydroxyethyl DNA (pos 6) 589424 0.214.4 21 Deoxy/5′-(R)- 3-9-3 ekk kke Hydroxyethyl DNA (pos 8) 5894370.73 >10.2 >14 Deoxy/5′-(R)- 3-9-3 ekk kke Hydroxyethyl DNA (pos 11)589426 0.91 5.1 5.6 Deoxy/5′-(S)- 3-9-3 ekk kke Hydroxyethyl DNA (pos 5)589427 0.91 >10 >11 Deoxy/5′-(S)- 3-9-3 ekk kke Hydroxyethyl DNA (pos 6)589428 1.1 >11 >10 Deoxy/5′-(S)- 3-9-3 ekk kke Hydroxyethyl DNA (pos 8)589425 1.5 >10.5 >7 Deoxy/5′-(S)- 3-9-3 ekk kke Hydroxyethyl DNA (pos11) e = 2′-MOE; k = cEt

Example 38 Modified Oligonucleotides Comprising Methyl PhosphonateInternucleoside Linkage Targeting HTT SNP—In Vitro Study

ISIS 558255 and 558256 from Example 10 were selected and evaluated fortheir effect on mutant and wild type HTT mRNA expression levelstargeting rs7685686. ISIS 46020 was included in the study forcomparison. The position on the oligonucleotides opposite to the SNPposition, as counted from the 5′-terminus is position 8.

Heterozygous fibroblast GM04022 cell line was used for the in vitroassay (from Coriell Institute). Cultured GM04022 cells at a density of25,000 cells per well were transfected using electroporation with 0.12,0.37, 1.1, 3.3 and 10 μM concentrations of modified oligonucleotides.After a treatment period of approximately 24 hours, cells were washedwith DPBS buffer and lysed. RNA was extracted using Qiagen RNeasypurification and mRNA levels were measured by quantitative real-time PCRusing ABI assay C_2229297_10 which measures at dbSNP rs362303. RT-PCRmethod in short; A mixture was made using 2020 μL 2×PCR buffer, 101 μLprimers (300 μM from ABI), 1000 μL water and 40.4 μL RT MIX. To eachwell was added 15 μL of this mixture and 5 μL of purified RNA. Themutant and wild-type HTT mRNA levels were measured simultaneously byusing two different fluorophores, FAM for mutant allele and VIC forwild-type allele. The HTT mRNA levels were adjusted according to totalRNA content, as measured by RIBOGREEN.

The IC₅₀s and selectivities as expressed in “fold” were measured andcalculated using methods described previously in Example 2. Asillustrated in Table 78, improvement in selectivity and potency wasachieved with the modified oligonucleotides comprising methylphosphonate internucleoside linkage as compared to ISIS 460209.

TABLE 78 Comparison of selectivity in inhition of HTT mRNA levels ofantisense oligonucleotides with ISIS 460209 targeted to rs7685686 inGM4022 cells Wing IC₅₀ (μM) Selectivity Gap Chemistry SEQ ISIS NO Mut Wt(wt vs mut) Motif chemistry 5′ 3′ ID NO 460209 0.30 0.99 3.3 3-9-3 Fulldeoxy ekk kke 10 558255 0.19 1.3 6.8 3-9-3 Deoxy/Methyl ekk kke 10phosphonate 558256 0.20 1.3 6.5 3-9-3 Deoxy/Methyl ekk kke 10phosphonate e = 2′-MOE (e.g. e5 = eeeee), k = cEt

Example 39 Modified Oligonucleotides Comprising Methyl Phosphonate orPhosphonoacetate Internucleoside Linkage(s) Targeting HTT SNP

A series of modified oligonucleotides were designed based on ISIS 460209wherein the gap region contains nine β-D-2′-deoxyribonucleosides. Themodified oligonucleotides were synthesized to include one or more methylphosphonate or phosphonoacetate internucleoside linkage modificationswithin the gap region. The oligonucleotides with modified phosphoruscontaining backbone were tested for their ability to selectively inhibitmutant (mut) HTT mRNA expression levels targeting rs7685686 whileleaving the expression of the wild-type (wt) intact. The potency andselectivity of the modified oligonucleotides were evaluated and comparedto ISIS 460209.

The position on the oligonucleotides opposite to the SNP position, ascounted from the 5′-terminus is position 8.

The modified oligonucleotides and their motifs are described in Table79. Each internucleoside linkage is a phosphorothioate (P═S) except forthe internucleoside linkage having a subscript “x” or “y”. Eachnucleoside followed by a subscript “x” indicates a methyl phosphonateinternucleoside linkage (—P(CH₃)(═O)—). Each nucleoside followed by asubscript “y” indicates a phosphonoacetate internucleoside linkage(—P(CH₂CO₂ ⁻)(═O)—). Nucleosides followed by a subscript “d” is aβ-D-2′-deoxyribonucleoside. Nucleosides followed by a subscript “e”indicates a 2′-O-methoxyethyl (MOE) modified nucleoside. Nucleosidesfollowed by a subscript “k” indicates a 6′-(S)—CH₃ bicyclic nucleoside(e.g. cEt). “^(m)C” indicates a 5-methyl cytosine modified nucleoside.

The modified oligonucleotides were tested in vitro. Heterozygousfibroblast GM04022 cell line was used (from Coriell Institute). CulturedGM04022 cells at a density of 25,000 cells per well were transfectedusing electroporation with 0.12, 0.37, 1.1, 3.3 and 10 μM concentrationsof modified oligonucleotides. After a treatment period of approximately24 hours, cells were washed with DPBS buffer and lysed. RNA wasextracted using Qiagen RNeasy purification and mRNA levels were measuredby quantitative real-time PCR using ABI assay C_2229297_10 whichmeasures at dbSNP rs362303. RT-PCR method in short; A mixture was madeusing 2020 μL 2×PCR buffer, 101 μL primers (300 μM from ABI), 1000 uLwater and 40.4 μL RT MIX. To each well was added 15 μL of this mixtureand 5 μL of purified RNA. The mutant and wild-type HTT mRNA levels weremeasured simultaneously by using two different fluorophores, FAM formutant allele and VIC for wild-type allele. The HTT mRNA levels wereadjusted according to total RNA content, as measured by RIBOGREEN.

The IC₅₀s and selectivities as expressed in “fold” were measured andcalculated using methods described previously in Example 2. Asillustrated in Table 80, most of the newly design oligonucleotidesachieved improvement in selectivity while maintaining potency ascompared to ISIS 460209.

TABLE 79 Modified oligonucleotides comprising methyl phosphonate orphosphonoacetate internucleoside linkage(s) targeting HTT SNP WingChemistry SEQ ISIS NO Sequence (5′ to 3′) Motif Gap Chemistry 5′ 3′ID NO 460209 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(e)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Full deoxy ekkkke 10 566276 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(dx)T_(d)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/Methyl phosphonate ekk kke 10 566277T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(dx) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/Methyl phosphonate ekkkke 10 566278 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d)^(m)C_(dx)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/Methyl phosphonate ekk kke 10 566279T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(dx)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/Methyl phosphonate ekkkke 10 566280 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(dx) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/Methyl phosphonate ekk kke 10 566283T_(e)A_(k)A_(k)A_(d)T_(dx)T_(dx)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/Methyl phosphonate ekkkke 10 573815 T_(e)A_(k)A_(k)A_(d)T_(dy)T_(d)G_(d)T_(d)^(m)C_(d)A_(d)T_(d) ^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3Deoxy/Phosphonoacetate ekk kke 10 573816T_(e)A_(k)A_(k)A_(d)T_(d)T_(dy)G_(d)T_(d) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/Phosphonoacetate ekk kke10 573817 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(dy) ^(m)C_(d)A_(d)T_(d)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/Phosphonoacetate ekk kke10 573818 T_(e)A_(k)A_(k)A_(d)T_(d)T_(d)G_(d)T_(d) ^(m)C_(d)A_(d)T_(dy)^(m)C_(d)A_(k) ^(m)C_(k) ^(m)C_(e) 3-9-3 Deoxy/Phosphonoacetate ekk kke10 e = 2′-MOE, k = cEt

TABLE 80 Comparison of selectivity in inhition of HTT mRNA levels ofantisense oligonucleotides with ISIS 460209 targeted to rs7685686 inGM4022 cells Mut Selectivity Wing SEQ ISIS IC₅₀ (wt vs Gap Chemistry IDNO (μM)) mut) Motif chemistry 5′ 3′ NO 460209 0.15 9.4 3-9-3 Full deoxyekk kke 10 566276 0.76 12.8 3-9-3 Deoxy/Methyl ekk kke 10 phosphonate566277 0.20 17 3-9-3 Deoxy/Methyl ekk kke 10 phosphonate 566278 0.25 8.93-9-3 Deoxy/Methyl ekk kke 10 phosphonate 566279 0.38 — 3-9-3Deoxy/Methyl ekk kke 10 phosphonate 566280 0.27 47 3-9-3 Deoxy/Methylekk kke 10 phosphonate 566283 0.8 >100 3-9-3 Deoxy/Methyl ekk kke 10phosphonate 573815 0.16 18.8 3-9-3 Deoxy/Phos- ekk kke 10 phonoacetate573816 0.55 18.1 3-9-3 Deoxy/Phos- ekk kke 10 phonoacetate 573817 0.1722.5 3-9-3 Deoxy/Phos- ekk kke 10 phonoacetate 573818 0.24 13.5 3-9-3Deoxy/Phos- ekk kke 10 phonoacetate e = 2′-MOE, k = cEt

1. A oligomeric compound comprising a modified oligonucleotideconsisting of 10 to 30 linked nucleosides, wherein the modifiedoligonucleotide has a modification motif comprising: a 5′-regionconsisting of 2-8 linked 5′-region nucleosides, each independentlyselected from a modified nucleoside and an unmodified deoxynucleoside,provided that at least one 5′-region nucleoside is a modified nucleosideand wherein the 3′-most 5′-region nucleoside is a modified nucleoside; a3′-region consisting of 2-8 linked 3′-region nucleosides, eachindependently selected from a modified nucleoside and an unmodifieddeoxynucleoside, provided that at least one 3′-region nucleoside is amodified nucleoside and wherein the 5′-most 3′-region nucleoside is amodified nucleoside; and a central region between the 5′-region and the3′-region consisting of 6-12 linked central region nucleosides, eachindependently selected from: a modified nucleoside and an unmodifieddeoxynucleoside, wherein the 5′-most central region nucleoside is anunmodified deoxynucleoside and the 3′-most central region nucleoside isan unmodified deoxynucleoside; wherein the modified oligonucleotide hasa nucleobase sequence complementary to the nucleobase sequence of atarget region of a nucleic acid associated with a huntingtin transcript.2. (canceled)
 3. The oligomeric compound of claim 1, the nucleobasesequence of the target region of the target nucleic acid differs fromthe nucleobase sequence of at least one non-target nucleic acid by asingle differentiating nucleobase. 4.-7. (canceled)
 8. The oligomericcompound of claim 3, wherein the single differentiating nucleobase is asingle-nucleotide polymorphism, and wherein the single-nucleotidepolymorphism is selected from: rs6446723, rs3856973, rs2285086,rs363092, rs916171, rs6844859, rs7691627, rs4690073, rs2024115,rs11731237, rs362296, rs10015979, rs7659144, rs363096, rs362273,rs16843804, rs362271, rs362275, rs3121419, rs362272, rs3775061,rs34315806, rs363099, rs2298967, rs363088, rs363064, rs363102,rs2798235, rs363080, rs363072, rs363125, rs362303, rs362310, rs10488840,rs362325, rs35892913, rs363102, rs363096, rs11731237, rs10015979,rs363080, rs2798235, rs1936032, rs2276881, rs363070, rs35892913,rs12502045, rs6446723, rs7685686, rs3733217, rs6844859, and rs362331.9.-20. (canceled)
 21. The oligomeric compound of claim 1, wherein atleast one central region nucleoside is a modified nucleoside. 22.-31.(canceled)
 32. The oligomeric compound of claim 21, wherein at least onemodified central region nucleoside comprises a 2′-substituted sugarmoiety comprising a 2′ substituent selected from: halogen, optionallysubstituted allyl, optionally substituted amino, azido, optionallysubstituted SH, CN, OCN, CF₃, OCF₃, O, S, or N(R_(m))-alkyl; O, S, orN(R_(m))-alkenyl; O, S or N(R_(m))-alkynyl; optionally substitutedO-alkylenyl-O-alkyl, optionally substituted alkynyl, optionallysubstituted alkaryl, optionally substituted aralkyl, optionallysubstituted O-alkaryl, optionally substituted O-aralkyl, O(CH₂)₂SCH₃,O—(CH₂)₂—O—N(R_(m))(R_(n)) or O—CH₂—C(═O)—N(R_(m))(R_(n)), where eachR_(m) and R_(n) is, independently, H, an amino protecting group orsubstituted or unsubstituted C₁-C₁₀ alkyl; wherein each optionallysubstituted group is optionally substituted with a substituent groupindependently selected from: hydroxyl, amino, alkoxy, carboxy, benzyl,phenyl, nitro (NO₂), thiol, thioalkoxy (S alkyl), halogen, alkyl, aryl,alkenyl and alkynyl. 33.-43. (canceled)
 44. The oligomeric compound ofclaim 21, wherein the 2^(nd), 3^(rd), 4^(th), 5^(th), 6^(th), 7^(th), or8^(th) nucleoside from the 5′-end of the central region is a modifiednucleoside. 45.-61. (canceled)
 62. The oligomeric compound of claim 1,wherein the central region has a nucleoside motif selected from:DDDDDDDDDD, DDDDXDDDDD; DDDDDXDDDDD; DDDXDDDDD; DDDDXDDDDDD; DDDDXDDDD;DDXDDDDDD; DDDXDDDDDD; DXDDDDDD; DDXDDDDDDD; DDXDDDDD; DDXDDDXDDD;DDDXDDDXDDD; DXDDDXDDD; DDXDDDXDD; DDXDDDDXDDD; DDXDDDDXDD; DXDDDDXDDD;DDDDXDDD; DDDXDDD; DXDDDDDDD; DDDDXXDDD; DXXDXXDXX; DDDDDDDDD;DXDDDDDDD; DDXDDDDDD; DDDXDDDDD; DDDDXDDDD; DDDDDXDDD; DDDDDDXDD;DDDDDDDXD; DXXDDDDDD; DDDDDDXXD; DDXXDDDDD; DDDXXDDDD; DDDDXXDDD;DDDDDXXDD; DXDDDDDXD; DXDDDDXDD; DXDDDXDDD; DXDDXDDDD; DXDXDDDDD;DDXDDDDXD; DDXDDDXDD; DDXDDXDDD; DDXDXDDDD; DDDXDDDXD; DDDXDDXDD;DDDXDXDDD; DDDDXDDXD; DDDDXDXDD; DDDDDXDXD; DDDDDD, DDDDDDD, DDDDDDDD,DDDDDDDDD, DDDDDDDDDD, DXDDDD, DDXDDD, DDDXDD, DDDDXD, DXDDDDD, DDXDDDD,DDDXDDD, DDDDXDD, DDDDDXD, DXDDDDDD, DDXDDDDD, DDDXDDDD, DDDDXDDD,DDDDDXDD, DDDDDDXD, DXDDDDDDD; DDXDDDDDD, DDDXDDDDD, DDDDXDDDD,DDDDDXDDD, DDDDDDXDD, DDDDDDDXD, DXDDDDDDDD, DDXDDDDDDD, DDDXDDDDDD,DDDDXDDDDD, DDDDDXDDDD, DDDDDDXDDD, DDDDDDDXDD, and DDDDDDDDXD; whereineach D is an unmodified deoxynucleoside; and each X is a modifiednucleoside. 63.-72. (canceled)
 73. The oligomeric compound of claim 62,wherein the nucleobase sequence of the target region of the targetnucleic acid differs from the nucleobase sequence of at least onenon-target nucleic acid by a single differentiating nucleobase, andwherein the location of the single differentiating nucleobase isrepresented by X. 74.-101. (canceled)
 102. The oligomeric compound ofclaim 1, wherein the 5′-region has a motif selected from: ADDA; ABDAA;ABBA; ABB; ABAA; AABAA; AAABAA; AAAABAA; AAAAABAA; AAABAA; AABAA; ABAB;ABADB; ABADDB; AAABB; AAAAA; ABBDC; ABDDC; ABBDCC; ABBDDC; ABBDCC; ABBC;AA; AAA; AAAA; AAAAB; AAAAAAA; AAAAAAAA; ABBB; AB; ABAB; AAAAB; AABBB;AAAAB; AABBB, AAA, BBB, BBBAA, AAB, BAA, BBAA, AABB, AAAB, ABBW, ABBWW,ABBB, ABBBB, ABAB, ABABAB, ABABBB, ABABAA, AAABB, AAAABB, AABB, ABBBB,BBBBB, AAABW, BBBBAA, and AAABW; wherein each A is a modified nucleosideof a first type, each B is a modified nucleoside of a second type, eachC and each W is a modified nucleoside of a third type, and each D is anunmodified deoxynucleoside. 103.-175. (canceled)
 176. The oligomericcompound of claim 1, wherein the 3′-region has a motif selected from:ABB, ABAA, AAABAA, AAAAABAA, AABAA, AAAABAA, AAABAA, ABAB, AAAAA, AAABB,AAAAAAAA, AAAAAAA, AAAAAA, AAAAB, AAAA, AAA, AA, AB, ABBB, ABAB, AABBB,BBA, AAB, AAA, BBB, BBAA, AABB, WBBA, WAAB, BBBA, BBBBA, BBBB, BBBBBA,ABBBBB, BBAAA, AABBB, BBBAA, BBBBA, BBBBB, BABA, BBAAAA, AABBBB, BAAAA,and ABBBB, wherein each A is a modified nucleoside of a first type, eachB is a modified nucleoside of a second type, and each W is a modifiednucleoside of a first type, a second type, or a third type. 177.-203.(canceled)
 204. The oligomeric compound of claim 1, wherein the5′-region has a motif selected from: AB, ABB, AAA, BBB, BBBAA, AAB, BAA,BBAA, AABB, AAAB, ABBW, ABBWW, ABBB, ABBBB, ABAB, ABABAB, ABABBB,ABABAA, AAABB, AAAABB, AABB, AAAAB, AABBB, ABBBB, BBBBB, AAABW, AAAAA,and BBBBAA; wherein the 3′-region has a motif selected from: BBA, AAB,AAA, BBB, BBAA, AABB, WBBA, WAAB, BBBA, BBBBA, BBBB, BBBBBA, ABBBBB,BBAAA, AABBB, BBBAA, BBBBA, BBBBB, BABA, AAAAA, BBAAAA, AABBBB, BAAAA,and ABBBB; wherein the central region has a nucleoside motif selectedfrom: DDDDDD, DDDDDDD, DDDDDDDD, DDDDDDDDD, DDDDDDDDDD, DXDDDDDDD,DDXDDDDDD, DDDXDDDDD, DDDDXDDDD, DDDDDXDDD, DDDDDDXDD, DDDDDDDXD,DXXDDDDDD, DDDDDDXXD, DDXXDDDDD, DDDXXDDDD, DDDDXXDDD, DDDDDXXDD,DXDDDDDXD, DXDDDDXDD, DXDDDXDDD, DXDDXDDDD, DXDXDDDDD, DDXDDDDXD,DDXDDDXDD, DDXDDXDDD, DDXDXDDDD, DDDXDDDXD, DDDXDDXDD, DDDXDXDDD,DDDDXDDXD, DDDDXDXDD, and DDDDDXDXD, DDDDDDDD, DXDDDDDD, DDXDDDDD,DDDXDDDD, DDDDXDDD, DDDDDXDD, DDDDDDXD, DXDDDDXD, DXDDDXDD, DXDDXDDD,DXDXDDDD, DXXDDDDD, DDXXDDDD, DDXDXDDD, DDXDDXDD, DXDDDDXD, DDDXXDDD,DDDXDXDD, DDDXDDXD, DDDDXXDD, DDDDXDXD, and DDDDDXXD, DXDDDDD, DDXDDDD,DDDXDDD, DDDDXDD, DDDDDXD, DXDDDXD, DXDDXDD, DXDXDDD, DXXDDDD, DDXXDDD,DDXDXDD, DDXDDXD, DDDXXDD, DDDXDXD, and DDDDXXD, DXDDDD, DDXDDD, DDDXDD,DDDDXD, DXXDDD, DXDXDD, DXDDXD, DDXXDD, DDXDXD, and DDDXXD; and whereineach A is a modified nucleoside of a first type, each B is a modifiednucleoside of a second type, each W is a modified nucleoside of a firsttype, a second type, or a third type, each D is an unmodifieddeoxynucleoside, and each X is a modified nucleoside or a modifiednucleobase.
 205. The oligomeric compound of claim 204, wherein the5′-region has a motif selected from: AB, ABB, AAA, BBB, BBBAA, AAB, BAA,BBAA, AABB, ABBW, ABBWW, ABBB, ABBBB, ABAB, ABABAB, ABABBB, ABABAA,AAABB, AAAABB, AABB, AAAAB, AABBB, ABBBB, BBBBB, AAABW, and BBBBAA; andwherein the 3′-region has a BBA motif.
 206. The oligomeric compound ofclaim 204, wherein one of A or B comprises a bicyclic sugar moiety,another of A or B comprises a 2′-MOE sugar moiety, and W comprises a2-thio-thymidine nucleobase or FHNA. 207.-213. (canceled)
 214. Theoligomeric compound of claim 1 comprising at least one modifiedinternucleoside linkage. 215.-217. (canceled)
 218. The oligomericcompound of claim 214 comprising one or two methylphosphonateinternucleoside linkages.
 219. (canceled)
 220. The oligomeric compoundof claim 218, wherein at least one of the 3^(rd), 4^(th), 5^(th), 6^(th)and/or 7^(th) internucleoside from the 5′-end and/or from the 3′-end isa methylphosphonate internucleoside linkage.
 221. (canceled)
 222. Theoligomeric compound of claim 218, wherein at least one of the 3^(rd),4^(th), 5^(th), 6^(th), 7^(th), 8^(th), 9^(th), 10^(th), 11^(th), and/or12^(th) internucleoside from the 5′-end is a methylphosphonateinternucleoside linkage, and wherein at least one of the 3^(rd), 4^(th),5^(th), 6^(th), 7^(th), 8^(th), 9^(th), 10^(th), 11^(th), and/or 12^(th)nucleoside from the 5′-end is a modified nucleoside.
 223. The oligomericcompound of claim 218, wherein at least one of the 3^(rd), 4^(th),5^(th), 6^(th), 7^(th), 8^(th), 9^(th), 10^(th), 11^(th), and/or 12^(th)internucleoside from the 3′-end is a methylphosphonate internucleosidelinkage, and wherein at least one of the 3^(rd), 4^(th), 5^(th), 6^(th),7^(th), 8^(th), 9^(th), 10^(th), 11th, and/or 12th nucleoside from the3′-end is a modified nucleoside.
 224. The oligomeric compound of claim 1comprising at least one conjugate group. 225.-259. (canceled)
 260. Amethod comprising contacting a cell with an oligomeric compound ofclaim
 1. 261.-265. (canceled)
 266. A method comprising administering apharmaceutical composition comprising the oligomeric compound of claim 1to an animal. 267.-269. (canceled)
 270. A method of ameliorating asymptom of Huntington's disease, comprising administering an oligomericcompound of claim 1 to an animal in need thereof. 271.-272. (canceled)